feel better live longer annual report shareholders navigate help find way c licking icon around around report buttons marked report navigation strip top right panel right hand c licking link c licking section contents takes bars takes start specific section home search print previous next previous view contents notice regarding limitations director liability english law uk companies act safe harbour limits liability directors respect statements omissions report directors statement responsibilities directors contained pages independent auditors report includes business review pages create value financial statements english law directors would liable company third deliver notes financial statements party report directors contains performed financial statements glaxosmithkline plc errors result recklessness knowing prepared uk gaap misstatement dishonest concealment material fact would otherwise liable report directors pages inclusive comprise report directors drawn presented accordance reliance upon english company law liabilities directors connection report shall subject limitations restrictions chairmans statement quarterly trend provided law chief executives review five year record marketplace product development pipeline website glaxosmithklines website wwwgskcom strategy growth products competition intellectual property gives additional information group grow diversified business share price dividends notwithstanding references make deliver products value annual general meeting annual report glaxosmithklines website none information made available simplify operating model investor relations registrars website constitutes part annual report financial architecture taxation information shareholders shall deemed incorporated responsible business glossary terms reference herein index cautionary statement regarding forwardlooking statements groups reports filed furnished us securities exchange commission sec including document written information released oral statements made public future behalf group may contain forwardlooking statements forwardlooking statements give groups financial review current expectations forecasts future events investor identify statements financial position resources fact relate strictly financial review historical current facts use words risk factors anticipate estimate expect intend project plan believe words terms similar meaning connection discussion future operating financial performance particular front cover clockwise top include statements relating future actions phase programme educates groups prospective products product approvals importance handwashing reducing spread diseases chris martin future performance results current anticipated products sales efforts expenses diskus inhaler one devices outcome contingencies legal board developed deliver inhaled proceedings financial results group medicines directly respiratory system undertakes obligation update forward corporate executive team inpress photography looking statements whether result new governance policy early research new biopharmaceuticals information future events otherwise share capital control including treatments based antibodies committee reports takes place large rd centre forwardlooking statements involve inherent stevenage uk george brooks risks uncertainties group cautions us law regulation investors number important factors total remuneration including document could cause remuneration policy actual results differ materially people work contained forwardlooking statement directors emoluments total rd search new medicines factors include limited remuneration vaccines consumer healthcare products discussed risk factors pages pierre charbonneau directors senior management annual report testing signs malaria children tanzania tom whipps number adjusted measures used report performance business sensodyne repair protect boosted performance consumer healthcare measures defined business andy robinson photofarm gsk annual report scienceled global healthcare company make innovative medicines vaccines consumer healthcare products used millions people around world allowing feel better live longer products develop manufacture contributes directly health patients consumers indirectly wider wellbeing economy society fundamentally changing recent years create balanced business address market challenges deliver sustainable performance returns shareholders committed generating performance responsible way visit website wwwgskcom gsk annual report overview scienceled global healthcare company researches develops broad range innovative products business three primary areas business pharmaceuticals vaccines consumer bn healthcare objective deliver sustainable growth across portfolio group turnover total turnover billion pharmaceuticals vaccines consumer healthcare bn bn bn turnover group turnover group turnover group pharmaceuticals business develops vaccines business one develop market range makes available medicines largest world producing consumer health products based treat broad range serious paediatric adult vaccines scientific innovation leading chronic diseases portfolio made range infectious diseases positions three main categories established brands newer distributed billion doses overthecounter otc medicines oral innovative patentprotected medicines countries healthcare nutritional healthcare supplied developing countries portfolio includes number wellknown brands panadol sensodyne lucozade horlicks sales therapy area sales vaccine sales category respiratory boostrix otc antivirals cervarix oral healthcare central nervous system fluarix flulaval nutritional healthcare cardiovascular urogenital flu pandemic metabolic hepatitis antibacterials infanrix pediarix oncology emesis rotarix dermatology synflorix viiv healthcare hiv rd business sustained investment rd bn rd expenditure allocation spent billion major restructuring billion total search develop new total rd expenditure medicines vaccines innovative consumer products allocate rd investment based view c scientific opportunities different disease areas assets late ability provide significant improvements existing stage pipeline treatments level returns generate also dedicated research programmes diseases affect developing world one estimated internal pharmaceuticals healthcare companies researching new vaccines vaccines rate return new medicines three world health consumer healthcare rd expenditure organizations priority diseases hivaids malaria major restructuring tuberculosis calculation results major restructuring described note financial statements presentation financial statements presented consolidated income statement pages gsk annual report geographic presence covers countries global reach since reshaping business capitalise higher growth potential markets outside europe usa territories account employees total sales time restructured developed markets employees region business reflect challenging commercial environment markets significant global manufacturing rd presence network manufacturing sites large rd centres uk usa spain belgium china usa europe emerging markets asia pacific japan turnover region bn usa europe emerging markets asia pacific japan structured commercial businesses structured around regional turnover segment units areas focus bn pharmaceuticals vaccines operate geographical us pharmaceuticals vaccines europe pharmaceuticals vaccines segments combine two businesses emerging markets pharmaceuticals vaccines consumer healthcare business functions global japan pharmaceuticals vaccines unit viiv healthcare specialist hiv company asia pacific pharmaceuticals vaccines founded pfizer viiv healthcare trading trading turnover includes canada puerto rico central consumer healthcare vaccine tender sales contract manufacturing sales gsk annual report overview create value business model relies innovation intellectual property protection brand allegiance deliver sustainable growth business model new medicines healthcare products critical element business model vulnerability generic competition needed people across globe protection intellectual property less marked vaccines address many illnesses create developing new treatments biopharmaceuticals including enzymes cancer diabetes heart disease technologies protection allows monoclonal antibodies large still wellcontrolled treated us generate income set period molecules created different time scientific research time enabling us recoup rd development manufacturing continuously uncovering new costs invest research processes small molecules understandings disease processes products typically patent protection prescription technologies difficult expensive manufacture medicines inventions two elements present us around years western development generic versions opportunity investigate develop countries however time new vaccines biopharmaceuticals new improved treatments medicine approved use patients also subject different regulatory create value applying science significant proportion exclusivity requirements requirement technology discover develop produce period passed patents carry trials humans incurs distribute medicines vaccines products also prevent additional expense required consumer healthcare products protection challenged generic manufacture small molecules expire therefore places barrier pharmaceuticals vaccines generic competition patent protection expires process discovering medicine often subject competition consumer healthcare developing new medicines vaccines generic manufacturers long expensive requires intellectual property protection rd overheads innovation creativity industry consumer healthcare products able offer products development times typically consumer healthcare business relies considerably lower prices declines years new medicines vaccines product innovation brand loyalty sales following patent expirations costs billion trademark protection competitive particularly rapid usa approved product rd process often create value development europe generic pressures different involves thousands patients trials timelines new consumer healthcare emerging markets brand allegiance investigate safety efficacy products significantly shorter greater influence markets potential new treatments pharmaceuticals vaccines known heritage brand existing pace innovation rapid medicines whether onpatent application science consumer valued provides opportunity insights key driving successful withstand generic competition product innovation consumer brands pharmaceutical discovery development process research development regulatory market discovery testing review market patent protection patent compounds compounds compound expiry years years indefinite final patent application product approval patent expiry gsk annual report different fundamentally changed broken commitment access business culture help us grow traditional hierarchical pharmaceutical actively seeking new ways improve performance rd business model creating instead delivering healthcare making approach one openness smaller units encourage greater products available affordable challenge innovation affects entrepreneurialism accountability people need wherever way business way work scientists live society external groups relationship striving develop new expects us right thing employees employees partnerships approaches adopting also good positive impact contribution different mindset business makes peoples lives one innovative openminded flexible key motivators working gsk effort expand access consultative value new products led industry breadth business different perspectives adopting flexible approach pricing groups bring thinking broadbased balanced medicines vaccines based open working research business across pharmaceuticals vaccines countrys wealth ability pay charities academia companies non consumer healthcare products resulted significant reductions governmental organisations also pharmaceuticals vaccines businesses price increases demand increasing consultation patients include established brands new products emerging economies payers ensure medicines innovative patentprotected medicines representing good outcome patients developing provide improvements many categoryleading brands governments shareholders healthcare systems value reward consumer healthcare business western markets developed committed researching new new reimbursement approaches diverse portfolio provides us better treatments diseases impact medicines agree risksharing range products drive business developing world research arrangements payers innovationdriven markets centre spain dedicated usa japan also provides us established special business discovery work one good opportunities growth unit responsible increasing companies researching treatments emerging markets rapidly access products least vaccines malaria tb hiv developing economies expanding developed countries world reported positive initial results number people access price patented medicines malaria vaccine successful would healthcare treatments region kept worlds first vaccine developed world prices reinvest changes made shape deadly disease flexible fifth profits make sales business intended provide intellectual property know territories back local healthcare broadlysourced sales growth provide areas research diseases infrastructure projects greater resilience face market developing world aim challenges loss patent stimulating progress search work many agencies protection government austerity new treatments distribute vaccines people measures countries lowest price commercial organisation billion vaccine doses new ways working pioneered new sales models align delivered changing market expectations fundamentally changed supplied protect people developing customers example rd organisation deliver large countries also significant introduced new remuneration system diverse latestage pipeline discovery medicine donation programmes targeted us sales representatives based organisation structure sustain disease elimination service deliver healthcare flow innovative new medicines professionals rather individual vaccines sales targets gsk annual report overview deliver strategy designed deliver sustainable growth reduce risk improve longterm financial performance returns shareholders strategic priorities grow deliver simplify diversified products operating global business value model creating balanced changed rd organisation change shape business business product portfolio capable better able sustain transforming operating delivering sustainable sales growth industryleading pipeline products model reduce complexity make centred three business areas offer valuable improvements efficient past four pharmaceuticals vaccines consumer treatment patients healthcare years implemented global healthcare well accessing growth providers restructuring programme markets creating business delivered significant savings increased level less vulnerable market volatility externalisation research allowing time manufacturing including generic pressures us access new areas science business unit relentlessly past three years share risk development focused streamlining production substantially increased investment partners also made decisions processes improve efficiency emerging markets japanese earlier around pipeline progressions eliminate waste operations well global medicines reorganised global support vaccines consumer healthcare significantly differentiated existing functions facilities real estate businesses therapies progressed procurement one centralised broken traditional hierarchical also maximising promotion group allow us become business model created smaller distribution synergies streamlined provide significant agile groups scientists pharmaceuticals vaccines economies scale accountable delivering consumer healthcare businesses projects rapidly growing emerging economies bn c bn days group turnover proportion new product assets late annual benefits working capital sales outside approvals stage pipeline restructuring cycle usa europe programme financial architecture established new financial architecture aligns addition improved financial reporting align planning execution performance measurement order closely architecture providing maximise financial performance returns shareholders data insights progress making designed drive improvements operating margin greater businesses regions progress key financial efficiency enhanced cash conversion sales drivers operational financial efficiency growth focused delivering lead stronger starting transitioning reporting core growth earnings per share better free cash generation basis enabling greater visibility underlying performance expected cash flow available dividends reinvestment business business share buybacks depending returns attractive gsk annual report underlying operating principles strong governance operating responsibly commitment responsible valuesbased business believe responsible business underlies everything values applied across grow create value shareholders society group values operate transparency long term think responsibilities four areas demonstrate respect people act integrity remain helping improve peoples health wellbeing wherever patientfocused strong policy compliance live whatever ability pay working support programmes expect standards suppliers development people well communities around contractors business partners chairman board world behaving open honest manner directors provide leadership corporate governance growing business protecting natural fundamental sound decision making supports resources need future executive management implementing strategy continue change way business risk oversight compliance council rocc oversees successful sustainable longer term management significant business risks including reputational nonfinancial risks compliance laws regulations well coordination governance bodies spirit values collaborative approach standards audit assurance group supports rocc boards audit risk committee providing business products touch many different groups independent view significant risks managed people take medicines across organisation products aim work groups transparent collaborative manner allow us succeed partners approach applies interactions payers regulators healthcare professionals work well suppliers business partners equally seek valuable participant scientific research collaborations researchers sharing significant scientific developments data appropriate routes actively seek work partnership public bodies nongovernmental organisations help progress health issues present wider societal challenges treatments neglected tropical diseases prevention childhood illnesses least developed countries gsk annual report overview performed measure performance number key indicators remuneration executives based many group turnover operating profit margin major restructuring bn bn reported underlying growth growth growth margin bn cer cer bn cer na important performed important performed key objective strategy reported turnover fell second key objective improve operating profit excluding legal deliver sustainable broadlysourced year past two years operating leverage order costs operating income sales growth delivered average annual deliver stronger operating profit significantly impacted underlying turnover growth growth margin indicates year rolloff pandemic underlying turnover growth adjusts costs managed products avandia valtrex impact rolloff included operating profit key sales pandemic products measure avandia valtrex e xcluding legal costs million million million calculation underlying turnover described operating income million million million earnings per share major restructuring free cash flow bn p growth growth pence cer bn important performed important performed eps shows portion profit eps grew significantly measure shows cash free cash flow allocated share key compared primarily generate available return impacted loss sales indicator performance result lower legal charges shareholders reinvest pandemic products avandia returns generating business well effectiveness valtrex associated converting earnings cash receivables legal settlements effective working capital million control investment discipline million million calculation free cash flow described reconciliation provided calculation results major restructuring described note financial statements presentation financial statements calculation cer growth described gsk annual report turnover major growth areas new pharmaceuticals vaccines product performance bn bn growth bn turnover bn cer turnover important performed important performed measure focuses major turnover business areas measure shows delivery sales totalling growth areas vaccines consumer totalled billion sales newly launched products billion represented healthcare emerging markets asia representing group creates incentives improved pharmaceuticals vaccines pacific japan dermatology turnover decrease compared rd performance new products turnover included performance highlights reflects loss defined products launched cervarix million progress making delivering avandia valtrex flu last five years included synflorix million strategy create broadbased pandemic sales key measure rotarix million sales growth resilient volatility cash returned shareholders total shareholder return bn growth bn dividends buybacks important performed continue focus delivering paid dividends dividend growth returning free billion spent billion cash flow shareholders repurchasing shares share buybacks offers attractive return glaxosmithkline total return alternative investments glaxosmithkline pharma peers return index ftse total return index index includes abbott laboratories astrazeneca bristolmyers squibb eli lilly johnson johnson merck novartis pfizer roche holdings sanofi gsk annual report strategic review chairmans statement behalf board management team driven late also received fundamental change business promising first data malaria pleased last years improve vaccine proved successful report gsk made growth prospects reduce risk potential prevent deaths deliver enhanced financial performance millions african children considerable progress demonstrable evidence terrible disease strategy starting deliver despite maintaining good corporate governance positively differentiate gsks outlook key priority pleased challenging economic companies sector introduce corporate governance would particularly like recognise environment report sets sir andrews vision leadership approach regulations identifying early scale change guidelines underpinning decision needed successfully making mindful starting execute change current environment around executive ultimately aim strategy remuneration remain committed deliver sustainable improved longterm linking pay delivery value returns shareholders performance set details year returned billion approach remuneration shareholders dividends report share buybacks increase several changes versus board simon dingemans current uncertain economic succeeded julian heslop chief environment management risk financial officer judy lewent remains key focus board stacey cartwright appointed senior executive team nonexecutive directors judy stacey reached agreement principle brought wealth experience settle groups outstanding litigation business finance respective us government historic sales knowledge pharmaceutical marketing practices agreement industry consumer brands represents adds settlements made strong additions board going outstanding litigation significantly forward james murdoch decided reduces overall legal exposure step board years agm offering board continue focus reelection would like thank james strengthening governance contribution board compliance procedures help reduce past three years future litigation minimise risk shareholders audit committed continuing risk committee retain good improve diversity board level visibility issues challenges aspiration faced management work female representation address example finally board pleased completed thorough review sir andrew knighted antibribery corruption abac new years honours services programme associated training economy pharmaceutical developed ensure compliance industry welldeserved uk bribery act recognition sir andrews contribution remains strong belief gsk also economy operating responsible ethical way essential success gsk chairman corporate responsibility committee pleased see progress made year improve global access medicines including agreements supply large quantities number vaccines poorest countries sir christopher gent world fraction western prices chairman gsk annual report chief executives review gsks record year delivered underlying emerging markets future pricing sales growth strong cash generation pressure ruled however demonstrates significant rd progress result organic investment succeeding increased shareholder returns targeted bolton acquisitions billion completed continue expect strategy create deliver growth ahead market underlying sales growth reflects region balanced business deliver portfolio breadth mix business japan outstanding sustainable financial underlying sales group grew year market innovationdriven growth broadly sourced performance provide gsks launch profile saw strong performances across areas exceptional last three years new value patients business pharmaceuticals japanese sales grown vaccines consumer consumers launched eight new products healthcare including cervarix especially expected saw transition well following implementation reported sales performance national immunisation programme year effects loss sales like japan usa proinnovation avandia valtrex flu pandemic environment gsk emerging products diminished reported sales period substantial patent year expirations first half second half significantly reshaped business clearly reflects changes redesigned commercial organisation made create business align better changed payer balanced less vulnerable volatility environment confident us including generic pressures business well placed deliver performance achieved improved performance despite continued economic pressures overall environment remains political instability europe challenging volatility emerging markets inevitable continue expect underlying sales growth translate reported sales growth driving cash generation returns shareholders gsk continues highly cash generative legal settlements billion net cash inflow operating activities billion free cash flow billion year announced full year ordinary dividend p also completed billion share repurchases part longterm programme also announced return net proceeds sale noncore north american otc brands shareholders payment supplemental dividend p paid fourth quarter ordinary dividend skoorb egroeg gsk annual report strategic review chief executives review continued focus rd productivity part continued focus summer announced new returns improving returns updated pricing structure vaccine calculation expected rate diarrhoeal disease offering gavi key element strategy return rd investment alliance vaccine fraction improve rd returns productivity increased cost developed western markets pleased progress healthcare company save countless lives rd organisation making towards publish analysis extremely future sustainable achieving encouraged progress recouping cost goods medicines vaccines track deliver long term goal manufacture phase iii development also cusp creating highlighted start operating transparency worlds first malaria vaccine know received data responsibility firsthand devastating impact nine expect complete disease africa lived development programmes six late remain committed operating several years stage assets indications transparency responsibility running business region course readouts year made multiple advances october latestage trials confirmed positive overall balance agenda ensure behaviour promise seen far showing importantly seeing productivity actions meet even exceed vaccine reduces risk translate real filings approvals expectations society malaria half african children three new medicines approved continue focus strongly aged months usa europe four procedures compliance marketing ready sufficient data inhouse file also reiterated commitment selling particularly usa price vaccine level covers example established new costs generates small return since new drugs compensation system reward us around ploughed back vaccines approved usa sales representatives quality research next generation new molecular entities service customers rather sales malaria medicines vaccines peers volumes delivered outlook comes positive indications environmental strategy replenish pipeline pleased see already look ahead clearly mindful ongoing basis making progress ambitious potential pressures face given goals set march across current global environment completed comprehensive entire value chain raw materials however continue expect drive reviews discovery performance product disposal shareholder returns seek units units comprised grow sales across business scientists group focusing another priority align improve operational leverage early stage discovery one particular commercial success forming new financial efficiency deliver strong disease pathway based review partnerships tackle healthcare cash generation believe progress needs people developing countries medicines latestage development early gsk began supplying conclusion would like thank next three years pneumococcal vaccines kenya gsks employees many partners innovative financing mechanism work around world known advance market outstanding contribution support commitment largest fund helping deliver successful ever designed single vaccine creating new opportunities dramatically increased sustainable access see growth performance vaccine babies across africa beyond sir andrew witty chief executive officer gsk annual report marketplace difficult market general overview austerity measures taken correct public deficits debt may become conditions stemming global economic growth mixed common events tsunami international earthquake japan political unrest pharmaceutical market financial crisis continued north africa middle east sales world pharmaceutical market turbulence eurozone affecting worth billion constant impact worlds international economy economic exchange rates cer months environment year economies end september particularly influenced large budget billion prior year sales world deficits developed world required significant action represented growth pharmaceutical markets countries greece italy growth year earlier showed significant latter part pressures share global sales fell usa prompted fears recession remained top pharmaceutical regional variation countries despite improvements market also europe number sectors including sales rise rest world world pharmaceutical market world pharmaceutical market share prices usa ended expected continue grow although point started year growth mature markets limited falls europe ftse compared emerging markets index leading uk shares ended year doubledigit growth may expected lower dax germany factors influencing growth lower cac france japans main share index significant need medicines nikkei closed lowest endofyear healthcare treatments around level since chinas shanghai world number factors give us composite index lost reason optimistic ability grow business researching based external assessments manufacturing selling healthcare outlook global economic growth treatments particularly new remains uncertain shape business however exists recovery likely slow factors affect performance unbalanced risks mature economies success researchbased healthcare greater developing ones companies exact impact social political unrest arising difficult predict value compound growth world pharmaceutical market geographic region bn total sep sep usa europe rest world emerging markets asia pacific japan canada total sales world market top therapeutic classes bn total central nervous system antineoplasticimmunomodulatory cardiovascular alimentary tract metabolic antiinfectives bacterial viral fungal excluding sales growth world vaccines pharmaceutical market respiratory data market share market growth rates gsk estimates based recent data independent external sources including ims health values cer constant exchange rate gsk annual report strategic review marketplace continued growth emerging marketsincreased estimated change world population millions access medicines treatments fastdeveloping economies wealth creates expanding opportunities people benefit medicines vaccines consumer healthcare products emerging markets china india large populations markets expected grow significantly years pop years pop years pop mature markets next years world population projected increase substantially current levels biggest proportional growth older age group lifestyle changes population growth source ims worlds population rapidly increasing number people living longer see world population relative percentage number impact regulatory background health risks changing biopharmaceuticals newly approved agency requirements continue grow success treating infectious diseases medicines continued rise see rise particularly around aspects product impact life expectancy biotechnology quality safety addition patterns physical activity price controls evaluation benefit risk continue food alcohol tobacco consumption paramount consideration changing low middleincome many countries prices approval new medicine usa countries face double burden pharmaceutical products controlled food drug administration fda increasing chronic noncommunicable law governments may also increasingly focused safety conditions well communicable influence prices control medicines approval diseases traditionally affect poor national healthcare organisations postmarketing phase product bear large part cost prevalence chronic disease supplying medicines consumers fda approved highest increasing middleincome countries recent government healthcare reforms number new molecular entities since beginning impact countries france spain nearly third approvals least developed countries germany may restrict pricing therapies treat rare diseases line fdas priority advances science technology reimbursement address public health needs special scientific advances continue translate usa currently populations enforcement compliance new medicines technologies government price controls private activity increased manufacturing although difficult predict sector purchases federal law requires global supply chain well ones rate instance pharmaceutical manufacturers pay drug advertising promotion following development monoclonal rebates certain medicines eligible fda developed goals renewal antibodies biopharmaceutical reimbursement several state prescription drug user fee act manufacturing techniques past two federal healthcare programmes pdufawith focus enhancing decades many new biopharmaceuticals rebates increased health science drug development improving medicines approved reform law affordable care act quality evidence applications aca came effect providing efficient predictable review process maintaining public rise biotechnology pressure control healthcare costs confidence continue beyond us government spending healthcare europe following adoption programmes crossborder trade revised european union eu legislation acceleration generics market new measures aimed strengthening comparative effectiveness research safety monitoring medicines pharmaceutical pricing issues discussion implemented importance industry part july continuing healthcare debate usa new eu laws protect citizens prescription otc biotechnology regulatory pressures threats posed fake medicines proportion biotechnology sales pharmaceuticals vaccines adopted discussions continue draft compared global prescription otc industry highly regulated regional legislation improving citizens access pharmaceutical sales within worlds reliable information medicines countryspecific laws regulations top drugs european medicines agency ema major factors determining whether source evaluatepharma published information product developed approved gsk annual report vision outlined fiveyear strategic name registrations critical ensuring sold eu seretide trademark plan road map expected reasonable return investment rd protection may generally extended developed eu commission continued long trademark used renewing policy try obtain patents review regulation clinical necessary gsks trademarks commercially important protectable trials europe legislative proposals important maintaining brand inventions discovered developed expected identity products enforce rd activities patent trademark rights prevent infringements regulatory environment emerging protection new active ingredients markets asia pacific continues available major markets competition evolve number countries patents also obtained new revising regulatory review systems drug formulations manufacturing within pharmaceutical industry participate number specific processes medical uses devices competition come regional national regulatory administering products companies making patentprotected initiatives provide opportunities medicines indications treat meaningful scientific regulatory although may obtain patents similar diseases medicines dialogue industry agencies products prevent manufacturers making generic copies stakeholders continue challenged medicines following patent expiration expire grant patent include broader sets patient populations principal pharmaceutical mean issued patent number countries vaccines competitors include necessarily held valid enforceable medicine development programmes court court determines abbott laboratories amgen astrazeneca order increase global patient access patent hold invalid non bristolmyers squibb eli lilly new innovative medicines optimise infringed unenforceable johnson johnson merck novartis regulatory approvals example china protect market third party pfizer roche holdings sanofi takeda russia india emerging market entry prior patent expiry significant teva pharmaceuticals countries updating regulations litigation concerning challenges consumer healthcare market local clinical experience summarised note financial become challenging consumers populations part registration statements legal proceedings demanding better quality better packages new chemical entities value retailers consolidated treatment many neglected tropical consumer healthcare industry globalised strengthened diseases little commercial subject national regulation comparable negotiation power principle market stimulate research reward prescription medicines competitors markets include innovation areas taking testing approval manufacturing labelling flexible approach help speed colgatepalmolive johnson johnson marketing products high standards rd new medicines includes procter gamble unilever pfizer technical appraisal frequently involve flexible patents novartis lengthy review approval process providing access knowhow addition many smaller companies new product may launched resources sharing data compete gsk certain markets generic pressures research community objective outlook ensure ip seen barrier patents expire medicine muchneeded research could spur operating environment remains medicines subject development new better treatments challenging made significant competition generic products neglected tropical diseases progress restructuring effect particularly acute rigorous returnsbased approach capital western markets generic products life patent countries allocation expect underlying sales rapidly capture large share years filing date however momentum translate reported market following patent expiration long development time new medicines growth constant exchange generic manufacturers typically mean substantial amount rates despite anticipated pricing incur significant costs research patent life eroded prior reductions many markets development education market launch markets possible development able offer lost time restored outlook timing impact products considerably lower prices leads variations amount substitutable competition seretideadvair branded competitors pressures patent life actually available europe usa uncertain apply significantly vaccines product market uncertainty part due intellectual property trademarks significant regulatory manufacturing requirements need satisfied intellectual property ip important commercial products produce inhaled medicine aspect business effective protected registered trademarks seretideadvair addition patents legal protection intellectual major markets may local delivery devices seretideadvair property via patents trademarks variations example usa referenced see also risk registered designs copyrights domain trademark advair covers product factors pages gsk annual report strategic review strategy growth grow diversified global business overview creating balanced business product portfolio capable delivering sustainable sales growth centred three business areas pharmaceuticals vaccines consumer healthcare substantially increased investment highergrowth areas operations emerging markets japan global vaccines consumer healthcare businesses well accessing newer markets broadlybased business creating less vulnerable volatility including generic pressures also see significant competitive advantage synergy ability distribute pharmaceuticals vaccines consumer healthcare products particularly rapidly growing emerging economies progress record demonstrates success approach although reported turnover fell delivered underlying sales growth past two years anticipate underlying sales growth translate reported sales growth details underlying growth see addition group turnover generated outside usa europe shift sales away reliance white pills western markets broader base including emerging markets vaccines consumer healthcare clear gsk annual report group turnover total sales performed bn underlying reported reported turnover declined growth growth however underlying turnover bn cer cer rose second bn consecutive year na bn turnover bn turnover bn turnover diversify sales away white pills western markets sales performed continue see proportion sales white pills western markets decline reducing susceptibility generic pressures markets priorities progress create balanced business sales outside usa europe performed sales markets outside usa europe increased total sales group turnover turnover major growth areas turnover major growth areas performed bn turnover major growth areas vaccines consumer healthcare emerging markets asia pacific bn japan pharmaceuticals dermatology totalled billion group turnover bn bn calculation underlying turnover described gsk annual report strategic review grow diversified global business continued usa pharmaceuticals vaccines made good marketplace year reported sales declined compared marked lower progress aim us healthcare market continues sales pandemic products avandia change significantly response generate sustainable sales valtrex underlying sales year government reforms patients healthcare flat billion despite impact growth challenging providers payers demanding healthcare reform higherquality care lower costs better market environment health outcomes despite fall reported sales us operating profit increased keeping passage healthcare reform efforts simplify standardise legislation government pays values work processes produced efficiencies majority us healthcare helped control costs offset decline next years reforms continue sales certain products combined implemented healthcare providers higher asset disposal income turnover payers change provide pay healthcare pharmaceuticals business reported bn turnover declined underlying payers demanding evidence turnover declined sales value studies compare growth economics effectiveness largest product advair declined bn cer follows drop us market ics treatment regimens therapies laba combination products following also increasingly linking provider reimbursement health outcomes revised class labelling implemented food drug administration among healthcare providers physicians fda hycamtin sales declined operating profit consolidating group practices due generic competition joining integrated delivery zovirax sales declined following bn networks hospitals consolidating divestment brand january effort obtain scale resources established promoted products growth needed perform effectively system account business bn cer rewards value rather volume whole performed strongly patient behaviour changing included contributions payers institute higher copayment respiratory business particular ventolin doctor visits prescription drugs cardiovascular drug lovaza patients becoming involved neuroscience medicine pharmaceuticals vaccines interested cost quality lamictal new oncology turnover care receive products promacta arzerra votrient farreaching changes environment operate vaccines business reported see opportunity work turnover increased reflecting patients payers healthcare providers strong performances flulaval meet evolving needs infanrixpediarix rotarix partly offset performance decline cervarix sales growth pharmaceuticals vaccines number fda cer business emerging period approvals potiga benlysta horizant respiratory substantial patent expirations usa along new indications boostrix antivirals seen fall sales central nervous system lamictal xr benlysta developed past three years focus cardiovascular urogenital gsk human genome sciences reshape business resource metabolic new areas growth oncology achieved results antibacterials oncology emesis rescale presence primary care working hard transform business vaccines also redesigned commercial including implementing industry dermatology organisation align better leading incentive compensation system changed payer environment sales professionals work directly healthcare providers see changing way incentivese sales teams gsk annual report changing way incentivise sales teams altered way reward customerfacing pharmaceutical vaccine sales professionals new system rewards sales professionals quality interactions healthcare professionals including element customer evaluation rather achieving individual sales targets approach aligns core value putting interests patients first goal share healthcare providers improving patient health substantial number increase transparency support communities fda approvals potiga conduct business added made million grant city benlysta horizant voluntary disclosures regarding payments philadelphia youth development made healthcare practitioners white house meeting us along new including payments healthcare education reforms pledged million indications boostrix professionals conducting clinical research next five years keeping us built commitment longterm support science lamictal xr made publish payments education healthcare professionals work new environmentally friendly speakers advisers facilities philadelphia navy yard continued longstanding area constructed commitments provide patients highest possible international designation access medicines improve green building highly access oncology speciality efficient energy water use medications launched cares manufacturing site zebulon gsk comprehensive programme north carolina reduced water offers speciality reimbursement consumption almost services free medicine also past four years working achieve oncology copay assistance programme goal sending zero waste landfill provide help eligible patients limited insurance coverage gain better access oral oncology speciality medicines segami yttegekcol naes gsk annual report strategic review grow diversified global business continued europe pharmaceuticals vaccines economic climate marketplace pharmaceuticals business reported turnover declined underlying government austerity many healthcare systems across europe turnover declined sales volume face dilemma ageing populations measures impacted seretide asthma copd product increases chronic illness lifestyle increased revenue declined sales revenues diseases creating growing demand price cuts mild flu season improved healthcare flu season also impacted antibacterial continue focus economic climate forcing governments portfolio sales declined tighten healthcare budgets expanding range new oncology products votrient promacta result governmentled price cuts arzerra performed well sales products enhancing costsaving initiatives created challenges duodart avodart treat benign transparency way us impact prostatic hyperplasia grew austerity measures doubled despite duodart market operate compared access approval france italy outlook european gaining approval economy highly uncertain expect governments market new products turnover pressure pricing addition continues challenge governments regulators add new products prolia treatment bn requirements evidence osteoporosis benlysta lupus value new medicines seeing launched majority markets growth longer lead times bringing products europe bn cer market vaccines business reported think current pricing turnover declined underlying reimbursement policies need turnover reflecting austerity redesigned achieve sustainable driven price cuts fewer tender orders framework ensures patients cervarix operating profit access effective treatments payers first implementation gsks new financial stability pharmaceutical bn global standard enterprise resource industry encouraged continue planning system designed standardise invest research improve financial commercial growth bn cer performance processes completed successfully germany deployment new european business sales european supply chain continues composed large contributions respiratory cardiovascularurogenital continued focus products vaccines evolving business towards greater pharmaceuticals vaccines transparency way operate turnover european management team introduced new global standards remained resilient challenging governing share scientific environment reported turnover clinical data medicines ensure fell billion underlying clear distinction scientific turnover excluding revenues dialogue promotional activity pandemic products avandia valtrex declined continued government also changed way reward austerity measures impacted underlying pharmaceuticals field sales staff replacing growth region approximately individual sales targets basis growth percentage points reward qualitative criteria overall cer business financial achievement performance underpinned respiratory individualindexed performance measures antivirals reduced operating costs compared central nervous system continuing invest continue work local cardiovascular urogenital products recent launches despite communities support charitable metabolic initiatives operating profit fell programmes innovative antibacterials primarily due loss sales sustainable strengthen oncology emesis pandemic products avandia valtrex healthcare infrastructure financial vaccines support year totals dermatology million europe excluding uk gsk annual report grow diversified global business continued emerging markets pharmaceuticals vaccines underlying growth marketplace continuing scale business around offpatent products emerging markets commercial environment reported sales grew billion emerging markets presented diverse outpacing growth helped acquisition challenges including political phoenix argentina pharmaceutical market instability parts north africa flagship heritage medicine antibiotic middle east toughening augmentin celebrated years work bring competition aggressive pricing market turning growth controls countries including diverse range relevant antiinfectives cns russia turkey portfolio also contributing affordable medicines pricing pressure ruled growth area many people however result organic although reported vaccine sales investment targeted bolton possible acquisitions completed million underlying sales rose million continue expect deliver growth flexible pricing approach synflorix successful launch ahead market region emerging markets sales performance million turnover approach emerging markets consolidated recent based growing pharmaceuticals acquisitions nanjing meirui bn vaccines businesses pharma co ltd china expanded increasing access newer patent portfolio inlicensing protected brands offpatent arrangements strengthened growth bn cer branded medicines vaccines business signing innovative technology agreements earlier established broad portfolio year transformed vaccine joint affordable international brands across venture neptunus china pharmaceuticals vaccines believe whollyowned operation offers us significant competitive operating profit advantage key strength adopting range flexible business emerging markets pricing models emerging markets bn based countrys ability pay since reported turnover growth year introduced approach flexible underlying growth growth pricing avamys avodart bn cer outpaced growth market seen volume sales increases third consecutive year underlying key markets growth driven relatively consistent respectively introduction flexible pharmaceuticals growth pricing cervarix enabled year operating profit fell us deliver double number doses reflecting loss sales pandemic pharmaceuticals vaccines vaccine cervical cancer products avandia valtrex turnover women throughout region latin american businesses seeing attractive returns especially strong growing reported sales announced two significant underlying basis commitments accelerate access india grew reported underlying vaccines childhood illness sales significant longstanding partnership market disruption middle eastern gavi alliance june countries social unrest committed supply rotavirus result middle eastafrica business vaccines gavi fraction growth grew reported sales developing world prices also cer underlying basis respiratory announced extension antivirals sales patentprotected pneumococcal vaccines agreement central nervous system medicines improved approximately gavi cardiovascular urogenital billion reported basis metabolic underlying antibacterials oncology emesis vaccines dermatology gsk annual report strategic review grow diversified global business continued japan pharmaceuticals vaccines gsk japan achieved marketplace also received approval lamictal bipolar disorder significant underlying japanese pharmaceutical market arixtra received additional indication grew around growth growth despite treatment venous thrombo helped partly embolism end major earthquake government price revisions drug development pipeline consisted pricing scheme government projects five tsunami march announced intention continue regulatory review five preparing provisional drug pricing scheme responded quickly new product approval submission introduced next price phase iii pipeline includes provide financial revision due treatments rare diseases product donations also helping market orphandesignated compounds implementation funding disease organise employee preventation cervical cancer vaccines business recorded sales million pneumoccocal vaccines volunteers million excluding sales flu performance pandemic vaccines million performance driven market japan encourages turnover sales cervarix reached innovation gsk performed strongly million following introduction bn pharmaceuticals vaccines governments national funding past three years launched programme cervical cancer prevention eight product indications growth bn cer potential launch number july japanese regulators approved new product indications next rotarix marking second approval three years gsk vaccine excluding pandemic vaccine country rotarix reported turnover billion flat launched november first compared underlying vaccine japan prevention operating profit turnover grew operating profit rotavirus gastroenteritis infants fell reflecting loss sales copromoted daiichisankyo bn pandemic products following natural disaster reported pharmaceutical sales grew earthquake tsunami march growth billion reflecting strong bn cer supported people affected growth adoair seretideadvair providing substantial financial rose performance newly product donations establishing launched products avolveavodart teams volunteers named team xyzal antihistamine licensed orange initial stage ucb pharmaceuticals vaccines provided critical supplies turnover cns paxil remained leader affected areas antidepressants market although sales later volunteers provided labour fell recent introduction teamed medical professionals antidepressant medicines provided offer medical counselling support range prescribing options supporting activities scholarships physicians students pharmaceutical studies maintained contribute regions recovery growth cer respiratory antivirals central nervous system cardiovascular urogenital metabolic antibacterials oncology emesis vaccines dermatology gsk annual report grow diversified global business continued asia pacific pharmaceuticals vaccines asia pacific region marketplace leading vaccines provider across asia pacific region reported contributor gsks economic growth across region vaccines sales growth continues exceed global average success showed underlying growth supported pharmaceutical market primarily sales newer positive underlying gross domestic product growth exceeding vaccines rotarix million worlds developed economies cervarix million growth markets pricing pressures number synflorix million particularly countries across region well public market performance manufacturing intellectual property strong performances particularly strong continuing challenges likely offset supply cervarix national malaysia vietnam growing populations increasing immunisation programme malaysia incomes emerging middle classes successful award new emerging markets business zealand national pneumococcal vaccine continue expect deliver growth tender synflorix ahead market region flexible pricing helping turnover performance build business asia pacific bn region increasing overall volume business asia pacific based products sell three main pillars vaccines offpatent growth established pharmaceutical products indonesia reduced prices bn cer augmentin ventolin across brands ensure medicines recently launched medicines reached people need votrient tyverb duodartavodart resulted volume increases neighbouring singapore strong performance seen across price reduction antibiotic three pillars asia pacific business operating profit augmentin led threefold increase reported sales asia pacific business volume sales grew reached billion thailand also launched initiative underlying sales growth reach patients access growth excluding pandemic products avandia programme two leading brands cer valtrex business seretide augmentin coupled outperformed market growth price reduction region products access also increased asia pacific operating profit increased addressing distribution channels pharmaceuticals vaccines turnover increase government hospitals introduced turnover reflecting favourable operating leverage flexible reimbursement policy private hospitals agreed reduce price paid portfolio newer brands sales patients seretide reached million rise products tykerb avamys contributing significantly growth continued strong performance established brands ventolin achieved sales million growth cer augmentin reached respiratory million antivirals central nervous system cardiovascular urogenital metabolic antibacterials oncology emesis vaccines dermatology gsk annual report strategic review grow diversified global business continued consumer healthcare consumer marketplace nutritional healthcare grew driven strong rest world healthcare business developed markets recent economic results acquisition turmoil weakened consumer demand performed well face europes leading sports nutrition brand slowed growth consumer healthcare maxinutrition early year horlicks economic uncertainty market increased competitive pressure continued register strong growth main competitors increased india functional beverages registered turnover boosted spending marketing begun strong results emerging markets discount aggressively effort gain strong key brand led doubledigit growth lucozade market share ribena africa business performance growth investment brands including benefited enhanced consumer emerging markets consumerdriven scientific innovation availability innovative specific industryleading consumer packaging markets marketing critical differentiating oral healthcare sales grew back products maintaining profitable strong performances brands like growth markets sensodyne sensitivity acid erosion turnover emerging markets continue register business grew driven strong economic consumer healthcare launch sensodyne repair protect bn category growth unprecedented brands ongoing rollout emerging number households enter consumer markets denture care delivered high growth segment nearly world consumer singledigit growth doubledigit cer healthcare growth forecast come growth key emerging markets bolstered markets next five years good growth japan usa performance build growth evaluated structure consumer consumer healthcare business business reshaped enable us operating profit based global approach create sustainable growth changing three main areas leading market bn brands overthecounter otc medicines oral healthcare nutritional healthcare significantly refocused brand growth turnover growth year portfolio identified four large high cer compared estimated market growth value categories define business driven continued focus footprint wellness oral health nutrition innovation geographic expansion skin health aim become operating profit year grew worlds successful fastmoving consumer healthcare company driven breakdown turnover strong growth emerging science values markets including africa middle east china part initiative announced india well positioned intention divest noncore success emerging markets make products predominantly usa onethird global europe aggregate annual sales consumer healthcare sales approximately million aim leadership positions key categories divestment realise value india china asian african shareholders simplify business middle eastern markets allow us focus priority brands growth markets cer sales developed markets flat overthecounter medicines strong performances japan january completed oral healthcare australia offset declines north divestment brands usa nutritional healthcare america europe posted canada prestige brands holdings falls million cash brands included bc goodys beano ecotrin fiberchoice otc sales year flat tagamet generated sales panadol franchise registered growth approximately million gastrointestinal health core divestment impact reported brands tums eno growth months respectively performances offset decline sales alli gsk annual report net cash proceeds shift allow us build stronger addition branding car transaction returned global brands enhance global drivers overalls lucozade supply shareholders supplemental dividend consumer insight design retail sports nutrition products play pence per share paid marketing capabilities enable integral role drivers preparation time fourth interim dividend development category strategies focused performance recovery also process divestment emerging markets work mclaren develop analytical remaining noncore otc performance management tools building gsks partnership brands continues subject delivering improve ability make faster mclaren september lucozade appropriate shareholder value decisions longerterm investment announced fiveyear performance allocations new product development shifted responsibility category partnership vodafone mclaren innovations brand strategy category teams mercedes formula motor racing team share profit loss accountability geographic regions sensodyne strength sensodyne repair protect strong contributor growth consumer healthcare business first everyday fluoride toothpaste contain novamin technology proven repair sensitive teeth since launch february sensodyne repair protect available markets across europe asia middle east additional launches planned sensodyne franchise registered doubledigit growth consecutive quarters patented novamin technology helps repair vulnerable areas teeth hydroxyapatite natural building blocks teeth comes contact saliva novamin releases calcium phosphate form protective mineral layer vulnerable areas enamel segami ytteg etybkcots mrafotohp nosnibor ydna gsk annual report strategic review grow diversified global business continued viiv healthcare viiv healthcare marketplace viiv healthcares operating profit declined reflecting increased comprehensive since recognition years ago hiv investment rd support four major epidemic become one biggest portfolio pipeline ongoing phase iii trials public health challenges approximately integrase inhibitor dolutegravir medicines million people worldwide living hiv million died comprehensive approach improving distinctive operating aidsrelated illnesses access medicines countries hardest hit hiv remains critical model enables however scientific progress improvements viiv healthcare multifaceted global public health programmes flexible responsive access medicines approach covers commitments universal access countries including middleincome needs hiv created improvements quality countries lowincome countries least availability care community developed countries subsaharan recent years multiple new market africa lowincome least entrants increasing number developed countries subsaharan generic competitors usa africa people europe hiv treatment remains hiv currently live viiv healthcare competitive dynamic marketplace offers royaltyfree voluntary licences turnover notforprofit pricing middleincome performance countries approach case bn viiv healthcare independent bycase basis taking account company focused hiv founded local needs tieredpricing policy growth gsk pfizer grew reported turnover based gross domestic product cer billion burden epidemic improve performance driven primarily affordability growth brands epzicomkivexa viiv healthcare made great progress selzentrycelsentri strong community partnerships performance brands connections collaborations operating profit also complemented later broader hiv community positive anticipated entry generic form action vida digna programme central epivir usa softened america tackles stigma expected decline sales among viiv discrimination communities growth healthcares mature product portfolio vulnerable hiv continues grow cer sales epzicomkivexa grew covered five additional countries million sales selzentry usa positive action southern celsentri million growth initiative extended total driven eight states additionally support breakdown turnover increasing earlyline use usa global effort reduce motherto broader uptake genotypic tropism child transmission hiv viiv testing europe expansion selzentry healthcare broadened reach celsentri also continued regions scope donations positive action firstline usage launch japan children fund pacf see responsible market authorisation russia business expansion reflects important strategic focus viiv healthcare international markets countries growth excluding europe north america cer growth continues build combivir epivir key focus region epzicomkivexa establish strengthen local lexiva partnerships example selzentry partnership jsc binnopharm trizivir deliver local secondary manufacturing number viiv healthcare antiretroviral products russia gsk annual report grow diversified global business continued sales performance disclosing reconciliation reported turnover underlying turnover excludes pandemic products avandia valtrex set believe underlying measure reported turnover assists shareholders gaining clearer understanding turnover performance growth underlying prospects size nature loss sales products growth shows growth cer clearly group turnover pandemic products avandia valtrex operational performance underlying group turnover business growth cer pharmaceuticals vaccines turnover pandemic products avandia valtrex underlying pharmaceuticals vaccines turnover growth cer pharmaceuticals turnover pandemic products avandia valtrex underlying pharmaceuticals turnover growth cer vaccines turnover pandemic products underlying vaccines turnover sales products geographic region segment emerging trading usa europe markets asia pacific japan unallocated total pandemic products avandia valtrex emerging trading usa europe markets asia pacific japan unallocated total pandemic products avandia valtrex gsk annual report strategic review strategy growth deliver products value overview changed rd organisation better able develop sustain industryleading pipeline products offer valuable improvements treatments patients healthcare providers increased level externalisation research allowing us access new areas science share risk development partners also made decisions earlier around pipeline progressions medicines believe significantly differentiated existing therapies progressed ensuring early stage research investments made science suggests greatest opportunity created smaller agile groups scientists accountable progressing projects discovery development underpinned focus improving rates return rd rigourous allocate investment across pharmaceutical vaccine consumer healthcare rd progress confident right model improve rd productivity returns past four years new drugs vaccines approved usa peers sustained significant latestage pipeline around assets signs recent review discovery research gives us confidence replenish pipeline ongoing basis gsk annual report priorities progress contribution sales new products performed bn total sales products launched past five years excluding pandemic vaccine grew bn investment rd performed proportion investment latestage portfolio continues grow total rd expenditure remains relatively flat new product approvals performed gained product approvals usa benlysta potiga horizant improving returns rd sales new pharmaceuticals vaccines products growth bn cer pharmaceuticals rd expenditure bn bn discovery development bn new product approvals usa new drugs vaccines approved usa last years projected rate return performed encouraged progress projected rate return investment rd track reach longterm goal gsk annual report strategic review deliver products value continued investment rd research primary goal rd develop costs incurred stage carefully innovative new medicines safely managed maximise likely future development critical efficiently concentrating return consistent overall ensuring developing new medicines offer objective increasing irr significant improvements existing rd activities current level sustainable business treatment options therefore returns generated however primarily provide value patients determined eventual commercial continue pay medicines impact new products achieve offer new medicines regulatory approval launched people work rd vaccines consumer majority based large rd start marked beginning centres uk usa spain belgium critical twoyear period products help china pharmaceuticals vaccines pipeline people live longer end expect split rd budget reported phase iii data latestage healthier lives pharmaceuticals vaccines consumer assets discuss progress healthcare aim allocate rd following pages details expenditure consistently across latestage development pipeline made areas levels investment highlights based see best pharmaceutical vaccine assets set pages full data received nine opportunities market pipeline chart pages science rather fixed phase iii assets website proportion sales total rd investment held constant rate return rate return rd investment rises pharmaceuticals vaccines discovery development process remain focused improving long expensive uncertain returns investment rd possible predict projects became first major pharmaceutical rd expenditure allocation succeed fail risks inherent company publish internal rate rd process described fully return irr rd investment risk factors section risk indicate value realised rd deliver commercially investment choices within successful products rd organisation rd expenditure early estimated rate major restructuring billion return investment made monetary terms amount recently launched latestage pipeline remained relatively flat past three approximately years however working updated analysis calculate pharmaceuticals reduce fixed costs rationalisation rate return increased vaccines infrastructure reinvest equivalent basis track consumer healthcare surplus back discovery deliver longterm goal improve major restructuring development research also returns around shifting balance spending projected rate return includes early stage projects fund growing products launched january late stage pipeline rd expenditure compounds phases iib iii discussed sections follow development process calculation respect three businesses based actual sales financial review forecast sales relevant products allocate rd investment adjusted reflect expected reference potential returns failure rates broadly line available target therapeutic standard industry failure rates markets technical cost base used calculation commercial risks associated products comprises estimate attributable rd pipeline factors reviewed costs actual projected milestone phase development process payments appropriate estimated central decision proceed profit margins capital investment next stage working capital requirements factored calculation based historical performance gsk annual report deliver products value continued pharmaceuticals rd successful pharmaceuticals rd therapy areas reviewed expenditure billion identify scientifically promising longterm need major restructuring areas drug discovery move investments people work pharmaceuticals organisation static culture rd business view research reinvestment existing areas making pipeline projects early stage discovery late result therapy area rebalancing stage development process changed business model lead new medicines moving away industrial launched three new valued sized therapy groups smaller agile medicines benlysta treatment focused discovery performance units patients systemic lupus erythematosus horizant dpus scientists dpu works treatment moderatetosevere pay treatments particular disease pathway restless legs syndrome trobaltpotiga responsible potential new medicines adjunctive treatment epilepsy early stage clinical trials since new medicines completion phase lla highlights vaccines approved usa part new model dpus three newly approved medicines new molecular entities given budgets threeyear benlysta horizant trobalt pharmaceutical window complete specific tasks company year active period early stage progress reviewed business plans dpu identified latestate pipeline activity data seven new collaborations signed specific targets investment across nine latestage medicines announced multiple years plans also included anticipate sufficient opportunities collaboration data inhouse file promacta pharmaceutical rd investment external organisations large hepatitis c relovair copd small companies academia mek inhibitor new potential treatment internal rd expertise gives us strong melanoma basis identifying forming year also saw failure collaborations drug discovery termination otelixizumab type typically inlicensing diabetes overall balance acquire ownership asset progression versus failure positive development commercialisation expect complete optionbased development programmes another exclusive opportunity license asset five latestage assets indications depending performance different development stages discovery pharmaceuticals rd development spending remained relatively flat original business plans dpu f acilities central support shifting investment initially reviewed discovery discovery development reflect investment board dib panel created increasing number latestage assets advise investment decisions dib portfolio proportion total evaluated proposals identified areas expenditure made development improvement suggested agreed latestage portfolio continues grow progress targets investment levels membership dib comprises senior management rd commercial discovering new medicines external individuals expertise early stage rd drug discovery areas life science investment seeks identify biological targets payer perspectives chaired svp involved development medicines discovery development diseases create small threeyear mark dpus molecules biopharmaceuticals reached progress interact disease targets dpus reviewed dib ultimately leading new medicines approach driven assessments wide range scientific discoveries potential returns investment makes essential highly scientific quality opportunity selective invest drug discovery resources focus areas consider likely lead significant medical advances gsk annual report strategic review deliver products value continued pharmaceuticals rd continued early stage investment startup companies make pitch venture capitalists funding discovery performance units dpus gsk demonstrate value business plans reviewed discovery investment board dib budget dpus presented remained relatively flat progress threeyear plans dib funds allocated shifting based scientific quality spend discovery opportunity potential returns investment result dpus development reflect grow others shrink close increasing number new dpus created latestage assets portfolio external discovery engines external discovery engines compared enhances discovery efforts opening new areas science us sharing risk partners hope reduce time get breakthrough clinic uaennobrahc erreip gsk annual report overall review positive portfolio investment board pib scientific review board srb led new investment allocations replaced pipeline governance boards governing body accountable discovery research result four assessing technical commercial scientific assessment rd portfolio new dpus created three investment case project support investment decisions made closed remaining dpus progress development pib pib srb establish view six received increased investment cochaired chairman rd overall scientific promise five investment decreased president north america asset development plan deliver pharmaceuticals includes heads asset cost effectiveness clinical across rd form alliances pharmaceutical region along plan opportunities risks likely external organisations accelerate head global manufacturing product profile gaps evidence discovery new medicines well missing remains uncertain share scientific understanding pib accountable investment ultimately improve patient care decisions funding allocation across two important signed seven new collaborations latestage pharmaceutical rd governance boards rd taking us alliances medicines discovery development technology investment board makes external groups complement biopharm rd oncology stiefel rare investment decisions new platform internal discovery units diseases emerging markets rd technologies licencing options allows investment decisions based collaborations point individual discovery project made holistic way ensuring entry clinical trials new product annual expenditure balance diversity assets differing supply board governing body total annual rd expenditure risk profile novelty opportunity accountable technical feasibility decisions investments continue development cost potential infrastructure assessments covering made science presents reimbursed payers aspects physical product compelling case remains supply chain need new treatments projects reviewed pib three key decision points commit medicine gsks chief medical officer chair developing medicines patients development commit phase iii global safety board accountable compound advances latestage commit file launch funding overseeing major decisions rd development typically generally allocated next regarding patient safety global phase iia undergo much larger scale key decision point typically safety board responsible approving studies humans investigate two four years ahead pib also pivotal studies investigating efficacy safety time carries annual latestage funding issues related patient safety arising work optimise compounds review investment projects development programme physical properties formulation reviewed adjusted necessary postlaunch information gsk produced efficiently prioritised individual latestage clinical trials available clinical sufficient quantities project incurred annual expenditure study register gsks website manufacturing process convert total annual wwwclinicaltrialsgov results activities file rd expenditure announced submission regulatory agencies governance developing global regulatory board medicine development teams enhance compliance company changes made rd small units people wide standards make regulatory services governance structure ensure clearer responsibility compound efficient agile align accountabilities oversight strategic later stages development filing capabilities business needs global issues overall budget management regulatory agencies local levels led across rd owned rd assets latestage development new role chief regulatory officer executive team dib pib control comprising individual investment decisions early late projects stage rd described previously also actively seek opportunities add products latestage portfolio alliances companies latestage assets typically take form inlicensing deals copromotion arrangements companies likely aligned existing areas therapy expertise investment gsk annual report strategic review deliver products value continued vaccines consumer rd vaccines rd invested nearly million vaccines rd investment vaccines rd increased since line centred discovering scientists working investment high growth areas developing development new vaccines discovery research prophylactic currently around vaccines discovery development new development range diseases vaccine complex process requiring therapeutic vaccines malaria tuberculosis longterm investment typically takes cancer currently four vaccine protect people years develop new vaccine candidates late stage development infectious diseases trials zoster malaria quadrivalent vaccine discovery begins identifying influenza vaccine therapeutic new antigens specific cancers chronic vaccine magea also two structures pathogens viruses bacteria disorders vaccine candidates regulatory filing parasites cancer cells meningitis menhibrix recognised immune system nimenrix usa europe produce pathogens yeast bacteria mammalian cells highlight vaccines rd genetically manipulate results adjuvanted key highlights malaria vaccine candidate rtss purified formulated vaccine antigen creates phase iii study conducted seven filings usa europe bodys immune response countries africa years work menhibrix nimenrix presented promising results often work academia phase iii data announced initial phase iii data candidate biotech industry identify malaria vaccine see milestone malaria new vaccine antigens cases formulation vaccine clinical rd effort focused lots involves mixing antigens gsk development new prophylactic proprietary adjuvant systems therapeutic vaccines alongside lifecycle management vaccines already market consumer healthcare rd people uk usa examples innovation included developed drive differentiating india china dedicated oral healthcare business speedofaction claim aimed rd efforts consumer healthcare launched new breakthrough alleviating stronger pain invested million dental care sensodyne implementing new million repair protect repair protect programmes increase flow pace developing sustainable flow new formulation first everyday value innovation portfolio scientificallydifferentiated products fluoride toothpaste contain aligned new fastmoving innovation portfolio critical patented novamin technology consumer healthcare model element consumer healthcare nutrition category developing strategy include new expanded products offered model aims combine industry technologies formulations well maxinutrition range include leading scientific capability product line extensions also maximilk chocolate strawberry superior consumer insights develop carry ongoing research assess three new flavours cyclone valuedriving global pipeline efficacy value products one muscle growth shake gsk across four newly formed global make validated claims acquired maxinutrition makes categories oral health wellness consumers products based around protein nutrition skin health enhanced functional nutritionals innovation products launched beginning year also established new past three years contributed sales million n otc continued roll global regulatory structure whereby consumer healthcare sales key panadol advance across markets local regulatory staff report centrally contributing products included launched panadol extra advance enabling us drive rapid sensodyne repair protect uk brands contain efficient rollout innovation sensodyne rapid relief horlicks optizorb superior patented biscuits panadol extra advance dissolution technology gsk annual report vaccine manufacturers use adjuvants milestone malaria improve specific immune systems response antigens contained vaccines innovating area years work adjuvant systems years milestone development malaria vaccine candidate proprietary adjuvant systems rtss reached combine adjuvants give publication phase iii data appropriate immune response showed vaccine provided young specific antigen expertise allows us african children significant understand combinations protection clinical severe antigen adjuvant system help malaria acceptable safety body mobilise effective tolerability profile trials immunological pathway provide continuing data infants aged maximum protection specific weeks expected end diseases targeted populations read corporate candidate vaccines usually responsibility report combination several antigens final composition vaccine antigens adjuvant may change time preclinical research usually takes two five years failure discovery process relatively low failures likely later stage clinical trials around candidates expected fail well discovery new vaccines early development projects rd supports latestage projects inclusion new antigens existing vaccines create new generation vaccines traditionally vaccines used prevent illness however pioneering different approach antigen specific cancer immunotherapies ascis approach designed programme bodys immune system fight existing diseases represents new treatment model therapeutic vaccine five key decision points board overall view evaluating asci concept vaccine development process commit projects early advanced projects variety tumour types research decide invest resources vdcbs core members come early clinical development commit across organisation vdcb governance phase iii registration launch recommendation progress project revised organisation commit lifecycle management submitted vib vaccine discovery development consider whether pursue next vib final decision whether teams simplify infrastructure generation product extend invest project taking account focus timely decisionmaking viability product scientific commercial perspectives enhance clarity accountability oversight key decisions rests reviewed vdcb vib evaluates vaccines research development led two bodies vaccine development public health benefit business project teams vaccine leadership commercial board vdcb opportunity development costs teams responsible day vaccine investment board vib risks project timing overall today progress including identifying vdcb reviews research project evolution portfolio vaccines developing new products strategy advises scientific vib also responsible assessing technical commercial feasibility overall fit project vaccines portfolio sppihw mot gsk annual report strategic review deliver products value continued late stage pipeline summary full diverse product development pipeline highlight projects comprising new chemical entities biological entities vaccines new combinations new indications existing compounds phase iii filed approval recently approved advanced status shown includes approvals assets moving phase iii approvals usa eu development registration january terminated crohns disease b enlysta belimumab systemic lmorexant primary insomnia lupus erythematosus usa eu olutegravir sgsk telixizumab type diabetes abacavir sulphate lamivudine robaltpotiga retigabineezogabine r evoladepromacta eltrombopag hiv infections epilepsy partial seizures usa chronic liver disease induced eu dabrafenib metastatic thrombocytopaenia melanoma h orizant gabapentin enacarbil v otrient pazopanib tykerbtyverb restless legs syndrome usa trametinib metastatic lapatinib inflammatory breast melanoma cancer vilanterol copd vodart dutasteride reduction risk prostate cancer duchenne muscular dystrophy asthma key phase iii large comparative study compound versus placebo andor established treatment patients establish clinical benefit safety filed following successful phase iii trials file product approval regulatory authorities approval approval granted begin market medicine vaccine full pipeline pages website inlicence alliance relationship third party gsk annual report phase iiiregistration pharmaceuticals vaccines pipeline summary therapeutic area compound indication phase iii filed approved biopharmaceuticals albiglutide type diabetes arzerra ofatumumab chronic lymphocytic leukaemia first line therapy arzerra ofatumumab diffuse large b cell lymphoma relapsed patients arzerra ofatumumab follicular lymphoma refractory relapsed patients benlysta belimumab systemic lupus erythematosus sc benlysta belimumab systemic lupus erythematosus iv xgeva denosumab bone metastatic disease cardiovascular metabolic darapladib atherosclerosis immunoinflammation crohns disease infectious diseases relenza iv zanamivir influenza neurosciences ipx parkinsons disease horizant gabapentin enacarbil postherpetic neuralgia horizant gabapentin enacarbil restless legs syndrome trobaltpotiga retigabine ezogabine epilepsy partial seizures oncology dabrafenib metastatic melanoma trametinib metastatic melanoma revoladepromacta eltrombopag hepatitis c induced thrombocytopaenia tyverbtykerb lapatinib breast cancer adjuvant therapy tyverbtykerb lapatinib gastric cancer tyverbtykerb lapatinib head neck squamous cell carcinoma resectable disease votrient pazopanib ovarian cancer maintenance therapy votrient pazopanib renal cell cancer adjuvant therapy tyverbtykerb lapatinib metastatic breast cancer combination trastuzumab votrient pazopanib sarcoma respiratory copd immunoinflammation vilanterol copd asthma vilanterol copd relovair vilanterol asthma relovair vilanterol copd paediatric vaccines mosquirix malaria rtss malaria prophylaxis plasmodium falciparum menhibrix hibmencytt neisseria meningitis groups c haemophilus influenzae type b disease prophylaxis nimenrix menacwytt neisseria meningitis groups c w disease prophylaxis vaccines zoster herpes zoster prevention flu pre pandemic prepandemic pandemic influenza prophylaxis flu vaccine seasonal influenza prophylaxis pumarix pandemic influenza prophylaxis antigen specific cancer magea treatment melanoma immunotherapeutic asci magea treatment nonsmall cell lung cancer rare diseases duchenne muscular dystrophy adenosine deaminase severe combined immune deficiency migalastat hcl fabry disease dermatology duac low dose acne vulgaris sorilux mild moderate scalp psoriasis tazarotene foam acne vulgaris hiv dolutegravir sgsk hiv infections dolutegravir sgsk abacavir sulphate lamivudine hiv infections inlicence alliance relationship third party gsk annual report strategic review strategy growth simplify operating model overview business continues change shape transforming operating model reduce complexity improve efficiency past three years implemented global restructuring programme designed deliver significant savings support investment higher growth markets well offset significant pressures savings derived improvements manufacturing operations consolidation streamlining support functions increased efficiencies rd progress date restructuring programme taken billion annual costs business identified annual savings approximately million brings total annual savings expected programme billion restructuring programme also allowed us reduce spending global functions since aim streamline organisation significantly reduced footprint manufacturing pharmaceuticals rd since gsk annual report priorities progress restructuring savings performed bn restructuring programme introduced continues deliver savings expected annual savings cost billion realise annual bn savings billion time complete rd footprint performed making pharmaceuticals rd operations efficient centralising activities reducing fixed costs possible bn manufacturing footprint performed seeking create streamlined global manufacturing function exited four sites year added one business acquisition support functions costs performed reduced support functions costs since bn annual savings pharmaceuticals rd footprint rd footprint support functions costs bn bn pharmaceuticals consumer healthcare manufacturing sites sites gsk annual report strategic review simplify operating model continued reducing cost increasing efficiency made substantial transformation operating biggest cost savings model reduce costs complexity programme generated progress objective improve efficiency continued manufacturing rd support simplify operations significant savings generated function organisations restructuring programme reduce inefficiencies reinvested back within rd focused reducing fixed costs rationalisation business used offset pressure infrastructure footprint resulting loss sales generics pharmaceutical rd footprint usa europe cut past three restructuring business years key element reshaping period manufacturing business implemented organisation achieved annual highlights global operational excellence oe savings approximately annual restructuring savings restructuring programme million restructuring initiated end rationalising network streamlining billion achieved operating model improving global support function spending met original target site performance since compared billion annual cost savings exited manufacturing sites including identified additional selling closing four factories annual savings approximately reduced total number million bringing total annual manufacturing sites savings expected programme billion programme expected cost billion reduced costs recycling pilot project recycle waste plastic track provide million carbon rebates reduced shipping costs next year time cutting carbon footprint project kicked uk ribena bottling plant converts postindustrial plastic waste sites material used make new bottles coleford site used tonnes rpet recycled polyethylene terephthalate last year bottling ribena time manufacturing sites uk france producing tonnes waste material suitable recycling disposal pet trays used delivery materials initial results suggest reduce raw materials ribena bottles annually addition anticipate cut tonnes annual carbon dioxide emissions reductions shipping costs material use skoorb egroeg gsk annual report third key source savings global manufacturing supply oe programme global support functions finance hr facilities reporting network sites announced intention functions centralised countries global manufacturing build new manufacturing allow better budgetary oversight supply gms responsible facility uk supply control significant savings since producing delivering medicines biopharmaceutical products subject generated including greater consumer products around world introduction patent box use shared services outsourcing legislation uk government people work within facilities example facility could built one gms network internal outsourced technical workplace four existing gsk sites barnard external manufacturing sites helps us security three global vendors castle ulverston north compete large range markets reducing costs almost england irvine montrose ensuring patients customers scotland representing overall support function costs receive quality products fair prices investment several hundred reduced compared supply chain model designed million pounds key objective oe programme ensure supply quality security gms comprehensive global release resources invest behind products every region anticounterfeiting strategy growth strategy significant portion world closely monitor industry leader anticounterfeiting savings generated therefore delivery products ensure packaging features holograms reinvested business areas offer customers never security seals complex background potential future profitable growth stock medicines products patterns difficult emerging markets vaccines need photocopy scan consumer healthcare similarly savings rd fixed costs reinvested back discovery part achieved reducing number packs skus development research implementation service delivery europe japan model focused partnering emerging markets balance savings gsk business units standardisation focused standardising remaining used offset pressure increase productivity pack formats improve packaging group margin resulting loss businesses time focus efficiency costs significant sales usa europe operations performance rather generics period addition manufacturing coordinating internal processes organisation actively seeking improve conscious impact standardisation data systems procurement processes particular employees changes outlined provide better decisionmaking purchasing active ingredients remain committed information chemical intermediates packaging full consultation via internal forums key enabler delivery benefits components partfinished external groups appropriate cbs enterprisewide finished products releasing possible attempted enterprise resource planning erp cost efficiencies allowing us reduce redeploy affected employees system significant investment working capital parts business making global erp programme consumer healthcare business focus simplification next five years enable cbs redesigning supply chain create standard business processes systems next years plan form integrated endtoend process data support growth build infrastructure footprint aligned customers change agenda across multiple businesses rationalisation already achieved commercial operations part erp programme simplify business business process also converting countrybased commercial configured support highgrowth following support function centralisation systems single sap system regions emerging markets early created core business replacing numerous fragmented non changes expected reduce cost services cbs group direct standardised applications freeup working capital streamlining economies scale system went live germany elements global support european pharmaceuticals marking start erp deployment functions services provided vaccines supply chain also across whole gsk businesses standardised redesigned simplify operations implemented changes consolidate distribution locations first year cbs delivered supply chain processes help supply reduce inventory increase service levels promising early results expect chain efficiency significantly cut operating costs see savings next simplified product portfolio three years gsk annual report strategic review financial architecture one key objectives established new financial expect groups core operating architecture aligns planning margin begin improve gradually deliver execution performance measurement improvement sustainable sales growth order maximise financial returns next two three years rate strategy designed drive extent depend new financial improvements operating margin precise mix businesses greater financial efficiency enhanced delivery rate pipeline architecture designed cash conversion sales growth drive sales growth high margin enhance returns focused delivering innovationled markets shareholders drive stronger growth addition improving core earnings per share better free cash operating margin enhancing strategy generation expected cash flow financial efficiency also key driver enhanced cash conversion earnings cash flow growth available dividends share buybacks reviewed manage reinvestment business cash balances relative debt depending returns portfolio sources debt attractive access intend make number sales growth changes believe taking advantage current interest rates well one key objectives strategy reducing cash balances delivery sustainable broadly reduce effective net interest cost sourced sales growth reported sales result overall effective financing fell year last two rate expected reduce years delivered average annual underlying sales growth move expect underlying tax second area sales growth translate reported opportunities improve efficiency sales growth sales headwinds shape group changed loss sales avandia valtrex materially recent years pandemic products diminish aligning tax strategy tightly changing shape operating leverage financial identified opportunities allow efficiencies us reduce tax rate also want drive operating leverage approximately beginning financial efficiencies business approximately order maximise operating made good progress profit earnings cash generated reducing tax rate sales growth remain excluding disposal quest focused managing cost base effectively improving financial efficiency throughout organisation gsk annual report financial architecture drive returns sales growth eps operating leverage focus focus returns returns returns shareholders financial efficiency free cash flow cash flow growth cash conversion earnings cash flow generation returned free cash flow shareholders paid billion also see significant opportunity sales growth operational leverage greater dividends ordinary dividend enhance cash conversion greater financial efficiency cash conversion grew p addition bought focus cash generation capital together drive enhanced earnings back billion shares part allocation per share free cash flow long term programme started last year support objective enhancing particular focus working also return proceeds returns shareholders strategy capital programme sale noncore north american otc reduced cash conversion cycle free cash flow expected brands shareholders via supplemental days working capital enhanced cash charges dividend p payable fourth percentage turnover associated longstanding quarter ordinary dividend focused delivering restructuring programme continue expect deliver continued improvements cycle decline free cash flow also dividend growth addition given medium term expected benefit demand current market conditions intend cash fund previously announced legal repurchase billion shares settlements diminishes reduction working capital measurement reporting cash conversion cycle focus return investment returns shareholders improved financial reporting days align closely financial cash generated deployed invest architecture providing business deliver returns data insights progress shareholders making businesses improved capital allocation regions progress process consistently key drivers operational rigorously based return investment financial efficiency starting metrics particularly cash flow return transitioning reporting core investment cfroi basis enabling greater visibility able benchmark opportunities underlying performance business internal external investment across details transition core business consistently reporting provided returns available share buyback returns shareholders gsk annual report strategic review responsible business believe recognise research recognise many barriers development manufacture sale obstacles path better health responsible business products raise ethical issues committed finding new good gsk aim open innovative ways tackling address also understand working partnership others society helps us important communicate challenging way things groups individuals business prepared change way create products affects seek understand views business aim find innovative patients healthcare transparent setbacks solutions create value society experience well progress well shareholders allow us payers need value made successful sustainable business also helps us operate growing business access healthcare developing world efficiently gain culture ensures decisions easy solutions guided values commit challenge providing sustainable access trust stakeholders transparency show respect people healthcare developing countries demonstrate highest integrity foster right poverty single biggest barrier conduct patientfocused many countries people conditions growth grow business sustainable enough food access supply clean business responsible way focus four areas water also access hospitals clinics provide professional help health helping improve treatments challenges make peoples health wellbeing important contribute regardless live ability pay committed playing full part people communities working addressing healthcare challenges support development people developing world taking communities around world innovative responsible sustainable behaviour behaving open approach gsk making contribution honest manner developing country healthcare guided values number areas include planet growing business tiered pricing vaccines protecting natural resources medicines capped prices least need future developed countries ldcs board committee chaired investing rd targets diseases chairman regularly particularly affecting developing reviews companys cr policy world performance details given flexible intellectual corporate responsibility committee property pursuing open report innovation strategy approach key areas community investment activities follows also publish information approach performance partnerships foster effective healthcare capacity building corporate responsibility report found website seeking innovative partnerships report published march solutions including reinvestment profits healthcare infrastructure health ldcs working make medicines preferential pricing viiv healthcare vaccines consumer healthcare access medicines index antiretrovirals hivaids products available affordable comprehensive approach many people need helped us rated leader possible irrespective live biannual access medicines ability pay aim generating return need atm index published atm able sustain business invest foundation research new products gsk annual report vaccines developing world organisations unicef pan american health organization paho gavi alliance helping save childrens lives protect peoples health increasing access immunisations poor countries leading vaccine supplier organisations billion vaccine doses business shipped went developing countries including least developed low middle income countries june offered supply million doses rotavirus vaccine rotarix gavi per dose small fraction developed world prices also supply million doses pneumococcal vaccine synflorix gavi heavily discounted price help expand immunisation programmes developing countries also signed agreement supply synflorix cervarix rotarix paho expanding protection women virus leads cervical cancer protecting children pneumonia gastrointestinal diarrhoeas cause rotavirus continue build also october became founder product pricing partnership member wipo research commitments help improve healthcare consortium group developing world report companies academic institutions fully progress corporate government research bodies established responsibility report provide access intellectual property highlights follow pharmaceutical compounds technologies importantly october published encouraging knowhow data available research initial phase iii results malaria development neglected tropical vaccine candidate showed diseases tuberculosis malaria reduces malaria half young african children aged months sppihw mot gsk annual report strategic review responsible business continued tres cantos open lab opened people communities employees region spanish medicines investing people communities development campus dedicated research diseases developing help us ensure longterm sustainability business world end year employment practices designed seven projects visiting scientists help us create right workplace culture developed employees feel valued developing world respected empowered inspired significant increase resources also want many communities global community still needed work prosper business support rd provide access usa grows community investment resultant medicines vaccines europe sustainable progress made strengthens business supporting emerging markets local economies operate asia pacific significant barriers stand helping us build relationships based japan way better access healthcare mutual understanding also boosting tackled shared responsibility employee morale sectors global society governments international agencies charities academic recruiting developing institutions pharmaceutical industry engaging employees business evolves others changes affect employees want gsk employer choice remain committed consulting investing significantly changes via number talent development every level internal consultation forums well recruiting developing engaging discussions european works employees critical meeting council similar bodies countries sustaining business objectives national practice overall performance assessment processes aligned core set diversity gsk competencies ethics focus creating inclusive integrity central engaging environment empowers take global view talent employees continually contribute strategic capabilities looking organisation enables us quality depth breadth talent achieve strategic business objectives across world strive good inclusive environment good succession plans place critical business brings different positions across organisation knowledge perspectives experiences proactive initiatives place recruit working styles enhance creativity specialist leadership talent innovation aim attract maintain robust leadership strategy diverse workforce reflects identify develop highly skilled communities operate leadership group offer employees proportion people employ range learning opportunities emerging markets asia pacific japan tailored development programmes growing increasing performance development total employees planning process means employees around senior managers businessaligned objectives report executive team also come behavioural goals reward systems regions focused promoting high performance helping attract retain best people performancebased pay bonuses visiting scientists working sharebased equity plans align employee interests business targets projects tres cantos open lab gsk annual report committed employment policies free discrimination environment tolerate harassment discrimination actual perceived race colour ethnic national origin age gender sexual orientation gender identity andor expression religion belief physical abilitydisability andor chronic health conditions genetic makeup protected characteristics relevant country healthy highperforming workforce zero harm meet mission strategy employee health safety initiatives focus factors enable employees perform highest level sustaining energy engagement drive towards zero harm workplace provide resources tools programmes employees support adopting healthier lifestyles managing pressures work life available many languages range options immunisations smoking control weight management process safety cuttingedge programmes team personal resilience ergonomics driver safety energy performance companywide programme living safety designed build culture zero harm goal serious environment health safety incidents positive action children fund support global effort eliminate mothertochild transmission hiv viiv healthcare broadened reach scope donations positive action children fund pacf one highlight programme grant care international future project seeks empower communities address effects sexual violence reduce stigma north kivu democratic republic congo promotion services empowerment communitybased campaigns ground another highlight new million small grants scheme supporting community based projects countries across globe projects selected receive funding effort specifically aimed improving health welfare women children families affected hiv viiv healthcare see dnuf noitacude utnubu gsk annual report strategic review responsible business continued work communities programmes support designed behaviour longterm sustainable impact investment communities commitment responsible values set ambitious commitments aim improve health education based business underlies everything work experienced partners also increase access medicines strong policy encourage employees get involved healthcare services targeting support compliance programmes expect volunteering initiatives needed standards suppliers orange day programme contractors business partners approach includes funding longerterm pulse scheme importantly building innovative programmes improve global community investment stronger culture based values health community engagement million overall giving transparency respect people behavioural change donating remained constant excluding integrity patient focus medicines expertise reinvesting donation million doses hn profits improve healthcare recognise need open vaccination total infrastructure also invest science includes donations products worth education support relief efforts challenges face million value using following natural disasters average cost goods rather know research maximise benefits higher wholesale acquisition price development manufacture sale community investment working believe accurate reflection products raise ethical issues partnership nongovernmental true cost gsk must meet consistently high quality organisations selecting projects ethical standards research product donation primarily made enable us apply expertise development parts business three programmes patient resources countries operate assistance programs million recognise aspects well benefiting communities humanitarian product donations research raise ethical concerns investment strengthens business million donation albendazole including relating animal improving reputation boosting tablets lymphatic filariasis lf research studies experimental employee morale helping us elimination programme million medicines people build trust build relationships based mutual cash giving million also stakeholders meeting understanding range groups included total targeted expectations behaviour primarily health education transparent open challenge initiatives including reinvestment discussion profits make least developed countries back healthcare ethical conduct infrastructure million ethical conduct priority gsk failure uphold high ethical standards community investment cash donations erode trust company type allocated products damage reputation result serious financial legal consequences code conduct sets fundamental standards employees supported employee guide business conduct available languages helps employees make ethical decisions emphasis values internal compliance systems cash health designed identify address breaches product education codes reinforce gsks values kind arts culture continual external pressure management environment enhance systems compliance oversight internal audits helping drive change compliance programmes designed embed valuesbased culture gsk gsk annual report launched one compliance reflect commitment consistently carbon initiative improve consistency high standards sales marketing longterm vision entire policy implementation monitoring reviewed expanded global value chain carbon neutral across business units code practice promotion around carbon footprint different countries operate customer interactions code results supply chain fully investigate suspected breaches covers areas providing propellants released take appropriate disciplinary action information healthcare professionals inhalers including dismissal appropriate samples payments healthcare professionals gifts hospitality grants less fifth total impact zerotolerance approach donations deployed comes directly operations bribery corruption set sales marketing employees continue increase energy preventing corrupt practices policy trained revised code efficiency use renewable established antibribery energy sites also focusing corruption expert forum meets planet supply chain use weekly answer employee questions revised environmental products especially inhalers advise antibribery corruption sustainability strategy focusing issues members forum include began footprinting key carbon water waste environmental representatives legal products identify priorities stewardship compliance functions well external developed sitebased events operations also across full value consultants answers posted analyse local carbon reduction potential chain raw materials product intranet employees visit act opportunities disposal part strategy set reduced energy consumption ambitious goals key impacts operations greenhouse including reduction carbon gas emissions use inhalers footprint reduction water use rose across value chain zero waste landfill almost doubling mass efficiency efficiency use materials new pharmaceutical products aim carbon neutral across entire supply chain gsk annual report strategic review responsible business continued water aim reduce volume continued improve packaging use recycled materials understanding environmental water particularly important natural possible encourage impacts purchased resource recognise gsk consumers recycle use materials begun work play positive role managing revised green packaging guide key suppliers held detailed sustainably endorsed united help designers choose discussions leading suppliers nations ceo water mandate sustainable option began using developing carbon footprints materials working signatories waste plastic make ribena bottles using data improve develop disclosure methodology provide quarter environmental performance aim agree measure annual bottle requirement saving companys water impact across environmental management approximately value chain essential first step managing gsks total water impact tonnes co emissions year new environmental sustainability steering team responsible shaping reduced water consumption environmental stewardship environmental sustainability operations increasing efficiency strategy integrated waste use materials priority target business strategy realistic achieve mass efficiency new stretching manage environmental goal zero waste going landfill pharmaceutical products transferred issues well occupational health reduced waste rd manufacturing safety using management system generation operations longterm aspiration achieve aligned recognised international reduced waste sent landfill mass efficiency five times standards environmental health also year continued trials typical level pharmaceutical safety data subject external takeback scheme recycle used industry reduce input materials assurance read inhalers following success usa waste average mass environmental strategy performance extended initial trial co efficiency new products transferred corporate responsibility report operative supermarket chain uk manufacturing reached cutting carbon around carbon footprint comes propellants released inhalers year extended takeback scheme inhalers usa uk working pharmacists seek encourage patients return empty inhalers collect new one used inhalers recycled plastics sent remanufacturing remaining aerosol propellant reused nonmedical applications saving propellant avoided equivalent tonnes co emissions ssenne nai gsk annual report financial review use number adjusted measures report performance transition core measures reporting business measures used management planning reporting purposes discussions announced intention introduce core measures presentations investment analysts rating agencies operating profit earnings per share report defined measures defined ifrs may performance group onwards primary comparable similarly described measures used purpose approach remove volatility created companies various items impairment intangible assets legal charges asset disposal gains losses believe underlying turnover provide clearer view underlying performance core underlying turnover excludes sales pandemic products avandia business expect make us comparable valtrex believe underlying measure assists shareholders majority peers gaining clearer understanding turnover performance addition emerging markets asia pacific prospects size nature loss sales pharmaceuticals vaccines regions amalgamated products reconciliation presented one region segmental reporting purposes various free cash flow nonprescription stiefel brands transferred pharmaceuticals business consumer healthcare free cash flow net cash inflow operating activities less capital expenditure interest dividends paid noncontrolling brand names interests plus proceeds sale property plant equipment dividends received joint ventures brand names appearing italics throughout report associated undertakings free cash flow growth calculated trademarks either owned andor licensed glaxosmithkline sterling basis reconciliation presented associated companies exception benlysta trademark human genome sciences bonivabonviva working capital conversion cycle trademark roche levitra trademark bayer nicoderm working capital conversion cycle calculated number trademark elan johnson johnson merrell novartis sanofi days sales outstanding plus days inventory outstanding less glaxosmithkline potiga trademark valeant prolia days purchases outstanding xgeva trademarks amgen vesicare trademark astellas pharmaceuticals many countries yamanouchi white pills western markets pharmaceuticals certain countries volibris trademark gilead white pills western markets refers sales tablets simple xyzal trade mark ucb glaxosmithkline injectables excluding biopharmaceuticals vaccines north used certain countries licence group america europe revolaire trade mark glaxosmithkline group cer growth companies use brand name revolaire ffvi approved regulatory authorities around world order illustrate underlying performance practice discuss results terms constant exchange rate cer growth represents growth calculated exchange rates used determine results overseas companies sterling remained unchanged used previous year cer represents growth constant exchange rates represents growth actual exchange rates commentaries report presented terms cer unless otherwise stated gsk annual report financial review financial review continued risk financial review discusses operating financial group turnover geographic region performance group financial outlook financial resources compare results year primarily reported turnover underlying turnover results preceding year performance explained using growth growth growth growth cer cer variety measures review discuss results usa major restructuring basis total basis europe growth rates included financial review constant emerging markets exchange rates cer unless otherwise stated calculation asia pacific underlying turnover described japan group turnover division reported turnover underlying turnover cer represents growth constant exchange rates represents growth growth growth growth growth actual exchange rates turnover quarter given pages cer cer group sales outside usa europe accounted pharmaceuticals turnover reported sales growth underlying growth vaccines reflecting strong growth across three businesses pharmaceuticals geographic regions vaccines consumer healthcare group turnover segment reported turnover underlying turnover reported turnover declined underlying turnover increased reflecting underlying growth across three areas growth growth growth growth cer cer business pharmaceuticals vaccines consumer pharmaceuticals healthcare breadth mix product geographic vaccines portfolio helped us mitigate economic volatility year usa reported group turnover fell billion europe pharmaceuticals vaccines pharmaceuticals emerging markets vaccines billion consumer asia pacific healthcare sales billion sales pandemic related japan products avandia valtrex declined billion viiv healthcare million significant adverse impact trading reported pharmaceuticals vaccines sales growth regions unallocated pharmaceuticals underlying turnover growth pharmaceuticals vaccines vaccines consumer healthcare consumer healthcare underlying pharmaceuticals growth reflected contribution new products partly offset generic competition older usa pharmaceuticals vaccines reported turnover products usa europe increased impact declined underlying turnover flat contribution european austerity measures full year incremental impact new products offset competition older established sales european austerity price cuts us healthcare reform products europe pharmaceuticals vaccines reported approximately million growth underlying vaccines turnover fell underlying turnover declined sales primarily reflected strong performances cervarix result austerity price cuts mild flu season emerging synflorix rotarix consumer healthcare strong growth markets reported turnover grew underlying growth oral healthcare nutritional healthcare partly offset flat driven relatively consistent pharmaceuticals growth overthecounter sales year part reflecting dermatology acquisitions made strong vaccines growth underlying quarterly volatility due tender phasing reported vaccines sales emerging markets declined political economic uncertainties impacted performance number territories emerging markets gsk annual report japan reported turnover flat largest driver antivirals underlying growth cervarix asia pacific antivirals decreased billion sales growth reported turnover increased underlying growth impacted lower sales relenza million principally came respiratory products vaccines viiv compared significant sales related pandemic flu healthcare sales grew consumer healthcare sales grew addition valtrex sales continued decline result declines usa europe reflecting generic competition usa europe difficult economic conditions offset consistent strong million sales zeffix grew million growth rest world markets strong growth emerging markets offset small pharmaceuticals turnover declines markets growth growth central nervous system cns cer cns sales decreased billion performance respiratory primarily impacted decline seroxatpaxil sales antivirals million partially offset lamictal sales growth central nervous system million benefiting growth japan product cardiovascular urogenital sales doubled million continuing strong metabolic performance lamictal xr usa antibacterials oncology emesis cardiovascular urogenital dermatology cardiovascular urogenital sales increased billion viiv healthcare hiv primarily driven avodart franchise million launches new combination product duodartjalyn usa europe avodart japan pharmaceuticals turnover therapeutic area lovaza million volibris sales doubled million arixtra declined turnover declined billion growth million result start generic competition cardiovascular urogenital respiratory dermatology anti usa third quarter bacterials hiv oncology emesis offset declines metabolic antivirals central nervous system metabolic respiratory metabolic sales decreased billion primarily reflecting loss sales avandia addition sales boniva respiratory sales increased billion reflecting strong negatively impacted termination copromotion performances japan emerging markets asia pacific agreements certain european countries seretideadvair sales flat growth japan asia pacific offset small declines usa europe addition ventolin antibacterials grew million avamysveramyst sales antibacterial sales grew billion growth million category led sales augmentin emerging markets usa sales advair billion million category held back austerity price line estimated underlying growth year cuts mild flu season northern hemisphere volume decline partly offset positive impact price oncology emesis mix flovent grew million ventolin grew million oncology emesis sales increased billion reflecting strong growth new products votrient promactarevolade europe respiratory sales seretide sales arzerra together doubled million billion impact price reductions partly offset generic competition older products european governments offset volume increases votrient achieved total prescription share us emerging markets respiratory sales grew growth advanced renal cell carcinoma market headtohead data many products portfolio seretide sales flat eventdriven study comparing votrient million volume growth offset continuing current market leader sutent market share impact price cuts particularly russia turkey approximately expected votrient also regulatory review usa europe new indication softtissue sarcoma ongoing launches promactarevolade continued throughout sales outside usa grew million million sales usa grew million strong performances new oncology products partly offset impact generic competition usa hycamtin continued decline zofran fell million gsk annual report financial review financial review continued risk dermatology strong reported growth rotarix million primarily reflected impact product market dermatology sales grew billion reported growth part benefited addition sales businesses acquired late early offset effect sales fluarixflulaval million strong disposal zovirax north america q excluding growth usa million offset lower factors growth category growth emerging sales europe primarily due price cuts china markets benefiting ongoing launches stiefel sales products included within infanrix franchise declined products new markets offset impact price cuts million sales usa grew million europe generic competition evoclin usa helped cdc stockpile orders pediarix kinrix sales viiv healthcare hiv europe declined million primarily due price cuts sales emerging markets declined million primarily viiv healthcare sales grew billion usa result lower sales china europe emerging markets rest world growth primarily driven epzicomkivexa hepatitis franchise declined million largely million selzentry million partly offset result austerity price cuts europe reduced cdc funding decline mature portfolio million adult hepatitis immunisations well return us market competitor vaccine third quarter epzicomkivexa sales growth driven strong performance usa europe usa sales epzicom sales new pharmaceutical vaccine launches million reflecting relatively equal mix volume price growth volume growth europe growth growth cer benefited improved positioning regional local avamysveramyst guidelines kivexa continued grow japan mexico lamictal xr number developing markets asia pacific requip xl selzentry sales growth primarily driven increase treximet market share usa sales million coreg cr europe sales million duodartjalyn volibris decline mature portfolio including combivir promacta declined million primarily driven decline arzerra western markets result newer treatment options tyverbtykerb vaccines sales votrient cervarix growth growth rotarix cer synflorix total vaccines sales others vaccines sales excluding pandemic related products total sales new products launched since beginning excluding pandemic vaccines billion grew vaccines loss flu pandemic vaccine sales year resulted launches three new products underway decline reported vaccines sales billion excluding benlysta lupus launched usa part effect flu pandemic vaccine sales underlying sales grew global partnership human genome sciences inc reflecting growth cervarix synflorix rotarix product also recently introduced germany partly offset lower sales hepatitis franchise infanrix turnover million year reflects share gross profit impact changes pharmacopeia china usa total sales markets underlying vaccine sales grew strongly regions except trobalt adjunctive addon treatment partial onset europe sales declined reflecting austerity price cuts seizures form epilepsy seizure begins specific fewer tender orders cervarix area one side brain launched europe cervarix sales doubled million primarily additionally product approved fda reflecting national hpv vaccination programme japan brand name potiga following review us drug started end catchup vaccination cohort enforcement administration launch product expected japan includes five age groups majority vaccine first half support programme shipped horizant treatment moderatetosevere primary remainder due shipped early restless legs syndrome adults received fda approval year launch product underway synflorix grew million reflecting continued growth additionally august supplemental new drug arising tenders emerging markets application snda submitted fda requesting approval horizant management postherpetic neuralgia adults accepted october gsk annual report consumer healthcare turnover results major restructuring total results october board approved implementation growth growth cer detailed formal plan announced significant new overthecounter medicines operational excellence restructuring programme second formal oral healthcare plan representing significant expansion operational excellence nutritional healthcare programme approved board announced february expansion approved board announced february cer represents growth constant exchange rates represents growth actual exchange rates turnover quarter given restructuring programme comprising detailed formal plans covers areas business including manufacturing selling growth growth cer rd infrastructure savings identified usa year estimated total cost increased approximately europe billion expanded programme expected deliver row annual pretax savings approximately billion time substantially complete approximately expanded programme costs incurred december consumer healthcare sales grew billion compared approximately expected incurred estimated market growth markets majority balance incurred total approximately compete net impact acquisitions disposals costs expected cash expenditures significant expected asset writedowns excluding otc brands targeted divestment consumer given extent cost operational excellence restructuring healthcare sales grew approximately likeforlike basis programme believe material impact operating disposal north american otc brands completed results manner business conducted january sales brands million present restructuring costs incurred solely direct result result impact reported growth months operational excellence restructuring programme process divesting remaining noncore otc brands amounted million million separate continuing subject delivering appropriate shareholder value column income statement titled major restructuring otc medicines addition restructuring costs operational excellence programme major restructuring column income statement otc sales flat billion strong growth several includes restructuring costs incurred solely direct result subcategories offset decline alli panadol franchise restructuring programmes follow relate material registered growth gastrointestinal care core acquisitions operations acquired business overlap brands tums eno respectively extensively existing operations oral healthcare restructuring activities follow relate acquisitions oral healthcare sales increased billion led nature undertaken operational sensodyne continues benefit successful launch excellence programme also carried following detailed repair protect ongoing geographic expansion formal plan therefore consider appropriate present pronamel acid erosion business costs restructuring activities manner nutritional healthcare restructuring costs incurred direct result acquisition stiefel laboratories inc july million nutritional healthcare grew billion led strong growth million restructuring costs incurred direct horlicks combined inclusion maxinutrition february result acquisition reliant pharmaceuticals inc nutritional healthcare growth excluding maxinutrition acquisition since october meets criteria set regional performance charged paid strong growth rest world partly offset small results costs operational excellence programme declines usa europe rest world markets continued acquisitionrelated restructuring programmes meeting criteria lead growth increase sales growth particularly described also presented separate column income strong emerging markets africa middle east statement described results major restructuring china india latin america presentation adopted show clearly results costs restructuring programmes europe recorded decline sales largely result lower believe presentation assists shareholders gaining clearer sales alli respiratory health products partly offset understanding financial performance making projections inclusion maxinutrition range february future financial performance results include costs environment europe continues challenging result virtue size nature limited comparative value economic pressures competitive market dynamics presentation also consistent way assessed us sales decreased result temporary interruption financial performance nicorette gum supply decline sales alli combined difficult economic conditions outweighing strong growth sensodyne gsk annual report financial review financial review continued risk restructuring costs incurred solely direct result profit tax total results operational excellence programme restructuring total results include restructuring costs related operational programmes following reliant stiefel acquisitions excellence programme acquisitions reliant stiefel reported major restructuring column income statement growth restructuring costs principally arisen impairments cer property plant equipment termination turnover employment contracts staff made redundant part cost sales restructuring activities set note financial selling general statements major restructuring programme asset impairments administration staff redundancies together accounted million research million restructuring costs incurred reported development major restructuring column operating income remaining costs million arose operating profit miscellaneous expenditures incurred solely direct result restructuring programmes including termination cost sales leases accelerated depreciation site closure costs consultancy cost sales increased turnover project management fees costs include million reflected impact reduction higher margin sales associated proposed divestment noncore pandemic related products avandia valtrex together consumer healthcare brands costs arising effect regional mix impact us healthcare reform ongoing operating activities reported major european austerity price cuts adverse impacts partially restructuring column offset lower restructuring costs lower inventory writeoffs restructuring costs arise solely direct result greater savings operational excellence programme operational excellence programme restructuring selling general administration programmes following relating acquisitions meeting criteria described continue reported operating sga costs turnover compared expenses within results major restructuring costs legal costs million million primarily included restructuring costs related minor acquisitions arose additional charges year product liability million cost million income related cases regarding paxil poligrip products various restructuring activity initiated commencement government investigations reflect best estimates operational excellence programme none restructuring additional amounts expected necessary resolve activity material impact operating results disputes excluding legal costs sga costs manner business conducted turnover percentage points lower reflected lower restructuring charges ongoing cost savings including anticipated duration operational excellence operational excellence programme partly offset programme currently expect incur material impact reduction sales pandemic related products restructuring costs except related programme avandia valtrex us healthcare reform levy acquisitions meeting criteria described million continuing investment growth businesses new unanticipated material restructuring costs arise product launches period would expect include also major restructuring advertising promotion declined selling distribution declined general administration excluding legal operating profit profit taxation taxation profit increased collectively items accounted decline year discussed terms total results sga legal costs include major restructuring costs results major restructuring research development remain focused delivering improved return investment rd sales contribution reduced attrition cost reduction important drivers improving internal rate return rd expenditure determined percentage sales instead capital allocated using strict returns based criteria operations pharmaceuticals rd broadly split discovery activities completion phase iia trials development work phase iib onwards table analyses group rd expenditure categories gsk annual report profit disposal interest associates pretax profit disposal interests associates discovery million million tax primarily reflecting development disposal remaining shares quest diagnostics facilities central support functions pharmaceuticals rd share tax profits associates joint ventures vaccines rd share tax profits associates million consumer healthcare rd million arose principally groups holding rd major restructuring aspen pharmacare decline reflected disposal major restructuring shares quest diagnostics february total rd profit taxation total results proportion pharmaceuticals rd investment made latestage portfolio continues grow total taking account net finance costs profit disposal pharmaceuticals rd costs interest associates share profits associates total profit taxation million compared rd expenditure turnover compared million increase cer reflecting lower restructuring costs efficiency savings sterling terms reflected impact lower legal charges lower intangible asset impairments partly offset increased investment latestage pipeline profit tax results major restructuring operating income results major restructuring set operating income million million growth primarily comprising royalty income million cer million profits asset disposals million turnover million partly offset equity investment cost sales impairments million million restructuring selling general costs million nil associated proposed administration divestment noncore consumer healthcare brands research operating profit total results development operating operating profit restructuring charges million income million year ended december operating profit million increase cer sterling terms compared excluding legal costs million cost sales million operating profit million cost sales increased turnover compared increase cer terms sterling terms principally reflected impact reduction higher margin reflecting decline turnover lower cost sales lower sales pandemic related products avandia valtrex together rd expenditure higher operating income effect regional mix impact us healthcare net finance costs reform european austerity price cuts adverse impacts partially offset lower inventory writeoffs greater finance income savings operational excellence programme interest finance income selling general administration fair value movements sga costs turnover compared legal costs million million primarily finance costs arose additional charges year product liability cases interest costs regarding paxil poligrip products various unwinding discounts liabilities government investigations reflect best estimates remeasurements fair value movements additional amounts expected necessary resolve finance expense disputes excluding legal costs sga costs turnover percentage points higher reflected impact reduction sales pandemic related products net finance expense fell slightly million million avandia valtrex us healthcare reform levy reflected relatively stable levels net debt million continuing investment growth businesses groups strong cash generation funded share repurchases new product launches partly offset ongoing cost savings billion increased dividend payments including operational excellence programme advertising promotion declined selling distribution declined general administration excluding legal costs increased owing us healthcare reform levy collectively items accounted decline sga excluding legal costs gsk annual report financial review financial review continued risk research development profit taxation results major restructuring see table discussion taking account net finance costs profit disposal operating income interests associates share profits associates profit operating income million million tax major restructuring million compared primarily comprising royalty income million million cer increase million profits asset disposals million increase sterling terms million partly offset equity investment taxation charge impairments million million operating profit results major restructuring operating profit major restructuring million uk corporation tax uk statutory rate increase cer terms result lower legal less double taxation relief costs overseas taxation excluding legal costs million million current taxation operating profit million last year deferred taxation operating profit margin excluding legal charges taxation total profits operating income fell percentage points decline resulted loss sales tax profit major restructuring charges amounted higher margin pandemic products avandia valtrex adverse million represented effective tax rate regional mix austerity price cuts introduction us excluding impact tax disposal healthcare reform levy continuing investment growth quest shares tax rate approximately businesses new product launches partly offset ongoing benefited early realisation tax strategies cost savings including operational excellence programme continue believe made adequate provision net finance costs liabilities likely arise open assessments ultimate liability matters may vary amounts provided dependent upon outcome litigation proceedings finance income negotiations relevant tax authorities interest income fair value movements profit year growth finance costs cer interest costs total profit taxation unwinding discounts liabilities year remeasurements fair value movements total profit attributable finance expense shareholders basic earnings per share pence p p basic earnings per ads us net finance expense fell slightly million million results major restructuring reflected relatively stable levels net debt profit taxation year groups strong cash generation funded share repurchases results major restructuring billion increased dividend payments profit attributable shareholders profit disposal interest associate adjusted earnings per share pence p p adjusted earnings per ads us pretax profit disposal interests associates weighted average number million million tax primarily reflecting shares millions disposal remaining shares quest diagnostics diluted total earnings per share pence p p share tax profits associates joint diluted total earnings per ads us ventures diluted weighted average number shares millions share tax profits associates million million arose principally groups holding total results including restructuring costs produced basic eps aspen pharmacare decline reflected disposal p compared p eps major share quest diagnostics february restructuring year p compared p excluding legal charges eps major restructuring declined cer terms sterling terms gsk annual report adverse percentage point currency impact eps c ustomer rebates offered key managed care group major restructuring arose predominantly strengthening purchasing organisations gpo direct indirect sterling us dollar partly offset weakening customers arrangements require customer achieve sterling japanese yen certain performance targets relating value product purchased formulary status predetermined market shares dividend relative competitors accrual customer rebates board declared four interim dividends resulting dividend estimated based specific terms agreement year pence pence increase pence per historical experience product growth rates share board also declared supplemental interim us medicaid programme stateadministered programme dividend pence per share related disposal certain providing assistance certain poor vulnerable patients noncore otc brands north america completed medicaid drug rebate program established january paid time fourth interim reduce state federal expenditure prescription drugs dividend see note dividends patient affordable care act became law reporting shareholders participate providing rebates states accruals medicaid rebates calculated based specific terms individual previously announced number changes way state agreements using combination historical experience report including transition core eps measure introduced product population growth anticipated price increases details see impact contracting strategies critical accounting policies c ash discounts offered customers encourage prompt consolidated financial statements prepared accordance payment accrued time invoicing ifrs adopted use european union also adjusted subsequently reflect actual experience ifrs issued iasb following accounting policies approved board described note financial w historical experience customer returns statements accounting principles policies required record accrual estimated sales returns applying make estimates assumptions affect amounts historical experience customer returns amounts assets liabilities revenue expenses reported financial invoiced together market related information stock statements actual amounts results could differ levels wholesalers anticipated price increases competitor estimates activity critical accounting policies information reconciliation gross turnover net turnover us judgements estimates made given note financial pharmaceuticals vaccines business follows statements key accounting judgements estimates relevant detailed notes financial statements indicated relate following areas gross turnover turnover taxation note chargebacks legal disputes notes managed care medicare property plant equipment note part gpo goodwill note rebates intangible assets note us government pensions postemployment benefits note state programmes cash discounts information judgements estimates made areas customer returns given note financial statements key accounting prior year adjustments judgements estimates items respect turnover accounting policy largest business total deductions us pharmaceuticals vaccines us market net turnover complex arrangements rebates discounts allowances overall return rebate rate decreased year following briefly describes nature arrangements primarily due lower sales highly discounted brands particularly existence us pharmaceuticals vaccines business managed medicaid segment adjustments prior year w e arrangements certain indirect customers whereby estimates customer able buy products wholesalers reduced prices chargeback represents difference invoice price wholesaler indirect customers contractual discounted price accruals estimating chargebacks calculated based terms agreement historical experience product growth rates gsk annual report financial review financial review continued risk total accruals rebates discounts allowances returns meetings appropriate detail status significant us pharmaceuticals vaccines business follows litigation governmental investigations review matters number claims notified us information potential claims yet notified assessment validity claims december december progress made settling claims recent settlement levels restated potential reimbursement insurers chargebacks meetings also include assessment whether managed care medicare part sufficient information available us able make reliable gpo rebates estimate potential outcomes disputes often external us government state programmes counsel assisting us various litigation matters cash discounts investigations also assist briefing board senior customer returns management following discussions matters possible make reliable estimate amount total provision may required level provision legal disputes reviewed adjusted appropriate information relating restated following changes classification items included certain categories financial position resources accrual rebates us government state programmes property plant equipment increased result us healthcare reform implemented business sciencebased technologyintensive highly regulated governmental authorities allocate significant monthly process operated monitor inventory levels financial resources renewal maintenance property wholesalers abnormal movements process uses gross plant equipment minimise risks interruption production sales volumes prescription volumes based third party data achieve compliance regulatory standards sources information received key wholesalers aim number processes use chemicals hazardous materials maintain inventories consistent level year year based pattern consumption total cost property plant equipment december million net book value basis us pharmaceuticals vaccines inventory levels million land buildings represented wholesalers distribution channels december million plant equipment million assets estimated amount approximately one month construction million invested million turnover calculation uses third party information accuracy new renewal property plant equipment mainly totally verified believed sufficiently related large number projects renewal improvement reliable purpose expansion facilities various worldwide sites property respect accounting policy legal disputes mainly held freehold new investment financed liquid following briefly describes process determine resources december capital contractual level provision necessary commitments future expenditure million operating lease commitments million believe facilities accordance requirements ias provisions adequate current needs contingent liabilities contingent assets provide anticipated settlement costs outflow resources observe stringent procedures use specialist skills manage considered probable reliable estimate may made environmental risks activities environmental issues likely outcome dispute legal expenses arising sometimes dating operations modified discontinued claims group may become involved reported environmental sustainability significant legal proceedings respect possible note financial statements legal proceedings make reliable estimate expected financial effect goodwill could result ultimate resolution proceedings cases appropriate disclosure cases would included goodwill increased year million annual report provision would made position december million increase primarily could change time therefore assurance reflects goodwill arising acquisition maxinutrition losses result outcome legal proceedings group holdings limited million partly offset exceed material amount amount provisions weakening overseas currencies reported groups financial statements intangible assets like many pharmaceutical companies faced various intangible assets include cost intangibles acquired complex product liability antitrust patent litigation well third parties computer software net book value investigations operations conducted various governmental intangible assets december million regulatory agencies throughout year general counsel million decrease reflected group head groups legal function senior vice amortisation impairment existing intangibles partly offset president head global litigation group additions million business combinations responsible litigation government investigations routinely additions brief chief executive officer chief financial officer board directors significant litigation pending group governmental investigations group gsk annual report financial position investments held investments including associates joint ventures carrying value december million assets million market value december noncurrent assets million million largest property plant equipment investments associate aspen pharmacare holdings goodwill limited book value december intangible assets million million investment investments associates joint ventures theravance inc book value december investments million million investments include equity deferred tax assets stakes companies group research collaborations derivative financial instruments provide access biotechnology developments potential noncurrent assets interest interests companies arise business total noncurrent assets divestments current assets derivative financial instruments assets inventories noncurrent current derivative financial current tax recoverable instruments held fair value million million trade receivables majority amount relates interest rate swaps derivative financial instruments foreign exchange contracts designated accounting hedges liquid investments cash cash equivalents inventories assets held sale inventory million increased million total current assets year increase reflects higher vaccine stocks principally total assets cervarix national hpv programme japan partly offset liabilities initiatives reduce manufacturing cycle times reduce current liabilities stockholding days efficient use inventory shortterm borrowings throughout supply chain trade payables trade receivables derivative financial instruments current tax payable trade receivables million decreased shortterm provisions reflecting specific actions taken reduce overdue total current liabilities receivables part initiative reduce working capital derivative financial instruments liabilities noncurrent liabilities longterm borrowings held current noncurrent derivative financial instruments deferred tax liabilities held fair value million million relating pensions postemployment benefits primarily foreign exchange contracts represent hedges provisions intercompany loans deposits legal provisions derivative financial instruments designated accounting hedges noncurrent liabilities trade payables total noncurrent liabilities total liabilities trade payables amounting million net assets increased reflecting working capital initiatives extend supplier terms towards day term objective equity share capital provisions share premium account carried deferred tax provisions shortterm retained earnings noncurrent provisions million december reserves million respect estimated future liabilities shareholders equity million million related legal noncontrolling interests disputes provision made legal total equity disputes indemnified disposal liabilities employee related liabilities costs restructuring programmes extent balance sheet date legal constructive obligation existed could reliably estimated gsk annual report financial review financial review continued risk pensions postemployment benefits summary movements equity set account pension postemployment arrangements accordance ias deficits net surpluses allowing deferred taxation million total equity beginning year million pension arrangements million total comprehensive income year million unfunded postemployment liabilities dividends shareholders pension liabilities increased following decrease asset values shares issued uk reductions rates used discount uk pension changes noncontrolling interests liabilities us pension liabilities forward contract relating noncontrolling partly offset lower long term inflation rate interest deficit reduction contributions million million shares purchased cancelled held treasury shares december uk scheme purchased insurance contract consideration received shares transferred guarantee payment specified pensioner liabilities esop trusts contract valued million december shares acquired esop trusts net debt sharebased incentive plans tax sharebased incentive plans distributions noncontrolling interests total equity end year cash cash equivalents liquid investments share purchases borrowings repayable within one year borrowings repayable one year employee share ownership plan esop trusts acquired net debt million shares gsk plc million shares held trusts satisfy future exercises options awards net debt increased million free cash flow asset group share option award schemes proportion disposal proceeds largely funded dividends shareholders shares held trusts respect awards share repurchases rules scheme require us satisfy exercises market movements net debt purchases rather issue new shares shares held trusts matched options awards granted december esop trusts held million net debt beginning year million gsk shares future exercise decrease cash bank overdrafts share options share awards carrying value million cash inflow liquid investments million deducted reserves net repayment shortterm loans market value shares million debt subsidiary undertakings acquired million exchange movements february announced would commence movements new longterm share buyback programme million shares net debt end year repurchased cost million see note total equity share capital intend make repurchases billion exact amount timing future december total equity decreased purchases whether shares held treasury million december million shares cancelled determined company decrease arose principally share repurchases year dependent market conditions factors december held million shares treasury shares million shares cost million million deducted retained earnings period january march million shares purchased cost million commitments contingent liabilities financial commitments summarised note financial statements commitments contingent liabilities obligations respect short longterm debt set note financial statements contingent liabilities note financial statements net debt gsk annual report amounts provided pensions postretirement benefits contingent liabilities set note financial statements pensions following table sets contingent liabilities comprising postemployment benefits amounts provided restructuring discounted bills performance guarantees letters credit programmes legal environmental disputes set items arising normal course business note financial statements provisions expected expire contractual obligations commitments total yr yrs yrs yrs following table sets contractual obligations commitments december fall due payment guarantees contingent liabilities total yr yrs yrs yrs total loans normal course business provided various interest loans indemnification guarantees respect business disposals finance lease obligations legal disputes subsequently arisen finance lease charges provision made outflow resources considered operating lease probable reliable estimate made likely outcome commitments dispute included note financial intangible assets statements provisions property plant equipment purchase noncontrolling provide outcome tax legal disputes interests outflow resources considered probable reliable investments estimate outflow may made december purchase commitments disputes provision made pensions possible make reliable estimate potential outflow commitments funds might required settle disputes possibility total outflow remote ultimate liability matters may vary significantly commitments respect loans future interest payable amounts provided dependent upon outcome loans disclosed taking account effect litigation proceedings negotiations relevant tax derivatives authorities discussed risk factors pages entered number research collaborations notes financial statements taxation develop new compounds pharmaceutical companies legal proceedings terms arrangements include upfront fees equity cash generation conversion investments loans commitments fund specified levels research addition often agree make payments summary consolidated cash flow set future milestones achieved agreements relate compounds early stages development milestone payments continue net cash inflow operating activities number years compounds move successfully net cash outflow investing activities development process generally closer product net cash outflow financing activities marketing approval greater possibility success decrease cash bank overdrafts amounts shown within intangible assets represent exchange adjustments maximum would paid milestones achieved cash bank overdrafts beginning year include billion relates externalised projects cash bank overdrafts end year discovery portfolio number new commitments made licensing agreements including cash bank overdrafts end year arrangements theravance inc janssen biologics bv comprise cash cash equivalents commitments purchase noncontrolling interests overdrafts investments represent maximum amounts payable reached agreement trustees uk net cash inflow operating activities taxation paid pension schemes make additional contributions five year million decrease million sterling terms period eliminate pension deficit identified compared december actuarial funding valuation table shows commitment excludes normal ongoing annual net cash outflow investing activities million funding requirement approximately million million lower primarily reflected information pension obligations see note financial proceeds disposal shareholding quest statements pensions postemployment benefits diagnostics inc lower purchases intangible assets year million million gsk annual report financial review financial review continued risk free cash flow capital expenditure financial investment free cash flow amount cash generated business cash payments tangible intangible fixed assets amounted meeting obligations interest tax dividends paid million million disposals realised noncontrolling interests capital expenditure million million cash payments acquire noncurrent tangible intangible assets equity investments million million made year sales equity investments realised million million free cash flow free cash flow growth future cash flow free cash flow adversely impacted legal settlements expect future operating cash flow sufficient fund million million free cash flow excluding operating debt service costs satisfy normal levels legal settlements million compared capital expenditure meet obligations existing licensing million decline reflecting lower contributions agreements meet expenditure arising major pandemic products avandia valtrex lower restructuring programmes precise timing uncertain reduction working capital compared partly offset outlined note financial statements major restructuring lower restructuring payments lower tax payments programmes meet routine outflows including tax dividends subject risk factors discussed pages commitment use free cash flow support increasing may time time additional demands finance dividends undertake share repurchases returns acquisitions share repurchases access attractive reinvest business including bolton acquisitions sources liquidity short longterm capital markets also intend use net proceeds disposals banks financial institutions addition cash noncore otc brands fund increased returns shareholders flow operations needs reconciliation net cash inflow operating activities working capital closest equivalent ifrs measure free cash flow shown working capital percentage turnover reconciliation free cash flow working capital conversion cycle days working capital reduced million compared net cash inflow operating activities reduction million reduction purchase property plant equipment boosted approximately million cash related purchase intangible assets pandemic receivables working capital conversion cycle reduced disposal property plant equipment days result lower receivables higher payables interest paid payment policies interest received group companies responsible monitoring managing dividends received joint ventures working capital terms sales collections supplier associated undertakings payments reflect local commercial practice distributions noncontrolling interests free cash flow uk company uk subsidiaries policies ensure suppliers paid time particular investment appraisal uk companies seek formal process assessing potential investment settle terms payment suppliers agreeing proposals order ensure decisions aligned overall terms transaction strategy process includes analysis impact project earnings return invested capital ensure suppliers made aware agreed term assessment return based discounted cash flows payment discount rate used perform financial analysis decided abide terms payment internally allow determination extent policy permits arrangements accelerated payment small investments cover cost capital specific investments suppliers discount rate may adjusted take account country risk weightings payment performance december average number days payable outstanding represented trade payables parent company nil nil respect company uk subsidiaries aggregate days days gsk annual report maturity profile gross debt equivalent gbp bonds eur bonds usd bonds bank borrowings leases treasury policies returned free cash flow asset disposal proceeds shareholders balance dividends glaxosmithkline plc reports sterling pays dividends share buybacks paid billion dividends sterling profits role corporate treasury manage completed billion share repurchases part monitor external internal funding requirements longterm programme also elected return net financial risks support strategic objectives treasury proceeds sale noncore north american otc activities governed policies procedures approved brands shareholders payment supplemental board directors recently july dividend treasury management group tmg meeting chaired details see note financial statements financial chief financial officer takes place monthly basis review instruments related disclosures treasury activities members receive management information relating treasury activities liquidity capital management december cash liquid investments held follows financial strategy regularly reviewed board manage capital structure group appropriate mix debt equity delivers best returns shareholders whilst maintaining credit ratings maximise flexibility bank balances deposits access debt capital markets attractive terms us treasury treasury repo money market funds capital structure group consists net debt corporate debt instruments billionsee note net debt shareholders equity government securities billion see consolidated statement changes equity total capital including provided non controlling interests billion billion centrally managed cash reserves amounted billion allocate capital deliver best returns december available within months excludes shareholders commitment use free cash flow support billion centrally managed cash held viiv healthcare dividends undertake share repurchases returns owned subsidiary date shortterm attractive invest bolton acquisitions investment opportunities borrowings repayable within one year billion continue assessed strict financial criteria net debt billion december table summarises cash gross debt effects hedging significant levels patent trademark protection pharmaceutical products compete largely product efficacy differentiation rather price selling margins sufficient cover normal operating costs operations continue cash liquid investments highly cash generative legal settlements billion gross debt fixed net cash inflow operating activities billion floating free cash flow billion noninterest bearing net debt gsk annual report financial review financial review continued risk policy borrow centrally order meet anticipated interest rate risk management funding requirements cash flow forecast funding gsks objective reduce effective net interest cost requirements monitored tmg monthly basis rebalance mix debt fixed floating interest rates european medium term note programme billion time policy interest rate risk management limits amount december billion notes issue floating interest payments prescribed percentage programme also us shelf registration statement trading profit december billion billion notes use series interest rate swaps redenominate one issue programme bonds floating interest rates duration swap gsks longterm borrowings mature dates matches duration principal instrument interest rate longterm debt ratings remained unchanged since derivative instruments accounted fair value cash flow february currently gsk rated stable outlook hedges relevant assets liabilities standard poors stable outlook moodys investors foreign exchange risk management service moodys shortterm debt ratings p standard poors moodys respectively foreign currency transaction exposures arising internal external trade flows hedged exposure overseas gsk access shortterm finance us billion operating subsidiaries transaction risk minimised matching commercial paper programme billion committed local currency income local currency costs purpose facilities facilities last renewed october internal trading transactions matched centrally manage increased billion billion time consider intercompany payment terms reduce foreign currency risk level committed facilities adequate given current exceptional foreign currency cash flows hedged selectively liquidity requirements information facilities management corporate treasury tmg please refer note financial statements net debt possible manage cash surpluses borrowing requirements well committed facilities gsk also substantial cash subsidiary companies centrally using forward contracts hedge cash equivalents liquid investments amounted future repayments back originating currency billion december reviewed cash order reduce foreign currency translation exposure seek balances relative debt portfolio sources debt denominate borrowings currencies principal assets access order improve efficiency balance cash flows primarily denominated us dollars euros sheet result intend reduce effective net funding sterling certain borrowings swapped cost maintaining lower level cash diversifying currencies required sources funding given current low interest rate environment borrowings denominated swapped foreign currencies treasury operations match investments overseas group assets may treated objective treasury activity manage posttax net cost hedge relevant assets forward contracts also used income financial operations benefit earnings major currencies reduce exposure investment corporate treasury operate profit centre use overseas group assets tmg reviews ratio borrowings variety financial instruments finance operations assets major currencies monthly derivative financial instruments manage market risks counterparty risk management operations derivatives principally comprising forward foreign currency contracts interest rate currency swaps policy counterparty risk management work used swap borrowings liquid assets required select group relationship banks global counterparty limits currencies manage exposure funding risks changes assigned gsks banking investment counterparties foreign exchange interest rates based longterm credit ratings moodys standard poors corporate treasurys usage limits hold issue derivatives speculative purposes monitored daily corporate compliance officer cco treasury policies specifically prohibit activity transactions operates independently corporate treasury breach financial instruments undertaken manage risks arising limits reported cfo immediately cco also underlying business activities speculation monitors credit rating counterparties changes ratings occur notifies corporate treasury changes made investment levels authority limits appropriate full counterparty analysis presented tmg annually approval gsk annual report financial review antivirals antivirals decreased billion accordance us sec disclosure requirements following discussion compares results year december relenza sales million million results year december previous year significant government pandemic orders received valtrex sales declined million financial information discussion follows presented reflecting generic competition usa europe basis gsk organised managed central nervous system cns pharmaceutical turnover cns sales decreased billion growth rates included review turnover constant exchange rates cer unless otherwise stated calculation majority cns franchise impacted generic underlying turnover described sterling growth rates competition usa wellbutrin decline primarily may found tables pharmaceutical turnover reflected sale wellbutrin xl usa biovail therapeutic areas geographic segment second quarter pharmaceutical turnover declined billion excluding cardiovascular urogenital pandemic products avandia valtrex underlying turnover cardiovascular urogenital sales increased billion increased reflecting continued strong growth key products arixtra million avodart growth million lovaza million cer usa metabolic europe metabolic sales decreased billion emerging markets avandia product sales declined million asia pacificjapan september european medicines agency suspended viiv healthcare marketing authorisation rosiglitazone containing products including avandia us food drug administration announced additional measures ensure benefits avandia continue outweigh risks including risk evaluation sales usa declined billion primarily due mitigation strategy rems programme generic competition valtrex significant reduction sales pandemic related products lower sales avandia new oncology emesis products excluding pandemic vaccines launched since grew oncology emesis sales increased billion contributed sales tyverbtykerb million grew strongly europe pharmaceuticals sales declined billion primarily segments newly launched oncology products votrient arzerra due impact significant reduction sales pandemic promacta delivered sales million million related products generic competition valtrex lower sales million respectively avandia vaccines emerging markets pharmaceuticals sales grew billion strong growth across product categories also total vaccine sales grew billion including billion helped pandemic related product sales million pandemic vaccine sales billion excluding flu million asia pacificjapan pharmaceuticals sales pandemic vaccine sales growth several new vaccines grew billion contributed growth including synflorix doubling million boostrix million cervarix pharmaceutical turnover therapeutic area million sales hepatitis vaccines grew million infanrixpediarix grew million pharmaceutical turnover declined impact seasonal flu sales grew million rotarix sales generic competition valtrex lower avandia pandemic million product continues recover product sales partly offset growth key products market share lost following temporary suspension several seretideadvair avamysveramyst avodart lovaza tyverbtykerb markets earlier year ventolin vaccines franchise dermatology respiratory dermatology sales billion including heritage gsk respiratory sales increased billion products acquired business acquisitions seretideadvair sales grew billion strong growth principally stiefel july estimated sales growth japan million emerging markets business proforma basis excluding acquisitions million sales usa level billion approximately addition heritage consumer grew europe billion dermatology portfolio reported within consumer healthcare contributed sales million several respiratory products delivered growth including avamysveramyst million ventolin million flovent million gsk annual report financial review financial review continued risk viiv healthcare hiv restructuring costs incurred direct result acquisition stiefel laboratories inc july million sales hiv products viiv healthcare million restructuring costs incurred direct result billion sales former pfizer products selzentry acquisition reliant pharmaceuticals inc viracept combined sales million growth acquisition since october meets criteria set epzicomkivexa million offset reductions charged paid sales hiv products including trizivir million combivir million epivir restructuring costs incurred solely direct result million operational excellence programme restructuring programmes following reliant stiefel acquisitions consumer healthcare turnover reported major restructuring column income growth statement set note financial statements total cer major restructuring programme asset impairments staff overthecounter redundancies together accounted million medicines million restructuring costs incurred reported major restructuring column oral healthcare nutritional healthcare latest position results major restructuring total results see results major restructuring total results financial review cer represents growth constant exchange rates represents growth actual exchange rates operating profit profit taxation taxation profit year discussed terms total results total consumer healthcare sales billion include major restructuring costs results significantly exceeding market growth estimated gsk major restructuring approximately sales rest world grew profit tax total results billion driven strong growth india china grew respectively europe sales level total results include restructuring costs related operational last year sales billion business excellence programme acquisitions reliant stiefel usa grew billion growth otc medicines cer otc product sales grew billion driven turnover sales panadol nicotine replacement therapy products cost sales dermatology products partly offset lower respiratory tract selling general products lower sales alli administration research oral healthcare development sales oral healthcare products rose billion sensodyne operating performed strongly denture care sales also grew sales income aquafresh declined slightly operating profit nutritional healthcare cost sales nutritional healthcare sales grew billion driven cost sales increased turnover strong performance horlicks growth lucozade sales reflecting impact generic competition higher margin results major restructuring total results products usa principally valtrex lower avandia sales us healthcare reforms european austerity price cuts inventory october announced significant new operational asset writedowns partially offset savings excellence restructuring programme second formal plan operational excellence programme lower restructuring costs announced february expansion million million announced february selling general administration addition restructuring costs operational excellence programme major restructuring column income sga costs percentage turnover increased statement includes restructuring costs incurred solely direct percentage points excluding legal costs result restructuring programmes follow relate million million sga costs material acquisitions operations acquired business turnover increase percentage points overlap extensively existing operations reflected sterling cer increase sga flat sterling turnover growth sga included restructuring costs restructuring activities follow relate million million investment growth markets acquisitions nature undertaken full year impact acquisition stiefel partly offset operational excellence programme consider appropriate operational excellence savings usa europe lower present costs restructuring activities manner exchange losses intercompany transactions advertising promotion declined selling distribution increased general administration excluding legal increased gsk annual report research development profit taxation total results rd expenditure total turnover taking account net finance costs profit disposal reflecting increase expenditure sterling cer interest associates share profits associates total flat sterling turnover growth included restructuring profit taxation million compared costs million million viiv healthcare rd million cer decline investments lower intangible asset impairments million sterling decline million savings operational excellence profit tax results major restructuring programme addition comparison prior year unfavourably impacted oneoff recognition recoverable results major restructuring set balance growth operating income cer operating income million million turnover primarily reflecting royalty income million cost sales million income transfer genentech selling general exclusive promotion rights boniva usa asset disposals million million partially offset equity administration investment impairments million million research income included disposal wellbutrin xl various asset development disposals aspen pharmacare royalty dispute settlement gain operating million accounting gain million creation income viiv healthcare operating profit operating profit total results cost sales operating profit restructuring charges million million million decrease cer cost sales increased turnover decrease sterling terms compared reflecting impact generic competition higher margin excluding legal costs million million products usa principally valtrex lower avandia sales operating profit million decline cer terms us healthcare reforms european austerity price cuts sterling terms principally reflecting decline inventory asset writedowns partially offset savings turnover higher cost sales higher rd expenditure lower operational excellence programme operating income selling general administration net finance costs sga costs percentage turnover increased percentage points primarily reflecting higher legal finance income charges million million interest finance income excluding legal costs sga costs turnover unwinding discounts assets decrease percentage points reflected fair value adjustments hedges sterling cer decline expenditure compared prior year flat sterling turnover growth decline expenditure finance costs reflected operational excellence savings usa europe interest costs lower exchange losses intercompany transactions partially unwinding discounts liabilities offset investment growth markets full year impact fair value adjustments hedges acquisition stiefel finance expense advertising promotion declined selling distribution declined general administration excluding legal declined collectively items accounted decline profit disposal interest associates total sga profit disposal interest associates million research development million profit arose sale million quest shares subsequent yearend rd expenditure total turnover group sold entire shareholding quest give rise reflecting flat expenditure flat sterling turnover growth pretax profit disposal associates approximately included savings operational excellence million million tax programme lower intangible asset impairments million million higher viiv healthcare rd share tax profits associates joint ventures investment comparison prior year unfavourably share tax profits associates million impacted oneoff recognition recoverable balance million arose principally groups holding quest gsk annual report financial review financial review continued risk operating income taxation charge operating income million million primarily reflecting royalty income million million income transfer genentech uk corporation tax uk statutory rate exclusive promotion rights boniva usa asset less double taxation relief disposals million million partially offset equity investment impairments million overseas taxation million income included disposal wellbutrin xl current taxation various asset disposals aspen pharmacare royalty dispute deferred taxation settlement gain million accounting gain taxation total profits million creation viiv healthcare lower tax charge reflects higher legal charges operating profit results major restructuring billion billion operating profit major restructuring year ended charge taxation total profits amounted million december million decline cer terms represented effective tax rate decrease sterling terms excluding legal costs charge taxation profit major restructuring million million operating profit charges amounted million represented effective million decline cer terms decrease tax rate sterling terms principally reflecting decline turnover higher cost sales higher rd expenditure lower operating latest position taxation see taxation financial income partly offset reduced sga costs operating profit review margin excluding legal costs operating income profit year net finance costs growth cer total profit taxation finance income year interest income total profit attributable unwinding discounts assets shareholders fair value adjustments hedges basic earnings per share pence p p basic earnings per ads us results major restructuring finance costs profit taxation year interest costs results major restructuring unwinding discounts liabilities profit attributable shareholders fair value adjustments hedges adjusted earnings per share pence p p finance expense adjusted earnings per ads us weighted average number net interest payable year million shares millions million company expects similar charge diluted total earnings per share pence p p diluted total earnings per ads us profit disposal interest associate diluted weighted average number profit disposal interest associates million shares millions million profit arose sale total results including restructuring costs produced basic eps million quest shares subsequent yearend gsk p compared p decline sold entire shareholding quest give rise cer terms decline sterling terms excluding major pretax profit disposal associates approximately restructuring costs eps p compared p million million tax decline cer decrease sterling terms share tax profits associates joint ventures percentage point currency benefit arose weakness sterling major international currencies compared share tax profits associates million last year partly offset strengthening sterling million arose principally groups holding euro quest diagnostics inc dividend profit taxation results major restructuring declared fourth interim dividend pence per share taking account net finance costs profit disposal resulting dividend year pence pence increase interests associates share profits associates profit pence per share tax major restructuring million compared million cer decline decline sterling terms gsk annual report property plant equipment provisions total cost property plant equipment group carried deferred tax provisions shortterm december million net book value noncurrent provisions million december million land buildings represented million respect estimated future liabilities million plant equipment million assets million million related legal construction million gsk invested million disputes reached settlements new renewal property plant equipment agreements principle settle number significant legal december capital contractual commitments disputes settlements agreements principle settle future expenditure million operating lease included investigation us government former commitments million manufacturing facility cidra puerto rico product liability antitrust litigation relating paxil product liability cases goodwill regarding avandia paxil poligrip usa goodwill increased year million investigation us government sales marketing st december million increase primarily practices usa settlement process involving discussions reflects goodwill arising acquisition laboratorios plaintiffs lawyers government prosecutors phoenix saicyf million impact strengthening matters facilitated ability make updated assessments overseas currencies potential exposure faced matters legal charge full year increased million intangible assets resulting provision legal disputes billion net book value intangible assets december december includes best estimate amounts million million increase expected necessary resolve disputes based reflected additions million business known facts circumstances date approval combinations currency movements partly offset financial statements directors believe amortisation impairment existing intangibles material additional legal charge necessary respect disputes investments net debt held investments including associates joint ventures carrying value december million net debt decreased million million million market value december december due free cash flow generated million million company exceeding amounts paid dividends shareholders invested new businesses derivative financial instruments assets total equity noncurrent current derivative financial instruments held fair value million million december total equity decreased small decrease primarily reflects decrease net investment million december million hedging volumes decrease arose principally increased provision legal charges year inventories cash flow inventory million decreased million year decrease reflected initiatives reduce manufacturing net cash inflow operating activities taxation paid cycle times reduce stockholding days efficient million decrease million use inventory throughout supply chain reflecting higher legal settlements year partly offset net working capital reduction trade receivables net cash outflow investing activities million trade receivables million decreased decrease million primarily reflected lower reflecting recovery significant levels hn debt business purchases million business year specific actions taken reduce overdue purchases million primarily stiefel laboratories inc receivables part initiative reduce working capital addition purchases property plant equipment lower derivative financial instruments liabilities million held current noncurrent derivative financial instruments capital expenditure financial investment held fair value million million current cash payments tangible intangible fixed assets amounted relating primarily hedging exchange translation currency million million disposals realised assets consolidation small increase reflects marginally million million cash payments acquire higher currency volatility euro us dollar yen equity investments million million trade payables made year sales equity investments realised trade payables amounting million million million increased reflecting working capital initiatives extend supplier terms towards day term objective strengthening yearend foreign exchange rates gsk annual report financial review risk factors risk risk factors new product candidates may appear promising development significant investment group economic human risks uncertainties relevant groups business resources may fail reach market may limited financial condition results operations may affect commercial success example could result groups performance ability achieve objectives efficacy safety concerns inability obtain necessary factors among group believes could cause regulatory approvals difficulty manufacturing excessive actual results differ materially expected historical manufacturing costs erosion patent coverage result results risks uncertainties may affect lengthy development period infringement patents groups performance ability achieve objectives intellectual property rights others inability differentiate currently known group deemed immaterial product adequately competes furthermore health authorities us food drug group reviews assesses significant risks regular basis administration european medicines agency japan implemented oversight programme help ensure pharmaceuticals medicines device agency increased system internal control place system includes focus safety product differentiation assessing policies procedures communication training programmes benefitrisk balance drugs made difficult supervision monitoring processes escalating issues pharmaceutical vaccine products gain regulatory approval appropriate level senior management system helps facilitate groups ability respond appropriately risks also increasing pressure healthcare budgets result achieve group objectives helps ensure compliance financial crisis increase average age applicable laws regulations internal policies groups population developed markets increase absolute management risks discussed pages population developing markets payers therefore increasingly corporate governance demanded greater incremental benefit pharmaceutical vaccine products agreeing reimburse drug possible however group implement controls manufacturers prices manufacturers consider appropriate respond risks may face failure develop commercially successful products develop assurance steps group taken address certain additional uses existing products reasons could risks manage risks effectively six principal materially adversely affect groups financial results risks uncertainties might affect gsks business broken following areas intellectual property protection risk rd deliver commercially successful failure obtain effective intellectual property new products protection products group operates highly competitive markets innovator pharmaceutical vaccine consumer healthcare pharmaceuticals vaccines businesses faces competition company group seeks obtain appropriate intellectual proprietary products large international manufacturers property protection products ability obtain producers generic pharmaceuticals pharmaceuticals enforce patents proprietary rights regard vaccines businesses also face increasing competition products critical groups business strategy success manufacturers emerging markets lower cost number markets group operates manufacturing base group consumer intellectual property laws patent offices still developing healthcare business group likewise faces competition markets may unwilling extend intellectual property large international consumer healthcare companies well local protection innovative products fashion similar markets consumer healthcare companies significant product innovations developed regions european union japan technical advances intensification price competition usa enforce previously granted intellectual property competitors may materially adversely affect groups rights groups inability obtain enforce effective financial results three businesses group always intellectual property protection products certain markets predict timing impact competitive products could material adverse result groups financial results potential impact sales groups products light countries group operates patent competitive environment group operates continued protection may significantly weaker usa development commercially viable new products well european union developing countries reduced development additional uses existing products critical threatened reduce effective patent protection groups ability replace sales older products decline pharmaceutical products generally particular therapeutic upon expiration exclusive rights increase overall sales areas facilitate early competition within markets developing new pharmaceutical vaccine products costly generic manufacturers loss patent protection including lengthy uncertain process new product candidate fail reducing scope patent rights compulsory licensing stage development process one late stage government forces manufacturer license intellectual product candidates could fail receive regulatory approval property competitor could materially adversely affect groups financial results markets absence adequate patent protection could limit opportunity rely markets future sales growth groups products gsk annual report expiry intellectual property rights protection potential changes intellectual property laws groups products competitive products regulations competition generic manufacturers proposals change existing patent data exclusivity laws pharmaceutical vaccine products usually protected regulations major markets group sells products copied generic manufacturers period continuing feature political process countries exclusivity provided issued patent related intellectual include proposals could effect making property rights regulatory data protection orphan prosecution patents new products difficult time drug status following expiry intellectual property rights consuming could adversely affect exclusivity period protection generic manufacturer may produce generic version groups products including biological products product proposals enacted may materially adversely affect groups financial results example part group faces intense competition manufacturers comprehensive healthcare reform usa biologics price generic pharmaceutical products major markets competition innovation act enacted introduced introduction generic products particularly usa new regulations followon biologics allow sufficiently group highest turnover margins typically leads similar biologic able rely innovators approval dramatic loss sales reduces groups revenues following year data exclusivity period regulations outlining margins proprietary products group eleven requirements establishing biosimilars interchangeable pharmaceutical vaccine products million products well operation complicated patent litigation annual global sales certain products provisions yet proposed fda europe generic competition usa markets europe ema finalised guidelines similar biological medicinal addition timing impact entry followon products containing mabs monoclonal antibodies product seretideadvair contains active ingredients uncertain loss patent protection groups products could material adverse impact sales us patent compositions containing combination groups products active substances seretideadvair expired outlook timing impact entry followon risk substantial adverse outcome litigation competition uncertain gsk notified government investigations acceptance us fda application followon product note financial statements legal proceedings contains refers seretideadvair contains active discussion material proceedings governmental investigations ingredients would expected precede introduction currently involving group proven could give rise product able predict may occur civil andor criminal liabilities unfavourable resolution followon product may enter us market similar future proceedings investigations may material generic drug manufacturers also exhibited readiness adverse effect groups financial condition results market generic versions many groups important operations group made provisions prior years products prior expiration groups patents efforts may related legal proceedings investigations reduced involve challenges validity enforceability patent earnings assertions generic product infringe groups future group may also make additional significant patents group successful defending attack provisions related legal proceedings investigations patents maintaining exclusive rights market one would reduce earnings many cases group believes major products particularly usa europe groups practice plaintiff bar claim damages amounts financial results would adversely affected expiration dates bear reasonable relationship underlying harm allegedly patents groups major products description caused groups products actions accordingly may litigation settlements may affect dates generic potentially misleading group quantify based versions groups products may introduced set amount damages claimed potential exposure claims legal proceedings involving patent challenges set proceedings investigations type described note note financial statements legal proceedings financial statements legal proceedings group may also experience impact sales one recent insurance loss experience including pharmaceutical product products due expiry loss patent protection liability exposures increased cost reduced capacity product marketed competitor similar product class insurers provide coverage pharmaceutical companies treatment similar disease condition availability generic generally including group products similar product class one groups products competes could material adverse impact order contain insurance costs recent years group sales groups products continued adjust coverage profile accepting greater degree uninsured exposure areas lesser degree others order optimise value insurance markets addition claims made insurance policies insurers regularly reserve right deny cover various grounds gsk annual report financial review risk factors continued risk product liability litigation usa example group reached agreement principle resolve certain federal governmental investigations preclinical clinical trials conducted development pricing marketing reimbursement prescription potential pharmaceutical vaccine consumer healthcare drug products detailed note financial statements products determine safety efficacy products legal proceedings related state investigations use humans following approval regulatory authorities initiated basis factual claims could result notwithstanding efforts group makes determine restitution civil litigation behalf state governments safety products regulated clinical trials unanticipated could also result related proceedings initiated group side effects may become evident drugs vaccines behalf consumers private payers proceedings widely introduced marketplace may result trebling damages awarded fines respect instances third parties may perform analyses published violation law conduct group could result clinical trial results although necessarily accurate additional investigations future us federal state meaningful may raise questions regarding safety governments similar civil litigation consequences pharmaceutical vaccine consumer healthcare products could materially adversely affect groups financial results may publicised media may result product liability governmental payer regulatory controls claims group currently defendant substantial number product liability lawsuits including class actions involve pricing significant claims damages related groups pharmaceutical vaccine products subject price controls pharmaceutical consumer healthcare products litigation pressures restrictions many markets including particularly usa inherently unpredictable class actions limited france germany italy japan spain sweep together persons prescribed groups governments intervene directly setting prices addition products inflate potential liability force numbers markets major purchasers pharmaceutical vaccine claims pain suffering punitive damages frequently products whether governmental agencies private health care asserted product liability actions allowed represent providers economic power exert substantial pressure potentially open ended exposure thus could materially prices terms access formularies difficult economic adversely affect groups financial results conditions particularly major markets europe could antitrust litigation increase pricing pressures groups pharmaceutical vaccine products group accurately predict whether usa become increasingly common patent existing controls pressures restrictions increase whether infringement actions prompt claims antitrust laws new controls pressures restrictions introduced violated prosecution patent measures may materially adversely affect groups ability litigation involving defence patent claims direct introduce new products profitably financial results indirect purchasers payers typically filed class actions relief sought may include treble damages example usa group highest margins restitution claims similarly antitrust claims may brought sales country direct government government entities private parties following settlement price controls private sector purchases federal law requires patent litigation alleging settlements anticompetitive pharmaceutical manufacturers pay prescribed rebates certain violation antitrust laws group may also subject drugs eligible reimbursement several state antitrust litigation involving competition claims unrelated federal healthcare programmes primarily medicare medicaid patent infringement prosecution successful antitrust pricing pressures likely increase us governments share claim private party government entity group national health spending continues increase additionally due could materially adversely affect groups financial results passage comprehensive health care reform us governments role providing subsidising health insurance sales marketing regulation expected significantly expand indicates group operates globally complex legal regulatory growing role leverage government bring bear environments often vary among jurisdictions failure groups rebate liability respect us federal programs comply applicable laws rules regulations recent years number states also proposed jurisdictions may result civil criminal legal proceedings implemented various schemes control pharmacy budget brought group governmental entities federal drugs used lowincome senior citizens programmes state levels private plaintiffs rules including increasing rebate liability pharmaceutical regulations change governmental interpretation companies importation countries bulk purchases rules regulations evolve conduct group may called drugs given new state mandates contained us health question care reform law increase number medicaid eligible participants economic pressures state government budgets pricing pressures groups pharmaceutical vaccine products likely increase trends may materially adversely affect groups financial results gsk annual report regulatory controls materials services provided thirdparty suppliers necessary commercial production products group must comply broad range regulatory controls including speciality chemicals commodities components manufacturing testing approval distribution marketing necessary manufacture packaging many many pharmaceutical vaccine consumer healthcare groups pharmaceutical vaccine consumer healthcare products affect cost product development products thirdparty services procured example also time required reach market uncertainty services provided clinical research organisations support successfully historically stringent development key products important operation regulatory requirements developed markets however recent groups businesses although group undertakes years emerging markets increasing regulatory business continuity planning single sourcing certain expectations based national interpretations us components bulk active materials finished products services eu standards detailed health authorities creates risk failure supply event regulatory developed markets increased focus safety noncompliance physical disruption manufacturing sites assessing riskbenefit balance drugs context failure small number singlesource thirdparty suppliers initial product approval also context approval service providers fulfil contractual obligations timely additional indications review information regarding manner result regulatory noncompliance physical marketed products stricter regulatory controls also heighten disruption manufacturing sites may result delays service risk changes product profile withdrawal regulators interruptions may materially adversely affect basis postapproval concerns product safety groups financial results could reduce revenues result product recalls product liability lawsuits also greater regulatory scrutiny especially taxation treasury usa advertising promotion particular groups effective tax rate driven rates tax directtoconsumer advertising jurisdictions higher lower applied addition cases group may voluntarily cease uk addition many jurisdictions uk belgium marketing product face declining sales based concerns usa currently offer regimes encourage innovation new efficacy safety example decline sales scientific endeavours providing tax incentives example rd groups product avandia beginning following publicity tax credits furthermore given scale international nature around questions regarding risks associated product groups business intragroup transfer pricing inherent tax whether scientifically justified even absence risk international businesses changes tax laws regulatory action development postapproval adverse application respect matters transfer pricing event profile product product class may materially foreign dividends controlled companies rd tax credits adversely affect groups financial results restriction tax relief allowed interest intragroup debt could increase groups effective tax rate materially risk interruption product supply adversely affect financial results manufacture pharmaceutical vaccine products tax charge included financial statements groups constituent materials requires compliance good manufacturing best estimate tax liability time audits tax practice regulations groups manufacturing sites subject authorities concluded degree uncertainty review approval fda regulatory agencies regarding final tax liability period groups policy compliance failure groups manufacturing facilities submit tax returns within statutory time limits engage suppliers key services materials could lead product recalls tax authorities ensure groups tax affairs current seizures interruption production delays approval possible differences interpretation tax new products revoking license operate pending legislation regulation resolved quickly possible resolution manufacturing issues example noncompliance exceptional cases matters settled agreement current good manufacturing practice cgmp requirements tax authorities gsk may resolve disputes us supply could ultimately result severe formal appeals proceedings example january circumstances fines disgorgement profits supreme court canada heard appeal respect interruption supply incurring fines disgorgement groups transfer pricing discussed note financial impacting significant products markets could materially statements taxation adversely affect groups financial results group deals high value transactions frequent basis may result increased risk financial loss due mismanagement cash entering high risk positions hedge transactions could materially adversely affect groups financial results gsk annual report financial review risk factors continued risk number risks could affect financial december group trade receivables due condition results group follows three wholesalers totalling million december million group exposed concentration credit implementing groups strategic priorities risk respect wholesalers one group established three strategic priorities grow affected financial difficulty could materially adversely diversified business deliver products value simplify affect groups financial results operating model group may able implement global political economic conditions strategic priorities fully even group able implement strategic priorities may deliver expected benefits described many worlds largest economies including major markets group operates example strategic priority grow diversified business financial institutions recent past faced extreme financial involves expanding groups business emerging markets difficulty including decline asset prices liquidity problems groups pharmaceutical sales emerging markets grew limited availability credit economic uncertainty continued nearly billion represented groups multiple downgrades sovereign credit ratings pharmaceutical turnover guarantee particularly eurozone high levels sovereign debt groups sales emerging markets continue grow negatively impacting growth global economy uncertain markets continue experience relatively high growth long effects last whether economic financial rates emerging markets may especially vulnerable trends worsen improve ongoing debt crisis certain ongoing global financial crisis may limited resources countries europe increased pressures payers spend healthcare competition markets staff countries force healthcare companies group skills training suitable employment enterprise decrease price products debt crisis also given rise groups may intense emerging markets concerns countries may able pay group may required rely third party agents may products current economic conditions may also adversely affect put group risk liability emerging markets lack ability distributors customers suppliers service sufficient protection crimes counterfeiting failure providers pay products otherwise buy necessary continue expand business emerging growth markets inventory raw materials perform obligations could materially adversely affect groups financial results agreements us could disrupt operations addition group undertaking restructuring programme negatively impact business cash flow estimated cost approximately billion distributors customers suppliers service providers may expected deliver annual pretax savings approximately unable pay bills timely manner may even become billion time substantially complete insolvent could negatively impact business results group may able execute fully transformation operations risks may elevated respect business furthermore changes groups structure interactions third parties substantial operations operations revenues costs efficiency resulting countries current economic conditions severe restructuring activities strategic initiatives could result particularly third parties exposed higher expected costs difficulties failure realise risk business interactions directly fiscallychallenged expected cost savings end restructuring programme government payers achieve maintain competitive cost base could materially continued economic weakness uncertainty could adversely affect groups financial results materially adversely affect groups revenues results antibribery corruption operations financial condition groups businesses including pharmaceuticals vaccines consumer healthcare groups extensive increasing international operations may may particularly sensitive declines consumer government give rise possible claims bribery corruption failure spending addition renewed declines asset prices comply applicable legislation us foreign corrupt may result lower return groups financial investments practices act uk bribery act similar legislation may cause value groups investments pension countries could expose group senior officers civil plans decrease requiring group increase funding criminal sanction including fines prosecution potential debarment pension plans public procurement reputational damage could materially adversely affect groups financial results group conducts substantial portion operations outside compliance mechanisms monitoring programmes uk groups management foreign exchange rates group place may adequately prevent detect possible discussed business review foreign exchange management violations applicable antibribery corruption legislation see fluctuations exchange rates sterling currencies especially us dollar euro risk concentration sales wholesalers japanese yen could materially adversely affect groups usa similar pharmaceutical vaccine companies financial results group sells products small number wholesalers group control changes inflation interest addition hospitals pharmacies physicians groups rates foreign currency exchange rates controls sales three largest wholesalers amounted approximately economic factors affecting businesses possibility groups us pharmaceuticals vaccines turnover political unrest legal regulatory changes nationalisation jurisdictions group operates gsk annual report group operates number markets experiencing failure implement appropriate safeguards adequately protect political social unrest events may lead business unauthorised unintentional access acquisition use disruption liquidity problems could adversely impact modification loss disclosure critical sensitive data may groups results adversely impact groups ability maintain patent rights competitive advantages may result regulatory noncompliance environmental liabilities resulting fines penalties inability sell product environmental laws various jurisdictions impose actual particular market potential obligations group remediate contaminated alliances acquisitions sites group also identified potentially responsible party us comprehensive environmental part groups strategy diversify new product areas response compensation liability act number sites markets group grown expects continue remediation costs relating groups use ownership grow part acquisitions business alliances sites failure manage properly environmental risks could intense competition alliance acquisition candidates result additional remedial costs may materially adversely pharmaceutical industry group may unable affect groups financial results see note financial make deals acceptable terms acquiring statements legal proceedings discussion environmental forming alliances companies group may assume related proceedings group involved group significant debt become subject unknown contingent routinely accrues amounts related liabilities matters liabilities fail realise benefits expected transactions example pharmaceutical companies accounting standards including group may consider acquiring involved new revised accounting standards rules interpretations patent disputes product liability litigation government issued time time international accounting standards investigations legal proceedings whose outcome board could result changes recognition income subject considerable uncertainty assumption debt expense may materially adversely affect groups unknown contingent liabilities failure realise financial results expected benefits may materially adversely affect groups financial results international financial reporting standards changes market valuation certain financial instruments required process integrating companies group may acquire may reflected groups reported results gains result disruption ongoing business effort losses actually realised could significant impact integrating organisations different locations among income statement given period accounting deferred things differing systems corporate cultures may divert taxation intercompany inventory may give rise volatility attention resources result loss key employees depending upon group entity owns inventory adverse consequences may materially adversely affect groups financial results regulators regularly review financial statements listed companies compliance accounting regulatory attraction retention requirements group believes complies group relies heavily recruiting retaining talented appropriate regulatory requirements concerning financial employees range skills capabilities meet statements disclosures however companies objectives group faces intense competition qualified experienced investigations potential noncompliance individuals supply people specific skills accounting disclosure requirements resulted significant leadership potential specific geographic regions restatements previously reported results sometimes may limited particularly given groups plans expand significant penalties investigation required operations emerging markets vaccines restatement could materially adversely affect groups financial results inability attract staff specific technical leadership skills retain key employees ensure effective succession planning protection electronic information assets critical positions may materially adversely affect groups group relies critical sensitive data corporate ability implement key strategic objectives ultimately impact strategic plans personally identifiable information trade secrets financial results intellectual property drive planning operations security type data exposed escalating external threats increasing sophistication changing goal disruption financially politically motivated group also subject various standards protection personally identifiable information year submitted application binding corporate rules status review uk information commissioners office gsk annual report governance remuneration board board responsible longterm success company corporate governance strategy risk management financial performance sir christopher gent committee memberships sir andrew witty audit risk professor sir roy anderson b remuneration dr stephanie burns c nominations stacey cartwright corporate responsibility larry culp sir crispin davis n ot standing reelection agm simon dingemans judy lewent n ot standing reelection agm sir deryck maughan james murdoch dr daniel podolsky dr moncef slaoui tom de swaan sir robert wilson trakcorc niai dna skoorb egroeg gsk annual report sir christopher gent stacey cartwright sir deryck maughan chairman b c nonexecutive director nonexecutive director c appointed board june appointed april stacey joined burberry appointed june sir deryck partner chairman january sir christopher group plc chief financial officer kohlberg kravis roberts co nonexecutive chairman nominations corporate appointed executive vice president chief financial director thomson reuters blackrock inc responsibility committees nonexecutive officer june previously held role well serving board directors lincoln director ferrari spa member kpmgs chief financial officer egg plc center trustee new york university chairmans advisory group senior adviser worked various langone medical center formerly chairman bain co sir christopher formerly chief executive financerelated positions granada group plc chief executive officer citigroup international officer vodafone group plc retirement salomon brothers inc july also formerly nonexecutive larry culp director lehman brothers holdings inc nonexecutive director b c james murdoch nonexecutive director b sir andrew witty appointed july larry president chief executive officer danaher corporation prior appointed may james deputy chief chief executive officer joining danaher held positions accenture operating officer chairman chief executive appointed october chief executive previously andersen consulting officer international news corporation also officer designate may chief nonexecutive chairman bskyb plc non executive officer ceo sir andrew joined group sir crispin davis executive director sothebys previously served held senior positions asia pacific nonexecutive director b c chief executive officer bskyb plc south africa usa immediately prior star tv appointed ceo president gsk pharmaceuticals appointed july sir crispin chairman europe position held january sir remuneration committee chairman dr daniel podolsky andrew served numerous advisory roles director starbev netherlands bv member nonexecutive director scientific expert governments around world including south africa citigroups global advisory board serves singapore guangzhou china currently council oxford university sir crispin previously appointed july daniel president member prime ministers business advisory chief executive officer reed elsevier plc prior university texas southwestern medical center group lead nonexecutive board member appointment chief executive aegis group holds phillip obryan montgomery jr department business innovation skills plc joined guinness plc md distinguished presidential chair academic board member insead business member main board group managing administration doris bryan wildenthal school january sir andrew president director united distillers earlier career distinguished chair medical science european federation pharmaceutical industries worked procter gamble president member institute medicine us national associations awarded knighthood north american food division academy sciences member board services economy uk pharmaceutical southwestern medical foundation director industry new year honours simon dingemans antibe therapeutics inc chief financial officer professor sir roy anderson dr moncef slaoui appointed january chief financial officer nonexecutive director scientific expert designate april chief financial officer chairman research development appointed october sir roy professor cfo simon joined gsk goldman sachs appointed may moncef joined gsk infectious disease epidemiology faculty managing director partner biologicals engineered medicine imperial college london member years experience investment banking development robust vaccines pipeline international advisory board hakluyt co goldman sachs simon worked gsk subsequently led worldwide business development ltd trustee natural history museum london decade closely involved number gsks pharmaceuticals appointment lead fellow member science policy advisory strategic projects including establishment rd moncef given overall responsibility gsks group royal society fellow viiv healthcare oncology business gsk vaccines academy medical sciences royal statistical phd molecular biology society sir roy member international judy lewent immunology universit libre de bruxelles advisory board hiv monitoring foundation nonexecutive director tom de swaan honorary fellow institute actuaries appointed april judy served executive foreign associate member institute medicine nonexecutive director b vice president chief financial officer merck us national academy sciences french co inc september also director appointed january tom chairman academy sciences former positions include thermo fisher scientific inc motorola solutions audit risk committee chairman rector imperial college chief scientific adviser inc served boards motorola inc supervisory board vanlanschot bankiers member ministry defence uk may dell inc board directors zurich financial services dr stephanie burns previously served board quaker oats nonexecutive member kpmg europe llps company since judy served boards public interest committee tom also vice chairman nonexecutive director purdue pharma inc napp pharmaceutical holdings supervisory board chairman audit appointed february stephanie limited certain mundipharma international limited committee royal ahold member formerly chairman president chief executive companies nonexecutive director also supervisory board royal dsm previously officer dow corning corporation trustee chairperson audit committee member managing board chief financial retirement december stephanie rockefeller family trust life member officer abn amro appointed nonexecutive director corning inc massachusetts institute technology corporation january sits us presidents export member american academy arts sir robert wilson council former chairman american sciences nonexecutive director senior independent chemistry council also officer society director c chemical industry america section also appointed november sir robert currently served boards michigan molecular nonexecutive chairman bg group plc institute society womens health research steps may previously executive chairman rio tinto plc retirement october chairman economist group gsk annual report governance remuneration corporate executive team corporate executive team supports chief executive officer management business activities sir andrew witty david pulman simon bicknell david redfern john clarke moncef slaoui deirdre connelly jean stphenne simon dingemans claire thomas marc dunoyer phil thomson eddie gray dan troy abbas hussain patrick vallance bill louv emma walmsley sppihw mot dna neslin nairb nala trakcorc niai skoorb egroeg gsk annual report sir andrew witty bill louv phil thomson chief executive officer senior vice president core business services senior vice president global communications chief information officer see phil appointed senior vice president global bill appointed chief information officer january communications august responsibility simon bicknell addition role appointed media relations investor relations corporate senior vice president governance ethics create lead core business services global responsibility global community partnerships assurance multifunction shared service april prior internal product business communications current role bill senior vice president rd phil joined glaxo wellcome commercial trainee simon appointed role january information technology bill joined gsk responsible risk management compliance vice president medical data sciences internal auditing data privacy security office dan troy product quality formerly svp company david pulman senior vice president general counsel secretary corporate compliance officer simon president global manufacturing supply joined corporate secretariat dan joined gsk senior vice president general appointed company secretary glaxosmithkline plc david responsible global manufacturing counsel september may combined position role supply organisation global procurement partner washington law firm sidley austin llp corporate compliance officer april joined glaxo broad experience chief counsel fda current appointment manufacturing operations previously led chaired american bar associations section primary supply european manufacturing north administrative law previously adjunct john clarke american manufacturing global logistics scholar american enterprise institute president consumer healthcare worldwide manufacturing strategy organisations washington dc john appointed president consumer healthcare david redfern patrick vallance january october inline agreed chief strategy officer president pharmaceuticals rd succession planning handed responsibility emma walmsley john continue member david responsible proactive exploration appointed president pharmaceuticals rd january corporate executive team march joined new business opportunities strategic planning patrick joined gsk may head drug beecham president future global leadership dermatology business discovery focused organisation science group current appointment january also chairman board viiv healthcare best chance leading new medicines ltd began career gsk corporate created small multidisciplinary teams called discovery deirdre connelly development appointed finance director performance units united discovery president north america pharmaceuticals europe pharmaceuticals appointed development create therapy area units group area director central europe northern led recent appointment patrick clinician deirdre joined gsk february working europe academic led division medicine eli lilly company years held variety university college london joining gsk positions including sales professional general moncef slaoui manager puerto rico senior vice president chairman research development emma walmsley human resources recently president president consumer healthcare worldwide us operations see emma assumed role president consumer simon dingemans jean stphenne healthcare worldwide october joining chief financial officer chairman president biologicals gsk may president consumer healthcare europe joined gsk loral worked see jean led gsks global vaccines business since years holding variety marketing general previously vice president human vaccines management roles paris london new york marc dunoyer research development production joined emma based shanghai general global head gsk rare diseases chairman group head bacterial viral manager consumer products loral china gsk japan vaccines production jean named baron king joining loral emma worked strategic consultancy albert ii belgians recognition usa uk marc appointed chairman gsk japan january leading contribution rd industry belgium february lead gsks rare diseases business rd commercialisation joined claire thomas group previously president senior vice president human resources pharmaceuticals japan january may president pharmaceuticals asia pacific claire leads global human resources hr japan may july function responsible gsks environmental sustainability strategy previously oversaw hr eddie gray pharmaceuticals international pharmaceuticals president pharmaceuticals europe europe claire joined group appointed director human resources uk eddie became responsible groups operations pharmaceuticals claire honoured europe january joined beecham outstanding european woman achievement prior current appointment senior vice president general manager pharmaceuticals uk abbas hussain president emerging markets asia pacific abbas joined gsk june eli lilly company spent years overseeing markets throughout europe africamiddle east australasia gsk annual report governance remuneration corporate governance dear shareholder good corporate governance provides structure delivering companys strategy fundamental sound decisionmaking process supports executive management achieving maximum performance business chairman recognise leadership board critical encouraging open transparent debate discussion constructive challenge support uk corporate governance code welcomed introduction financial reporting councils uk corporate governance code code report year structured report corporate governance arrangements practice five sections one new provisions code requirement directors retire year annual general meeting agm wish continue office offer election reelection shareholders complied provision ahead time agm intend follow practice going forward also conducted second external board evaluation year line code intend continue external evaluation every three years board composition year board reviewed composition made number changes ensure membership continuously refreshed provides leadership expected take global business forward simon dingemans appointed board january succeeded julian heslop cfo april james murdoch decided stand reelection years agm process refreshing board continues three nonexecutive directors sir crispin davis sir robert wilson larry culp completed nine years service offer reelection agm next year replacing directors priority given candidates knowledge emerging markets chief executive officers global companies support initiatives increase diversity boards public companies although view diversity much wider context gender diversity reflected wide range backgrounds skills board members year pleased welcome judy lewent stacey cartwright bring particular experience global business finance nonexecutive directors completing tailored induction programmes already active contributors board debate management risk current uncertain economic climate recognise important maintain increased focus risk spent significant amount time resources assessment monitoring risk throughout group led audit risk committee oversees risk management internal control activities antibribery corruption programme enhanced following introduction uk bribery act gsk annual report communications shareholders value open constructive effective communication shareholders ceo sir andrew witty cfo simon dingemans continued regular dialogue major shareholders holding meetings shareholders year also attended meetings chairman remuneration committee sir crispin davis discussed remuneration policy governance matters always available meet shareholders would anticipate continue programme meetings year corporate governance debate debate good corporate governance continues national eu international level sought contribute debate responding numerous consultation documents issued subject feel strongly companies advisers representative bodies contribute structure governance processes going forward corporate governance report follows sets complied code sir christopher gent chairman march gsk annual report governance corporate governance continued remuneration governance policy senior independent director sir robert wilson senior independent director since section describes management structure governance may role act sounding board procedures together remuneration report pages chairman trusted intermediary directors includes details applied complied also available additional point contact shareholders principles provisions code us legislation responsibilities include evaluation performance regulations copy code available financial chairman request chairman evaluating reporting councils website wwwfrcorguk throughout board committees collaboration committee complied provisions code except larry chairmen years evaluation conducted internally culp unable attend agm due another pressing senior independent director also works chairman business commitment process selection new chairman appropriate leadership chairs nominations committee agreeing recommendation board chairmans successor board sir robert maintains understanding issues concerns board responsible longterm success company major shareholders meetings shareholders accountable shareholders ensuring group reports investor relations team appropriately managed achieves strategic objectives sir deryck maughan succeed sir robert senior independent board also responsible system corporate governance director effect end agm strategy risk management financial performance ceo sir christopher gent led board chairman since january board comprises three executive directors ceo sir andrew witty responsible management nonexecutive directors including chairman executive business developing groups strategic direction directors ceo cfo chairman research consideration approval board implementing development agreed strategy ceo assisted members cet biographies directors given board meets least times year often required pages short biographies members cet given corporate executive team pages chairman company secretary role chairman lead manage business board provide direction focus ensuring company secretary victoria whyte appointed clear structure effective operation board january solicitor fellow institute committees sets agenda board discussions promote chartered secretaries administrators victoria formerly effective constructive debate support sound deputy secretary secretary remuneration committee decisionmaking process ensuring board receives acted secretary board boards accurate timely clear information particular committees since appointment company secretary companys performance victoria supports chairman delivery corporate chairman works closely ceo ensure governance agenda particular planning agendas strategies actions agreed board effectively annual cycle board committee meetings ensuring implemented provides support advice ceo information made available board members timely respecting executive responsibility managing group fashion advises directors board procedures division responsibilities chairman ceo corporate governance matters arranges nonexecutive agreed board set governance section directors attend internal management meetings visits website business operations chairman responsible performance group example year larry culp visited gsks site shareholders leads discussions development shanghai china also met chairman general manager relations gsk india mumbai tom de swaan attended various internal compliance assurance meetings well conference chairman considered independent character audit assurance team stacey cartwright visited gsks judgement appointment manufacturing site ware hertfordshire nonexecutive directors nonexecutive directors provide strong independent element board well placed constructively challenge support management help develop proposals strategy bring experience independent judgement gained senior levels international business operations academia gsk annual report corporate governance framework board monitors performance group whole e ngaging board meetings challenging ceo members cet appropriate financial operating performance group external issues material groups prospects e valuating progress towards achievement groups financial business objectives annual plans nonexecutiv e directors scrutinise performance management meeting objectives plans onitoring reports received various committees significant risks facing group board appraises approves major financing investment licensing decisions excess defined thresholds ceo accountable reports board performance business board discharges responsibilities annual programme meetings include approval overall budgetary planning business strategy board chairman executive directors independent nonexecutive directors audit risk committee remuneration committee nominations committee independent independent nonexecutive independent nonexecutive chief executive nonexecutive directors directors chairman directors chairman officer corporate responsibility finance committee corporate administration committee executive nonexecutive transactions committee cet independent nonexecutive directors directors cet members directors chairman company secretary key board committees management committee board ultimately responsible activities group strategy governance risk management financial performance following matters specifically reserved board strategy approval strategic plans ensuring strategic objectives achieved major organisation changes acquisitions disposals licensing transactions mergers joint ventures governance composition board committees approval appointments succession plans executive directors cet members senior management terms employment corporate governance matters groups code conduct risk management determination groups risk appetite risk management policies monitoring major risks exposures review approval internal controls risk management policies processes financial performance appropriation distribution profits capital investments regular reviews business performance objectives gsk annual report governance corporate governance continued remuneration board met six times member attending board agenda follows agendas board meetings included number number following business meetings held whilst meetings board member attended january review board evaluation report sir christopher gent review investor relations strategy sir andrew witty review financial results simon dingemans review notice agm dr moncef slaoui consideration reappointment auditors professor sir roy anderson review rd commercial interface dr stephanie burns review risk internal control processes stacey cartwright march annual review biologicals operations larry culp annual review gms sir crispin davis update investor relations strategy judy lewent sir deryck maughan may review financial strategy james murdoch annual review european operations dr daniel podolsky annual review operations japan tom de swaan agm preparation sir robert wilson review licensing capital projects julian heslop july review changes financial strategy simon dingemans appointed director january consideration funding strategy tacey cartwright judy lewent appointed nonexecutive consideration tax strategy directors april julian heslop retired early director march annual review rd annual review talent leadership addition scheduled meetings board also met development strategy quorate basis three occasions october annual review projects transactions approved director unable attend board committee meeting board still receives papers materials discussion annual review us pharmaceuticals meeting review advise chairman vaccines operations committee chairman views comments annual review emerging markets asia pacific matters discussed conveyed operations members meeting december review board evaluation report approval plan consideration external economic environments impact pharmaceuticals sector review strategy diseases developing world b oard agendas shaped create time strategic discussion debate including deep dive reviews key issues business ensure focused consideration strategic priorities items asterisk represent deep dive reviews took place addition meeting board receives regular updates ceo groups operations reports cfo financial performance updates developments companys compliance corporate governance requirements regulations company secretary cet members make regular presentations board areas responsibility directors meet cet members annual basis discuss develop proposals collectively relation groups strategy gsk annual report board committees meet best corporate governance practice audit risk remuneration nominations corporate responsibility committees long established part system corporate governance summary terms reference board committee set table full terms reference available website reports committee including activities year attendance meetings given pages minimum number meetings committee committee role terms reference membership per year report pages audit risk reviews financial internal reporting process independent integrity financial statements system internal nonexecutive directors controls identification management risks external internal audit processes committee also proposes shareholders appointment external auditors directly responsible remuneration oversight work remuneration determines terms service remuneration independent executive directors members cet nonexecutive directors assistance external independent advisers evaluates chairman makes recommendations board overall executive remuneration policy chairman ceo responsible evaluating making recommendations board remuneration nonexecutive directors nominations reviews structure size composition board independent appointment members board cet nonexecutive directors making recommendations board appropriate chairman committee also monitors planning succession board cet corporate provides boardlevel forum regular review independent responsibility external issues potential serious impact nonexecutive directors upon groups business reputation committee chairman also responsible oversight gsks worldwide donations community support finance reviews approves behalf board annual executive necessary report form f convening agm together nonexecutive directors preliminary quarterly statements trading results also approves certain major licensing capital transactions changes groups investment instrument counterparty limits corporate reviews approves matters connection executive necessary administration administration groups business certain corporate nonexecutive transactions transactions directors cet members company secretary gsk annual report governance corporate governance continued background gender remuneration academia female pharmaceutical male healthcare general business effectiveness breakdown experience directors different regions world set board composition number directors experience seek build effective complementary board whose capability appropriate scale complexity strategic positioning business process board appointments led nominations committee described pages mindful need balance composition board committees refresh progressively time draw upon experience longer serving directors tapping new external perspectives insights recent appointees bring boards deliberations europe us emap global nonexecutive directors drawn wide range industries emerging markets asia pacific backgrounds including pharmaceutical healthcare medical time allocation research academia media retail financial services appropriate experience complex organisations global reach nonexecutive director letter appointment sets considerable experience pharmaceutical industry terms conditions directorship recent appointees bring new approach group boards discussions chairman nonexecutive directors expected devote time necessary proper performance january simon dingemans appointed board duties precise timings given vary year year chief financial officer designate assumed role cfo depending companys activities directors expected april succession julian heslop retired early attend board meetings additional meetings required board march april judy lewent also expected attend meetings committees stacey cartwright appointed nonexecutive directors members latter parts audit risk part boards ongoing refreshment programme committee meetings open directors strategy changes board announced january sessions make visits operational sites addition board james murdoch offer reelection agm members invited attend least one cet meeting year agm following nine years service may attend certain research development executive sir crispin davis sir robert wilson larry culp stand operational meetings reelection board length tenure board diversity length tenure independence nonexecutive committed equal opportunities recruitment director shown employees board members representing elements considered society aspire create inclusive environment date first years seek value draw differing knowledge perspectives elected first election independent experiences styles resident global community shareholders agm board sir christopher gent may good representation women management professor sir roy anderson may positions recognise need increase dr stephanie burns may proportion female employees senior levels stacey cartwright may company well board currently directors larry culp may female would like increase least sir crispin davis may made progress towards achieving judy lewent may objective appointment judy lewent sir deryck maughan may stacey cartwright james murdoch may backgrounds gender mix directors illustrated dr daniel podolsky may tom de swaan may background gender sir robert wilson may considered independent appointment academia female board considers nonexecutive directors pharmaceutical male independent character judgement free healthcare business relationship could materially interfere general exercise judgement throughout business nonexecutive directors excluding chairman independent nonexecutive directors met criteria independence set code number directors experience date publication throughout majority board members excluding chairman independent nonexecutive directors europe us emap global emerging markets asia pacific gsk annual report board induction training company secretary assists chairman designing facilitating tailored induction programme new directors ongoing training induction programme nonexecutive directors includes meetings members cet senior executives explain companys business environment operate investors perspective well guidance duties obligations director gsk visits business operations also part induction programme ensure nonexecutive directors gain maintain greater insight understanding business invited attend internal management meetings including meetings cet research development executive portfolio investment board scientific review board risk oversight compliance council also meet employees visits companys operations receptions held around board meetings board kept date legal regulatory governance matters regular papers company secretary presentations internal external advisers year board briefed boardroom diversity various developments narrative reporting executive remuneration risk management impact uk eu reviews audit market market abuse insider trading compliance new uk bribery act developments corporate governance reporting including european commissions review comply explain principle chairman meets director annually onetoone basis discuss individual performance contribution agree ongoing training development requirements board evaluation board carries evaluation performance performance committees every year evaluation normally carried senior independent director every third year evaluation conducted external facilitator dr tracy long boardroom review carried evaluation also conducted evaluation dr long connection company action points previous board evaluations set table date action progress utilise board committee time effectively board committee papers reviewed appropriateness timeliness facilitate contribution nonexecutive circulation improved meetings structured create time directors debate enhance continuous education process nonexecutive directors encouraged attend range internal nonexecutive directors management meetings visit group sites provide greater visibility executive talent annual presentation made board executive talent succession management succession planning process plans opportunities emerging talent meet board included annual board committee programmes increase board time devoted strategic discussion board increased focus rd activities pleased indicators success delivery progress rd year separately february remuneration rd pipeline committee granted incentive awards linked rd new product performance devote time focused consideration board sought assistance audit risk committee arc companys key risks ongoing basis fully understand groups key risks continued consider regular reports arc provide board regular updates board pleased operation nominations committee insights newly enhanced management enhanced succession planning process resulted appointment succession planning process chief financial officer designate positive progress made recruitment new board members refresh board appointment stacey cartwright judy lewent nonexecutive directors allocate time regular basis strategic board agendas revised create time strategic discussion issues significant challenges facing debate fundamental reviews key issues introduced ensure industry enhance returns shareholders focused consideration strategic priorities enhance information flow providing board members provided external reports reviews industry board members wider variety external company inform deliberations perspectives company industry assess extent new rd policies board programme enhanced inclusion deep dive implemented recent years added value discussions aspects rd rd commercial interface diseases developing world continue support executive management groups compliance function reviewed enhanced provide ethical leadership within group support management driving ethical leadership across group gsk annual report governance corporate governance continued remuneration board evaluation summary conclusions committee evaluations included committees report board evaluation process included onetoone interview director company secretary topics discussed nonexecutive directors led senior independent director circulated directors advance included met separately without chairman present discuss variety aspects associated board effectiveness including chairmans performance considered leadership board committee information flows handling strategic performance overall contribution high standard issues collective effectiveness exploration ways addition chairman met nonexecutive directors improve way board operates independently executive directors key conclusions evaluation presented reelection directors discussed board agm entire board retired offered consistent dr longs findings review concluded election reelection director elected reelected board highly effective way approached director received less votes cast work developed relationships used time ceo agm directors retire executive management welcoming nonexecutive exception james murdoch offer reelection directors quality debate high strong leadership chairman committee chairmen use james murdoch decided stand reelection board board dinners board calendar agendas following decision relocate united states focus effective previously reviewed quality duties deputy chief operating officer chairman papers presentations improved chief executive officer international news corporation role nonexecutive chairman bskyb challenge given environment within company operated build boards contribution impact directors standing reelection subject formal evaluation process believed continue board agreed following recommendations view effective demonstrate commitment respective increasing ability add value roles accordingly board recommends shareholders external landscape approve resolutions proposed agm relating reelection directors board agenda dedicate time throughout year fo r consideration major external influences including sir crispin davis sir robert wilson larry culp tom de swaan competitive business models market developments gsks served nonexecutive directors six relative strengths weaknesses help expand boards years performance subject rigorous review knowledge board concluded continue effective nonexecutive directors board would look increase understanding knowledge individual nonexecutive director board directors conflicts interest site visits directors duty companies act avoid g iven size board important nonexecutiv e situation could direct indirect directors assisted company secretary continued engage conflict interest possible conflict authorisations formally informally company drawing company duty applies particular exploitation relevant personal experience inside outside board meetings property information opportunity whether gsk could attending relevant internal executive meetings industry take advantage articles association provide general events keep abreast current developments power board authorise conflicts anagement demonstrate board nominations committee authorised board embedding culture risk awareness within emerging grant periodically event annually review markets emerging risks captured within potential actual conflict authorisations directors assurance process counted quorum authorisation actual potential conflicts authorisations granted recorded ii board contribution composition company secretary register noted board board opportunity build relevant skills next meeting competencies future composition due change ongoing basis directors responsible informing next two years would helpful board plan company secretary new actual potential conflicts composition next five six years optimise may arise changes circumstances may effectiveness affect authorisation previously given even provided directors identified two significant gaps board authorisation director absolved statutory current composition global ceo experience knowledge duty promote success company actual conflict experience emerging markets aspects arises post authorisation board may choose exclude addressed recruitment new board members director receipt relevant information participation nominations committee debate suspend director board last resort require director resign gsk annual report nominations committee reviewed register potential also attach importance clear principles procedures conflict authorisations october reported board designed achieve appropriate accountability control conflicts appropriately authorised group policy risk management legal compliance mandates process authorisation continues operate effectively business units establish processes managing monitoring risks significant businesses group independent advice business units majority global support functions board recognises may occasions one prepare reports annually collaboration global compliance directors feel necessary take independent legal see summarising risk management activities andor financial advice companys expense reports reviewed relevant risk management agreed procedure set website enable compliance board rmcb operation subsequently reported risk oversight compliance council rocc indemnification directors arc qualifying third party indemnity provisions defined risk oversight compliance council companies act force benefit directors rocc council senior executives authorised board former directors held office signing assist arc overseeing risk management internal annual report control activities group membership comprises several cet accountability members company secretary heads departments internal control risk management assurance internal control framework audit compliance responsibilities board recognises responsibility present balanced rocc meets regular basis review assess significant understandable assessment groups position prospects risks mitigation plans provide oversight internal controls ensure compliance applicable laws regulations board accountability reviewing approving internal policies rocc responding group risk adequacy effectiveness internal controls operated management legal compliance policy provided group including financial operational compliance controls business units framework risk management upward risk management board delegated responsibility reporting significant risks mitigation planning identification review audit risk committee arc receives regular individual overall responsibility management reporting aligned assurance programme given risk mandatory responsibility management cet risk management compliance boards implement board policies risk control cet responsible identifying approving monitoring enforcing key policies rmcbs established major business units go heart group conducts business often comprise members senior executive team respective business unit augmented specialists internal control framework includes central direction resource appropriate rmcbs oversee management risks allocation oversight risk management key activities considered important respective business units including rd manufacturing marketing sales legal human resources risks designated significant gsk whole information systems financial practice part thus increasing number risks actively managed framework financial planning system annual across group budget approved board results operating units reported monthly compared budget forecasts business unit global support function must periodically prepared regularly year review significant risks facing operations review include identifying operational risks legal compliance risks risks also place established procedures identify achievement strategic goals objectives review consolidate reporting entities control activities include policies generally occurs annually embedded within practices covering appropriate authorisation approval aligned annual planning process ensure significant transactions application financial reporting standards risks identified changes management direction reviews significant judgments financial performance external environment extensive financial regulatory operational controls procedures risk activities reviewed groups internal auditors responsibility risk management control clearly delegated local business units supported regional management structure principles designed provide environment central leadership coupled local operating autonomy framework exercise accountability control within group gsk annual report governance corporate governance continued remuneration internal control framework interaction various elements set risk oversight audit risk compliance committee council risk global management quality compliance council boards global business units product audit assurance quality office independent external audit emerging business business internal review business regulatory incidents risk control quality audit business unit monitoring agency events management infrastructure heads activity internal outcome audit activity gsk risk universe management quality internal assurance audit global compliance global compliance conducted review global strategy structure supporting processes focus rocc rmcbs assisted global compliance standardisation simplification intention providing department responsible supporting development consistent effective oversight within increasingly implementation practices facilitate employees complex business model compliance laws group policy year global compliance leadership team agreed thrust compliance efforts promotion ethical global strategy common roles responsibilities baseline behaviour corporate responsibility accordance expectations organisation held accountable values due diligence preventing detecting misconduct new global compliance organisation comprises three groups noncompliance laws regulations supported effective compliance systems g lobal compliance business partners aligned business unit role proactively partner senior employees encouraged seek help report concerns leaders drive values compliancebased culture suspected cases misconduct without fear retaliation improve risk identification management practices employees line management via integrity confidential reporting lines managed global g lobal compliance operations centrally manages compliance compliance concerns allegations fairly activities eg analytics reporting communications policy independently investigated disciplinary action applicable administration project management training focus commensurate issues presented efficiency consistency continuous improvement global compliance department managed head g lobal compliance investigations coordinates compliance governance ethics assurance cet member reports related investigations ensuring consistency efficiency directly ceo chairs rocc provides summary investigations across geographies business units reports roccs activities groups significant risks cet arc regular basis direct reporting line arc provides mechanism bypassing executive management need ever arise gsk annual report global product quality office assurance excellence operations provides central oversight support drive integration holistic assurance delivery raise new central global product quality office standards assurance enhanced talent development established strengthen independence leadership continuous improvement benchmarking quality oversight governance good manufacturing practice gmp product enhance assurance reporting business units arc quality activities company wide regarding state control key risks organisation global product quality office provide common deliver assurance emerging risks gsk strategic governance framework risk area oversight risk evaluations sres responsibility developing common quality standards sres supplement internal audit programme examining systems across gsk manufacture consumer emerging risks facing gsk sres conducted assurance pharmaceutical vaccine products accordance gmp teams partnership business approach designed chief product quality officer serves ultimate evaluate risk areas enable development implementation independent central point contact escalation product andor evolution appropriate mitigation plans quality issues anywhere across group need resolution additional attention antibribery corruption programme abac part response risk bribery corruption builds audit assurance values existing standards form comprehensive audit assurance responsibility independently assessing practical approach compliance complex risk area adequacy effectiveness management significant abac programme overseen antibribery corruption risk areas reporting outcomes arc line team provide advisory support routine audits risk agreed assurance plan internal audit group comprised details abac programme available website seven principal teams focused following areas head audit assurance acts global risk officer c ommercial financial internal audit support director risk management risk management responsible maintaining gsks risk nformation technology internal audit management framework supporting business identifying anufacturing internal audit including environment health key risks management risks owned business safety sustainability see risk management r internal audit arc ongoing oversight effectiveness audit assurance review assurance plan related ssurance excellence operations delivery commitments well periodic quality ntibribery corruption assessment reviews conducted external auditors r isk management assurance reporting internal audit activity conducted single organisation assurance reporting arc follows structured programme leadership head audit assurance integrating reporting business units audit assurance reports head governance ethics assurance business units majority global support functions also independent reporting line arc chairman prepare reports annually detail risk management global audit function allows holistic assurance compliance approaches providing balanced assessments consistency approach independence reporting status internal controls key risks highlighting helped eliminate overlaps gaps potential significant compliance issues support functions report least auditing biennially managers must oversee risks considered internal audit undertakes continuous process risk assessment important respective business units including risks contributes evolution audit strategies designated significant group information compilation delivery audit schedule approach regarding controls place manage risks provided allows audit assurance respond expeditiously changes assure arc risks adequately managed within business risk environment ensure audit internal control framework strategies fitforpurpose addition significant compliance issues internal audit results issues control deficiencies identified escalated rocc arc earliest opportunity audit engagements internal audit recommends processes improvement managers develop corrective action plans address causes noncompliance gaps internal controls internal audit tracks plans completion reports results executive management arc internal audit results also compiled reported rocc arc detailed assurance reporting section gsk annual report governance corporate governance continued remuneration risk management relations shareholders risk management programme extends beyond legal work engage effectively shareholders regulatory issues considers overall strategy changes regular communications agm investor relations external environment furthermore risk management principles activities embedded within management practices part business strategy objective setting process announce financial results quarterly basis annual results included annual report shareholders receive details risks affecting group see risk factors annual summary leaflet advises annual pages note financial statements report notice annual general meeting available legal proceedings website monitoring risk effectiveness controls ceo cfo give live presentations institutional investors internal control framework operation whole analysts media half full year results year review continues operate date also available via webcast teleconference first approval report system internal controls designed third quarter results hold webcast teleconferences manage rather eliminate risk achieving business audience results available website objectives provide reasonable absolute investor relations department offices london assurance material misstatement loss philadelphia acts focal point communications arc receives reports areas significant risk group investors ceo cfo chairman maintain continuous related internal controls following consideration dialogue institutional shareholders performance plans reports received via assurance framework arc objectives programme regular meetings reports annually board effectiveness controls year meetings held major shareholders areas business necessary take risks company secretary acts focal point communications achieve satisfactory return shareholders investment corporate governance matters also small central rd acquiring new products businesses corporate responsibility cr team coordinates strategy arc conjunction full board considered reviewed policy development reporting specifically respect cr nature extent risks risks associated communicates socially responsible investors achieving companys strategic objectives stakeholders cases objective apply expertise prudent chairman also meets regularly institutional shareholders management rather elimination risk boards review hear views discuss issues mutual importance relates company subsidiaries extend communicates views members board material associated undertakings joint ventures senior independent director nonexecutive directors investments although considers risk participation available meet shareholders activities remuneration committee chairman chairman head board arc reviewed assessment risks human resources company secretary hold annual internal control framework operates gsk meetings major shareholders discuss executive considered effectiveness system internal control remuneration governance matters operation group year covered report briefing process place managed chairman date approval board process followed nonexecutive directors focus sector specific issues board reviewing system internal controls accords general shareholder preferences guidance internal control issued turnbull committee agm accordance new provisions uk corporate governance code provide board responsible agm held london notice given shareholders determining nature extent significant risks willing least one month meeting agm includes take achieving strategic objectives board provides presentation business directors answer shareholder oversight ensure gsk maintains sound risk management questions meeting informally afterwards internal control systems directors attended agm may exception larry culp unable attend due pressing business remuneration commitment arising responsibilities president chief executive officer danaher corporation sir deryck maughan remuneration report describes level participated meeting telephone unable components remuneration directors set travel pages voting resolutions agm poll full results including votes withheld published website gsk annual report total votes cast resolution ranged billion shareholders entitled appoint one proxies attend shares percentages votes shown agm speak vote behalf provided table together number votes withheld event single shareholder appoints multiple proxies resolution please note vote withheld vote law proxy appointed exercise rights attached different counted calculation proportion votes share shares held member resolution share capital control total total votes votes votes details issued share capital number shares held withheld treasury december found note million financial statements share capital share premium account adoption financial statements shares listed london stock exchange also approval remuneration quoted new york stock exchange nyse form report american depositary shares ads ads represents two election reelection ordinary shares directors reappointment auditors holders ordinary shares entitled receive dividends remuneration auditors declared companys annual report attend speak authorise company general meetings company appoint proxies make donations political exercise voting rights organisations incur political restrictions transfer limitations expenditure holding ordinary shares requirements obtain prior authority allot shares approval transfers ordinary shares carry special disapplication preemption rights regard control company rights restrictions voting rights major shareholders authority company voting rights per share shareholders purchase shares exemption statement known arrangements financial rights senior statutory auditors name held person holder shares known reduced notice general agreements restrictions share transfers voting rights meeting agm shares acquired share schemes plans rank equally ncludes discretionary votes shares issue special rights indicates special resolution trustees employee share ownership plan trusts waived rights dividends shares held trusts agm held may queen elizabeth ii conference centre broad sanctuary westminster london change control essential contracts swp ee business proposed meeting together contracts arrangements individually explanatory notes set separate notice fundamental ability business operate effectively meeting ordinary business meeting include company party material agreements would r eceiving adopting annual report take effect altered terminate upon change control pproving remuneration report following takeover bid retirement reelection directors agreements director would provide reappointment remuneration auditors compensation loss office employment resulting takeover except provisions companys share plans may special business seek authority cause options awards granted plans vest ake donations eu political organisations incur eu takeover details termination provisions companys political expenditure framework contracts executive directors given llot ordinary shares company interests voting rights llow directors disapply preemption rights allotting stated far aware new shares connection rights issues otherwise persons significant direct indirect holdings company maximum current issued share capital information provided company pursuant financial purchase companys ordinary shares maximum services authoritys fsa disclosure transparency rules dtrs current issued share capital published regulatory information service e xempt auditors state name thei r companys website senior statutory auditor company annual report r educe notice required call general meeting annual general meeting less clear days r enew glaxosmithkline sharesave plan glaxosmithkline sharereward plan gsk annual report governance corporate governance continued remuneration march company received notifications articles association accordance fsas dtrs following notifiable interests directors powers determined uk legislation voting rights companys issued share capital articles association available website percentage articles may amended special resolution members issued directors may exercise companys powers provided shares capital articles applicable legislation stipulate blackrock inc powers must exercised members legal general group plc board authorised issue allot ordinary shares p ercentage ordinary shares issue excluding treasury shares article power article authority bank new york mellon depositary companys company make purchases shares subject ads listed nyse ordinary shares representing shareholder authorities sought annual basis companys adr program managed depositary agm shares purchased company may cancelled registered name bny nominees limited details held treasury shares number ordinary shares held depositary share buyback programme found acquired disposed interests february initiated new longterm share buyback shares period review connection programme expected buyback billion shares share buyback programme expected upper level billion band subsequently increased billion october directors senior management million shares purchased total cost interests directors senior management million shares purchased period january connected persons issued share capital company february period february given remuneration report pages march million shares purchased cost million rules appointment replacement directors contained articles association programme covers purchases shares cancellation held treasury shares accordance authority articles provide directors may appointed renewed shareholders agm may ordinary resolution members resolution company authorised purchase maximum directors provided latter instance director appointed million shares details shares purchased cancelled way retires first agm following appointment held treasury shares disclosed note articles also provide directors normally subject financial statements share capital share premium account reelection agm intervals three years annually exact amount timing future purchases held office continuous period nine years extent repurchased shares held treasury shares however board agreed directors wish rather cancelled determined company continue members board seek reelection dependent market conditions factors annually accordance code members may remove donations political organisations political director passing ordinary resolution special notice given passing special resolution director may expenditure automatically cease director effect january ensure consistent approach h e becomes bankrupt compounds r political contributions across group introduced global creditors generally policy stop voluntarily corporate political contributions h e ceases director virtue companies ac period january december articles group make political donations eu noneu organisations h e suffering mental physical ill health notwithstanding introduction policy accordance h e missed directors meetings continuous period federal election campaign act us continue six months without permission board resolves support employeeoperated political action committee shall cease director pac facilitates voluntary political donations eligible h e prohibited director law gsk employees h e resigns pac controlled gsk decisions amounts recipients contributions made participating employees h e offers resign board accepts offer r exercising legal right pool resources make political directors least three number require contributions subject strict limitations total resign us us donated political organisations gsk employee pac gsk annual report agm may shareholders first authorised audit risk committee report company make donations eu political organisations incur eu political expenditure provisions political parties elections referendums act year authority since renewed annually companies act requires companies continue obtain shareholder approval make donations eu political organisations incur eu political expenditure however make intend make donations political parties independent election candidates dear shareholder make donations eu political organisations incur eu political expenditure current global political economic environment created additional challenges business committees work definitions political donations political expenditure audit assurance compliance models continue adapt political organisations used legislation wide evolve help maintain improve integrity financial particular definition eu political organisations may extend internal controls effective identification bodies concerned policy review law reform management risk response challenges representation business community special interest groups concerned environment committees agenda included usual review company subsidiaries might wish support result financial results controls business operations across definitions may cover legitimate business activities world management risk well focusing ordinary sense considered political donations political consideration matters including expenditure activities designed support c oncluding us government investigations sales political party independent election candidate authority marketing practices board sought annually precautionary measure verseeing management sovereign debt ensure company subsidiaries inadvertently p rotecting security prevention cyber crime breach legislation u nderstanding nature problems corporate committee reports governance failures occurred olympus japanese camera manufacturer reports audit risk nominations corporate responsibility committees describing activities onitoring progress implementation globa l committees year set enterprise resource planning system r eviewing establishment enhanced antibribery corruption programme meeting also considered emerging risks could impact group discussions provided opportunity committee members attendees raise issues warranted consideration investigation attention internal control framework strengthened establishment new global product quality office increase independence leadership governance good manufacturing practice product quality activities across group addition consolidated compliance network new global compliance organisation provide consistent effective oversight across group delighted welcome stacey cartwright chief financial officer burberry judy lewent former president chief financial officer merck co inc members committee bring considerable financial experience expertise result board determined like designated audit committee financial experts last year chairman audit risk committee remain member committee judy succeed chair committee effect january tom de swaan audit risk committee chairman gsk annual report governance corporate governance continued remuneration membership main responsibilities membership audit risk committee committee main responsibilities committee set together appointment dates attendance meetings committees oversight role requires address regularly set relationships management internal external auditors understand monitor reporting relationships attendance full meetings tiers accountability members committee member since tom de swaan committee receives regular reports members cet chairman senior managers covering key risk management september january compliance activities group including covering rd professor sir roy anderson may manufacturing sales marketing corporate functions stacey cartwright april details reporting framework committee judy lewent april set pages accountability sir deryck maughan january committee also reviews quarterly results group dr daniel podolsky january prepared management considers reports key sir robert wilson december accounting issues committees meetings split two parts committee reviews terms reference annual basis material changes terms reference made p art one deals fundamental aspects interna l financial control considers standing items receiving qualifications audit risk committee members reports external auditors audit assurance committee members exception professor sir roy entire board invited attend part two committee anderson dr daniel podolsky bring considerable financial meetings usually considers developments external accounting experience committees work members risk environment receives legal updates new business unit past employment experience either finance accounting corporate function reports reports outcome roles comparable experience corporate activities sir roy strategic risk evaluations topical issues dr podolsky respectively worldrenowned medical addition six scheduled meetings committee also met scientist worldrenowned researcher enables quorate basis five occasions bring scientific expertise committees deliberations attendees committee meetings include regular attends attendee attendee required chairman ceo cfo general counsel financial controller head audit assurance company secretary secretary committee chairman research development chief medical officer part two head governance ethics assurance chief product quality officer external auditors gsk annual report committee worked structured programme financial accounting experience activities standing items committee required tom de swaan c hief financial officer abn amro unti l consider meeting together matters timed december coincide key events annual financial reporting cycle n onexecutive director kpmg europe llps public interest committee external auditors reported critical accounting policies significant judgements practices used stacey cartwright e xecutive vice president chief financial officer group alternative accounting treatments burberry group plc discussed management f ormer chief financial officer egg plc resultant conclusion material written v arious financerelated positions granada communications management group plc restrictions access information judy lewent f ormer executive vice president chief cfo reported financial performance financial officer merck co inc group technical financial accounting matters sir deryck maughan partner kohlberg kravis roberts co general counsel reported material litigation f ormer chairman chief executive officer citigroup international company secretary r eported corporate governance f ormer chairman chief executive officer salomon brothers inc head governance reported activities undertaken ethics rocc sir robert wilson c hairman bg group plc assurance economist heads audit majority heads groups f ormer chairman economist group assurance reported audit scope annual coverage f ormer executive chairman rio tinto groups compliance audit resources results audits audit groups conducted throughout year scientific expertise company secretary reported matters affected quality chair timely disclosure financial professor sir roy worldrenowned medical scientist disclosure committee material information board public anderson advanced knowledge infectious disease markets shareholders enabled epidemiology committee review clarity p rofessor infectious disease epidemiology completeness disclosures published faculty medicine imperial college london annual financial statements interim reports f ellow royal society quarterly preliminary results announcements f oreign associate member institute formal announcements relating medicine us national academy financial performance prior approval sciences board f oreign associate member french academy sciences head audit reported progress global assurance f ormer chief scientific adviser ministry f assurance plan review assurance significant defence uk risk throughout group dr daniel podolsky worldrenowned researcher advanced ee sarbanesoxley act knowledge underlying mechanisms disease committee management internal auditors full board new therapies gastrointestinal disorders work together ensure quality companys corporate p resident university texas accounting financial reporting committee serves southwestern medical center primary link board external internal member institute medicine us national academy sciences auditors facilitates necessary independence oris bryan wildenthal distinguished chair management encourages external internal auditors medical science communicate freely regularly committee former mallinckrodt professor medicine committee met collectively separately external harvard medical school auditors head audit assurance head f ormer chief academic officer partners governance ethics assurance without members healthcare management present board determined members audit committee financial chairman committee also member experts purposes sarbanesoxley act addition remuneration committee provides input committees board satisfied members recent relevant financial experience purposes code review groups performance oversight risk factors relevant remuneration matters gsk annual report governance corporate governance continued remuneration external auditors appointment fees consideration also given committee need include risk withdrawal external auditors committee primary responsibility making market risk evaluation planning recommendation shareholders appointment reappointment removal external auditors assessing external auditors required rotate audit engagement annual basis qualifications expertise resources partner every five years current audit partner commenced independence external auditors effectiveness engagement january subject rotation previous audit process audit gsks financial statements concluded evaluating effectiveness audit process prior making recommendation reappointment external auditors sarbanesoxley act prohibits engagement committee reviews effectiveness performance external auditors provision certain services legal criteria agrees conjunction management actuarial internal audit outsourcing financial information beginning years audit part process systems design external auditors permitted committee considers feedback prior years external audit provide nonaudit services committee ensures auditor gathered client satisfaction survey facilitated objectivity independence safeguarded policy requiring auditors client service review team independent preapproval committee services total fees engagement team undertook audit work survey seeks nonaudit work exceed audit fee except feedback financial management team corporate special circumstances would clear advantage business unit level reviewed feedback provided companys auditors undertaking additional work committee satisfied effectiveness external audit services may include audit auditrelated tax services process recommend reappointment auditors preapproval detailed particular service categories forthcoming agm services subject specific budget details criteria judging effectiveness external guidelines set groups policy engaging auditors set external auditors provide nonaudit services include scertaining skills experience externa l eliver smoothrunning thorough efficiently executed auditors make suitable supplier nonaudit services audit e nsuring adequate safeguards place objectivity p rovide accurate date knowledge technical issues independence group audit threatened timely basis compromised erve industry resource communicating best practice e nsuring fee levels relative annual audit fee industry trends reporting within limits set committee dhere independence policies including gsks policies isa uki sec requirements external auditors management report regularly committee regarding extent services provided accordance eliver focused consistent audit approach globally tha preapproval fees services performed reflects local risks materiality committee may also preapprove additional services caseby l iaise audit assurance function avoid duplication f case basis fees paid companys auditor associates work set details given note financial statements operating profit provide consistency advice levels agreeing audit fee proposed external auditors reviewed management committee considers cost comparisons ensure fair appropriate gsk contractual obligations restrict committees capacity recommend particular firm external auditors group pricewaterhousecoopers llp remained place auditors since groups inception december performance audit assurance services reviewed annually committee since time services including tax regulatory compliance making assessment committee considers papers treasury related services detail relevant uk legislative regulatory professional requirements relating external auditors evaluates reports external auditors compliance requirements safeguards established internal quality control procedures gsk annual report code conduct reporting lines nominations committee report also number well established policies including code conduct available website confidential reporting lines reporting investigation unlawful conduct waivers code conduct made committee reviews regular reports arrangements available employees encourage seek help report concerns suspected cases misconduct without fear sir christopher gent retaliation nominations committee chairman committee evaluation membership committee considered dr longs evaluation board membership nominations committee committee committee particular concluded committee together appointment dates attendance meetings continued operate effectively respect dr longs specific set observations agreed committee ask management demonstrate embedding culture attendance risk awareness within emerging markets emerging full meetings risks captured within assurance process members committee member since sir christopher gent chairman january december larry culp march sir crispin davis july sir deryck maughan july sir robert wilson march addition four scheduled meetings committee met quorate basis one occasion attendees committee meetings regular attends attendee attendee required ceo head human resources company secretary secretary committee appropriate external advisers main responsibilities main responsibilities committee set work committee committees main focus search new nonexecutive directors refresh board recruiting nonexecutive directors committee considers particular skills knowledge independence diversity experience would benefit board significantly appointment broad selection criteria used focus achieving balance representation continental european uk us emerging markets experience individuals expertise developed various sectors specialities search process focused need candidates current recently retired ceos cfos audit partners significant financial expertise sought candidates increased diversity boards composition gsk annual report governance corporate governance continued remuneration professional search agencies engaged specialise committee evaluation recruitment high calibre nonexecutive directors dossiers committee considered dr longs evaluation board potential nonexecutive appointees considered committee particular concluded committee committee candidates shortlisted interview continued operate effectively respect dr longs specific objective criteria considering relevant qualifications observations agreed replacing nonexecutive interviewing several candidates committee pleased directors due retire agm priority recommend board stacey cartwright judy lewent given candidates global ceo experience knowledge nonexecutive directors appointed board experience emerging markets committee also agreed april recruiting new nonexecutive directors would helpful plan composition board longer time frame board considered experience global business finance respective knowledge consumer brands pharmaceutical industry would bring fresh perspectives boards deliberations process refreshing board continues number board members approach nine years service january announced james murdoch would stand reelection agm sir crispin davis sir robert wilson larry culp served nonexecutive directors nine years would stand reelection agm next year committee recommended sir deryck maughan succeed sir robert senior independent director tom de swaan succeed sir crispin chairman remuneration committee judy lewent succeed tom de swaan chair audit risk committee terms executive succession planning committee also recommended appointment emma walmsley phil thomson cet may president designate consumer healthcare worldwide senior vice president global communications respectively emma walmsley joined gsk may president consumer healthcare europe subsequently assumed role president consumer healthcare worldwide october joined gsk loral previously held number marketing general management roles phil thomson joined glaxo wellcome held senior positions media relations investor relations appointed role senior vice president global communications august responsibility media relations investor relations corporate responsibility global community partnerships internal product business communications ensure orderly succession global manufacturing supply gms committee recommended appointment roger connor vice president office ceo corporate strategy role president designate gms effect january roger succeed david pulman retires gsk join cet late detailed biographical information emma walmsley phil thomson given corporate executive team cet pages gsk annual report corporate responsibility committee report main responsibilities main responsibilities corporate responsibility committee set committee rolling agenda receives reports members cet senior managers ensure progress meeting gsks corporate responsibility cr principles reviewed committee annually reviews progress following five cr principles sir christopher gent access medicines corporate responsibility committee chairman standards ethical conduct membership research innovation membership corporate responsibility committee employment practices committee together appointment dates attendance community investment meetings set gsks cr principles discussed least every two attendance years committee also reviews approves corporate full meetings responsibility report members committee member since sir christopher gent work committee chairman committee focused attention several issues january december including dr stephanie burns december james murdoch may gsks cr principles committees area focus dr daniel podolsky july access medicines access pricing medicines attendees committee meetings may include middle income least developed countries regular attends standards ethical embedding ethical values attendee attendee required conduct organisation ceo general counsel reinforcing valuesbased decision making head global communications business head corporate responsibility research innovation replacement refinement reduction head governance ethics assurance use animals research company secretary secretary development committee research integrity transparency independent external corporate including medical governance ethical responsibility adviser standards human subject research employment practices inclusion diversity independent external corporate responsibility adviser leading developing employees augment gsks engagement stakeholder opinion march employee relations including consultation ms sophia tickell appointed independent external arrangements adviser committee ms tickell cofounder director employee health safety wellbeing meteos directs pharma futures series aims align better societal shareholder value also community investment pulse volunteering programme sits expert review committee access medicines caring environment progress environmental foundation member european healthcare sustainability strategy innovation leadership network products customers adoption global principles ms tickell attended meetings committee provided practices ensure distinction independent advice guidance corporate social interaction exchange responsibility matters chairman ceo avoid scientific medical information product promotional activity conflict interest new role due take ms tickell decided retire adviser committee disclosure payments healthcare summer professionals gsk annual report governance corporate governance continued remuneration corporate responsibility integrated management us law regulation gsks business throughout report read advances ensure gsk works efficiently effectively possible number provisions us law regulation apply gsk ensuring always act responsibly shares quoted new york stock exchange nyse form ads publish information approach performance annual corporate responsibility report report nyse rules found website published march general nyse rules permit company follow uk committee evaluation corporate governance practices instead applied us provided explain significant variations explanation committee considered dr longs evaluation board contained form f filing accessed committee particular concluded committee securities exchange commissions sec edgar database continued operate effectively part committees via website nyse rules came effect require review operation activities agreed time us file annual interim written affirmations concerning could allocated meetings discussion around key cr audit risk committee statement significant subjects risk areas hot topics strategic thinking differences corporate governance emerging areas concern sarbanesoxley act following number corporate accounting scandals usa congress passed sarbanesoxley act sarbanes oxley wideranging piece legislation concerned largely financial reporting corporate governance recommended sec gsk established disclosure committee committee reports ceo cfo audit risk committee chaired company secretary members consist senior managers finance legal corporate communications investor relations external legal counsel external auditors internal experts invited attend meetings periodically responsibility considering materiality information timely basis determining disclosure information responsibility timely filing reports sec formal review annual report form f committee met times sarbanesoxley requires annual report contains statement whether member audit risk committee arc audit committee financial expert defined sarbanesoxley summary regarding boards judgement matter please refer additional disclosure requirements arise section section sarbanes oxley respect disclosure controls procedures internal control financial reporting section corporate responsibility financial reports sarbanesoxley also introduced requirement ceo cfo complete formal certifications confirming hey reviewed annual report form f b ased knowledge contains material misstatements omissions b ased knowledge financial statements financial information fairly present material respects financial condition results operations cash flows dates periods presented annual report form f gsk annual report hey responsible establishing maintaining disclosure section managements annual report internal controls procedures ensure material information control financial reporting made known evaluated effectiveness accordance requirements section sarbanes controls procedures yearend results oxley following report provided management respect evaluation contained annual report companys internal control financial reporting form f defined rules af df us securities hey responsible establishing maintaining interna l exchange act control financial reporting provides reasonable anagement responsible establishing maintaining assurance regarding reliability financial reporting adequate internal control financial reporting group preparation financial statements external purposes internal control financial reporting designed provide accordance generally accepted accounting principles reasonable assurance regarding reliability financial hey disclosed annual report form f reporting preparation financial statements changes internal controls financial reporting external purposes accordance ifrs period covered annual report form f management conducted evaluation effectiveness f materially affected reasonably likely affect materially internal control financial reporting based framework companys internal control financial reporting internal control integrated framework issued committee hey disclosed based recent evaluation f sponsoring organisations treadway commission internal control financial reporting external auditors changes groups internal control ove r arc significant deficiencies material weaknesses financial reporting materially affected design operation internal controls financial reasonably likely affect materially groups internal reporting reasonably likely affect adversely control financial reporting companys ability record process summarise report financial information fraud regardless materiality anagement assessed effectiveness internal contro l involving persons significant role companys financial reporting december internal control financial reporting conclusion filed part groups form f carried evaluation supervision p ricewaterhousecoopers llp audited consolidated participation groups management including financial statements group year ended ceo cfo effectiveness design operation december also assessed effectiveness groups disclosure controls procedures groups internal control financial reporting auditing december standard public company accounting oversight board united states audit report filed inherent limitations effectiveness system groups form f disclosure controls procedures including possibility human error circumvention overriding controls procedures accordingly even effective disclosure controls procedures provide reasonable assurance achieving control objectives ceo cfo expect complete certifications report conclusions effectiveness disclosure controls procedures march following certificates filed sec part groups form f gsk annual report governance remuneration remuneration report dear shareholder behalf board pleased present remuneration report seeking approval agm may recent changes executive remuneration recent years remuneration committee implemented number changes executive remuneration extensive consultation good support major shareholders changes included tailored benchmarking versus local market simplifying aligning remuneration across cet linking reward longterm incentive plans closely performance companys key strategic priorities although early days encouraged increased motivation focus amongst management team delivery priorities promised last year provided full annual update performance longterm incentive targets annual bonus structure year committee undertook review annual bonus structure place executives concluded measures remained sound continue focus annual delivery strong financial performance given change moncefs role includes overall responsibility rd vaccines amended measures weightings financial element bonus based rd performance vaccines performance group profit interest tax ceo remuneration committee mindful responsibility pay appropriately excessively apply rigorous data driven process assessing competitive positioning setting remuneration determining performance targets assessed competitiveness remuneration executive directors cet members satisfied instances remuneration appropriate however identify significant competitiveness gap ceo particular concern committee sir andrews strong performance widely acknowledged appointment ceo set sir andrews remuneration conservatively significantly predecessor set primary benchmark uk crossindustry comparator group rather much higher benchmark global pharmaceutical companies also took account new ceo needed demonstrate performance role increased remuneration three years since sir andrews appointment continual marked improvement groups performance recently underlying sales profits performed well groups increase tsr upper quartile ftse uk corporate comparator group global pharmaceutical peer group groups best tsr performance since formation gsk gsks strategy momentum sir andrews vision leadership fundamental performance gsk annual report committee believes reward level offered ceo reflect achievements date therefore increased level performance related remuneration raising performance share award salary within limit previously approved shareholders performance shares continue vest based group performance three years shares vesting grant retained two years also increased sir andrews base salary line average salary increase gsks uk employees changes position competitively uk peers noted even adjustments remuneration still bottom quartile compared gsks pharmaceutical peers also see sir andrews total remuneration achieved increased significantly directly reflects pay performance policy gsk delivered good underlying financial performance pipeline progress strong cash generation together upper quartile share price performance enabled best annual total shareholder returns since sir andrew deserves credit reward full details given report follows governance committee aware sensitive environment surrounding executive pay time real economic challenge one britains largest companies gsk recognises leadership role aware importance balanced approach every year discussed proposals policies extensively major shareholders annual meetings autumn listened carefully feedback believe following report reflects year substantial initiative government improve corporate communication executive pay many proposals still formative stage following report attempts capture spirit governments direction particularly regards simplification separation past pay future policy transparency year last year chairman committee tom de swaan member committee since may succeed chairman effect january like thank shareholders support tenure chairman committee always welcome shareholders feedback report sir crispin davis remuneration committee chairman march gsk annual report governance remuneration report continued remuneration total remuneration value earned base salary benefits annual bonus longterm total remuneration incentive awards pay performance total remuneration current executive directors set table sir andrew witty simon dingemans dr moncef slaoui ceo cfo chairman rd total total total total total total salary na benefits na na na pay performance annual bonus including amount deferred see na value earned lti awards performance share plan na na share option plan na na sharesave na na na na total remuneration na number number number shares shares ads deferral annual bonus amount deferred number shares ads purchased maximum matching award full details elements total remuneration given following pages report fixed pay details pay performance details base salary pages annual bonus pages benefits pages investment bonus deferred annual bonus plan see table pages value earned lti awards performance share plan pages share option plan pages sharesave pages notes imon dingemans appointed board january performance period simon dingemans first award performance share plan ends december eligible receive remuneration respect plan earliest matching award subject performance targets maximum number shares ads shown matching award include dividends reinvested performance period details pensions accrued date executive directors given pages gsk annual report pay performance annual bonus annual bonus based following performance targets executive director financial performance personal performance sir andrew witty group operating profit group profit simon dingemans individual objectives interest tax dr moncef slaoui rd performance performance targets financial g roup operating profit group profit interest tax year exceeded stretching targets set performance committee performance reflected delivery underlying sales growth continued cost control context roll pandemic products avandia valtrex together impact price reductions usa europe emerging markets r performance targets year exceeded data received nine phase iii assets highlighted start sufficient data received house file four products rate return rd spend estimated versus end new drugs expected enter late stage development next three years personal c eo group delivered continued underlying sales growth cer terms compared growth performance across pharmaceuticals vaccines consumer healthcare businesses strong cash generation disciplined allocation capital enabled total billion returned shareholders dividends billion shares repurchased billion increase together gsk achieving top quartile share price performance ftse generated companys best annual total shareholder return since formation gsk reached agreement principle us government resolve several significant federal government investigations made progress orderly succession several key executive team roles cfo established financial architecture new three year planning process enable business strategy translate optimised shareholder returns identified savings ongoing operational excellence programme million made initial progress delivering financial efficiencies introduced core measures performance enable easier comparison peers c hairman rd exceeded pipeline development value targets detailed established new governance structure rd value earned longterm incentive awards performance share plan share option plan structure awards granted executives share option plan awards granted executives performance levels achieved three years ended december split two elements dependent set performance three year period ended december performance four year period ending vesting december performance measures award performance achieved maximum award performance achieved vesting adjusted adjusted free cash flow free cash three years billion companys eps declined compound cer basis flow included adjustments number three years december material distorting items threshold vesting level growth rpi plus none principally legal settlements part award therefore vested favourable exchange rate movements special pension vesting remaining assessed four contributions year performance period ending december relative tsr gsks tsr rank position th years median position comparator group pharmaceutical companies gsk companies total vested relative gsks tsr rank position th tsr performance years maintained vesting relative december tsr would potential total vesting award vesting remaining assessed four year performance period ending december gsk annual report governance remuneration report continued remuneration remuneration policy table summarises committee sets remuneration members cet executives key elements remuneration including requirement hold minimum levels shares gsk principal pension arrangements committee reviews total remuneration executive executives comparable committee sets companies focus local rather global comparisons committee aims ensure total remuneration remuneration levels competitive set reference median appropriate comparator group balance fixed elements pay performance carefully considered overall packages weighted heavily towards latter fixed pay base salary salaries reviewed annually data relevant comparator groups influenced executives role experience performance average increases broader gsk workforce benefits principally healthcare car personal financial advice life assurance relevant cash lieu money purchase pension contribution secondment travel expenses pay performance safeguards clawback mechanism incorporated annual bonus award process committee retains risk discretion reduce grant vesting levels performance awards appropriate management annual bonus target maximum targets bonus opportunities majority bonus based achievement challenging financial executive directors follows targets groupbusiness unit operating profit group profit arget maximum interest tax agreed board committee salary salary individual performance predetermined personal objectives ceo cfo rdspecific key performance indicators chairman rd vaccinesspecific key performance indicators deferred annual individuals may choose invest awards vest end threeyear performance period based bonus plan bonus earned four equally weighted performance measures dabp deferred bonuses may business diversification performance matched oneforone rd new product performance subject performance criteria adjusted free cash flow relative tsr performance performance share share plan awards executive directors vests threshold rising stretching performance exceeding psp follows set threshold specified margin comparator group comprising gsk pharmaceutical companies salary ceo vests median vesting upper quartile performance cfo chairman rd ceo must retain shares vesting award two years following vesting share ownership align interests executives shareholders executives required build maintain significant requirements holdings shares gsk ceo x base salary executive directors x base salary cet members x base salary pensions uk executives gsk operates defined contribution plan uk executives participating defined contribution plan benefit company contributions base salary plus matched contributions base salary certain executives members legacy final salary plans closed new entrants since us executives gsk operates cash balance pension plan us plan us executives participating us plan benefit contributions base salary gsk annual report estimates total future potential remuneration remuneration packages tables provide estimates potential total future remuneration executive directors respect remuneration opportunity granted range potential outcomes provided executive director sir andrew witty ceo total annual total pay salary benefits fixed pay bonus dabp psp performance total threshold threshold maximum simon dingemans cfo total annual total pay salary benefits fixed pay bonus dabp psp performance total threshold threshold maximum dr moncef slaoui chairman rd total annual total pay salary benefits fixed pay bonus dabp psp performance total threshold threshold maximum remuneration granted recorded follows earned awarded recorded remuneration respect annual report salary benefits annual bonus dabp bonus deferred psp assumptions underlying scenario outlined scenarios ther benefits estimated based upon actual amounts received respect e ach executive director assumed defer annual bonus maximum permitted amount matching awar shown dabp reflects amount shown dabp reflects matching award amount bonus deferred individual included annual bonus amounts shown dabp psp based bonus amounts relevant multiples sala ry respectively include amounts respect dividends reinvested performance periods actual amounts recorded remuneration dabp psp respectively calculated using share ads prices vesting dates include amounts respect related dividends reinvested relevant performance periods dabp psp subject performance measures three year periods respectively threshold n one pay performance would payable threshold minimum levels pay performance would payable assumed performance executive director would result individual performance multiplier therefore increase financial performance element bonus threshold levels payment annual bonus vesting awards dabp psp discussed det ail maximum assumed annual bonus payable maximum percentages set awards dabp psp vest full gsk annual report governance remuneration report continued remuneration committee sets remuneration committees review ceos proposed remuneration identified competitiveness gap highlighted committee gives consideration remuneration policy diagram address committees preference levels wider employee population group well increase level pay performance within ceos ensuring remuneration consistent industry broader remuneration package accordingly committee raised market norms committee sets total remuneration psp award salary reference median level executives pay comparator group summary total package competitive positioning ceo benchmarking total remuneration following principal elements considered total remuneration based benchmarking criteria base salary nnual bonus comparison purposes assumed company achieves target performance abp psp awards assumed awards vest maximum amount dabp assumed executive chooses defer maximum annual bonus committee also considers pension arrangements significant proportion executives total remuneration uk crossindustry global pharmaceutical european crossin dustry group group group package based pay performance particular lower quartile median median upper quartile emphasis longterm sharebased incentives closely align previous position new position executives interests shareholders balance fixed pay pay performance elements remuneration varies depending performance fixed pay committee uses two primary pay comparator groups base salary base salaries set reference relevant comparator uk crossindustry global pharmaceutical comparator group comparator group group level considered appropriate secure retain anglo american france sanofi talent needed deliver gsks strategic priorities salary astrazeneca switzerland novartis levels reviewed annually influenced barclays roche holdings wider pay environment executives role experience bg group uk astrazeneca performance bhp billiton usa abbott laboratories bp amgen committee considers prevailing economic conditions british american tobacco bristolmyers squibb diageo eli lilly market competitiveness executives package hsbc johnson johnson positioning relativities pay across broader gsk workforce reckitt benckiser merck average salary increases employees rio tinto pfizer royal dutch shell executive directors approximately uk standard chartered approximately usa tesco committee decided give executive directors salary unilever vodafone increases line average salary increases gsk employees uk usa sir andrew witty amgen included remuneration benchmarking included simon dingemans received base salary increase tsr comparator group dr moncef slaoui primary comparator group executive directors shown table table sets base salaries executive directors last three years since appointment board primary comparator group salaries salary increases typically take effect first uk global quarter year director crossindustry pharmaceutical sir andrew witty ceo base salary simon dingemans cfo change dr moncef slaoui chairman rd sir andrew witty reviewing ceos remuneration ceo primarily set reference uk crossindustry comparator simon dingemans na na cfo group committee also referenced pay group dr moncef slaoui european companies selected based size complexity chairman rd imon dingemans joined board january gsk annual report benefits financial measures bonus threshold target maximum payable achievement executives receive benefits including healthcare car target bonus threshold reflects stretching nature personal financial advice life assurance matching shares bonus targets sharereward plan measures executive director set simon dingemans accumulating benefits gsks pension plans receives cash lieu money purchase personal pension contribution executive director financial performance performance sir andrew witty group dr moncef slaoui seconded uk two year period november enable closer simon dingemans operating profit group profit individual vaccines business assumes operational responsibility dr moncef slaoui rd interest objectives part group receives appropriate performance tax secondment travel expenses vaccines performance cash value benefits received executive directors shown uring dr moncef slaoui assumed responsibility groups vaccines business financial element bonus therefore pay performance adjusted accordingly safeguards risk management ceo committee believes payment performance individual performance objectives sir andrew witty set specifically committee want reward failure board january year board focuses views important incentive payouts strategic priorities developed company made circumstances performance outcomes reflect set reasons commercial sensitivity genuine achievements original targets specific objectives kept confidential following end financial year board reviews performance generally given nature gsks business increased focus risk set objectives determine appropriate bonus within group committee taken number steps payable performance ensure performance related pay underpins effective risk management chairman rd chairman audit risk committee member bonus measures rd employees including dr moncef slaoui committee provides input audit risk committees linked pipeline performance robust governance structure review groups performance oversight risk established ensure bonus payable fairly reflects factors relevant remuneration decisions rd productivity performance well achievement committee reviews ongoing financial impact prio r profit targets performance targets reviewed rd year activities role individual executives bonus compensation review committee includes activities continuity executive sir andrew witty companys two designated scientific responsibility initiation adverse event expert nonexecutive directors professor sir roy anderson emergence problem adverse event taken dr daniel podolsky equivalently robust process account assessing pay performance year problem implemented review vaccines performance measures identified future periods committee may make executives appropriate adjustments individual annual bonus amounts executives ceo sets individual objectives grant vesting levels lti awards reflect line company strategy makes recommendations circumstances clawback mechanism committee regarding performance objectives also safeguards relating end year recommendations considered businessspecific performance measures longterm committee determines level bonuses payable incentive plans set detail ontarget maximum bonuses executive l ongterm incentive awards good leavers normally vest directors given table end original vesting period rather year departure ensures continued alignment shareholders ontarget bonus maximum interests following cessation employment base salary base salary sir andrew witty ceo annual bonus simon dingemans cfo dr moncef slaoui chairman rd annual bonus designed drive achievement gsks annual financial strategic business targets delivery table sets bonuses earned executive personal objectives directors last three years since appointment majority annual bonus opportunity based formal review performance stretching financial targets sir andrew witty outcome adjusted reflect individual performance simon dingemans na na applying individual performance multiplier dr moncef slaoui imon dingemans appointed board january gsk annual report governance remuneration report continued remuneration longterm incentive plans performance measures longterm incentives take form maximum number focus committee improve shares award number shares received executive alignment executive remuneration arrangements depends performance performance period key strategic priorities provide closer link shareholder returns payments consultation shareholders dabp psp executives notional dividends reinvested paid awards made executives comprised two businessspecific proportion shares earned performance measures business diversification performance rd new product performance together adjusted free deferred annual bonus plan cash flow relative tsr deferred annual bonus plan encourages longterm board recognises possibility companys goals shareholding discourages excessive risk taking helps may evolve time therefore committee intends review focus gsks key strategic priorities performance measures periodically ensure annual bonus earned may deferred remain appropriate shares ads appropriate three years company details performance measures targets performance match shares ads oneforone depending thresholds longterm incentive awards given companys performance measures outlined table set threeyear performance period safeguards vesting levels participation last three years executive directors shown table together addition setting robust targets committee also maximum matching awards granted respect implemented number safeguards ensure targets deferrals bonuses matching awards may vest met sustainable way performance outcome subject continued employment achievement reflects genuine achievement original targets performance measures therefore represents delivery value shareholders performance measure impact acquisition total bonus deferred matching divestment quantified adjusted event executive director award major adjustment calculation performance measures sir andrew witty shares disclosed shareholders vesting simon dingemans na na shares dr moncef slaoui na ads table sets principal safeguards performance measures performance share plan performance measure safeguards vesting performance share plan ensures focus delivery business diversification nclude impact revenue gsks strategic priorities longterm shareholder performance opportunistic events eg pandemics unless returns relative pharmaceutical companies committee considers add shareholder value provided performance share plan awards made vest underlying performance sufficiently depending companys performance three year positive performance period measures outlined djust major distorting events limit six times base salary maximum initial value espite reaching target vesting normally performance shares may granted individual reduced market growth achieved one year rd new product v esting may reduced insufficient progress table shows award levels february performance made period towards march executive director line policy gsks target return rd investment award level award level award level nclude impact revenue opportunistic events eg pandemics unless base salary base salary base salary award committee considers sir andrew witty add shareholder value provided ceo shares underlying performance sufficiently positive simon dingemans na cfo shares adjusted free cash flow djust materially distorting items may include exchange rate movements major dr moncef slaoui legal taxation settlements special chairman rd ads pension contributions gsk annual report performance targets inevitably measures linked directly strategy commercially sensitive particular committee consider appropriate disclose targets business diversification performance rd new product performance grant may result competitive harm however targets disclosed fully remuneration report end performance period together details extent met committee also undertaken provide updates achievements date targets performance period performance targets set table longterm incentive measures awards award vesting schedule awards business diversification performance incentivises growth global diversified business designed focus turnover major growth areas vaccines consumer healthcare emerging markets asia pacific proportion japan pharmaceuticals businesses excluding vaccines award dermatology dermatology businesses achievement available threshold aggregate revenue target four business divisions threshold threeyear performance period reflect strong growth maximum previous periods market growth rd new product performance maximum recognises importance rd future business growth expressed measure threshold revenue target based new product sales incentivise better business diversification rd performance new products defined products launched performance performance period two preceding years therefore performance period products launched rd new product years included measurement performance aggregate threeyear revenue target awards new product sales reflect growth historic performance adjusted free cash flow three year adjusted free recognises importance effective working capital cash flow targets vesting cash management threshold threshold billion billion billion maximum billion relative tsr proportion vesting focuses delivery value shareholders relative tsr using comparator group comprising gsk global pharmaceutical companies relative tsr measured three years using twelvemonth averaging period tsr measured local currency tsr rank position median upper quartile performance performance gsk annual report governance remuneration report continued remuneration historical vesting gsks ltis share ownership requirements following table shows vesting levels gsks performance align interests executives share share option awards executives since tsr shareholders executives required build vesting percentage indicates gsks relative tsr maintain significant holdings shares gsk time performance median comparator group current share ownership requirements sor set performance period table share option performance share plan plan share ownership requirement vesting ceo x base salary adjusted executive directors x base salary vesting free total vesting performance tsr cash flow vesting eps cet members x base salary period measure measure measure shareholdings purpose sor march na achievement sor based upon average share price na working days preceding date na na holding ordinary shares sor purposes december march increase achievement award made included respect relative tsr shareholding sor respect adjusted free cash flow three year performance sir andrew witty period remaining respect relative tsr four year simon dingemans na performance period assessed next year dr moncef slaoui allemployee share plans executives required continue satisfy shareholding executives participate various allemployee share plans requirements minimum twelve months following retirement either uk usa including sharereward sharesave company sharereward plan uk hm revenue customs approved pensions plan open uk employees terms participants pensions provide important tool creating longterm contribute month gross salaries purchase culture loyalty gsk shares company matches number gsk shares bought month arrangement sir andrew witty executives participate groups senior executive pension simon dingemans contribute month buy shares plans pension arrangements structured accordance sharereward plan plans operated executives country likely retire details individual arrangements executive sharesave plan uk hm revenue customs approved plan directors set pages open uk employees participants may save month net salaries fixed term three years new executives eligible participate either defined end savings period option buy gsk contribution scheme uk depending personal shares discount market price set circumstances relevant tax restrictions cash balance launch savings contract pension plan usa dilution limits existing obligations legacy defined benefit schemes uk continue honoured awards made plans incorporate dilution limits consistent guidelines provided association british insurers current estimated dilution existing awards made last years set table issued share capital abi dilution december december share plans limit gsk employee share plans executive share plans gsk annual report uk pension arrangements company currently operates defined contribution plan legacy final salary plans closed new entrants executives participating defined contribution plan receive company contribution base salary also opportunity receive matched contributions line policy members pension plan uk government announced series changes taxation pensions continue impact pensions employees within gsk taxation changes significant negative consequences effectiveness pensions much reduced pensions continue important tool creating longterm culture promoting employee retention therefore committee decided existing pension promises would honoured employees pensions impacted changes would opportunity pension new limit delivered via gsks existing unfunded scheme legacy final salary plans provide twothirds final salary age employees subject cap benefits excess cap currently provided unfunded arrangements legacy final salary plans actuarial reduction factors apply participant leaves employment accord age us pension arrangements usa gsk operates us cash balance plan provides annual contribution interest sum accumulated cash balance plan contractual promise provide specific levels retirement income plan incorporates executive pension credit senior us executives contribution rates plan range base salary depending grade current senior us executives eligible executive pension credit capped employees usa benefits cap provided unfunded nonqualified plan update performance ongoing awards committee undertook provide update performance outstanding lti awards noted actual vesting levels determined based performance full three four year performance periods interim positions provided regarded indication management performed date regarded predictions final vesting levels awards performance periods december december committee reviewed performance criteria deferred annual bonus plan performance share plan awards granted executive directors performance achieved two years january december follows dabp award subject performance relative tsr three years estimate likely vesting based performance date maximum total performance measures award performance achieved date vesting award adjusted free cash flow target three year period december billion threshold vesting billion maximum vesting based performance measure adjusted free cash flow two year period december billion relative tsr years gsks tsr rank position th two year period december pharmaceutical comparator relative tsr years group gsk companies potential total vesting psp award full vesting schedules performance criteria given pages report levels performance measure maintained ends performance periods december vesting awards would shown however performance measured ends performance periods performance date necessarily indication final vesting level gsk annual report governance remuneration report continued remuneration awards performance period december committee reviewed performance deferred annual bonus plan performance share plan awards granted executive directors performance achieved year december follows estimate likely vesting based performance date performance maximum total measures award performance achieved date vesting award business vaccines diversification lack flu pandemic vaccine sales year resulted decline reported vaccines performance sales million flu pandemic vaccine sales million year compared million cervarix sales doubled million primarily reflecting national hpv vaccination programme japan started end synflorix grew million reflecting continued growth related tenders emerging markets strong reported growth rotarix million primarily reflected impact product market part excluding pandemic vaccines sales cer growth estimated market growth excluding pandemic vaccines sales consumer healthcare consumer healthcare sales grew year million sales usa europe declined slightly largely result reductions sales alli declines offset strong growth rest world oral healthcare nutritional healthcare sales grew strongly overthecounter sales flat estimated market growth markets gsk competes emerging markets asia pacific japan excluding vaccines dermatology emerging markets asia pacific japan pharmaceuticals businesses excluding vaccines dermatology reported combined sales million year representing growth compared three regions respiratory products provided strong growth supported antibacterial products emerging markets avodart lamictal japan estimated market growth dermatology dermatology sales grew year million growth emerging markets benefiting ongoing launches stiefel products new markets offset impact price cuts europe generic competition evoclin usa reported growth full year benefited addition sales businesses acquired late early offset effect disposal zovirax north america first quarter estimated market growth markets gsk competes rd new new product sales product sales products launched since totalled million year grew performance largest product group synflorix million return rd investment increased approximately end end adjusted free award aggregate threeyear adjusted free cash flow target threshold cash flow vesting billion billion maximum vesting based performance measure adjusted free cash flow year billion relative tsr period january december companys tsr ranked rd pharmaceutical comparator group gsk companies potential total vesting award vesting schedules performance criteria given pages report levels performance measure maintained end performance period december vesting awards would shown however performance measured end three year period performance date necessarily indication final vesting level committee reviewed performance year remains view targets awards new measures remain suitably robust stretching actual targets together details extent met disclosed full time vesting gsk annual report remuneration committee committee meetings usually begin closed session members committee company role committee secretary external adviser present individuals may also invited attend committee meetings year role committee set companys remuneration executives committee attendees involved policy gsk able recruit retain motivate decisions present discussions regarding executives policy regularly reviewed ensure remuneration consistent companys scale scope operations supports business strategy growth plans helps drive attendees committee meetings include creation shareholder value regular attends terms reference attendee attendee required ceo committees full terms reference available cfo companys website terms reference reviewed head human resources minimum annual basis last revised december head reward light best practice corporate governance company secretary secretary developments committee governance committee adviser deloitte llp board considers members committee adviser committee independent nonexecutive directors accordance uk committee access external advice required deloitte corporate governance code exception sir christopher llp deloitte appointed committee provide gent chairman company independent independent advice executive remuneration appointment year deloitte provided independent commentary matters committee met six times member consideration committee updates best practice attending follows legislative requirements market practice attendance deloitte also provided consulting tax assurance services committee full gsk year provide advice executive member meetings remuneration matters committee members since sir crispin davis committee conducted formal review deloittes chairman may july performance july established set criteria larry culp january enabled full consideration committees needs sir christopher gent january deloitte member remuneration consultants group james murdoch october voluntarily operates code conduct relation tom de swaan may executive remuneration consulting uk code conduct j ames murdoch tom de swaan unable attend one found wwwremunerationconsultantsgroupcom meeting personal reasons meetings unable attend reviewed papers provided views matters towers watson pay governance provided additional market consideration committee chairman advance data committee om de swaan also chairman audit risk committee commitment shareholders committee engages regular dialogue shareholders addition six scheduled meetings committee also met holds annual meetings gsks largest investors discuss quorate basis two occasions principally approve take feedback remuneration policy governance matters formal grant based performance vesting longterm particular committee discusses significant changes incentive awards accordance gsks remuneration policy policy measures used assess performance annual meetings held november sir crispin davis committee chairman shared progress remuneration matters last months proposals sir christopher gent chairman updated attendees corporate governance developments gsk annual report governance remuneration report continued remuneration principal activities matters addressed committees principal activities matters addressed set remuneration items specific month overall annual bonus ltis governance matters january approve executives review approve review lti measures review shareholder voting remuneration including executives targets policy guidelines salaries ceo cfo bonuses remuneration chairman rd set ceo bonus review draft remuneration objectives report overview bonuses annual committee employees cet evaluation results february review lti performance review feedback targets outcomes shareholders approve lti award remuneration policy vesting approve remuneration set lti award report targets grant lti awards executives approve deferred annual bonus plan elections matching awards march review pay comparators initiate review annual initiate review currency review shareholder voting strategic overview wider bonus plan calculation tsr policy guidelines remuneration environment remuneration july approve remuneration complete review complete review tsr review committee new cet appointees annual bonus plan currency calculation adviser review general market grant interim lti review voting outcomes developments awards executives remuneration initiate review ceo report agm remuneration feedback october agree salary review review bonus review lti performance review uk government process executives approval process reporting meet remuneration consultations review ceo remuneration executives commitments proposals shareholders tsr currency update november annual meetings investors december review executives review proposed consider feedback remuneration market data annual bonus targets annual meetings competitiveness investors annual committee evaluation results gsk annual report executive director terms conditions following table sets details executive directors service contracts executive director contracts current directors date contract effective date expiry date policy set provides framework contracts sir andrew witty june may august executive directors simon dingemans september january april dr moncef slaoui december december august policy ir andrew wittys contract renewed june following appointment ceo amended february remove notice period calendar months entitlement bonus part severance terms termination r moncef slaouis previous contract dated may replaced employing company new contract december reflect changes severance executive terms outlined termination payment x annual salary termination payments made respect part payable termination company notice period extending beyond contract expiry date vesting ltis rules relevant incentive plan entitlements approved shareholders addition contractual provisions outlined pension based existing arrangements event dr moncef slaouis service agreement terminated terms relevant pension plan employing company following apply noncompete clause months termination n case outstanding awards due notice date glaxosmithkline annual investment plan closed ability impose month noncompete period nonsolicitation new deferrals effect first quarter restriction executive considered important company provided agreement terminated cause ability protect groups intellectual property staff light dr moncef slaoui must exercise bonus investment rights committee believes would appropriate provide within six months termination receive deferred mitigation contracts amounts income gains contracts new executives normally include bonus n line policy applicable us senior executives element termination payment dr moncef slaoui may become eligible future date receive continuing medical dental insurance retirement terms contracts seek balance commercial imperatives best practice company considers important outside appointments executives individual work elsewhere notice board encourages executives hold one external directorship period may make compensatory payment respect bonus become established role broaden period restraint experience development help increase pool julian heslop retired early company march candidates nonexecutive directors terms contract entered prior outside appointments considered nominations framework introduced entitled receive one committee ensure would cause conflict interest years notice termination payment included one years approved chairman behalf board annual salary months ontarget bonus companys policy remuneration earned simon dingemans joined board january appointments may kept individual executive appointed cfo april following julian heslops early retirement line companys policy simon dingemans contract provides termination payment based one years base salary gsk annual report governance remuneration report continued remuneration chairman nonexecutive directors shares ads notionally awarded non executive directors allocated interest accounts set nonexecutive director fees set table included within directors interests table accumulated balance company aims provide chairman non shares ads together notional dividends subsequently executive directors fees competitive paid reinvested paid nonexecutive directors companies equivalent size complexity subject retirement board upon retirement nonexecutive limits contained gsks articles association directors receive either shares ads cash amount chairman ceo responsible evaluating equal value shares ads date retirement making recommendations board fees payable date payment later nonexecutive directors letters appointment fees terms engagement nonexecutive directors chairmans fees currently per annum plus set letters appointment available inspection allocation shares value per annum companys registered office agm nonexecutive director initial appointment nonexecutive directors fees applying december subsequent reappointment subject election thereafter follows periodic reelection shareholders per annum nonexecutive directors letters appointment standard annual cash retainer fee contain provision notice periods compensation supplemental fees appointments terminated chairman audit risk committee following table shows date initial letter appointment nonexecutive director senior independent director scientificmedical experts nonexecutive director date letter appointment chairmen remuneration corporate sir christopher gent may responsibility committees professor sir roy anderson september dr stephanie burns february nonexecutive director undertaking stacey cartwright march intercontinental travel meetings per meeting larry culp june fee chairman audit risk committee reflects increased sir crispin davis june focus within group compliance risk time commitment judy lewent march required committee chairman approximately days per annum sir deryck maughan may full details operation audit risk committee given james murdoch february pages dr daniel podolsky july ir christopher gent chairman corporate responsibility tom de swaan december committee receive additional fee listed sir robert wilson june recent years increase time sir christopher gents letter appointment agreed commitment demands responsibility placed role would serve company deputy chairman nonexecutive director generally led increase december january chairman fees result developments market conclusion agm following third anniversary nonexecutive director fees gsk independently reviewed appointment extended term three years review highlighted scope mutual agreement effect reelection director increase nonexecutive director fees however light agm held may extended current environment decided increase fees period five years effect january subject time continue kept review annual reelection agms nonexecutive directors share allocation plan exchange rate enhance link directors shareholders gsk fees paid us dollars converted following requires nonexecutive directors receive significant part exchange rates fees form shares least nonexecutive directors total fees excluding chairman paid exchange rate form shares ads allocated share account period rate applied us january december us nonexecutive directors may also take opportunity invest january december us part balance fees share january december us ads account exchange rate set annually based average daily rate last quarter year prior payment rate reviewed moves significantly year gsk annual report tsr performance graph following graph sets performance company relative ftse index company constituent pharmaceutical performance comparator group five year period december graph prepared accordance regulations defined basis preparation indication likely vesting awards granted companys incentive plans tsr performance glaxosmithkline total return glaxosmithkline pharma peers return index ftse total return index index includes abbott laboratories astrazeneca bristolmyers squibb eli lilly johnson johnson merck novartis pfizer roche holdings sanofi gsk annual report governance remuneration report continued remuneration directors emoluments total remuneration addition statutory disclosure total emoluments year also provided total remuneration includes value ltis earned relevant performance period ended year compen sation total value total total value total fees annual loss emolu ltis remune fees annual emolu ltis remune footnote salary benefits bonus office ments earned ration salary benefits bonus ments earned ration executive directors sir andrew witty abcdh simon dingemans bceh julian heslop abdg dr moncef slaoui acfh total executive directors nonexecutive directors professor sir roy anderson stacey cartwright sir crispin davis sir christopher gent james murdoch tom de swaan sir robert wilson dr stephanie burns larry culp judy lewent sir deryck maughan dr daniel podolsky total nonexecutive directors former directors dr jeanpierre garnier total former directors total remuneration directors us payroll reported dollars average exchange rates year none directors received reimbursement expenses year requiring separate disclosure regulations defined basis preparation n analysis value ltis earned sir andrew witty julian heslop dr moncef slaoui set b ir andrew witty simon dingemans participate salary sacrifice schemes including sharereward julian heslop also participated early retirement march c ir andrew witty simon dingemans dr moncef slaoui elected participate gsks deferred annual bonus plan respect bonuses sir andrew witty deferred bonus simon dingemans deferred bonus dr moncef slaoui deferred bonus f ollowing merger glaxo wellcome smithkline beecham encourage employees convert holdings nonsavings related options legacy shares ads options glaxosmithkline shares ads employees granted additional cash benefit equal grant price original option additional benefit known exchange offer incentive eoi payable new option exercised lapsed underwater qualify additional cash benefit participants retain options least second anniversary effective date merger sir andrew witty received julian heslop received amounts included within benefits awards eligible eoi e imon dingemans joined board january remuneration recorded date participate gsks pension plans instead received respect lieu money purchase pension contribution respect life assurance contributions included benefits f r moncef slaoui stepped nonexecutive director agency science technology research astar january received nil included g j ulian heslop retired early march received one years annual salary months ontarget bonus compensation loss office set terms contract h total remuneration executive director office december last five years since date appointment later follows sir andrew witty na simon dingemans na na na na dr moncef slaoui ir andrew witty appointed board january simon dingemans appointed january tacey cartwright judy lewent joined board april fees recorded date gsk annual report nonexecutive directors fees cash sharesads total cash sharesads total fees nonexecutive directors professor sir roy anderson stacey cartwright sir crispin davis sir christopher gent james murdoch tom de swaan sir robert wilson dr stephanie burns larry culp judy lewent sir deryck maughan dr daniel podolsky total fees nonexecutive directors required take least part total fees form shares ads allocated shareads account paid retirement board see details share allocation plan nonexecutive director total value shares ads date award together cash payment forms total fees included within table fees salary table sets value fees received form cash shares ads table sets accumulated number shares ads held nonexecutive directors share allocation plan relation fees received board members december together movements accounts year number shares ads december allocated dividends december share allocation plan elected reinvested nonexecutive directors shares professor sir roy anderson stacey cartwright sir crispin davis sir christopher gent james murdoch tom de swaan sir robert wilson ads dr stephanie burns larry culp judy lewent sir deryck maughan dr daniel podolsky gsk annual report governance remuneration report continued remuneration directors interests following interests directors company office december connected persons shown accordance fsa listing rules shares ads march december january march december january footnote executive directors sir andrew witty ab simon dingemans ac dr moncef slaoui bd nonexecutive directors professor sir roy anderson e dr stephanie burns e stacey cartwright ef larry culp e sir crispin davis e sir christopher gent e judy lewent ef sir deryck maughan e james murdoch e dr daniel podolsky e tom de swaan e sir robert wilson e one glaxosmithkline ads represents two glaxosmithkline shares interests abovementioned directors march reflect change yearend date includes shares purchased glaxosmithkline sharereward plan sir andrew witty totalling shares december december shares march simon dingemans totalling shares december december nil shares march b totals march include shares ads vested elements award performance share plan less sold satisfy tax liabilities amount plan award see pages details c imon dingemans joined board january holdings disclosed date ncludes ads purchased glaxosmithkline stock fund within us retirement savings plan us executive supplemental savings plan e ncludes shares ads received part fees described nonexecutive directors share allocation plan dividends received shares ads converted shares ads december f tacey cartwright judy lewent joined board april holdings disclosed date longterm incentive plans value ltis earned value ltis earned current former executive directors includes amounts vesting gsks lti plans share option plan performance share plan relevant performance periods ended reporting year together amounts vesting sharesave plan contracts ended year totals analysed follows sir andrew witty dr moncef slaoui julian heslop total vesting performance share plan award performance share plan award sharesave total gsk annual report share option plan awards respect options granted share option plan sop remuneration receivable executive director calculated date options first vest remuneration difference amount executive director required pay buy shares ads total value shares ads vesting date executive director chooses exercise options vesting date may exercise options time next seven years subsequent increase decrease amount realised due movements share ads price initial vesting date date exercise increase decrease value result investment decision executive director recorded remuneration options outstanding december march movements periods shown table december december march options shares exercised lapsed exercised lapsed sir andrew witty dr moncef slaoui julian heslop exercised options shares market date number price gain date grant exercise shares grant price exercise sir andrew witty dr moncef slaoui julian heslop sir andrew witty december december march options ads footnote exercised lapsed exercised lapsed dr moncef slaoui total ads dr slaoui includes interests connected person also employee gsk following table shows gains exercises options set analysed remuneration executive directors subsequent gainslosses result investment decisions market remuneration investment net date vesting price date gainloss gain plan grant date vesting exercise year sir andrew witty sop dr moncef slaoui sop julian heslop sharesave sop sop sir andrew witty sharesave gsk annual report governance remuneration report continued remuneration share option plan awards continued options outstanding december earliest latest vesting lapse dates options market price glaxosmithkline share ads yearend given table weighted average vesting date lapse date sir andrew witty grant price number earliest latest earliest latest total share options share options market price december vested weighted average vesting date lapse date dr moncef slaoui grant price number earliest latest earliest latest shares total share options share options market price december vested ads options market price yearend vested options market price yearend vested unvested total ads options december includes ads options held dr moncef slaouis connected person also employee gsk weighted average vesting date lapse date julian heslop grant price number earliest latest earliest latest total share options options market price december vested gsk granted share options executive directors annual basis directors hold options various share option plans referred note financial statements employee share schemes none nonexecutive directors interest option companys shares highest lowest closing prices year ended december glaxosmithkline shares ads respectively market price glaxosmithkline share december december glaxosmithkline ads december tables set share options granted performance periods performance targets whether options vested december march performance target vesting status annualised growth percentage grant footnote performance period december eps award vesting february lapsed rpi rpi rpi rpi rpi performance target vesting status annualised growth percentage grant footnote performance period march december eps award vesting february award lapsed unvested rpi february award unvested unvested rpi rpi rpi rpi performance targets share options met result lapsed third anniversary date grant gsk annual report deferred annual bonus plan awards deferred annual bonus plan dabp awards made executive directors annually based individuals voluntary bonus deferral election company match shares ads oneforone depending companys performance three year performance period amount remuneration receivable respect matching shares ads calculated using share ads price date relevant dabp award vests sir andrew witty shares performance period market price grant unvested december granted dividends reinvested unvested december granted dividends reinvested unvested march simon dingemans shares performance period market price grant unvested december granted unvested march dr moncef slaoui ads performance period market price grant unvested december granted dividends reinvested unvested december granted dividends reinvested unvested march following vesting schedules apply dabp awards made award vests three years subject relative tsr vesting schedule given psp award award performance period vesting criteria psp award given gsk annual report governance remuneration report continued remuneration performance share plan awards performance share plan psp awards made executive directors annual basis directors hold awards various psp plans referred note financial statements employee share schemes amount remuneration receivable respect performance shares calculated using share ads price date relevant psp award vests sir andrew witty shares performance period market price grant unvested december granted dividends reinvested vested lapsed unvested december granted dividends reinvested vested lapsed unvested march sir andrew witty vested shares number shares market price vesting gain remuneration remuneration simon dingemans shares performance period market price grant unvested december granted dividends reinvested unvested december granted dividends reinvested unvested march julian heslop shares performance period market price grant unvested december dividends reinvested vested lapsed unvested december dividends reinvested vested lapsed unvested march julian heslop vested shares number shares market price vesting gain remuneration remuneration gsk annual report performance share plan awards continued dr moncef slaoui ads performance period market price grant unvested december granted dividends reinvested vested lapsed unvested december granted dividends reinvested vested lapsed unvested march dr moncef slaoui vested ads number ads market price vesting gain remuneration remuneration terms psp number shares ads actually vesting determined following end relevant performance period dependent gsks performance period committee adjusted comparator group relative tsr removing scheringplough wyeth following delistings revised vesting schedule accordingly outstanding future awards relative tsr performance measured revised comparator group set dividends reinvested performance shares ads awarded executives throughout performance period date final award terms psp us participants may defer receipt part vested awards following vesting schedules apply psp awards made business diversification performance vesting schedule maximum performance expressed award award performance period percentage award vesting percentage threshold rd new product performance vesting schedule maximum performance expressed award award performance period percentage award vesting percentage threshold adjusted free cash flow vesting schedule cash flow targets award award performance period bn percentage award vesting relative tsr vesting schedule award award performance period tsr rank companies percentage award vesting median median due commercial sensitivity targets business diversification performance rd new product performance measures disclosed along outcomes remuneration report gsk annual report governance remuneration report continued remuneration share value plan awards dr moncef slaoui ads market price unvested unvested unvested date december december march plan year grant granted vested vested executive director dr moncef slaoui eligible receive awards share value plan awards shown reflect holdings dr moncef slaouis connected person also employee gsk awards subject threeyear vesting periods vesting contingent continued employment gsk gains arising vesting included total remuneration dr moncef slaoui set pension benefits accrued annual pension benefits transfer values retirement executive directors office year set companies act requires disclosure accrued benefit end year change accrued benefit year transfer value beginning end year change transfer value year fsas listing rules require additional disclosure change accrued benefit net inflation transfer value change pensions executive directors disclosed currency pension payable change transfer value accrued accrued change personal transfer transfer accrued change benefit benefit accrued contributions value value change benefit accrued december december benefit made december december transfer year net benefit net executive director year year value inflation inflation sir andrew witty dr moncef slaoui na dr moncef slaoui na julian heslop shown net contributions made individual change accrued benefit shown julian heslop excludes impact inflation sir andrew witty julian heslop participate glaxo wellcome final salary plan accrual rate th final pensionable salary per annum benefits accrued glaxo wellcome uk pension arrangements augmented trustees plans reflect distribution surplus augmentation apply element sir andrew wittys julian heslops pension earnings march transfer values sir andrew witty julian heslop calculated accordance pensions regulation represent present value potential payments pension plan conditions underlying calculation changed particular yields indexlinked gilts changes increased transfer values increase sir andrew witty increase julian heslop remaining increases transfer values result increased valuation pension benefit accrued period sir andrew witty reduced period service assumed retirement age julian heslop early retirement march simon dingemans joined gsk january accumulating benefits gsks pension plans receives cash contribution lieu money purchase pension contribution dr moncef slaoui member us executive cash balance pension plan plan provides executive pension credit gsk makes annual contributions calculated percentage executives base salary gsk makes contributions base pay fund increases interest rate set annually advance based year us treasury bond rate provide cash sum retirement plan entitlement spouses pension pension increases transfer value cash sum increased dr moncef slaoui year result accumulation interest contributions paid company dr moncef slaoui active participant belgium fortis plan may plan defined benefit plan lump sum payable normal retirement age plan transfer value cash sum dr moncef slaouis plan increased year result accumulation interest gsk annual report dr moncef slaoui member us retirement savings plan basis preparation k savings scheme open us employees executive supplemental savings plan savings scheme open executives remuneration report prepared accordance accrue benefits us government limits imposed companies act large mediumsized retirement savings plan contributions plans invested companies groups accounts reports regulations range funds value accumulated funds paid regulations meets relevant requirements fsa retirement listing rules accordance regulations following sections remuneration report subject audit directors contributions paid emoluments total remuneration nonexecutive directors fees two schemes gsk respect dr moncef slaoui longterm incentive plans including share option plan awards directors interests contracts deferred annual bonus plan awards performance share plan awards share value plan awards pension benefits except described note financial statements related opinion thereon expressed party transactions end financial year remaining sections subject audit pages director connected person material interest referred within audited sections remuneration contract significance group company report approved board directors signed behalf directors senior management information provided compensation interests directors senior management group group purpose group defined nonexecutive executive directors members cet company secretary financial year total compensation sir crispin davis paid members group periods remuneration committee chairman served capacity aggregate increase march accrued pension benefits net inflation aggregate payment defined contribution schemes members group awarded shares ads deferred annual bonus plan shares ads performance share plan shares ads share value plan options granted members group share option plan notional shares ads granted deferred investment award plan members group awarded reinvestment dividends shares ads performance share plan shares ads deferred annual bonus plan notional shares deferred investment award plan march group comprising persons owned shares ads constituting less issued share capital company group also held date options purchase shares ads shares ads awarded performance share plan including shares ads vested deferred vested deferred ads legacy smithkline beecham midterm incentive plan shares ads awarded share value plan shares ads deferred annual bonus plan notional shares awarded deferred investment award plan holdings issued various executive share plans described note financial statements employee share schemes gsk annual report financial statements statements directors statement responsibilities directors statement responsibilities relation business review pages includes fair review group financial statements development performance business position group together description directors responsible preparing annual report principal risks uncertainties faces remuneration report group financial statements accordance applicable law regulations disclosure information auditors company law requires directors prepare financial directors office date report statements financial year law directors confirmed required prepare group financial statements far aware relevant audit accordance international financial reporting standards ifrs information companys auditors unaware adopted european union preparing group taken steps ought financial statements directors also elected comply taken director make aware ifrs issued international accounting standards relevant audit information establish companys board iasb company law directors must approve auditors aware information group financial statements unless satisfied give true fair view state affairs group confirmation given interpreted accordance profit loss group period provisions section companies act preparing financial statements directors required going concern basis elect suitable accounting policies apply business review pages contains information consistently performance group financial position cash flows net debt ake judgements accounting estimates position borrowing facilities information including reasonable prudent treasury risk management policies exposures market credit risk hedging activities given note financial tate group financial statements comply ifrs statements financial instruments related disclosures adopted european union ifrs issued iasb making enquiries directors reasonable expectation subject material departures disclosed explained group adequate resources continue operational group financial statements existence foreseeable future reason continue directors responsible keeping adequate accounting adopt going concern basis preparing financial statements records sufficient show explain companys internal control transactions disclose reasonable accuracy time financial position group enable ensure board audit risk committee reviewed group financial statements remuneration report assessment risks internal control framework operates comply companies act article ias gsk considered effectiveness system internal regulation also responsible safeguarding assets control operation group year covered report group hence taking reasonable steps date approval board directors prevention detection fraud irregularities uk corporate governance code group financial statements year ended december board considers glaxosmithkline plc applies comprising principal statements supporting notes set principles provisions uk corporate governance code financial statements pages report maintained financial reporting council described responsibilities auditors relation group financial corporate governance section pages statements set independent auditors report complied provisions except disclosed group financial statements year ended december required financial services authoritys listing rules included annual report published hardcopy auditors considered directors statement compliance printed form made available website directors relation points uk corporate governance code responsible maintenance integrity annual report specified review website accordance uk legislation governing annual report preparation dissemination financial statements access website available outside uk comparable annual report year ended december legislation may different comprising report directors remuneration report financial statements additional information investors current directors whose names functions approved board directors signed listed corporate governance section annual report behalf confirms best knowledge group financial statements prepared accordance ifrs adopted eu ifrs issued sir christopher gent iasb give true fair view assets liabilities chairman financial position profit group march gsk annual report independent auditors report separate opinion relation ifrs issued iasb members glaxosmithkline plc explained note group financial statements audited group financial statements group addition complying legal obligation apply glaxosmithkline plc year ended december ifrs adopted european union also applied ifrs comprise consolidated income statement consolidated issued international accounting standards board iasb statement comprehensive income consolidated balance sheet consolidated statement changes equity opinion group financial statements comply ifrs consolidated cash flow statement related notes issued iasb financial reporting framework applied opinion matter prescribed companies preparation applicable law international financial reporting act standards ifrs adopted european union opinion information given directors report respective responsibilities directors auditors financial year group financial statements explained fully directors statement prepared consistent group financial statements responsibilities set directors responsible matters required report preparation group financial statements exception satisfied give true fair view responsibility audit express opinion group nothing report respect following financial statements accordance applicable law companies act required report international standards auditing uk ireland opinion standards require us comply auditing practices boards ethical standards auditors c ertain disclosures directors remuneration specified law made report including opinions prepared companys members body accordance chapter w e received information explanations part companies act purpose require audit giving opinions accept assume listing rules required review responsibility purpose person report shown whose hands may come save directors statement set relation expressly agreed prior consent writing going concern scope audit financial statements part corporate governance statement relating companys compliance nine provisions uk audit involves obtaining evidence amounts corporate governance code specified review disclosures financial statements sufficient give reasonable assurance financial statements free material c ertain elements report shareholders board misstatement whether caused fraud error includes directors remuneration assessment whether accounting policies appropriate matters groups circumstances consistently applied reported separately parent company financial adequately disclosed reasonableness significant statements glaxosmithkline plc year ended accounting estimates made directors overall december information directors presentation financial statements addition read remuneration report described audited financial nonfinancial information annual report identify material inconsistencies audited financial company passed resolution accordance section statements become aware apparent material companies act senior statutory misstatements inconsistencies consider implications auditors name stated report opinion financial statements pricewaterhousecoopers llp opinion group financial statements chartered accountants statutory auditors g ive true fair view state groups affairs london december profit cash flows year march ended h ave properly prepared accordance ifrs adopted european union prepared accordance requirements companies act article las regulation gsk annual report financial statements financial statements consolidated income statement year ended december results results results major major major major major major restructuring restructuring total restructuring restructuring total restructuring restructuring total notes turnover cost sales gross profit selling general administration research development operating income operating profit finance income finance costs profit disposal interest associates share tax profits associates joint ventures profit taxation taxation profit taxation year profit attributable noncontrolling interests profit attributable shareholders basic earnings per share pence p p p diluted earnings per share pence p p p calculation results major restructuring described note presentation financial statements consolidated statement comprehensive income year ended december profit year exchange movements overseas net assets net investment hedges reclassification exchange liquidation disposal overseas subsidiaries tax exchange movements fair value movements availableforsale investments deferred tax fair value movements availableforsale investments reclassification fair value movements availableforsale investments deferred tax reversed reclassification availableforsale investments fair value movements cash flow hedges deferred tax fair value movements cash flow hedges reclassification cash flow hedges income statement fair value movement subsidiary acquisition cash flow hedge reclassified goodwill actuarial losses defined benefit plans deferred tax actuarial movements defined benefit plans share comprehensive expense associates joint ventures comprehensive expenseincome year total comprehensive income year total comprehensive income year attributable shareholders noncontrolling interests total comprehensive income year gsk annual report results results results major major major major major major restructuring restructuring total restructuring restructuring total restructuring restructuring total notes turnover cost sales gross profit selling general administration research development operating income operating profit finance income finance costs profit disposal interest associates share tax profits associates joint ventures profit taxation taxation profit taxation year profit attributable noncontrolling interests profit attributable shareholders basic earnings per share pence p p p diluted earnings per share pence p p p calculation results major restructuring described note presentation financial statements consolidated statement comprehensive income year ended december profit year exchange movements overseas net assets net investment hedges reclassification exchange liquidation disposal overseas subsidiaries tax exchange movements fair value movements availableforsale investments deferred tax fair value movements availableforsale investments reclassification fair value movements availableforsale investments deferred tax reversed reclassification availableforsale investments fair value movements cash flow hedges deferred tax fair value movements cash flow hedges reclassification cash flow hedges income statement fair value movement subsidiary acquisition cash flow hedge reclassified goodwill actuarial losses defined benefit plans deferred tax actuarial movements defined benefit plans share comprehensive expense associates joint ventures comprehensive expenseincome year total comprehensive income year total comprehensive income year attributable shareholders noncontrolling interests total comprehensive income year gsk annual report financial financial statements continued statements consolidated balance sheet december notes noncurrent assets property plant equipment goodwill intangible assets investments associates joint ventures investments deferred tax assets derivative financial instruments noncurrent assets total noncurrent assets current assets inventories current tax recoverable trade receivables derivative financial instruments liquid investments cash cash equivalents assets held sale total current assets total assets current liabilities shortterm borrowings trade payables derivative financial instruments current tax payable shortterm provisions total current liabilities noncurrent liabilities longterm borrowings deferred tax liabilities pensions postemployment benefits provisions derivative financial instruments noncurrent liabilities total noncurrent liabilities total liabilities net assets equity share capital share premium account retained earnings reserves shareholders equity noncontrolling interests total equity approved board march sir christopher gent chairman gsk annual report consolidated statement changes equity year ended december shareholders equity non share share retained controlling total capital premium earnings reserves total interests equity january profit year comprehensive expenseincome year total comprehensive income year distributions noncontrolling interests changes noncontrolling interests put option noncontrolling interest dividends shareholders ordinary shares issued ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december profit year comprehensive income year total comprehensive income year distributions noncontrolling interests dividends shareholders ordinary shares issued ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december profit year comprehensive expense year total comprehensive income year distributions noncontrolling interests dividends shareholders changes noncontrolling interests forward contract relating noncontrolling interest ordinary shares issued ordinary shares purchased cancelled held treasury shares ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december gsk annual report financial financial statements continued statements consolidated cash flow statement year ended december notes cash flow operating activities profit taxation year adjustments reconciling profit tax operating cash flows cash generated operations taxation paid net cash inflow operating activities cash flow investing activities purchase property plant equipment proceeds sale property plant equipment purchase intangible assets proceeds sale intangible assets purchase equity investments proceeds sale equity investments purchase businesses net cash acquired investments associates joint ventures proceeds disposal subsidiary interest associate decrease liquid investments interest received dividends associates joint ventures net cash outflow investing activities cash flow financing activities proceeds shares employee share options shares acquired esop trusts issue share capital purchase shares cancellation held treasury shares increase longterm loans increase shortterm loans repayment shortterm loans net repayment obligations finance leases interest paid dividends paid shareholders distributions noncontrolling interests financing cash flows net cash outflow financing activities decreaseincrease cash bank overdrafts exchange adjustments cash bank overdrafts beginning year cash bank overdrafts end year cash bank overdrafts end year comprise cash cash equivalents overdrafts gsk annual report notes financial statements presentation financial presentation restructuring costs statements october board approved implementation detailed formal plan gsk announced significant new description business operational excellence restructuring programme glaxosmithkline major global healthcare group second formal plan representing significant expansion engaged creation discovery development manufacture operational excellence programme approved board marketing pharmaceutical products including vaccines announced february expansion overthecounter otc medicines healthrelated consumer approved board announced february products gsks principal pharmaceutical products include restructuring programme comprising detailed formal plans medicines following therapeutic areas respiratory covers areas gsks business including manufacturing antivirals including hiv central nervous system cardiovascular selling rd infrastructure savings urogenital metabolic antibacterials oncology emesis identified year estimated total cost vaccines dermatologicals increased approximately billion expanded compliance applicable law ifrs programme expected deliver annual pretax savings approximately billion time substantially complete financial statements prepared accordance given extent cost operational excellence companies act article ias regulation programme management believes material impact international accounting standards ias international gsks operating results manner gsks financial reporting standards ifrs related interpretations business conducted gsk presents restructuring costs adopted european union incurred solely direct result operational excellence financial statements also compliance ifrs issued programme separate column income statement titled international accounting standards board major restructuring composition financial statements addition restructuring costs operational excellence programme major restructuring column income consolidated financial statements drawn sterling statement includes restructuring costs incurred solely direct functional currency glaxosmithkline plc accordance result restructuring programmes follow relate ifrs accounting presentation financial statements material acquisitions operations acquired comprise business overlap extensively gsks existing operations consolidated income statement restructuring activities follow relate consolidated statement comprehensive income acquisitions nature undertaken operational excellence programme also carried consolidated balance sheet following detailed formal plan management therefore considers consolidated statement changes equity appropriate present costs restructuring activities consolidated cash flow statement manner billion million acquisition reliant pharmaceuticals december billion notes financial statements billion acquisition stiefel laboratories july accounting convention acquisitions since october meet criteria set financial statements prepared using historical acquisitions costs incurred cost convention modified revaluation certain items direct result related restructuring programme stated accounting policies included within major restructuring column financial period groups results costs operational excellence programme acquisitionrelated restructuring programmes financial statements cover financial year january meeting criteria described also presented december comparative figures financial separate column income statement described years january december appropriate results major restructuring presentation january december adopted show clearly groups results composition group costs restructuring programmes management believes presentation assists investors gaining clearer list subsidiary associated undertakings understanding groups financial performance opinion directors principally affected amount profit making projections future financial performance results net assets group given note principal include costs virtue size nature limited group companies comparative value presentation also consistent way management assessed groups financial performance gsk annual report financial notes financial statements continued statements presentation financial accounting principles policies statements continued consolidation restructuring costs arise solely direct result consolidated financial statements include operational excellence programme restructuring assets liabilities results cash flows programmes following relating acquisitions meeting company subsidiaries including esop trusts criteria described continue reported operating expenses within results major restructuring groups share results net assets associates joint ventures accounting principles policies preparation financial statements conformity financial statements entities consolidated made generally accepted accounting principles requires management december year make estimates assumptions affect reported entities group power govern amounts assets liabilities disclosure contingent financial operating policies accounted subsidiaries assets liabilities date financial statements group ability exercise joint control reported amounts revenues expenses entities accounted joint ventures group reporting period actual results could differ estimates ability exercise significant influence accounted financial statements prepared accordance associates results assets liabilities groups accounting policies approved board associates joint ventures incorporated described note accounting principles policies consolidated financial statements using equity method information application accounting policies accounting including areas estimation judgement given note interests acquired entities consolidated date key accounting judgements estimates appropriate group acquires control interests sold deconsolidated comparative figures reclassified ensure consistent date control ceases presentation current year information transactions balances subsidiaries eliminated implementation new accounting standards profit tax taken sales subsidiaries effect january gsk implemented products sold customers outside group amendment ias financial instruments presentation relevant proportion profits transactions joint classification rights issues ias revised related party ventures associates also deferred products disclosures minor amendments number sold third parties transactions noncontrolling interests accounting standards revisions material impact recorded directly equity deferred tax relief unrealised current period intragroup profit accounted extent considered recoverable parent company financial statements goodwill capitalised separate item case financial statements parent company glaxosmithkline subsidiaries part cost investment case plc prepared accordance uk gaap joint ventures associates goodwill denominated uk accounting presentation company balance sheet currency operation acquired presented accounting policies given cost acquisition fair value net assets acquired difference recognised directly income statement business combinations business combinations accounted using acquisition accounting method identifiable assets liabilities contingent liabilities acquired measured fair value acquisition date consideration transferred measured fair value includes fair value contingent consideration costs acquisition charged income statement period incurred equity subsidiary acquired noncontrolling interest recognised either fair value noncontrolling interests share net assets subsidiary casebycase basis changes groups ownership percentage subsidiaries accounted within equity gsk annual report accounting principles policies expenditure continued expenditure recognised respect goods services received supplied accordance contractual terms foreign currency translation provision made obligation exists future liability foreign currency transactions booked functional respect past event amount obligation currency group company exchange rate ruling reliably estimated manufacturing startup costs date transaction foreign currency monetary assets validation achievement normal production liabilities retranslated functional currency rates expensed incurred advertising promotion expenditure exchange ruling balance sheet date exchange differences charged income statement incurred shipment costs included income statement intercompany transfers charged cost sales distribution costs sales customers included selling general consolidation assets liabilities including related goodwill administrative expenditure overseas subsidiaries associates joint ventures translated sterling rates exchange ruling balance restructuring costs recognised provided sheet date results cash flows overseas subsidiaries appropriate respect direct expenditure business associates joint ventures translated sterling using reorganisation plans sufficiently detailed well average rates exchange advanced appropriate communication affected undertaken exchange adjustments arising opening net assets profits year retained overseas subsidiaries research development associates joint ventures translated sterling less research development expenditure charged income exchange differences arising related foreign currency statement period incurred development borrowings hedge groups net investment expenditure capitalised criteria recognising operations taken separate component equity asset met usually regulatory filing made translating sterling assets liabilities results major market approval considered highly probable cash flows overseas subsidiaries associates joint ventures property plant equipment used research reported currencies hyperinflationary economies development capitalised depreciated accordance adjustments made material reflect current price groups policy levels loss net monetary assets charged environmental expenditure consolidated income statement environmental expenditure related existing conditions resulting revenue past current operations current revenue recognised income statement goods future benefit discernible charged income statement services supplied made available external customers group recognises liability sitebysite basis orders received title risk loss passed reliably estimated liability includes groups customer reliable estimates made relevant deductions portion total costs also portion potentially relevant obligations fulfilled responsible parties costs probable earnings process regarded complete able satisfy respective shares cleanup obligation recoveries reimbursements recorded assets turnover represents net invoice value deduction virtually certain discounts allowances given accruals estimated future rebates returns methodology assumptions legal disputes used estimate rebates returns monitored adjusted provision made anticipated settlement costs legal regularly light contractual legal obligations disputes group outflow resources historical trends past experience projected market considered probable reliable estimate made conditions market conditions evaluated using wholesaler likely outcome addition provision made legal thirdparty analyses market research data internally expenses arising claims received disputes generated information value added tax sales taxes respect product liability claims related certain products excluded revenue sufficient history claims made settlements group copromotes product third party enable management make reliable estimate provision records sale group records share revenue required cover unasserted claims certain cases incurred copromotion income within turnover nature co reported ibnr actuarial technique used determine promotion activities group records costs estimate sales pharmaceutical turnover includes copromotion revenue group may become involved legal proceedings respect million million million possible make reliable estimate royalty income recognised operating income expected financial effect could result ultimate accruals basis accordance terms relevant resolution proceedings cases appropriate licensing agreements disclosure cases would included provision would made costs associated claims made group third parties charged income statement incurred gsk annual report financial notes financial statements continued statements accounting principles policies disposal ppe cost related accumulated continued depreciation impairments removed financial statements net amount less proceeds taken pensions postemployment benefits income statement costs providing pensions defined benefit schemes leases calculated using projected unit credit method spread leasing agreements transfer group substantially period benefit expected derived benefits risks ownership asset treated employees services consistent advice finance leases asset purchased outright qualified actuaries pension obligations measured assets included ppe computer software capital present value estimated future cash flows discounted rates elements leasing commitments shown obligations reflecting yields high quality corporate bonds finance leases assets held finance leases pension scheme assets measured fair value balance depreciated basis consistent similar owned assets sheet date actuarial gains losses differences lease term shorter interest element lease rental expected actual returns assets effect changes included income statement leases operating actuarial assumptions recognised statement leases rental costs charged income statement comprehensive income year arise straightline basis lease term groups contributions defined contribution plans goodwill charged income statement incurred costs goodwill stated cost less impairments goodwill deemed postemployment liabilities calculated similar way indefinite useful life tested impairment annually defined benefit pension schemes spread period benefit expected derived fair value interest acquired entitys assets employees services accordance advice qualified liabilities contingent liabilities exceeds consideration paid actuaries excess recognised immediately gain income statement employee share plans intangible assets incentives form shares provided employees share option share award schemes intangible assets stated cost less provisions amortisation impairments fair values options awards calculated grant dates using blackscholes option pricing model licences patents knowhow marketing rights separately charged income statement relevant vesting acquired acquired part business combination periods amortised estimated useful lives generally exceeding years using straightline basis time group provides finance esop trusts purchase company available use estimated useful lives shares open market meet obligation provide determining amortisation charge take account patent shares employees exercise options awards costs lives applicable well value obtained running esop trusts charged income statement periods nonexclusivity asset lives reviewed shares held esop trusts deducted reserves appropriate adjusted annually contingent milestone payments transfer made reserves retained earnings recognised point contingent event becomes vesting periods related share options awards certain development costs incurred group reflect ultimate proceeds receivable employees associated acquired licences patents knowhow exercise marketing rights written income statement property plant equipment incurred unless criteria recognition internally generated intangible asset met usually regulatory property plant equipment ppe stated cost filing made major market approval purchase construction less provisions depreciation considered highly probable impairment financing costs capitalised within cost qualifying assets construction acquired brands valued independently part fair value businesses acquired third parties brand depreciation calculated write cost less residual value value substantial longterm brands ppe excluding freehold land using straightline basis either contractual legal nature sold separately expected useful life residual values lives reviewed rest businesses acquired brands amortised appropriate adjusted annually normal expected estimated useful lives years except useful lives major categories ppe considered useful economic life indefinite freehold buildings years costs acquiring developing computer software internal leasehold land use internet sites external use capitalised intangible buildings lease term years fixed assets software site supports significant business plant machinery years system expenditure leads creation durable asset fixtures equipment years erp systems software amortised seven ten years computer software three five years gsk annual report accounting principles policies trade receivables continued trade receivables carried original invoice amount less provisions doubtful debts provisions made impairment noncurrent assets evidence risk nonpayment taking account ageing carrying values noncurrent assets reviewed previous experience general economic conditions impairment either standalone basis part larger trade receivable determined uncollectable written cash generating unit indication assets firstly provision available income might impaired additionally goodwill intangible assets statement indefinite useful lives intangible assets yet subsequent recoveries amounts previously provided available use tested impairment annually provision credited income statement longterm receivables impairment charged income statement year discounted effect material concerned trade payables impairments goodwill reversed impairment losses noncurrent assets reversed trade payables initially recognised fair value held change estimates used determine recoverable amounts amortised cost equates nominal value longterm extent revised recoverable amounts payables discounted effect material exceed carrying values would existed net cash cash equivalents depreciation amortisation impairments cash cash equivalents comprise cash hand current recognised balances banks similar institutions highly liquid investments associates joint ventures investments generally maturities three months less investments associates joint ventures carried readily convertible known amounts cash consolidated balance sheet groups share net assets insignificant risk changes value date acquisition postacquisition retained profits borrowings losses together goodwill arising acquisition borrowings initially recorded amount proceeds availableforsale investments received net transaction costs borrowings subsequently liquid investments investments classified carried amortised cost difference availableforsale investments initially recorded fair proceeds net transaction costs amount due value plus transaction costs remeasured subsequent redemption recognised charge income reporting dates fair value unrealised gains losses statement period relevant borrowing availableforsale investments recognised directly taxation comprehensive income impairments arising significant current tax provided amounts expected paid prolonged decline fair value equity investment reduce applying tax rates enacted substantively carrying amount asset directly charged enacted balance sheet date income statement deferred tax provided full using liability method disposal impairment investments gains temporary differences arising tax bases assets losses deferred comprehensive income liabilities carrying amounts financial statements reclassified income statement dividends equity deferred tax assets recognised extent probable investments recognised income statement future taxable profits available groups right receive payment established equity temporary differences utilised deferred tax provided investments recorded noncurrent assets unless temporary differences arising investments subsidiaries expected sold within one year associates joint ventures except timing purchases sales equity investments accounted reversal temporary difference controlled trade date purchases sales availableforsale probable temporary difference reverse investments accounted settlement date foreseeable future deferred tax provided using rates tax inventories enacted substantively enacted balance sheet date deferred tax liabilities assets discounted inventories included financial statements lower cost including raw materials direct labour direct costs related production overheads net realisable value cost generally determined first first basis prelaunch inventory held asset high probability regulatory approval product point provision made carrying value recoverable amount provision reversed point high probability regulatory approval determined gsk annual report financial notes financial statements continued statements accounting principles policies amounts estimated may fully reflect continued final outcome amounts subject change dependent upon amongst things types buying group derivative financial instruments hedging product sales mix derivative financial instruments used manage exposure level accrual reviewed adjusted regularly market risks principal derivative instruments used gsk light contractual legal obligations historical trends past foreign currency swaps interest rate swaps forward foreign experience projected market conditions market conditions exchange contracts group hold issue derivative evaluated using wholesaler thirdparty analyses financial instruments trading speculative purposes market research data internally generated information future events could cause assumptions derivative financial instruments classified heldfortrading accruals based change could affect future carried balance sheet fair value derivatives results group designated hedging instruments classified inception cash flow hedges net investment hedges fair value hedges taxation changes fair value derivatives designated cash flow current tax provided amounts expected paid hedges recognised comprehensive income deferred tax provided temporary differences extent hedges effective ineffective portions tax bases assets liabilities carrying amounts recognised profit loss immediately amounts deferred rates enacted substantively enacted comprehensive income reclassified income balance sheet date statement hedged item affects profit loss deferred tax assets recognised extent probable net investment hedges accounted similar way future taxable profits available cash flow hedges temporary differences utilised based managements assumptions relating amounts timing future taxable changes fair value derivatives designated fair value profits factors affecting tax charge future years set hedges recorded income statement together note taxation change groups effective tax changes fair value hedged asset liability rate would changed total tax charge year changes fair value derivative instruments approximately million qualify hedge accounting recognised immediately group open tax issues number revenue income statement authorities outflow funds believed probable discounting reliable estimate outcome dispute made management provides best estimate liability time effect money material balances estimates take account specific circumstances discounted current values using appropriate rates interest dispute relevant external advice inherently unwinding discounts recorded finance income judgemental could change substantially time new finance costs facts emerge dispute progresses details relating key accounting judgements significant unresolved disputes set note taxation gsk continues believe made adequate provision estimates liabilities likely arise open assessments open preparing financial statements management required issues exist ultimate liability matters may vary make estimates assumptions affect amounts amounts provided dependent upon outcome assets liabilities revenue expenses reported financial negotiations relevant tax authorities necessary statements actual amounts results could differ litigation proceedings estimates following considered key accounting legal disputes judgements estimates made gsk provides anticipated settlement costs outflow turnover resources considered probable reliable estimate may revenue recognised title risk loss passed made likely outcome dispute legal customer reliable estimates made relevant deductions expenses arising claims group estimates relevant obligations fulfilled take account specific circumstances dispute earnings process regarded complete relevant external advice inherently judgmental could change substantially time new facts emerge gross turnover reduced rebates discounts allowances dispute progresses details status various uncertainties product returns given expected given vary involved significant unresolved disputes set note product arrangements buying groups arrangements legal proceedings purchasing organisations dependent upon submission claims time initial recognition sale accruals made time sale estimated rebates discounts allowances payable returns made based available market information historical experience gsk annual report key accounting judgements case valuations indicate sufficient headroom estimates continued reasonably possible change key assumptions unlikely result impairment related goodwill assumptions companys directors taken legal advice relating future cash flows discount rates based established provisions taking account relevant facts business forecasts therefore inherently judgemental circumstances matter accordance future events could cause assumptions used accounting requirements respect product liability claims impairment tests change consequent adverse effect related certain products sufficient history claims future results group made settlements enable management make reliable intangible assets estimate provision required cover unasserted claims certain cases incurred reported ibnr actuarial intangible assets acquired gsk third parties technique used determine estimate group may costs acquisition capitalised licences compounds become involved legal proceedings respect development amortised point possible make reliable estimate expected financial available use estimated useful lives may effect result ultimate resolution include periods nonexclusivity estimated useful lives proceedings cases appropriate disclosure reviewed annually impairment tests undertaken events cases would included provision would made occur call question carrying values assets contingent liability quantified december brands acquired businesses capitalised independently provisions legal disputes amounted billion separable expected life billion one year brands amortised straightline basis estimated useful lives exceeding years except ultimate liability legal claims may vary amounts end useful economic life foreseen brands provided dependent upon outcome litigation amortised subject annual impairment tests proceedings investigations possible settlement negotiations position could change time therefore initial valuations valuations subsequent impairment assurance losses result outcome tests based established market multiples riskadjusted legal proceedings exceed amount provisions future cash flows estimated useful life asset reported groups financial statements material limited discounted using appropriate interest rates set amount note intangible assets assumptions relating future cash flows estimated useful lives discount rates property plant equipment based business forecasts therefore inherently set note property plant equipment judgemental future events could cause assumptions used carrying values property plant equipment tested impairment reviews change consequent adverse impairment indication values effect future results group assets might impaired impairment determined reference pensions postemployment benefits higher fair value less costs sell value use measured assessing riskadjusted future cash flows costs providing pensions postemployment estimated useful life asset discounted using appropriate benefits charged income statement accordance interest rates ranges estimated useful lives applied ias employee benefits period benefit category property plant equipment set derived employees services costs assessed note accounting principles policies assumptions basis assumptions selected management relating future cash flows estimated useful lives discount assumptions include future earnings pension increases rates based business forecasts therefore inherently discount rates expected long term rates return assets judgemental given large number individual items mortality rates disclosed note pensions property plant equipment considered likely postemployment benefits reasonably possible change assumptions applied expected long term rates return bonds determined impairment test one item would lead material adverse based portfolio mix indexlinked government effect future results group however future events corporate bonds equity risk premium added could cause assumptions used impairment tests equities change consequent adverse effect future results discount rates derived aa rated corporate bond yields group except countries deep market corporate goodwill bonds government bond yields used sensitivity goodwill arising business combinations capitalised analysis provided note pensions post allocated appropriate cash generating unit deemed employment benefits reduction discount indefinite life amortised rate would lead increase net pension deficit approximately million increase annual pension annual impairment tests relevant cash generating units cost selection different assumptions could affect performed impairment tests based established market future results group multiples riskadjusted future cash flows discounted using appropriate interest rates assumptions used impairment tests set note goodwill gsk annual report financial notes financial statements continued statements new accounting requirements amendment ias employee benefits issued june implemented gsk january following new amended accounting standards ifric amendment eliminates ability defer recognition gains interpretations issued iasb likely losses corridor method requires remeasurements affect future annual reports although current forms presented comprehensive income requires funding none expected material impact results cost calculated net defined benefit liability financial position group makes several minor accounting disclosure changes amendment ifrs disclosures transfers financial amendment ifrs disclosures offsetting financial assets assets issued october implemented financial liabilities issued december gsk january amendment requires additional implemented gsk january amendment disclosures regarding risk exposures relating transfers requires additional disclosures financial assets financial financial assets liabilities offset balance sheet iasbs annual improvements project published may amendment ias offsetting financial assets financial changes effective january liabilities issued december implemented project makes minor amendments number standards gsk january amendment provides additional areas including consolidation business combinations guidance financial assets financial liabilities may financial instruments offset following new standards interpretations yet ifrs financial instruments first issued november endorsed eu amended october implemented gsk january standard eventually amendment ias deferred tax recovery underlying replace ias covers classification measurement assets issued december implemented derecognition financial assets financial liabilities iasb gsk january amendment requires intends expand ifrs add new requirements impairment deferred tax nondepreciable assets measured using hedge accounting become complete revaluation model calculated sale basis replacement ias due course ifrs consolidated financial statements issued may exchange rates replaces parts ias separate financial statements previously dealt consolidated financial group uses average exchange rates prevailing statements sic consolidation special purpose entities period translate results cash flows overseas implemented gsk january standard subsidiaries joint ventures associated undertakings uses control single basis determining whether sterling period end rates translate net assets entity consolidated undertakings currencies influence ifrs joint arrangements issued may translations relevant exchange rates implemented gsk january standard requires entity report share assets liabilities revenue average rates expenses joint operation financial statements us apply equity method accounting joint ventures euro consolidated financial statements yen ifrs disclosures interests entities issued may implemented gsk january period end rates standard requires disclosures related financial effects us risks associated entitys investments subsidiaries euro joint arrangements associates unconsolidated structured yen entities ifrs fair value measurement issued may implemented gsk january standard provides guidance fair value measurement introduces consistent disclosure requirements situations another standard permits requires fair value measurement amendment ias presentation items comprehensive income issued june implemented gsk january amendment changes required disclosures financial statements particularly respect statement comprehensive income gsk annual report segment information gsk revised segmental information disclosures reflect changes internal reporting structures effect january pharmaceuticals vaccines business japan shown separate segment comparative information restated consistent basis gsks operating segments reported based financial information provided chief executive officer responsibilities corporate executive team cet individual members cet responsible geographic segment pharmaceuticals vaccines business viiv healthcare consumer healthcare business whole respectively rd investment essential sustainability pharmaceutical businesses however segment reporting usa europe emerging markets asia pacific japan pharmaceuticals vaccines operating profits exclude allocations globally funded rd well central costs principally corporate functions unallocated manufacturing costs gsks management reporting process allocates intragroup profit product sale market sale recorded profit analyses presented basis trading unallocated pharmaceuticals vaccines includes canada puerto rico central vaccine tender sales contract manufacturing sales together costs vaccines rd central dermatology costs central manufacturing costs attributed segments pharmaceuticals rd segment responsibility chairman research development reported separate segment corporate unallocated costs disposal profits include corporate functions costs legal matters fair value movements financial instruments investments profits global asset disposals restated restated turnover segment pharmaceuticals vaccines usa europe emerging markets asia pacific japan viiv healthcare trading unallocated pharmaceuticals vaccines turnover consumer healthcare turnover restated restated pharmaceuticals vaccines turnover therapeutic area respiratory antivirals central nervous system cardiovascular urogenital metabolic antibacterials oncology emesis vaccines dermatologicals viiv healthcare hiv consumer healthcare turnover category otc medicines oral healthcare nutritional healthcare gsk annual report financial notes financial statements continued statements segment information continued us pharmaceuticals viiv healthcare made sales three wholesalers approximately million million million million million million million million million respectively allocating finalcustomer discounts wholesalers segment profit restated restated pharmaceuticals vaccines usa europe emerging markets asia pacific japan viiv healthcare pharmaceuticals rd trading unallocated costs pharmaceuticals vaccines operating profit consumer healthcare operating profit segment profit corporate unallocated costs disposal profits operating profit major restructuring major restructuring total operating profit finance income finance costs profit disposal interest associate share tax profits associates joint ventures profit taxation taxation profit taxation year depreciation amortisation segment restated restated pharmaceuticals vaccines usa europe emerging markets asia pacific japan viiv healthcare pharmaceuticals rd trading unallocated pharmaceuticals vaccines depreciation amortisation consumer healthcare depreciation amortisation segment depreciation amortisation corporate unallocated depreciation amortisation depreciation amortisation major restructuring major restructuring total depreciation amortisation gsk annual report segment information continued ppe intangible asset goodwill impairment segment restated restated pharmaceuticals vaccines usa europe emerging markets asia pacific japan viiv healthcare pharmaceuticals rd trading unallocated pharmaceuticals vaccines impairment consumer healthcare impairment segment impairment corporate unallocated impairment impairment major restructuring major restructuring total impairment ppe intangible asset impairment reversals segment restated restated pharmaceuticals vaccines usa europe emerging markets asia pacific japan viiv healthcare pharmaceuticals rd trading unallocated pharmaceuticals vaccines impairment reversals consumer healthcare impairment reversals segment impairment reversals corporate unallocated impairment reversals impairment reversals major restructuring major restructuring total impairment reversals gsk annual report financial notes financial statements continued statements segment information continued restated net assets segment pharmaceuticals vaccines usa europe emerging markets asia pacific japan viiv healthcare pharmaceuticals rd trading unallocated pharmaceuticals vaccines net operating assets consumer healthcare net operating assets segment net operating assets corporate unallocated net operating assets net operating assets net debt investments associates joint ventures derivative financial instruments current deferred taxation assets held sale net assets trading unallocated pharmaceuticals segment includes assets centrally managed pharmaceutical vaccine manufacturing operations depreciation totalling million million million recovered standard cost product charged businesses geographical information uk regarded groups country domicile restated restated turnover location customer uk usa rest world external turnover turnover location subsidiary uk usa rest world turnover including intersegment turnover uk usa rest world intersegment turnover uk usa rest world external turnover gsk annual report segment information continued operating profit location uk usa rest world total operating profit restated net operating assets location uk usa rest world net operating assets restated noncurrent assets location uk usa rest world noncurrent assets noncurrent assets location excludes amounts relating investments deferred tax assets derivative financial instruments pension assets amounts receivable insurance contracts certain noncurrent receivables major restructuring programme october board approved implementation detailed formal plan gsk announced significant new operational excellence restructuring programme improve effectiveness productivity operations second formal plan representing significant expansion operational excellence programme approved board announced february expansion approved board announced february restructuring programme comprising detailed formal plans covers areas gsks business including manufacturing selling rd infrastructure savings identified year estimated total cost increased approximately billion expanded programme expected deliver annual pretax savings approximately billion time substantially complete approximately programme costs incurred december approximately expected incurred majority balance incurred total approximately costs expected cash expenditures expected asset writedowns uncertainties exist exact amount timing cash outflows result potential future exchange rate fluctuations many elements restructuring programme subject employee consultation procedures making difficult predict precision procedures completed however majority remaining cash payments expected made total restructuring costs million incurred million incurred operational excellence programme following areas cost saving projects rd focused primarily simplification streamlining support infrastructure including site rationalisations principally clinical imaging centre hammersmith harlow uk verona italy adoption customised sales approaches leading staff reductions number sales forces principally italy closure number manufacturing sites principally usa ireland giving rise asset writedowns staf f reductions rationalisation consumer healthcare business projects simplify eliminate processes leading staff reductions administrative support functions remaining costs million incurred year restructuring programme related integration stiefel laboratories inc business usa following acquisition july gsk annual report financial notes financial statements continued statements major restructuring programme continued analysis costs incurred programmes follows asset staff impairment reductions costs total cost sales selling general administration research development operating income effect operating profit net finance expense effect profit taxation effect taxation effect earnings asset staff impairment reductions costs total cost sales selling general administration research development effect operating profit net finance expense effect profit taxation effect taxation effect earnings asset staff impairment reductions costs total cost sales selling general administration research development effect operating profit net finance expense effect profit taxation effect taxation effect earnings costs major restructuring programmes arisen follows increase provision major restructuring programmes see note amount provision reversed unused see note impairment losses recognised foreign exchange gain recognised liquidation subsidiary noncash charges cash costs net finance expense effect profit taxation asset impairments million million million noncash charges totalling million million million noncash items principally accelerated depreciation asset lives shortened result major restructuring programmes charges settled cash include termination leases site closure costs consultancy project management fees restructuring costs reported major restructuring column income statement costs resulting minor restructuring activity initiated prior october amounted million million income million cost amounts reported within results major restructuring gsk annual report operating income royalty income milestone income impairment equity investments disposal equity investments disposal businesses assets legal settlements gain recognised creation viiv healthcare fair value adjustments derivative financial instruments income royalty milestone income principally core recurring income outlicensing intellectual property disposal businesses assets legal settlements includes costs million associated proposed divestment noncore consumer healthcare brands costs reported consolidated income statement major restructuring programme operating profit following items included operating profit employee costs note advertising distribution costs depreciation property plant equipment impairment property plant equipment net reversals amortisation intangible assets impairment intangible assets goodwill net reversals net foreign exchange losses inventories cost inventories included cost sales writedown inventories reversal prior year writedown inventories operating lease rentals minimum lease payments contingent rents sublease payments fees payable companys auditor associates relation group see reversals prior year writedowns inventories principally arise reassessment usage demand expectations prior inventory expiration fees payable companys auditor associates audit parent company consolidated financial statements audit accounts groups uk overseas subsidiaries pursuant legislation assurance services pursuant legislation including attestation sarbanesoxley act audit assurance services tax services services including regulatory compliance treasury related services december amount due pricewaterhousecoopers llp associates fees yet invoiced million comprising statutory audit million taxation services million addition fees paid respect gsk pension schemes audit services gsk annual report financial notes financial statements continued statements employee costs wages salaries social security costs pension postemployment costs including augmentations note cost sharebased incentive plans severance costs integration restructuring activities group provides benefits employees commensurate local practice individual countries including markets healthcare insurance subsidised car schemes personal life assurance cost sharebased incentive plans analysed follows share value plan performance share plan share option plans plans average number persons employed group including directors year number number number manufacturing selling general administration research development average number group employees excludes temporary contract staff numbers group employees end financial year given financial record average number persons employed glaxosmithkline plc nil nil compensation directors senior management members cet aggregate follows wages salaries social security costs pension postemployment costs cost sharebased incentive plans finance income interest income arising cash cash equivalents availableforsale investments derivatives fair value profit loss loans receivables realised gains liquid investments fair value movements derivatives fair value profit loss derivatives fair value profit loss designated effective hedging instruments see note financial instruments related disclosures classified heldfortrading financial instruments ias interest income arising derivatives fair value profit loss relates swap interest income gsk annual report finance costs interest expense arising financial liabilities amortised cost derivatives fair value profit loss fair value hedges fair value movements derivatives designated hedging instruments fair value adjustments hedged items fair value movements derivatives fair value profit loss reclassification cash flow hedge comprehensive income unwinding discounts provisions movements amounts owed noncontrolling interests finance expense derivatives fair value profit loss except designated effective hedging instruments classified heldfor trading financial instruments ias interest expense arising derivatives fair value profit loss relates swap interest expense associates joint ventures associates share tax profits quest diagnostics inc share tax profits aspen pharmacare holdings limited share tax losses associates share tax losses joint ventures share turnover joint ventures sales joint ventures associates summarised income statement information respect groups associates set total turnover quest diagnostics inc aspen pharmacare holdings limited others total profit quest diagnostics inc aspen pharmacare holdings limited others results aspen pharmacare holdings limited included summarised income statement information represent estimated earnings aspen group year results quest diagnostics inc summarised income statement represent estimated earnings quest diagnostics inc february february gsk sold entire shareholding quest diagnostics inc gsk annual report financial notes financial statements continued statements taxation taxation charge based profits year uk corporation tax uk statutory rate less double taxation relief overseas taxation current taxation deferred taxation reconciliation taxation rate group profits uk statutory rate taxation differences overseas taxation rates benefit special tax status rd credits intercompany stock profit impact share based payments tax profit associates reductionincrease tax rate recognisedunrecognised losses permanent differences prior year items disposal associate tax unremitted earnings restructuring tax rate disposal associate undertaking reflects impact disposal shareholding quest diagnostics inc higher tax rate year ended december reflects impact relatively low tax relief arising billion legal provisions charged year nondeductability costs associated certain site closures partly offset settlement certain historical tax matters percentages within reconciliation exacerbated relatively low reported profit group operates countries tax rate differs uk tax rate impact overseas taxes overall rate tax shown profits arising certain operations singapore accorded special status taxed reduced rates compared normal rates tax territory effect reduction taxation charge increased earnings per share p p p group required ifrs create deferred tax asset respect unrealised intercompany profit arising inventory held group yearend applying tax rate country inventory held rather tax rate country profit originally made tax paid practice uk us gaap result difference accounting treatment group tax rate current period intercompany profit ifrs decreased increase increase arising changes location workinprogress finished goods tax items charged equity statement comprehensive income current taxation share based payments foreign exchange movements deferred taxation share based payments defined benefit plans fair value movements cash flow hedges fair value movements availableforsale investments total creditcharge equity statement comprehensive income items charged statement comprehensive income except tax share based payments gsk annual report taxation continued issues relating taxation integrated nature groups worldwide operations involves significant investment research strategic manufacture limited number locations consequential crossborder supply routes numerous endmarkets gives rise complexity delay negotiations revenue authorities profits individual group companies liable tax resolution issues continuing fact life gsk year gsk agreed settled open years major tax authorities including january supreme court canada heard appeal gsk canadian revenue agency federal court appeal judgement respect gsks transfer pricing early judgement awaited gsk continues believe made adequate provision liabilities likely arise periods open yet agreed tax authorities ultimate liability matters may vary amounts provided dependent upon outcome agreements relevant tax authorities litigation appropriate provision deferred tax liabilities million made respect taxation would arise distribution profits retained certain overseas subsidiaries provision made grounds group able control timing reversal remaining temporary differences probable reverse forseeable future aggregate amount unremitted profits balance sheet date approximately billion billion unprovided deferred tax unremitted earnings december estimated million million relates taxes payable repatriation dividend withholding taxes levied overseas tax jurisdictions uk legislation relating company distributions provides exemption tax repatriated profits subject certain exceptions movement deferred tax assets liabilities pensions manu share accelerated intra post legal facturing stock option net offset capital group employment tax restruct valuation award temporary within allowances intangibles profit benefits losses disputes uring adjustments schemes differences countries total deferred tax assets january deferred tax liabilities january january exchange adjustments chargecredit income statement credit equity credit statement comprehensive income acquisitions december deferred tax assets december deferred tax liabilities december deferred tax credit income relating changes tax rates million million million deferred tax movements arise origination reversal temporary differences net temporary differences mainly include accrued expenses tax deduction available paid basis gsk annual report financial notes financial statements continued statements taxation continued tax losses recognised unrecognised trading losses expiring within years years available indefinitely december deferred tax asset addition group capital losses december approximately billion billion respect deferred tax asset recognised deferred tax assets recognised probable future taxable profit available utilise losses factors affecting tax charge future years global organisation many factors could affect future effective tax rate group mix profits across different territories transfer pricing disputes tax authorities location research development activity significant impact groups effective tax rate changes tax legislation territories gsk business operations could also impact groups effective tax rate uk government proposed significant changes uk taxation system march uk government announced phased reduction main rate corporation tax years april deferred tax movements reflect reduction uk tax rate effect april effect april substantively enacted december uk government published draft legislation introduce patent box regime enacted apply reduced rate corporation tax income patents effect april uk government also continues consult business draft legislation relating controlled foreign companies expected affect gsk january earnings per share pence pence pence basic earnings per share adjustment major restructuring basic earnings per share major restructuring diluted earnings per share adjustment major restructuring diluted earnings per share major restructuring basic adjusted earnings per share calculated dividing profit attributable shareholders weighted average number shares issue period deducting shares held esop trusts treasury shares trustees waived rights dividends shares held esop trusts adjusted earnings per share calculated using results major restructuring earnings calculation results major restructuring described note presentation financial statements diluted earnings per share calculated adjusting weighted average number shares used basic calculation assume conversion potentially dilutive shares potentially dilutive share forms part employee share schemes exercise price average market price gsk shares period performance conditions attaching scheme met balance sheet date numbers shares used calculating basic diluted earnings per share reconciled weighted average number shares issue millions millions millions basic dilution share options awards diluted gsk annual report dividends dividend total dividend total dividend total per share dividend per share dividend per share dividend paidpayable pence paidpayable pence paidpayable pence first interim july july july second interim october october october third interim january january january fourth interim april april april annual total supplemental april total supplemental dividend board declared supplemental dividend pence per share related disposal certain noncore otc brands north america completed january paid time fourth interim dividend ifrs interim dividends recognised financial statements paid declared gsk normally pays dividend two quarters quarter relates one quarter declared financial statements recognise dividends paid namely third fourth interim dividends first second interim dividends amounts recognised year follows dividends shareholders property plant equipment plant land equipment assets buildings vehicles construction total cost january exchange adjustments additions additions business combinations capitalised borrowing costs disposals writeoffs reclassifications transfer assets held sale cost december exchange adjustments additions additions business combinations capitalised borrowing costs disposals writeoffs reclassifications transfer assets held sale cost december gsk annual report financial notes financial statements continued statements property plant equipment continued plant land equipment assets buildings vehicles construction total depreciation january exchange adjustments charge year disposals writeoffs transfer assets held sale depreciation december exchange adjustments charge year disposals writeoffs transfer assets held sale depreciation december impairment january exchange adjustments disposals writeoffs impairment losses reversal impairments transfer assets held sale impairment december exchange adjustments disposals writeoffs impairment losses reversal impairments transfer assets held sale impairment december total depreciation impairment december total depreciation impairment december net book value january net book value december net book value december net book value december groups land buildings comprises freehold properties million million properties leases years million million properties leases less years million million included land buildings december leased assets cost million million accumulated depreciation million million impairment million nil net book value million million included plant equipment vehicles december leased assets cost million million accumulated depreciation million million impairment million nil net book value million million lease agreements include renewal purchase options escalation clauses impairment losses principally arise decisions rationalise facilities calculated based either fair value less costs sell value use value use calculations determine net present value projected riskadjusted posttax cash flows relevant asset cash generating unit applying discount rate group posttax weighted average cost capital wacc adjusted appropriate relevant specific risks impairment indicated pretax cash flow calculation expected give materially different result test would reperformed using pretax cash flows pretax discount rate group wacc equivalent pretax discount rate approximately impairment losses charged cost sales million million rd million million sga million million include million million arising major restructuring programmes reversals impairment arise subsequent reviews impaired assets conditions gave rise original impairments deemed longer apply reversals credited cost sales gsk annual report goodwill cost january exchange adjustments additions business combinations note impairment losses cost december net book value january net book value december impairment losses year carrying value goodwill translated yearend exchange rates made balances arising acquisition following businesses cash generating unit stiefel laboratories inc us europe emerging markets asia pacific pharmaceuticals vaccines id biomedical corporation us europe emerging markets asia pacific japan pharmaceuticals vaccines reliant pharmaceuticals inc us pharmaceuticals vaccines sirtris pharmaceuticals inc us europe emerging markets asia pacific japan pharmaceuticals vaccines glaxosmithkline kk japan pharmaceuticals vaccines pfizer hiv business viiv healthcare domantis limited us europe emerging markets asia pacific japan pharmaceuticals vaccines cns inc consumer healthcare maxinutrition group holdings limited consumer healthcare polfa poznan sa europe pharmaceuticals vaccines certain businesses ucb sa emerging markets asia pacific pharmaceuticals vaccines laboratorios phoenix saicyf emerging markets pharmaceuticals vaccines novamin technology inc consumer healthcare others goodwill arising acquisition stiefel allocated us europe emerging markets asia pacific pharmaceuticals vaccines cash generating units impairment testing purposes benefits acquired business expected arise businesses goodwill arising acquisitions id biomedical sirtris pharmaceuticals domantis split us europe emerging markets asia pacific japan pharmaceutical vaccines cash generating units impairment testing purposes either benefit acquired businesses split among cash generating units acquired businesses generate independent cash flows gsk annual report financial notes financial statements continued statements goodwill continued recoverable amounts cash generating units assessed fair value less costs sell basis using groups acquisition valuation model fair value less costs sell cash generating unit goodwill allocated calculated net present value projected riskadjusted posttax cash flows plus terminal value posttax discount rate applied calculate net present value cash flows discount rate used based group wacc cash generating units integrated operations across large parts group discount rate adjusted appropriate specific country currency risks details relating discounted cash flow models used impairment tests pharmaceuticals vaccines consumer healthcare cash generating units follows valuation basis fair value less costs sell key assumptions sales growth rates advertising promotion investment profit margins terminal growth rate discount rate determination assumptions growth rates internal forecasts based internal external market information margins reflect past experience adjusted expected changes advertising promotion investment based historical levels adjusted managements view support needed innovation expansion terminal growth rates based managements estimate future longterm average growth rates discount rates based group wacc adjusted appropriate period specific projected cash flows years terminal growth rate discount rate terminal growth rate discount rate us pharmaceuticals vaccines pa europe pharmaceuticals vaccines pa emerging markets pharmaceuticals vaccines pa asia pacific pharmaceuticals vaccines pa japan pharmaceuticals vaccines pa viiv healthcare pa pharmaceuticals vaccines pa consumer healthcare pa terminal growth rates exceed longterm projected growth rates relevant markets terminal growth rates used fair value less costs sell calculations cash generating units reflect impact future generic competition take account new product launches pharmaceutical vaccines cash generating units comprise collection smaller cash generating units including assets indefinite lives carrying value million million consumer healthcare cash generating unit also comprises collection smaller cash generating units including brands indefinite lives carrying value billion billion details indefinite life brands given note intangible assets case valuations indicate sufficient headroom reasonably possible change key assumptions unlikely result impairment related goodwill gsk annual report intangible assets computer licences amortised indefinite life software patents etc brands brands total cost january exchange adjustments capitalised internal development costs additions business combinations capitalised borrowing costs additions disposals asset writeoffs reclassifications cost december exchange adjustments capitalised internal development costs additions business combinations capitalised borrowing costs additions disposals asset writeoffs reclassifications transfer assets held sale cost december amortisation january exchange adjustments charge year disposals asset writeoffs amortisation december exchange adjustments charge year disposals asset writeoffs transfer assets held sale amortisation december impairment january exchange adjustments impairment losses disposals asset writeoffs impairment december exchange adjustments impairment losses reversal impairments disposals asset writeoffs transfer assets held sale impairment december total amortisation impairment december total amortisation impairment december net book value january net book value december net book value december gsk annual report financial notes financial statements continued statements intangible assets continued amortisation impairment losses net reversals charged income statement follows amortisation net impairment losses cost sales selling general administration research development included impairments nil million million arising major restructuring programmes net book value computer software includes million million internally generated costs licences patents etc includes large number acquired licences patents knowhow agreements marketing rights either marketed use still development net book value includes million million internally generated costs impairment losses million million principally arise assets development longer actively pursued note acquisitions disposals gives details additions business combinations year book values largest individual items follows flulavalfluviral lovaza selzentry arzerra duac fraxiparine others indefinite life brands comprise portfolio consumer healthcare products primarily acquired acquisitions sterling winthrop inc block drug company inc cns inc together number pharmaceutical brands acquisition stiefel laboratories inc book values major brands follows panadol sensodyne stiefel trade name breathe right physiogel polident corega biotene poligrip solpadeine others brands considered indefinite life given strength durability brand level marketing support brands relatively similar stable profitable market sectors similar risk profiles size diversification market shares mean risk marketrelated factors causing reduction lives brands considered relatively low group aware material legal regulatory contractual competitive economic factor could limit useful lives accordingly amortised brand tested annually impairment applying fair value less costs sell methodology generally using five year posttax cash flow forecasts terminal value calculation discount rate equal group posttax wacc adjusted appropriate country currency specific risks main assumptions include future sales price volume growth product contribution future expenditure required maintain products marketability registration relevant jurisdictions assumptions based past experience reviewed part managements budgeting strategic planning cycle changes market conditions sales erosion competition terminal growth rates applied nil managements estimates future longterm average growth rates relevant markets case valuations indicate sufficient headroom reasonably possible change key assumptions unlikely result impairment brands gsk annual report investments associates joint ventures joint associated joint associated ventures undertakings total ventures undertakings total january exchange adjustments additions disposals transfer investments distributions received movements lossprofit tax recognised consolidated income statement december group held one significant associated undertaking december december group owned million shares aspen pharmacare holdings limited aspen listed johannesburg stock exchange africas largest pharmaceutical manufacturer major supplier branded generic pharmaceutical healthcare nutritional products southern african selected international markets investment book value december million million market value million million although group holds less ownership interest voting control aspen group ability exercise significant influence shareholding nominated directors active participation aspen board directors february gsk disposed entire shareholding quest diagnostics inc us clinical laboratory business listed new york stock exchange sale comprised secondary public offering accompanying repurchase shares quest diagnostics together generated profit disposal million tax transfer investments relates groups holding longwood founders fund lp previously classified within investments summarised balance sheet information respect groups associates set total assets quest diagnostics inc aspen pharmacare holdings limited others total liabilities quest diagnostics inc aspen pharmacare holdings limited others net assets summarised balance sheet information respect aspen pharmacare holdings limited based preliminary results information analysts forecasts available december investments joint ventures comprise million share gross assets million million share gross liabilities million principally arise interests two joint ventures shionogiviiv healthcare holdings lp developing specified chemical compounds viiv healthcare shire canada primarily comarkets combivir trizivir epivir certain territories part viiv healthcare business investments joint ventures also include interest pharmaceutical insurance limited mutual insurance company covering pharmaceutical business risk gsk made additional capital contributions million shionogiviiv healthcare holdings lp million gsk annual report financial notes financial statements continued statements investments january exchange adjustments additions net fair value movements impairment losses transfer investments associates joint ventures disposals december investments comprise noncurrent equity investments availableforsale investments recorded fair value balance sheet date investments traded active market fair value determined reference relevant stock exchange quoted bid price investments fair value estimated management reference relevant available information including current market value similar instruments discounted cash flows underlying net assets group holds number equity investments entities group entered research collaborations investments include listed investments million million decrease primarily arising fair value adjustments impairments disposal investments fair value movements reclassified equity income statement based average cost shares acquired different times impairment losses recorded tables recognised income statement year within operating income together amounts reclassified fair value reserve recognition impairments impairments initially result prolonged significant declines fair value equity investments acquisition cost subsequent declines fair value immediately taken income statement investments include assets impaired follows original cost cumulative impairments recognised income statement subsequent fair value increases carrying value december noncurrent assets amounts receivable insurance contracts pension schemes surplus receivables inventories raw materials consumables work progress finished goods gsk annual report trade receivables trade receivables net provision bad doubtful debts prepaid pension contributions prepayments accrued income interest receivable employee loans advances receivables trade receivables include million million provision bad doubtful debts million provision million due state hospital authorities greece ireland italy portugal spain trade receivables also include million million due associates joint ventures bad doubtful debt provision january exchange adjustments charge year subsequent recoveries amounts provided utilised december cash cash equivalents cash bank hand shortterm deposits assets held sale land buildings plant equipment vehicles assets construction intangible assets inventory noncurrent assets transferred assets held sale expected carrying amounts recovered principally disposal sale considered likely held lower carrying amount fair value less costs sell increase assets held sale primarily arises transfer certain noncore consumer healthcare otc products group divesting impairment carrying value recognised transfer divestment designed realise value shareholders simplify gsks consumer healthcare business allow focus priority brands markets disposal north american otc brands completed january proceeds million net profit disposal estimated approximately million tax net cash proceeds expected million process divesting remaining noncore otc brands continuing gsk annual report financial notes financial statements continued statements trade payables trade payables wages salaries social security payables deferred income customer return rebate accruals accruals customer return rebate accruals provided group point sale respect estimated rebates discounts allowances payable customers principally usa accruals made time sale actual amounts paid based claims made time initial recognition sale amounts estimated may fully reflect final outcome subject change dependent upon amongst things types buying group product sales mix level accrual reviewed adjusted quarterly light historical experience actual rebates discounts allowances given returns made changes arrangements future events could cause assumptions accruals based change could affect future results group trade payables include million million due associates joint ventures pensions postemployment benefits pension postemployment costs uk pension schemes us pension schemes overseas pensions schemes unfunded postretirement healthcare schemes analysed funded defined benefithybrid pension schemes unfunded defined benefit pension schemes unfunded postretirement healthcare schemes defined benefit schemes defined contribution pension schemes costs defined benefit pension postretirement healthcare schemes charged income statement follows cost sales selling general administration research development gsk entities operate pension arrangements cover groups material obligations provide pensions retired employees arrangements developed accordance local practices countries concerned pension benefits provided state schemes defined contribution schemes whereby retirement benefits determined value funds arising contributions paid respect employee defined benefit schemes whereby retirement benefits based employee pensionable remuneration length service hybrid defined benefit schemes also include defined contribution sections gsk annual report pensions postemployment benefits continued pension costs defined benefit schemes accounting purposes calculated using projected unit method certain countries pension benefits provided unfunded basis administered trustee companies formal independent actuarial valuations groups main plans undertaken regularly normally least every three years actuarial movements year recognised statement comprehensive income discount rates derived aa rated corporate bond yields except countries deep market corporate bonds government bond yields used discount rates selected reflect term expected benefit payments expected rate return bonds reflects portfolio mix indexlinked government corporate bonds expected rate return equities represents groups long term view includes higher risk premium bonds past reflecting current low bond yields projected inflation rate pension increases longterm predictions based yield gap longterm indexlinked fixed interest gilts uk mortality rates determined adjusting pca standard mortality tables reflect recent scheme experience rates projected reflect improvements life expectancy line medium cohort ie improvements recently observed higher levels assumed continue minimum improvements thereafter per year males females usa mortality rates calculated using rp fully generational table projected using scale aa white collar adjustment average life expectancy assumed individual age projected apply individual age follows uk usa male female male female years years years years current projected assets funded schemes generally held separately administered trusts either specific assets proportion general fund insurance contracts assets invested different classes order maintain balance risk return investments diversified limit financial effect failure individual investment group reviewed investment strategy uk plans anticipated asset allocation uk plans adjusted approximately return seeking assets liability matching assets target asset allocation us plans currently return seeking assets liability matching assets uk defined benefit pension schemes operated benefit former glaxo wellcome employees former smithkline beecham employees remain separate schemes closed new entrants subsequent uk employees entitled join defined contribution scheme usa former glaxo wellcome smithkline beecham defined benefit schemes merged addition group operates number postretirement healthcare schemes principal one usa group applied following financial assumptions assessing defined benefit liabilities uk usa rest world pa pa pa pa pa pa pa pa pa rate increase future earnings discount rate expected pension increases na na na cash balance creditconversion rate na na na inflation rate gsk annual report financial notes financial statements continued statements pensions postemployment benefits continued amounts recorded income statement statement comprehensive income three years ended december relation defined benefit pension postretirement healthcare schemes follows postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service cost expected return pension scheme assets interest scheme liabilities settlements curtailments actuarial losses recorded statement comprehensive income postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service cost expected return pension scheme assets interest scheme liabilities settlements curtailments actuarial gainslosses recorded statement comprehensive income postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service cost expected return pension scheme assets interest scheme liabilities settlements curtailments actuarial lossesgains recorded statement comprehensive income amounts included within settlements curtailments include million million million augmentation costs arising major restructuring programmes see note provisions total actuarial losses recorded statement comprehensive income since january amount million gsk annual report pensions postemployment benefits continued summarised balance sheet presentation group defined benefit pension schemes postretirement benefits set table recognised noncurrent assets pension schemes surplus recognised pensions postemployment benefits pension schemes deficit postretirement benefits fair values assets liabilities uk us defined benefit pension schemes together aggregated data defined benefit pension schemes group follows uk usa rest world group average expected rate fair expected rate fair expected rate fair fair december return value return value return value value equities property bonds assets fair value assets present value scheme obligations unrecognised past service cost recognised balance sheet included noncurrent assets included pensions postemployment benefits actual return plan assets december uk scheme purchased insurance contract guarantee payment specified pensioner liabilities included within assets present value scheme obligations table value million million uk usa rest world group average expected rate fair expected rate fair expected rate fair fair december return value return value return value value equities property bonds assets fair value assets present value scheme obligations unrecognised past service cost recognised balance sheet included noncurrent assets included pensions postemployment benefits actual return plan assets gsk annual report financial notes financial statements continued statements pensions postemployment benefits continued uk usa rest world group average expected rate fair expected rate fair expected rate fair fair december return value return value return value value equities property bonds assets fair value assets present value scheme obligations unrecognised past service cost recognised balance sheet included noncurrent assets included pensions postemployment benefits actual return plan assets postretirement pensions benefits uk usa rest world group group movements fair values assets assets january exchange adjustments expected return assets settlements curtailments actuarial gains employer contributions scheme participants contributions benefits paid acquisitions assets december exchange adjustments expected return assets actuarial gains employer contributions scheme participants contributions benefits paid assets december exchange adjustments expected return assets actuarial lossesgains employer contributions scheme participants contributions benefits paid assets december uk defined benefit schemes include defined contribution sections account balances totalling million december million million group made special funding contributions uk pension schemes totalling million million million million million million us scheme gsk reached agreement trustees uk pension schemes make additional contributions eliminate pension deficit identified december actuarial funding valuation additional contributions expected million per year contributions based discount rate inflation assumption next review contribution levels progress based actuarial valuation december employer contributions including special funding contributions estimated approximately million respect defined benefit pension schemes million respect postretirement benefits gsk annual report pensions postemployment benefits continued postretirement pensions benefits movements defined benefit obligations uk usa rest world group group obligations january exchange adjustments service cost interest cost settlements curtailments actuarial lossesgains scheme participants contributions benefits paid transfers provisions obligations december exchange adjustments service cost interest cost settlements curtailments actuarial losses scheme participants contributions benefits paid obligations december exchange adjustments service cost interest cost settlements curtailments actuarial losses scheme participants contributions benefits paid obligations december unrecognised past service cost recognised balance sheet december uk defined benefit schemes include defined contribution sections obligations totalling million december million million liability us postretirement healthcare scheme assessed using assumptions us pension scheme together assumption future medical inflation grading thereafter us pension postretirement healthcare schemes amended changes resulted oneoff gain million recognised income statement december us postretirement healthcare scheme obligation million million million however accordance ias unvested part benefit improvement recognised immediately balance sheet recognised gradually income statement december group unrecognised past service cost million million million primarily relates effect change us postretirement healthcare scheme amounted million million million defined benefit pension obligation analysed follows funded unfunded postretirement benefits unfunded gsk annual report financial notes financial statements continued statements pensions postemployment benefits continued postretirement pensions benefits history experience gains losses uk usa rest world group group experience lossesgains scheme assets percentage scheme assets december experience lossesgains scheme liabilities percentage scheme obligations december fair value assets present value scheme obligations deficits schemes experience gainslosses scheme assets percentage scheme assets december experience lossesgains scheme liabilities percentage scheme obligations december fair value assets present value scheme obligations deficits schemes experience gains scheme assets percentage scheme assets december experience gainslosses scheme liabilities percentage scheme obligations december fair value assets present value scheme obligations deficits schemes experience losses scheme assets percentage scheme assets december experience lossesgains scheme liabilities percentage scheme obligations december fair value assets present value scheme obligations deficits schemes experience gains scheme assets percentage scheme assets december experience gainslosses scheme liabilities percentage scheme obligations december fair value assets present value scheme obligations deficitssurpluses schemes gsk annual report pensions postemployment benefits continued sensitivity analysis effect changes assumptions used annual defined benefit pension postretirement costs benefit obligations decrease discount rate would following approximate effect increase annual pension cost decrease annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation one year increase life expectancy would following approximate effect increase annual pension cost increase annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation decrease expected rates return assets would following approximate effect increase annual pension cost increase rate future healthcare inflation would following approximate effect decrease annual postretirement benefits cost increase postretirement benefits obligation increase inflation would following approximate effect increase annual pension cost increase pension obligation provisions integration legal major employee restructuring related manufacturing disputes programmes provisions reorganisation provisions total january exchange adjustments charge year reversed unused unwinding discount utilised transfer pensions obligations reclassifications movements december settled within one year settled one year december gsk annual report financial notes financial statements continued statements provisions continued legal disputes group involved substantial number legal disputes including notification possible claims set note legal proceedings provisions legal disputes include amounts relating product liability principally relating avandia paxil poligrip antitrust principally relating wellbutrin flonase government investigations principally relating colorado investigation avandiarelated investigations awp nominal price investigations cidra puerto rico manufacturing settlement contract terminations selfinsurance environmental cleanup property rental charge year million million net reversals estimated insurance recoveries primarily relates provisions relation product liability cases regarding paxil poligrip products various government investigations discount provisions decreased million million calculated using riskadjusted projected cash flows riskfree rates return movement includes decrease million million arising change discount rate year respect product liability claims related certain products sufficient history claims made settlements enable management make reliable estimate provision required cover unasserted claims certain cases ibnr incurred reported actuarial technique used determine estimate ultimate liability matters may vary amounts provided dependent upon outcome litigation proceedings investigations possible settlement negotiations nature groups business number matters including provided using ibnr actuarial technique may subject negotiation litigation many years litigation proceedings including various appeal procedures often take many years reach resolution outofcourt settlement discussions also often protracted group potential settlement discussions number disputes amounts provided based current assessment progress disputes estimates billion amount provided december settled within one year december expected million million provision made legal disputes reimbursed third party insurers amount included within receivables balances note noncurrent assets note trade receivables discussion legal issues see note legal proceedings major restructuring programmes october group announced significant new operational excellence programme improve effectiveness productivity operations see note major restructuring programme significant expansion operational excellence programme approved board announced february expansion approved board announced february savings identified year estimated total cost increased approximately billion expanded programme expected deliver annual pretax savings approximately billion time substantially complete provisions staff severance payments made management made formal decision eliminate certain positions communicated groups employees affected provision made staff severance payments made immediately pension augmentations arising staff redundancies million million charged year transferred pension obligations provision shown note pensions postemployment benefits asset write downs recognised impairments property plant equipment note property plant equipment majority amounts provided expected utilised next two years employee related provisions employee related provisions include certain medical benefits disabled employees spouses usa december provision benefits amounted million million employee benefits reflect variety provisions severance costs jubilee awards longservice benefits integration manufacturing reorganisation provisions integration manufacturing reorganisations reflect costs related ongoing restructuring programmes included within costs disclosed note major restructuring programmes provisions included provisions contingent consideration respect business acquisitions principally stiefel laboratories inc contingent consideration payable upon certain criteria met certain specified dates future aggregate provision items amounts million december million gsk annual report noncurrent liabilities accruals deferred income payables contingent liabilities december contingent liabilities comprising guarantees discounted bills items arising normal course business amounted million million december million million financial assets pledged collateral contingent liabilities provision made outcome tax legal disputes probable group suffer outflow funds possible make reliable estimate outflow december disputes provision made possible make reliable estimate potential outflow funds might required settle disputes possibility outflow remote descriptions significant tax legal disputes group party set note taxation note legal proceedings net debt listing exchange current assets liquid investments cash cash equivalents shortterm borrowings bank loans overdrafts obligations finance leases european medium term note london stock exchange european medium term note london stock exchange longterm borrowings european medium term note london stock exchange european medium term note london stock exchange us us medium term note new york stock exchange us us medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange us us medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange bank loans obligations finance leases net debt gsk annual report financial notes financial statements continued statements net debt continued current assets liquid investments classified availableforsale investments december included us treasury notes government bonds effective interest rate liquid investments st december approximately approximately liquid investment balances december earning interest floating fixed rates amount million million respectively million million effective interest rate cash cash equivalents december approximately approximately cash cash equivalents balances st december earning interest floating fixed rates amount million million respectively million million gsks policy regarding credit quality cash cash equivalents referred note financial instruments related disclosures shortterm borrowings gsk us billion billion commercial paper programme billion billion none issue december also committed facilities days duration billion billion billion billion renewable annually liquid investments cash cash equivalents shown table weighted average interest rate current bank loans overdrafts december longterm borrowings yearend gsk longterm borrowings billion billion billion billion falls due five years average effective preswap interest rate notes december approximately approximately longterm borrowings repayable five years carry interest effective rates repayment dates range secured liabilities gsk loans secured charges noncurrent current assets year nil group pledged investments us treasury notes par value million million million million security irrevocable letters credit issued groups behalf respect groups selfinsurance activity provisions respect selfinsurance included within provisions legal disputes discussed note provisions finance lease obligations rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total future rental payments future finance charges total finance lease obligations finance lease obligations december bearing interest floating fixed rates amount million million respectively million million gsk annual report share capital share premium account share ordinary shares p premium number share capital authorised december december december share capital issued fully paid january issued employee share schemes december issued employee share schemes december issued employee share schemes share capital purchased cancelled december december december number shares issuable employee share schemes note number unissued shares option december issued share capital shares held esop trusts shares held treasury shares shares free issue issued shares fully paid nominal carrying market values shares held esop trusts disclosed note employee share schemes total million shares purchased company cost million year million shares cancelled million shares added treasury shares monthly purchases shares follows average share price excluding number shares commission stamp duty february march april may june july august september october november december total company expects make share repurchases billion exact amount timing purchases whether shares held treasury shares cancelled determined company dependent market conditions factors shares purchased period january february period february march million shares purchased cost million details substantial shareholdings refer gsk annual report financial notes financial statements continued statements movements equity retained earnings reserves amounted million december million million million million million relates joint ventures associated undertakings cumulative translation exchange equity shown following table net translation exchange included non total retained fair value controlling translation earnings reserve interests exchange january exchange movements overseas net assets reclassification exchange liquidation overseas subsidiary december exchange movements overseas net assets reclassification exchange liquidation overseas subsidiary december exchange movements overseas net assets reclassification exchange liquidation disposal overseas subsidiaries december analysis comprehensive income equity category follows retained noncontrolling earnings reserves interests total exchange movements overseas net assets net investment hedges reclassification exchange liquidation disposal overseas subsidiaries fair value movements availableforsale investments deferred tax fair value movements availableforsale investments reclassification fair value movements availableforsale investments reclassification cash flow hedges income statement actuarial losses defined benefit plans deferred tax actuarial movements defined benefit plans share comprehensive expense associates joint ventures comprehensive expense year retained noncontrolling earnings reserves interests total exchange movements overseas net assets net investment hedges reclassification exchange liquidation disposal overseas subsidiaries fair value movements availableforsale investments deferred tax fair value movements availableforsale investments reclassification fair value movements availableforsale investments deferred tax reversed reclassification availableforsale investments fair value movements cash flow hedges deferred tax fair value movements cash flow hedges reclassification cash flow hedges income statement cash flow hedge reclassified goodwill actuarial losses defined benefit plans deferred tax actuarial movements defined benefit plans comprehensive income year gsk annual report movements equity continued retained noncontrolling earnings reserves interests total exchange movements overseas net assets net investment hedges reclassification exchange liquidation disposal overseas subsidiaries tax exchange movements fair value movements availableforsale investments deferred tax fair value movements availableforsale investments deferred tax reversed reclassification availableforsale investments fair value movements cash flow hedges deferred tax fair value movements cash flow hedges reclassification cash flow hedges income statement fair value movement subsidiary acquisition actuarial losses defined benefit plans deferred tax actuarial movements defined benefit plans comprehensive expenseincome year analysis reserves follows esop trust fair value cash flow shares reserve hedge reserve reserves total january transferred income expense year disposals transferred income expense year impairment net fair value movement year ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts put option noncontrolling interest december transferred income expense year disposals transferred income expense year impairment net fair value movement year ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts december transferred income expense year disposals transferred income expense year impairment net fair value movement year ordinary shares purchased cancelled ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts forward contract noncontrolling interest december reserves include various nondistributable merger premerger reserves amounting million december million million reserves also include capital redemption reserve created result share buyback programme amounting million december million million gsk annual report financial notes financial statements continued statements related party transactions february gsk sold entire shareholding quest diagnostics inc sale comprised secondary public offering accompanying repurchase shares quest diagnostics together generated profit disposal million gsk held interest aspen pharmacare holdings limited december gsk distributed million million products aspens extensive distribution network december balance due gsk aspen million million balance payable gsk aspen million million gsks subsidiary viiv healthcare company shionogi co ltd entered transactions us joint venture company support research development activities conducted joint venture company viiv healthcare company provided services joint venture million million december balance due viiv healthcare company joint venture million million december gsk held interest viiv healthcare shire canada subsidiary viiv healthcare ulc primarily comarkets combivir trizivir epivir certain territories december balance payable viiv healthcare shire canada million million aggregate compensation directors cet given note employee costs adjustments reconciling profit tax operating cash flows profit tax tax profits share tax profits associates joint ventures finance income net finance costs depreciation amortisation intangible assets impairment assets written profit sale intangible assets profit sale investments associates profit sale equity investments changes working capital increasedecrease inventories decreaseincrease trade receivables increasedecrease receivables increase trade payables increasedecrease payables decreaseincrease pension provisions sharebased incentive plans cash generated operations decrease pension provisions primarily reflects legal settlements billion contributions defined benefit pension schemes gsk annual report reconciliation net cash flow movement net debt net debt beginning year decreaseincrease cash bank overdrafts cash inflow liquid investments net increase longterm loans net increaserepayment shortterm loans net repayment obligations finance leases debt subsidiary undertakings acquired exchange adjustments noncash movements movement net debt net debt end year analysis changes net debt exchange reclassifications acquisitions cash flow liquid investments cash cash equivalents overdrafts debt due within one year eurobonds mediumterm notes debt due one year eurobonds mediumterm notes private financing net debt information significant changes net debt see note net debt gsk annual report financial notes financial statements continued statements acquisitions disposals details acquisition disposal significant subsidiaries associates joint ventures businesses given acquisitions year gsk completed four subsidiary acquisitions cash total purchase price million included million cash acquired fair value book value adjustments fair value net assets acquired intangible assets property plant equipment trade receivables assets including cash cash equivalents deferred tax provision liabilities goodwill investment associate converted subsidiary total consideration acquisitions made beginning year estimated group turnover would increased million year subsidiaries fully integrated gsk business practicable separately identify impact acquisitions group profit year goodwill arising acquisitions reflects potential business synergies sales growth increase gsks market presence following acquisitions businesses addition goodwill million recognised respect fair value adjustments prior year acquisitions none goodwill recognised expected deductible income tax purposes results acquisitions reported part consumer healthcare emerging markets reportable operating segments group recognised loss million result remeasuring fair value associate held prior acquisition date loss reported loss disposal interest associates income statement acquisition costs expensed arising acquisitions totalled million investments joint ventures gsk made cash contributions million joint venture group share made cash investments associates totalling million transferred million equity investment associates group increased share disposals gsk disposed one subsidiary cash outflow disposal million net cash disposed february gsk disposed entire shareholding quest diagnostics inc us clinical laboratory business listed new york stock exchange sale comprised secondary public offering accompanying repurchase shares quest diagnostics together generated profit disposal million tax associates joint cash flows acquisitions ventures total total cash consideration cash cash equivalents acquired cash consideration net cash acquired net cash consideration paid deferred consideration cash consideration net cash acquired net cash outflowproceeds disposals net cash disposed gsk annual report acquisitions disposals continued acquisitions laboratorios phoenix sacyf june gsk acquired issued share capital laboratorios phoenix sacyf leading pharmaceutical business focused development marketing sale branded generic overthecounter products latin america cash purchase price million included million net cash million intangible assets million goodwill million net liabilities goodwill arising acquisition business reflects potential business synergies sales growth increase gsks market presence following acquisition established market participant none goodwill recognised expected deductible income tax purposes results phoenix reported part emerging markets operating segment transaction accounted using purchase method accounting proforma results laboratorios phoenix sa cyf full year turnover million loss tax major restructuring million since acquisition gsk recorded turnover million tax losses major restructuring million business transaction costs expensed arising acquisition laboratorios phoenix sacyf amounted million fair value book value adjustments fair value net assets acquired intangible assets property plant equipment assets including cash cash equivalents deferred tax provision liabilities goodwill total consideration acquisitions year gsk completed three smaller subsidiary acquisitions cash total purchase price million included million net cash fair value book value adjustments fair value net assets acquired intangible assets property plant equipment assets including cash cash equivalents deferred tax provision liabilities goodwill fair value gain recognised conversion associate subsidiary total consideration acquisitions made beginning year estimated group turnover would increased million year subsidiaries fully integrated gsk business practicable separately identify impact acquisitions group profit year gsk annual report financial notes financial statements continued statements acquisitions disposals continued acquisitions continued goodwill arising acquisitions reflects potential business synergies sales growth increase gsks market presence following acquisition established market participants addition goodwill million recognised respect consideration prior year acquisition none goodwill recognised expected deductible income tax purposes results acquisitions reported primarily part emerging markets reportable operating segment group recognised gain million result measuring fair value associate held prior acquisition date gain reported profit disposal interest associates income statement acquisition costs expensed arising acquisitions totalled million investments joint ventures gsk made cash noncash contributions million joint venture group share million joint venture group share investment associate million increase groups share investments associates totalling million associates joint phoenix acquisitions ventures total cash flows total cash consideration cash cash equivalents acquired cash consideration net cash acquired net cash consideration paid deferred consideration cash consideration net cash acquired acquisitions certain businesses ucb sa march group acquired ucb sa marketed product portfolio across certain territories africa middle east asia pacific latin america included several leading pharmaceutical brands number disease areas subsequent date group completed country acquisitions formed part original transaction purchase price million included million net cash million intangible assets million goodwill million net liabilities goodwill arising acquisition business reflects potential product growth throughout regions expected synergies group transaction accounted purchase method accounting transaction included acquisition number legal entities product rights previously marketed outside entities product portfolio acquired integrated gsk business acquisition therefore practicable identify result tax arising result transaction period acquisition prior acquisition estimated product portfolio recorded turnover million since acquisition gsk recorded turnover million products acquired book fair value fair value adjustment value net assets acquired intangible assets property plant equipment cash cash equivalents deferred tax provision liabilities goodwill total consideration gsk annual report acquisitions disposals continued acquisitions continued stiefel laboratories inc july group acquired share capital stiefel laboratories inc worlds largest private dermatological company cash consideration million net cash acquired including million debt repaid acquisition purchase price million including contingent cash consideration million payable upon certain criteria met specified dates future included million cash cash equivalents million intangible assets million goodwill representing potential additional growth combination stiefel business gsks existing dermatology portfolio million net liabilities purchase price included potential obligations make additional payments million million depending future performance certain products stiefel laboratories inc turnover million loss tax including restructuring costs million year ended december million turnover million loss tax including restructuring costs related period since acquisition included group accounts since acquisition stiefel made operating profit million restructuring costs intangible assets amortisation business provide significant opportunities sales cost synergies stiefels products benefit gsks global distribution commercial organisations particularly markets brazil russia india china japan gsks products benefit stiefels speciality sales force relationships experienced management dermatology cost synergies business expected primarily combining manufacturing administrative functions previously reported gsk expects deliver annual pretax cost savings million restructuring costs approximately million excluding restructuring costs stiefel acquisition resulted dilution gsks earnings per share less book fair value fair value adjustment value net assets acquired intangible assets property plant equipment assets including cash cash equivalents deferred tax provision liabilities goodwill total consideration viiv healthcare limited october gsk acquired pfizer incs hiv business combined hiv business form viiv healthcare limited subgroup owned gsk pfizer consideration given gsk representing net value gsks hiv business contingent consideration transaction costs valued million represented million intangible assets million deferred tax liability million net assets million increase noncontrolling interests million goodwill representing economies scale gained combination two businesses potential growth partners hiv products within viiv healthcare noncontrolling interest represents pfizers interest viiv healthcare including right preferential dividends based sales performance certain products gsk recognised accounting gain million transaction arising disposal interest gsks hiv business pfizer recorded book value return pfizers hiv business recorded fair value gsk annual report financial notes financial statements continued statements acquisitions disposals continued acquisitions continued acquired pfizer hiv business turnover million loss tax million taking account transition status various territories million turnover million loss tax including restructuring costs recognised group accounts book fair value fair value adjustment value net assets acquired intangible assets assets including cash cash equivalents deferred tax provision noncontrolling interests goodwill total consideration consideration fair value assets contributed gsk fair value contingent equity contributed gsk direct costs total consideration acquisitions investments year included million five subsidiaries million joint venture group share million associate group initial share certain stiefel businesses laboratories cash flows ucb sa inc total cash consideration cash cash equivalents acquired net cash consideration contingent consideration net purchase consideration acquisitions subsidiaries made beginning year estimated group turnover would increased million year acquisitions fully integrated gsk business practicable separately identify impact acquisitions group profit year gsk annual report commitments contractual obligations commitments contracted provided financial statements intangible assets property plant equipment investments purchase commitments business combinations pensions commitments interest loans finance lease charges commitments related intangible assets include milestone payments dependent successful clinical development meeting specified sales targets represent maximum would paid milestones however unlikely achieved amounts riskadjusted discounted number commitments made licensing agreements including arrangements theravance inc janssen biologics ireland new arrangements offset reduced commitments due prior year transactions including amendments agreements anacor pharmaceuticals inc concert pharmaceuticals inc chroma therapeutics inc oncomed pharmaceuticals inc tolerx inc also mpex pharmaceuticals inc terminated year gsk reached agreement trustees uk pension schemes make additional contributions eliminate pension deficit identified december actuarial funding valuation table shows commitment excludes normal ongoing annual funding requirement approximately million group also commitments principally relate revenue payments made licences alliances commitments respect future interest payable loans disclosed taking account effect interest rate swaps commitments noncancellable operating leases rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total commitments noncancellable operating leases post balance sheet events january gsk completed disposal noncore north american otc brands proceeds million january gsks copromotion agreement vesicare astellas pharma inc terminated result gsk recording cumulative income attributable performance brand first quarter approximately million million within turnover gsk annual report financial notes financial statements continued statements financial instruments related expect deliver continued dividend growth disclosures part longterm share buy back programme targeting share repurchases billion depending market conditions glaxosmithkline plc reports sterling pays dividends net debt increased year billion sterling profits role corporate treasury manage billion december billion december monitor external internal funding requirements groups positive cash generation cash holdings financial risks support strategic objectives treasury largely sufficient finance groups acquisitions activities governed policies procedures approved dividends share buybacks payment legal costs year board directors recently july gsk operates global basis primarily subsidiary treasury management group tmg meeting chaired companies established markets trade chief financial officer takes place monthly basis review manage capital ensure subsidiaries able treasury activities members receive management information operate going concerns optimise return shareholders relating treasury activities internal audit reviews treasury appropriate balance debt equity internal control environment regularly liquidity risk gsk uses variety financial instruments finance operations derivative financial instruments manage risks gsks policy borrow centrally order meet anticipated operations derivatives principally comprising forward funding requirements cash flow forecast funding foreign currency contracts interest rate currency swaps requirements monitored tmg monthly basis used swap borrowings liquid assets currencies required european medium term note programme billion group purposes manage exposure funding risks december billion notes issue changes foreign exchange rates interest rates programme also us shelf registration statement gsk hold issue derivatives speculative purposes december billion billion notes treasury policies specifically prohibit activity issue programme transactions financial instruments undertaken manage december gsk borrowings billion risks arising underlying business activities speculation repayable within one year gsks longterm borrowings mature capital management dates longterm debt ratings remained unchanged since february currently gsk rated gsks financial strategy regularly reviewed board gsk stable outlook standard poors stable outlook manages capital structure group appropriate moodys investors service moodys shortterm debt ratings mix debt equity delivers best returns shareholders p standard poors moodys respectively whilst maintaining credit ratings maximise flexibility access debt capital markets attractive terms gsk access shortterm finance us billion commercial paper programme billion committed capital structure group consists net debt facilities facilities last renewed october billion see note net debt shareholders equity increased billion billion time consider billion see consolidated statement changes equity level committed facilities adequate given current total capital including provided non liquidity requirements information facilities controlling interests billion billion please refer note net debt allocate capital deliver best returns well committed facilities gsk also substantial cash shareholders commitment use free cash flow support cash equivalents liquid investments amounted dividends undertake share repurchases returns billion december reviewed cash attractive invest bolton acquisitions investment opportunities balances relative debt portfolio sources debt continue assessed strict financial criteria access order improve efficiency balance significant levels patent trademark protection sheet result intend reduce effective net funding pharmaceutical products compete largely product efficacy cost maintaining lower level cash diversifying differentiation selling margins sufficient cover normal sources funding given current low interest rate environment operating costs operations continue highly cash market risk generative net cash inflow operating activities billion free cash flow billion interest rate risk management returned free cash flow asset disposal gsks objective reduce effective net interest cost proceeds shareholders balance dividends share rebalance mix debt fixed floating interest rates time buybacks paid billion dividends completed policy interest rate risk management limits amount billion share repurchases part longterm floating interest payments prescribed percentage trading profit programme alongside also elected use series interest rate swaps redenominate one return net proceeds sale noncore north bonds floating interest rates duration swaps american otc brands shareholders payment match duration principal instrument interest rate supplemental dividend derivative instruments accounted fair value cash flow hedges relevant assets liabilities gsk annual report financial instruments related disclosures continued foreign exchange risk management foreign currency transaction exposures arising internal external trade flows hedged exposure overseas operating subsidiaries transaction risk minimised matching local currency income local currency costs purpose internal trading transactions matched centrally manage intercompany payment terms reduce foreign currency risk exceptional foreign currency cash flows hedged selectively management corporate treasury tmg possible manage cash surpluses borrowing requirements subsidiary companies centrally using forward contracts hedge future repayments back originating currency order reduce foreign currency translation exposure seek denominate borrowings currencies principal assets cash flows primarily denominated us dollars euros sterling certain borrowings swapped currencies required borrowings denominated swapped foreign currencies match investments overseas group assets may treated hedge relevant assets forward contracts also used major currencies reduce exposure investment overseas group assets see net investment hedges section note details tmg reviews ratio borrowings assets major currencies monthly credit risk group considers maximum credit risk million million total groups financial assets exception investments bear credit risk see details groups total financial assets gsks greatest concentration credit risk billion investments us treasury treasury repo money market funds funds aaaaaa rated moodys standard poors respectively bear credit exposure us government aaa aa rated moodys standard poors respectively greatest concentration credit risk billion jp morgan chase aaaa rated time moodys standard poors respectively comprising billion invested deposits billion derivatives treasuryrelated credit risk gsk managed exposure credit risk actively recent financial crisis reducing surplus cash balances particular middle east africa europe part treasury strategy regionalise cash management concentrate cash centrally much possible gsk continued maintain conservative approach counterparty risk throughout period report relationship banks credit ratings presented annually tmg approval aggregate credit risk respect financial instruments group may one counterparty limited reference longterm credit ratings assigned counterparty moodys standard poors table sets credit ratings counterparties liquid investments cash cash equivalents derivatives gross asset position derivative contract considered purpose table although isda contracts amount risk net position counterparty million invested baabbb rated investments includes proportion gsks indian assets bank deposits hdfc bank state bank india indian government bonds counterparties used either local cash management purposes local investment purposes gsk sole shareholder million invested babb rated counterparties comprises bank balances held operating companies overseas credit rating counterparty aaaaaa aaaa aaaa aaaa aa aa aabaabbb baabbb baabbb babb babb total bank balances deposits us treasury treasury repo money market funds corporate debt instruments government securities rd party financial derivatives total credit rating counterparty aaaaaa aaaa aaaa aaaa aa aa aabaabbb baabbbbaabbb babb babb total bank balances deposits us treasury treasury repo money market funds corporate debt instruments government securities rd party financial derivatives total credit ratings tables assigned moodys standard poors respectively opinion two rating agencies differ gsk assigns lower rating two counterparty local rating agency data source available ratings converted global ratings equivalent moodys investor services standard poors using published conversion tables gsk annual report financial notes financial statements continued statements financial instruments related following methods assumptions used estimate disclosures continued fair values cash cash equivalents approximates centrally managed cash reserves amounted billion carrying amount december available within months excludes billion centrally managed cash held viiv healthcare l iquid investments based quoted market prices owned subsidiary group invested centrally managed calculated based observable inputs case marketable liquid assets bank deposits aaaaaa rated us treasury securities based principal amounts case non treasury repo money market funds noted bear marketable securities short repricing periods credit exposure us government aaaaa rated ther investments investments traded active market global counterparty limits assigned gsks banking determined reference relevant stock exchange quoted investment counterparties based longterm credit ratings bid price investments determined reference moodys standard poors corporate treasurys usage current market value similar instruments reference limits monitored daily corporate compliance officer discounted cash flows underlying net assets cco operates independently corporate treasury hortterm loans overdrafts approximates carrying breach limits would reported cfo immediately amount short maturity instruments cco also monitors credit rating counterparties changes ratings occur notifies corporate treasury l ongterm loans based quoted market prices case changes made investment levels authority eurobonds fixed rate borrowings approximates limits appropriate carrying amount case floating rate bank loans loans wholesale retail credit risk f orward exchange contracts based market data usa line pharmaceutical companies exchange rates balance sheet date group sells products small number wholesalers addition hospitals pharmacies physicians groups currency swaps based market data balance sales three largest wholesalers amount approximately sheet date groups us pharmaceuticals vaccines turnover nterest rate swaps based net present value f december group trade receivables due discounted cash flows three wholesalers totalling million million group exposed concentration credit r eceivables payables approximates risk respect wholesalers one carrying amount encounters financial difficulty could materially c ompanyowned life insurance policies based cash adversely affect groups financial results surrender value groups credit risk monitoring activities relating l ease obligations approximates carrying amount wholesalers include review quarterly financial information standard poors credit ratings development gsk internal fair value investments gsk shares risk ratings establishment periodic review credit limits december employee share ownership plan however group believes credit risk provision esop trusts held gsk shares carrying value million required excess normal provision bad doubtful million fair value million debts see note trade receivables outside million based quoted market price shares usa customer accounts groups represent purchases esop trusts satisfy future exercises trade receivables balance options awards employee incentive schemes fair value financial assets liabilities carrying value lower cost expected proceeds shares recognised deduction table presents carrying amounts reserves december gsk held treasury fair values groups financial assets liabilities shares cost million million december december deducted retained earnings fair values financial assets liabilities included committed facilities amount instrument could exchanged current transaction willing parties forced group committed facilities billion billion liquidation sale billion billion renewable annually facilities last renewed october december undrawn gsk annual report financial instruments related disclosures continued carrying fair carrying fair value value value value cash cash equivalents availableforsale investments liquid investments government bonds total liquid investments investments loans receivables trade receivables certain noncurrent assets scope ias financial assets fair value profit loss noncurrent assets derivatives designated fair value profit loss derivatives classified held trading ias total financial assets financial liabilities measured amortised cost borrowings bonds designated hedging relationship bonds bank loans overdrafts obligations finance leases total borrowings trade payables provisions noncurrent liabilities scope ias financial liabilities fair value profit loss derivatives designated fair value profit loss derivatives classified held trading ias total financial liabilities net financial assets financial liabilities trade receivables certain noncurrent assets well trade payables provisions noncurrent liabilities reconciled relevant notes financial assets liabilities classified measured fair value balance sheet valuation methodology described categorised derivative balances analysed instrument type hedging programme gsk annual report financial notes financial statements continued statements financial instruments related disclosures continued following tables categorise groups financial assets liabilities held fair value valuation methodology applied determining fair value possible quoted prices active markets used level prices available asset liability classified level provided significant inputs valuation model used based observable market data one significant inputs valuation model based observable market data instrument classified level investments classified level tables comprise equity investments unlisted entities group entered research collaborations also investments emerging life science companies level level level total december financial assets fair value availableforsale financial assets liquid investments investments financial assets fair value profit loss noncurrent assets derivatives designated fair value profit loss derivatives classified held trading ias financial liabilities fair value financial liabilities fair value profit loss derivatives designated fair value profit loss derivatives classified held trading ias level level level total december financial assets fair value availableforsale financial assets liquid investments investments financial assets fair value profit loss noncurrent assets derivatives designated fair value profit loss derivatives classified held trading ias financial liabilities fair value financial liabilities fair value profit loss derivatives designated fair value profit loss derivatives classified held trading ias movements year financial instruments measured using level valuation methods presented january losses recognised income statement gainslosses recognised comprehensive income additions disposals transfers level exchange december net losses million million attributable level financial instruments held end year reported operating income transfers level million million relate equity investments listed stock exchanges transferred investments associates year reasonably possible change assumptions unlikely result material change fair value level instruments gsk annual report financial instruments related disclosures continued trade receivables noncurrent assets scope ias following table reconciles financial assets within trade receivables noncurrent assets fall within scope ias relevant balance sheet amounts financial assets predominantly noninterest earning financial instruments within noncurrent assets balance include companyowned life insurance policies assets include tax receivables pension surplus balances prepayments outside scope ias financial financial assets assets fair value fair value loans financial loans financial profit loss receivables instruments total profit loss receivables instruments total trade receivables note noncurrent assets note following table shows age financial assets past due provision bad doubtful debts made past due days past due days past due days past due days past due days amounts past due greater days provision bad doubtful debts made total million million balance million million relates receivables due state hospital authorities greece ireland italy portugal spain total receivables due state hospital authorities countries current past due net provisions million million trade payables provisions noncurrent liabilities scope ias following table reconciles financial liabilities within trade payables provisions noncurrent liabilities fall within scope ias relevant balance sheet amounts financial liabilities predominantly noninterest bearing accrued wages salaries included within financial liabilities liabilities include payments account tax social security payables provisions constitute contractual obligations deliver cash another financial asset outside scope ias financial financial instruments total instruments total trade payables note provisions note noncurrent liabilities note gsk annual report financial notes financial statements continued statements financial instruments related disclosures continued debt interest rate repricing table following table sets exposure group interest rates debt effect interest rate swaps maturity analysis fixed rate debt stated contractual maturity floating rate debt interest rate repricing dates purpose table debt defined classes borrowings obligations finance leases effect effect interest interest debt rate swaps total debt rate swaps total floating fixed rate debt less one year one two years two three years three four years four five years five ten years greater ten years total original issuance profile fixed rate interest floating rate interest total interest bearing noninterest bearing group holds interest rate swaps designated fair value hedges convert million fixed rate debt maturity two three years million maturity three four years floating rate exposure sensitivity analysis sensitivity analysis prepared assumption amount net debt ratio fixed floating interest rates debt derivatives portfolio proportion financial instruments foreign currencies constant basis hedge designations place december financial instruments affected market risk include borrowings deposits derivative financial instruments following analyses intended illustrate sensitivity financial instruments changes relevant foreign exchange interest rates foreign exchange sensitivity tables show groups sensitivity foreign exchange rates us dollar euro yen financial instruments excluding obligations finance leases certain nonderivative financial instruments net debt present material exposure three currencies major foreign currencies gsks financial instruments denominated gsk considered movements currencies last three years concluded cent yen movement rates gbp reasonable benchmark table financial instruments considered sensitive foreign exchange rates functional currency entity holds intercompany loans fully hedged maturity currency swap excluded analysis increase reduction increase reduction nonfunctional currency foreign exchange exposure income equity income equity cent appreciation us dollar cent cent appreciation euro cent yen appreciation yen yen equivalent depreciation stated currencies would equal opposite effect movements income statement relate primarily hedging instruments us legal provisions trade payables trade receivables whilst hedging instruments provide economic hedges related provisions financial instruments therefore included table combined sensitivity hedging instruments provisions would insignificant provisions included movements equity relate foreign exchange positions used hedge group assets denominated euro therefore movement value currency swap largely offset corresponding opposite movement group asset foreign exchange sensitivity group assets financial instruments included gsk annual report financial instruments related disclosures continued table presents groups sensitivity foreign exchange rates based composition net debt increasedecrease increasedecrease impact foreign exchange movements net debt net debt net debt cent appreciation us dollar cent cent appreciation euro cent yen appreciation yen yen equivalent depreciation stated currencies would equal opposite effect interest rate sensitivity table shows groups sensitivity interest rates floating rate sterling us dollar euro financial instruments currencies gsk historically issued debt held investments gsk considered movements interest rates last three years concluded basis points increase reasonable benchmark debt maturity less one year floating rate calculation interest rate movements derivative financial instruments designated fair value hedges deemed immaterial effect group income statement due compensating amounts carrying value debt basis points movement interest rates deemed material effect equity increasedecrease increasedecrease income income basis points increase sterling interest rates basis points increase us dollar interest rates basis points increase euro interest rates interest rates could decreased currently less maximum increasedecrease income would therefore limited million million million sterling us dollar euro interest rates respectively million million million contractual cash flows nonderivative financial liabilities derivative instruments following analysis anticipated contractual cash flows including interest payable groups nonderivative financial liabilities undiscounted basis impact interest rate swaps excluded purpose table debt defined classes borrowings except obligations finance leases interest calculated based debt held december without taking account future issuance floating rate interest estimated using prevailing interest rate balance sheet date cash flows foreign currencies translated using spot rates december finance charge trade payables obligations obligations interest finance finance liabilities december debt debt leases leases net debt total due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows finance charge trade payables obligations obligations interest finance finance liabilities december debt debt leases leases net debt total due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows gsk annual report financial notes financial statements continued statements financial instruments related disclosures continued following table provides analysis anticipated contractual cash flows groups derivative instruments excluding embedded derivatives equity options material using undiscounted cash flows cash flows foreign currencies translated using spot rates december gross cash flows foreign exchange contracts presented purposes table though practice group uses standard settlement arrangements reduce liquidity requirements instruments amounts receivable payable less one year increased compared due higher levels hedging inter company loans deposits legal provisions indicated increased principal amounts shown table receivables payables receivables payables less one year one two years two three years three four years gross contractual cash flows derivative financial instruments hedging programmes following table sets fair values derivatives held gsk fair value fair value assets liabilities assets liabilities fair value hedges interest rate swaps principal amount million million net investment hedges foreign exchange contracts principal amount million million derivatives designated fair value profit loss foreign exchange contracts principal amount million million embedded derivatives derivatives classified held trading ias total derivative instruments analysed current noncurrent total derivative financial instruments principal amount foreign exchange contracts absolute total outstanding positions balance sheet date majority contracts periods months less december group held outstanding foreign exchange contracts consisting primarily currency swaps net credit fair value million million credit represent hedges intercompany loans deposits legal provisions designated accounting hedges changes fair value taken income statement period offset exchange gains losses related intercompany lending borrowing cash flow hedges group designated cash flow hedges group carries balance reserves arose prehedging interest rate exposure euro sterling bonds issued balance reclassified finance costs life bonds gsk annual report financial instruments related disclosures continued fair value hedges group designated series interest rate swaps fair value hedge risk hedged variability fair value bond arising interest rate fluctuations gains losses fair value hedges disclosed note finance costs net investment hedges year certain foreign exchange contracts designated net investment hedges respect foreign currency translation risk arising consolidation groups net investment euro foreign operations foreign exchange contracts also designated net investment hedges groups net investment us dollar yen foreign operations december december group held net investment hedges respect euro foreign operations addition euro loan capital billion issued previous years designated net investment hedge respect foreign currency translation risk arising consolidation groups net investment euro operations employee share schemes group operates share option schemes whereby options granted employees acquire shares ads glaxosmithkline plc grant price savingsrelated share option schemes share award schemes addition gsk operates performance share plan whereby awards granted employees acquire shares ads glaxosmithkline plc cost subject achievement group specified performance targets share value plan whereby awards granted employees acquire shares ads glaxosmithkline plc cost three year vesting period granting restricted share awards replaced granting options employees cost scheme readily equates potential gain made employee onwards grants made savingsrelated share option schemes grants share option schemes normally exercisable three ten years date grant grants restricted shares share awards normally exercisable end three year vestingperformance period grants savingsrelated share option schemes normally exercisable three years saving grants share option schemes awards performance share plan normally granted employees acquire shares ads gsk plc circumstances settled cash options share option schemes granted market price ruling date grant accordance uk practice majority options savingsrelated share option schemes granted price market price ruling date grant share options awarded directors effect grant cet subject performance criteria option pricing purposes valuing options awards arrive share based payment charge blackscholes option pricing model used assumptions used model follows riskfree interest rate dividend yield volatility expected lives options granted share option schemes years years years savingsrelated share option share award schemes years years years weighted average share price grants year shares ads plans dividends reinvested volatility determined based three five year share price history appropriate fair value performance share plan grants take account market conditions expected lives options determined based weighted average historic exercises options gsk annual report financial notes financial statements continued statements employee share schemes continued share option share option savingsrelated options outstanding schemes shares schemes ads share option schemes weighted weighted weighted weighted weighted weighted number exercise fair number exercise fair number exercise fair price value price value price value january options granted options exercised options lapsed december options granted options exercised options lapsed december options granted options exercised options lapsed december range exercise prices weighted average market price exercise weighted average remaining contractual life years years years share option share option savingsrelated options outstanding schemes shares schemes ads share option schemes december weighted latest weighted latest weighted latest number exercise exercise number exercise exercise number exercise exercise year grant price date price date price date total options normally become exercisable three years date grant may certain circumstances vest earlier set within various scheme rules change effective exercise price outstanding options year share option share option savingsrelated options exercisable schemes shares schemes ads share option schemes weighted weighted weighted number exercise number exercise number exercise price price price december december december gsk annual report employee share schemes continued glaxosmithkline share award schemes performance share plan group operates performance share plan whereby awards granted directors senior executives cost percentage award vests based upon performance group defined measurement period dividends reinvested period awards granted onwards directors members cet performance conditions based four equally weighted measures three year performance period first measure based achievement adjusted free cash flow targets second measure based relative tsr performance comparator group remaining two measures based businessspecific performance measures business diversification rd new product performance details calculation measures see remuneration report pages awards granted directors members cet award based achievement adjusted free cash flow targets three year measurement period remaining award based relative tsr performance comparator group described pages half tsr element award measured three years half four years awards granted directors members cet prior subject single performance condition compares gsks tsr period tsr companies comparator group period awards made eligible employees prior performance conditions consist two parts applies award first part performance condition compares gsks eps growth increase uk retail prices index three year measurement period second part performance condition compares gsks tsr period tsr companies comparator group period awards granted onwards first part performance condition continues based eps second part performance condition based strategic operational business measures three year measurement period specific employees business area shares weighted ads weighted number shares ads issuable number fair value number fair value january awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december year additional shares additional ads awarded dividends reinvested share value plan group operates share value plan whereby awards granted form shares certain employees cost awards vest three years performance criteria attached shares weighted ads weighted number fair value number fair value january awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december gsk annual report financial notes financial statements continued statements employee share schemes continued deferred investment award plan group operates deferred investment award plan whereby awards granted form notional shares certain senior executives cost awards typically vest threeyear period commencing fourth anniversary date grant award initially vesting subsequent two years performance criteria attached shares weighted ads weighted number shares ads issuable number fair value number fair value january awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december year additional shares additional ads awarded dividends reinvested employee share ownership plan trusts group sponsors employee share ownership plan esop trusts acquire hold shares glaxosmithkline plc satisfy awards made employee incentive plans options granted employee share option schemes trustees esop trusts purchase shares open market finance provided group way loans contributions costs running esop trusts charged income statement shares held esop trusts deducted reserves held value proceeds receivable employees exercise deemed permanent diminution value reflected transfer retained earnings trusts also acquire hold shares meet notional dividends reinvested deferred awards smithkline beecham midterm incentive plan trustees waived rights dividends shares held esop trusts shares held share award schemes number shares nominal value carrying value market value shares held share option schemes number shares nominal value carrying value market value gsk annual report principal group companies following represent principal subsidiary associated undertakings glaxosmithkline group december details given principal country operation location headquarters business sector business activities equity share capital undertakings wholly owned group except percentage interest shown otherwise companies incorporated principal country operation except stated europe location subsidiary sector activity england brentford glaxosmithkline holdings limited phch h brentford glaxosmithkline holdings one limited phch h brentford glaxosmithkline services unlimited phch brentford glaxosmithkline mercury limited ph h brentford glaxosmithkline finance plc phch f brentford glaxosmithkline capital plc phch f brentford smithkline beecham limited phch e h p r brentford wellcome limited phch h brentford glaxo group limited ph h brentford glaxo operations uk limited ph p brentford glaxosmithkline export limited ph e brentford glaxosmithkline research development limited ph r brentford glaxosmithkline uk limited ph p brentford glaxochem pte ltd ph h brentford setfirst limited phch h brentford wellcome foundation limited ph p cambridge domantis limited ph r brentford viiv healthcare limited ph h brentford viiv healthcare uk limited ph brentford viiv healthcare trading services uk limited ph e f austria vienna glaxosmithkline pharma gmbh ph belgium wavre glaxosmithkline pharmaceuticals sa ph rixensart glaxosmithkline biologicals sa ph e p r czech republic prague glaxosmithkline sro phch denmark orestadt glaxosmithkline consumer healthcare ch e brndby glaxosmithkline pharma ph finland espoo glaxosmithkline oy ph france marly le roi groupe glaxosmithkline sas ph h marly le roi laboratoire glaxosmithkline sas ph r marly le roi glaxo wellcome production sas ph p marly le roi glaxosmithkline sante grand public sas ch marly le roi viiv healthcare sas ph st amand les eaux glaxosmithkline biologicals sas ph p germany buehl glaxosmithkline consumer healthcare gmbh co kg ch h p r munich glaxosmithkline gmbh co kg ph h greece athens glaxosmithkline aebe phch hungary budapest glaxosmithkline medicine healthcare products limited phch e italy verona glaxosmithkline spa ph h milan glaxosmithkline consumer healthcare spa ch verona glaxosmithkline manufacturing spa ph p luxembourg mamer glaxosmithkline international luxembourg sarl phch f h netherlands zeist glaxosmithkline bv ph zeist glaxosmithkline consumer healthcare bv ch norway oslo glaxosmithkline ph poland poznan glaxosmithkline pharmaceuticals sa ph p poznan gsk services spz oo ph warsaw glaxosmithkline consumer healthcare spz oo ch e portugal alges glaxosmithklineprodutos farmaceuticos limitada ph gsk annual report financial notes financial statements continued statements principal group companies continued europe location subsidiary sector activity republic carrigaline smithkline beecham cork limited ii ph p r ireland cork glaxosmithkline trading services limited ii ph e dublin glaxosmithkline consumer healthcare ireland limited ii ch dublin glaxosmithkline ireland limited ii ph dungarvan stafford miller ireland limited ii ch p dungarvan glaxosmithkline dungarvan limited ii ch p sligo stiefel laboratories ireland limited ii ph p romania brasov europharm holding sa phch bucharest glaxosmithkline gsk srl ph r russian moscow glaxosmithkline trading zao ph federation moscow glaxosmithkline healthcare zao ch spain madrid glaxosmithkline sa ph madrid glaxosmithkline consumer healthcare sa ch aranda de duero glaxo wellcome sa ph p sweden solna glaxosmithkline ab ph switzerland muenchenbuchsee glaxosmithkline ag ph usa usa research triangle park stiefel laboratories inc ph h p marietta corixa corporation ph p r philadelphia glaxosmithkline llc phch e h p r pittsburgh glaxosmithkline consumer healthcare lp ch p pittsburgh block drug company inc ch h wilmington glaxosmithkline holdings americas inc phch h wilmington glaxosmithkline capital inc ph f cambridge sirtris pharmaceuticals inc ph r research triangle park viiv healthcare company ph americas bermuda hamilton glaxosmithkline insurance ltd phch canada mississauga glaxosmithkline inc ph p r mississauga glaxosmithkline consumer healthcare inc ch laval id biomedical corporation quebec ph e p r mexico delegacion tlalpan glaxosmithkline mexico sa de cv phch e p asia pacific australia boronia glaxosmithkline australia pty ltd phch e p r china beijing glaxosmithkline china investment co ltd phch h hong kong glaxosmithkline limited phch shanghai glaxosmithkline biologicals shanghai ltd ph p tianjin sinoamerican tianjin smith kline french laboratories ltd ch e p india mumbai glaxosmithkline pharmaceuticals limited ph p new delhi glaxosmithkline consumer healthcare limited iii ch e p r malaysia petaling jaya glaxosmithkline pharmaceutical sdn bhd ph selangor glaxosmithkline consumer healthcare sdn bhd ch new zealand auckland glaxosmithkline nz limited phch pakistan karachi glaxosmithkline pakistan limited phch e p r philippines makati glaxosmithkline philippines inc phch e singapore singapore glaxo wellcome manufacturing pte ltd ph e p r singapore glaxosmithkline pte ltd phch e r south korea seoul glaxosmithkline korea limited ph ch thailand bangkok glaxosmithkline thailand limited phch gsk annual report principal group companies continued japan location subsidiary sector activity japan tokyo glaxosmithkline kk phch p latin america argentina buenos aires glaxosmithkline argentina sa phch e p r buenos aires laboratorios phoenix sociedad anonima industrial comercial financiera ph e p r brazil rio de janeiro glaxosmithkline brasil limitada phch e p colombia bogota glaxosmithkline colombia sa phch venezuela caracas glaxosmithkline venezuela ca phch middle east africa egypt cairo glaxosmithkline sae phch e p south africa johannesburg glaxosmithkline south africa pty limited phch e p turkey istanbul glaxosmithkline ilaclari sanayi ticaret phch middle east africa associate south africa johannesburg aspen pharmacare holdings limited iv phch p r incorporated singapore ii exempt provisions section companies amendment act ireland iii c onsolidated subsidiary undertaking accordance section companies act grounds dominant influence iv e quity accounted grounds significant influence directly held wholly owned subsidiary glaxosmithkline plc key business sector ph pharmaceuticals ch consumer healthcare business activity development e exporting f finance h holding company insurance marketing p production r research service full details group subsidiary associated undertakings attached companys annual return filed registrar companies glaxosmithkline capital inc glaxosmithkline capital plc whollyowned finance subsidiary company company fully unconditionally guaranteed securities issued glaxosmithkline capital inc glaxosmithkline capital plc gsk annual report financial notes financial statements continued statements legal proceedings intellectual property advairseretide group involved significant legal administrative proceedings principally product liability intellectual property number companies challenged groups patents tax antitrust governmental investigations well covering advairseretide salmeterolfluticasone propionate related private litigation group makes provision certain european jurisdictions including uk belgium proceedings regular basis summarised note france germany ireland netherlands february accounting principles policies note actions brought mylan pharmaceuticals inc hexal provisions group may become involved significant legal pharmaceuticals hexal neolab ltd ivax international proceedings respect possible make federal court munich revoked groups german seretide reliable estimate expected financial effect combination patent lack inventive step group could result ultimate resolution proceedings appealed decision netherlands action brought cases appropriate disclosures cases would sandoz pharmaceuticals sandoz hexal district included provision would made court hague january revoked supplementary protection certificate spc extends respect legal proceedings described protection product september provision made group unable make reliable estimate expected financial revocation action basic patent covering seretide effect stage group believe information combination ireland filed high court dublin amount sought plaintiffs known behalf ivax july high court handed would meaningful respect legal proceedings decision june finding patent invalid due number factors including limited obviousness group filed appeal decision stage proceedings entitlement parties appeal october trial date set appeal decision clarity theories liability damages currently generic salmeterolfluticasone governing law intellectual property claims include challenges proportionate products markets validity enforceability groups patents various products processes well assertions noninfringement july group entered settlement agreement patents loss cases could result loss sandoz pursuant parties resolved pending patent protection product issue consequences litigation relating groups combination patents seretide loss could significant decrease sales europe settlement agreement provides group product could materially affect future results operations pursue legal action combination patents group sandoz block launch generic salmeterolfluticasone propionate product european country sandoz legal expenses incurred provisions related legal claims received regulatory approval salmeterolfluticasone charged selling general administration costs provisions proportionate product european country date made taking appropriate legal specialist advice outflow resources considered probable argatroban reliable estimate made likely outcome december encysive pharmaceuticals inc mitsubishi kasei dispute respect product liability claims related certain corporation group filed action united states products sufficient history claims made district court southern district new york barr settlements enable management make reliable estimate laboratories inc infringement mitsubishis pharmaceutical provision required cover unasserted claims certain composition patent covering argatroban pursuant licence cases incurred reported ibnr estimate using actuarial mitsubishi encysive developed argatroban treatment techniques appropriate used determine estimate heparininduced thrombocytopenia holds new drug groups exposure described note provisions application approved us food drug administration december groups aggregate provision legal fda encysive licensed us marketing rights argatroban disputes including tax matters described group mitsubishi patent expires june barr note taxation billion ultimate liability teva pharmaceuticals inc filed abbreviated new drug legal claims may vary amounts provided application anda fda certification dependent upon outcome litigation proceedings invalidity unenforceability noninfringement mitsubishi investigations possible settlement negotiations patent june group partners prevailed groups position could change time therefore teva trial judge ruling mitsubishis patent assurance losses result covering formulation injectable argatroban infringed outcome legal proceedings exceed material invalid august united states court amount amount provisions reported groups appeal federal circuit affirmed decision result financial accounts happen could material courts decision teva precluded launching generic adverse impact results operation group product june reporting period judgments incurred settlements entered significant matters described gsk annual report legal proceedings continued group subsequently received similar notices anchen pharmaceuticals anchen roxane laboratories roxanne arzerrabenlystacabilly patents watson laboratories inc watson mylan pharmaceuticals inc mylan variously challenging either patent february group filed declaratory action patents united states district court northern district california declaration us patent known group filed suit banner anchen united cabilly ii patent owned jointly genentech inc states district court district delaware january city hope invalid unenforceable infringed infringement avodart patents consequence groups product arzerra ofatumumab approved stay fda approval banners anchens products fda refractory chronic lymphocytic leukaemia cll effect earlier may decision adverse genentech city hope counterclaimed infringement group separate complaint filed roxane suit subsequently transferred united states district watson court june september court middle district california group filed suit mylan thirtymonth stays fda approval subsequent generic products april obtaining third cabilly patent extend past anchenbanner stay may cases cabilly iii patent genentech filed suit group avodart consolidated original case united states district court middle district california anchen banner twoweek trial scheduled commence alleging group lonza manufacturer arzerra october infringed cabilly iii patent making selling arzerra group contractually required defend indemnify lonza may group settled earlier patent challenge claims related arzerra cabilly patents genentech avodart teva pharmaceuticals inc teva also sued group human genome sciences inc hgs terms settlement teva permitted launch claiming infringement making selling benlysta generic dutasteride product fourth quarter cabilly ii iii patents hgs groups licensor earlier certain conditions tevas generic dutasteride benlysta product approved fda december september district court decided stay december anchen notified group cabilly iii cases group hgs notice filed anda jalyn paragraph iv certification alleging decided consolidate arzerra benlysta cases patent expires invalid relating cabilly ii patent december district unenforceable infringed jalyn combination court stayed benlystacabilly ii case resolution dutasteride tamsulosin covered three patents summary judgment motions filed arzerracabilly ii case cover avodart subsequently group received similar discovery completed arzerracabilly ii case notices impax laboratories inc watson challenging summary judgment motions pending one patents covering jalyn group sued anda applicants jalyn united states district court march genentech biogen idec filed suit district delaware cases consolidated group united states district court southern trial avodart cases twoweek trial scheduled district california alleging groups sale arzerra commence october induces contributes infringement patent claims treatment cll anticd monoclonal benlysta antibody group counterclaimed patent invalid february uk court appeal upheld earlier high infringed october district court issued court decision revoking human genome sciences inc ruling construed claims manner arzerra hgs uk patent ep grounds would infringe patent genentech biogen idec susceptible industrial application inventive step claim stipulated judgment infringement filed appeal revocation brought eli lilly patent claim construction issue united states court claims cytokine blys antibody binds appeals federal circuit dates yet set blys benlysta belimumab group licence appeal patent hgs party litigation avodartjalyn proceedings equivalent european patent upheld october final appeal european patent office november banner pharmacaps inc banner following opposition proceeding filed eli lilly hgs notified group filed anda market generic group appealed uk decision november uk version avodart dutasteride banners notification contained supreme court reversed uk court appeal affirmed paragraph iv certification alleging two patents expiring validity patent grounds uk supreme one patent expiring patent covering court remanded case uk court appeal compound dutasteride invalid infringed proceedings remaining grounds including banners proposed generic dutasteride product sufficiency disclosure previously decided favour hgs unless court appeal decides hgs remaining issues patent considered valid force gsk annual report financial notes financial statements continued statements legal proceedings continued march pronova entered agreement apotex settle patent litigation usa related november eli lilly brought action uk patents lovaza settlement grants apotex license enter us court revocation european patent owned biogen idec market generic version lovaza first quarter covering use antibody baff also known b earlier depending certain circumstances terms lymphocyte stimulatory blys treatment autoimmune settlement confidential diseases group hgs exclusively licensed trial involving teva par held march april patent responsible defending action ruling yet issued pronova group also european patent also challenged parallel proceedings received paragraph iv notice endo pharmaceuticals merck serono european patent office actions endo mylan pharmaceuticals mylan advising endo early days patent one number patents mylan submitted anda fda lovaza protect benlysta prevent unlawful copying benlysta pronova chosen assert patents endo outcome revocation action direct effect mylan awaiting ruling litigation teva ability hgs group market benlysta validity par united states district court district delaware patents cover benlysta trizivir epzicom may viiv healthcare received notice lupin ltd june viiv healthcare received notice teva lupin filed anda containing paragraph iv pharmaceuticals teva amended anda epzicom certification trizivir triple combination lamivudine azt combination lamivudine abacavir contain paragraph abacavir alleging three patents listed orange iv certification two additional patents listed orange book trizivir either invalid unenforceable infringed book alleging patents invalid unenforceable patents relate method treating hiv using triple infringed patents challenged new certification relate combination expiring hemisulfate salt abacavir method treating hiv using combination expiring expiring certain crystal form lamivudine certain crystal form lamivudine expiring expiring june viiv healthcare filed suit august viiv healthcare filed suit teva lupin patent covering triple combination challenged patents united states district court united states district court district delaware district delaware stay place fda approval october district court consolidated case tevas anda earlier december decision discovery viiv healthcares patent infringement suit involving adverse viiv healthcare matter district court teva pharmaceuticals epzicom pending court consolidated discovery epzicom case viiv healthcares stay place fda approval lupins anda patent infringement suit lupin ltd relating trizivir earlier november decision adverse viiv healthcare cases involve patent covering combination matter lamivudine abacavir veramyst levitra november group received notice sandoz inc group participates marketing levitra pursuant filed anda paragraph iv certification veramyst copromotion agreement bayer healthcare july fluticasone furoate nasal spray challenging three patents bayer brought suit teva pharmaceuticals teva listed orange book veramyst invalid unenforceable united states district court district delaware infringed three patents expire infringement patent relating levitra teva filed december group filed suit sandoz anda fda certification patent covering united states district court district delaware active ingredient levitra expires invalid three patents stay fda approval sandozs generic unenforceable infringed parties settled case product place earlier court decision dismissed november terms adverse group least may confidential group party suit product liability lovaza preclinical clinical trials conducted march group received notice teva development potential products determine safety pharmaceuticals usa inc teva par pharmaceuticals inc efficacy products use humans following approval par apotex inc apotex filed andas regulatory bodies notwithstanding efforts drugs paragraph iv certification alleging two patents covering vaccines introduced marketplace unanticipated lovaza omegaacid ethyl esters invalid unenforceable safety issues may become believed evident infringed patents expire group group currently defendant number product licensee patents marketing rights liability lawsuits related groups pharmaceutical usa puerto rico pronova biopharma norge pronova consumer healthcare products significant owner patents sued teva par apotex matters described group able make united states district court district delaware fda reliable estimate expected financial effect matters approval andas stayed earlier may discussed category included provision decision favourable one generics group matters provision legal disputes party suits also noted note provisions gsk annual report legal proceedings continued poligrip beginning number product liability lawsuits claims avandia filed group state federal courts group named product liability lawsuits behalf usa including purported class actions alleging zinc individuals asserting personal injury claims arising poligrip causes copper depletion permanent neurologic injury use avandia federal cases filed group part federal cases part denture cream adhesive multi multidistrict litigation proceeding pending united district litigation mdl united states district court states district court eastern district pennsylvania cases southern district florida established june also filed number state courts cases filed group procter gamble defendants state court philadelphia coordinated mass tort litigation included mdl purported class actions program cases state court california coordinated asserting economic loss claims state consumer protection los angeles additionally number purported laws claims medical monitoring three current class actions seeking economic damages behalf third party exceptions one state court case pennsylvania one ohio payers consumers asserting claims arising various state one tennessee state court cases federal laws including racketeer influenced corrupt consolidated philadelphia mass tort program mtp organizations act rico state unfair trade practices andor purported class actions asserting consumer fraud claims also consumer protection laws filed canada group reached agreements principle settle vast majority current cases lawsuits pending february group reached agreements settle mtp litigation settlement discussions substantial majority federal state cases pending ongoing group voluntarily withdrawn zinccontaining usa eleven purported class actions avandia pending formulations poligrip market canada one purported class action israel sales marketing regulation paxil paxil cr group able make reliable estimate group received numerous lawsuits claims alleging expected financial effect matters discussed category use paxil paroxetine caused variety injuries included provision matters provision lawsuits recent years alleged use paxil legal disputes except noted matters pregnancy resulted birth child birth defects group made provision also noted note health issues lawsuits claims alleged provisions patients took paxil committed attempted commit suicide acts violence patients suffered symptoms colorado investigation discontinuing treatment paxil february group received subpoena group reached agreements settle substantial majority united states attorneys office colorado regarding groups us claims relating paxil use pregnancy sales promotional practices relating nine largest february number claims related use selling products period january pregnancy still pending including several scheduled trial investigation later taken united states attorneys philadelphia mass tort program matters office district massachusetts expanded dismissed without payment remains purported class action present respect advair november group litigation canada concerning use paxil pregnancy announced reached agreement principle united states government conclude groups parties filing motion preliminary approval significant ongoing united states federal investigations proposed class settlement certified statewide class action specifically colorado investigation groups sales seeking restitution alleged violations california unfair marketing practices begun february ii united competition law relating symptoms discontinuing use states department justices investigation possible paxil inappropriate use nominal price exception uk public funding withdrawn hundreds medicaid rebate program iii department justices claimants received funding pursue common issues investigation development marketing avandia litigation alleging paroxetine caused suffer settlement payment billion final settlement withdrawal reactions dependency legal services corporate integrity agreement expected address civil commissions decision withdraw funding appealed criminal liabilities groups sales marketing special cases review panel claimants outcome practices remains subject ongoing negotiation united appeal remains outstanding claimants states government expected finalised discontinued claims trial scheduled commence amount settlement covered groups existing early high court london vacated provisions funded existing cash resources us government also inquired groups response october letter fdas division drug marketing advertising communication requesting information groups alleged promotion wellbutrin sr offlabel use resolution enquiry part agreement principle federal government described gsk annual report financial notes financial statements continued statements legal proceedings continued cidra puerto rico manufacturing site october group finalised agreement avandiarelated matters us attorneys office district massachusetts us noted november group reached department justice respect investigation agreement principle united states federal government groups former manufacturing facility cidra puerto rico resolve governments investigation development agreement comprehensive settlement pending marketing avandia claims group arising investigation group paid total million million civil criminal attorneys general offices states louisiana penalties sb pharmco puerto rico inc subsidiary mississippi south carolina utah filed suit group pleaded guilty certain charges group group asserting various statutory common law claims relating process negotiating corporate integrity agreement development marketing avandia multistate group office inspector general cover manufacturing attorneys general conducting investigation relating compliance matters development marketing avandia group cooperating offices group also defending june group announced agreement pay action county santa clara california total million us states district brought californias consumer protection laws seeking columbia settle investigation related events civil penalties restitution early former manufacturing facility cidra puerto rico group admit wrongdoing liability average wholesale price settlement united states department justice doj number hiv division enquiry states putative classes private payers several years investigating andor bringing civil litigation regarding july group received subpoena eastern allegations numerous pharmaceutical companies including district new yorks us attorneys office regarding sales group violated federal state fraud abuse laws marketing practices three hiv products well educational result way average wholesale price awp programmes grants payments physicians regarding wholesale acquisition cost wac determined drug used treat hivinfected adults group cooperating reported various drugs reimbursed medicare investigation provision made matter medicaid insurance programmes group nominal pricing reached million civil settlement federal government resolve allegations relating pricing may group advised us department marketing zofran kytril doj settlement group justice investigating certain groups nominal also amended existing corporate integrity agreement pricing bundled sale arrangements nominal price requirement settlement group received final exception best price reporting requirements approval million nationwide private payer class action medicaid drug rebate programme noted settlement relating groups price reporting multi november group reached agreement principle district litigation proceeding united states district court us federal government resolve governments district massachusetts investigation possible inappropriate use nominal price exception medicaid drug rebate programme amount number states respective attorneys general settlement covered groups existing provisions counties new york state filed civil funded existing cash resources lawsuits state federal courts group many drug companies claiming damages restitution due group also received subpoenas requests documents awp andor wac price reporting pharmaceutical products information delaware michigan related covered states medicaid programmes states seek groups nominal price arrangements group cooperated recovery behalf states payers cases investigations produced responsive documents behalf instate patients consumers group anticipates delaware michigan investigations resolved part us federal settlement group group separately resolved awp claims state medicaid entered nominal price arrangements since programmes almost states doj december settlement separate negotiations litigation concerning awp issues continuing four states gsk annual report legal proceedings continued antitrustcompetition group able make reliable estimate b programme expected financial effect matters discussed category group defending action filed federal court included provision matters provision united states district court northern district legal disputes except noted matters california county santa clara one county group made provision also noted note sought represent putative class hospitals clinics provisions entities california eligible receive discounted eu sector enquiry ceiling prices pharmaceuticals federal programme known b programme plaintiffs alleged group january european commission announced numerous pharmaceutical manufacturers enquiry certain aspects competition pharmaceutical setting ceiling prices higher allowed law sector july commission published final report contract governs programme therefore suggesting defensive patenting strategies may impose overcharged entities california eligible obstacles innovation innovator companies employ participate b programme measures hinder generics coming onto market final report also conceded delays generic entry much united states supreme court agreed review issue fault regulatory environment innovator companies whether b entities standing sue manufacturers defensive strategies manufacturers b contract government trial court stayed proceedings case supreme january commission requested information courts decision march supreme court group number pharmaceutical companies unanimously held plaintiffs thirdparty beneficiaries relating patent settlement agreements affecting european contract issue could sue challenge union european economic area markets request calculation b programme ceiling prices essentially ending information second monitoring exercise commission plaintiffs case parties working finalising patent settlement agreements pharmaceuticals sector dismissal case resolution potential claims results exercise published july january commission repeated exercise lovaza third patent settlement monitoring exercise group april group received subpoena office responded february provision made inspector general us department health matter human services requesting production documents relating uk office fair trading competition act investigation groups marketing promotion lovaza scope document request january present august uk office fair trading oft launched group responding subpoena provision formal investigation group pharmaceutical made matter companies potential infringement competition act investigation focuses whether litigation settlements paxilseroxat group potential suppliers generic paroxetine group settled lawsuit filed new york state formulations entered attorney generals office alleging group failed disclose object effect prevention restriction distortion data use paxil children adolescents competition uk ii group infringed group made class settlements lawsuits brought dominant position making payments potential suppliers consumers thirdparty payers respectively economic generic paroxetine aim restricting development damages allegedly resulting prescriptions paxil children full generic competition uk group terminated adolescents group denied liability settlements agreements issue oft investigation covers issues plaintiffs voluntarily dismissed similar purported class also investigated european commission action filed behalf governmental entities paid respect paroxetine european union prescriptions paxil minors remains similar purported also part european commission pharmaceutical class action canada seeking economic damages behalf sector enquiry march commission announced individuals third party payers governmental entities formally concluded enquiry action purchased paxil use patients age group provided information documentation secdoj fcpa enquiry response ofts request held initial meeting us securities exchange commission sec us oft december group continue cooperate department justice conducting industrywide enquiry oft investigation provision made whether pharmaceutical companies may engaged matter violations foreign corrupt practices act relating sale pharmaceuticals including argentina brazil canada china germany italy poland russia saudi arabia group one companies asked respond enquiry cooperating sec doj provision made matter gsk annual report financial notes financial statements continued statements legal proceedings continued securitieserisa class actions stiefel wellbutrin sr july class action suit brought behalf current december january february lawsuits former employees stiefel laboratories inc stiefel several purported class actions filed filed united states district court southern district united states district court eastern district pennsylvania florida complaint alleges stiefel officers group behalf direct indirect purchasers directors violated us employee retirement income security act wellbutrin sr complaints allege violations us antitrust erisa federal state securities laws inducing stiefel laws sham litigation fraud patent office employees sell shares employee stock plan back group obtaining enforcing patents covering stiefel greatly undervalued price without disclosing wellbutrin sr complaints followed introduction employees stiefel sold group generic competition wellbutrin sr april district january defendants motion dismiss granted part appellate court rulings generic manufacturer denied part specifically district court infringe groups patents determined erisa claims individual stiefel november district court approved groups defendants well federal securities claims settlement certified class direct purchasers individual defendants stiefel could go forward district january group reached agreement principle court dismissed florida securities act common law settle claims indirect purchasers million breach fiduciary duty claims holding erisa preempts settlement presented district court approval state common law well malpractice claim near future stiefels former accountants july district court denied plaintiffs motion class certification october wellbutrin xl district court granted defendants motions summary actions filed biovail corporation biovail judgment dismissing one remaining plaintiffs group purported classes direct indirect purchasers litigation district court also granted allege unlawful monopolisation antitrust defendants motions limine limiting scope evidence violations related enforcement biovails wellbutrin xl plaintiffs may offer trial additionally november patents filing biovail citizen petitions direct district court granted defendants daubert motion indirect purchaser classes certified group meaning plaintiffs experts left testify moved reconsideration regard certification behalf trial trial scheduled may indirect purchaser class oral argument groups motion three separate lawsuits stiefel charles stiefel scheduled march trial date yet set former ceo stiefel also filed individual former flonase stiefel employees case asserts claims similar contained class action purported direct indirect purchaser class actions filed united states district court eastern district december us securities exchange pennsylvania alleging group illegally maintained monopoly commission sec filed formal complaint stiefel power market flonase charged plaintiffs charles stiefel united states district court district supracompetitive prices additionally suit filed florida alleging stiefel principals violated federal roxane laboratories inc generic competitor seeking lost securities laws inducing stiefel employees sell shares profits groups alleged actions unlawfully delaying employee stock plan back company greatly roxanes entry market predicate undervalued price without disclosing employees allegations filing group allegedly sham citizen company sold group responded petitions subsequent litigation district court granted secs complaint motion direct purchasers certify class hearing avandia erisa litigation certification indirect purchaser class held february decision motion yet made putative class action suit filed group court groups motion dismiss roxanes complaint august united states district court denied trial suit brought putative class southern district new york direct indirect purchasers scheduled october complaint alleges group officers directors commercial corporate certain employees made misleading public statements avandia alleged misleading statements group able make reliable estimate exposed value groups stock dropped plaintiff expected financial effect matters discussed brought suit behalf participants category included provision respect matters groups retirement plans claiming group provision legal disputes set note individual defendants breached fiduciary duties plan provisions provision made participants employee retirement income security following matters act erisa gsk annual report legal proceedings continued plaintiffs sought double damages overtime allegedly worked groups pharmaceutical sales representatives plaintiffs subsequently amended complaint add three year period november district court allegations concerning wellbutrin sr paxil include granted groups motion summary judgment dismissed additional group defendants individual members lawsuit ground sales representatives groups benefits committees group filed motion dismiss exempt employees outside sales exemption february may district court ruled flsa plaintiffs appealed decision united states court favour group dismissing plaintiffs complaint appeals ninth circuit prejudice june plaintiffs filed appeal february ninth circuit issued opinion united states court appeals second circuit favour group affirming judgment united states benlysta securities litigation district court district arizona finding groups pharmaceutical sales representatives exempt employees november class action suit filed united outside sales exemption flsa therefore entitled states district court district maryland alleging overtime pay plaintiffs filed petition seeking review human genome sciences inc hgs certain individual decision united states supreme court november officers directors group made statements supreme court agreed review case oral argument clinical trials benlysta failed disclose suicides among supreme court scheduled april trial participants withholding information defendants caused hgs stock artificially inflated harming november purported class action filed anyone purchased hgs stock inflated price group united states district court northern district november second action filed federal new york behalf groups pharmaceutical sales court lead plaintiff yet named case representatives working new york previous six years group evaluating complaints plaintiff makes similar allegations set forth flsa cases well claims new york wage hour wage hour claims laws closely follow us fair labor standards act january december two purported class actions filed plaintiff filed similar purported class action florida state group behalf groups entire us pharmaceutical court alleging groups pharmaceutical sales representatives sales representatives actions filed entitled overtime flsa court issued stay transferred united states district court central activities new york case parties agreed district california initially alleged representatives ask court stay activities florida case exempt employees california law andor us fair united states supreme court decided applicability labor standards act flsa consequently entitled outside sales exemption pharmaceutical sales representatives overtime pay among things plaintiffs subsequently environmental matters amended complaints assert class action limited solely pharmaceutical sales representatives working california group notified potential responsibility relating asserting claims californias wage hour laws past operations past waste disposal practices certain sites primarily usa matters subject suits seek variety compensatory punitive statutory litigation including proceedings initiated us federal damages group moved summary judgment dismissing state governments waste disposal site remediation costs claims putative class representatives ground tort actions brought private parties exempt employees appeals pending united states court appeals ninth circuit cases group advised may responsible party involving manufacturers virtually factual approximately sites appear national legal arguments district court deferred ruling priority list created comprehensive environmental summary judgment motion stayed activity response compensation liability act superfund case appellate court ruled least one proceedings seek require operators hazardous waste companies pending cases ninth circuit deferred ruling facilities transporters waste sites generators companies pending cases california supreme hazardous waste disposed sites clean sites court issued opinion case addressing application reimburse government cleanup costs instances administrative exemption california state law group involved alleged generator hazardous waste january california supreme court issued ruling although superfund provides defendants jointly case requesting briefing effect ruling severally liable cleanup costs proceedings frequently california supreme court companies pending resolved basis nature quantity waste pharmaceutical sales representative cases disposed generator site groups third case filed united states district court proportionate liability cleanup costs substantially district arizona august sought establish determined sites referred nationwide collective action behalf groups entire us groups potential liability varies greatly site site pharmaceutical sales representatives ground cost investigation study remediation representatives exempt employees flsa sites could time substantial group routinely accrues amounts related share liability matters gsk annual report financial financial statements glaxosmithkline plc statements prepared uk gaap directors statement responsibilities relation disclosure information auditors companys financial statements directors office date report directors responsible preparing parent company confirmed glaxosmithkline plc financial statements remuneration far aware relevant audit report accordance applicable law regulations information companys auditors unaware company law requires directors prepare financial taken steps ought statements financial year law directors taken director make aware elected prepare parent company financial statements relevant audit information establish companys accordance united kingdom accounting standards auditors aware information applicable law united kingdom generally accepted accounting practice company law directors must approve confirmation given interpreted accordance parent company financial statements unless satisfied provisions section companies act give true fair view state affairs going concern basis company period making enquiries directors reasonable preparing financial statements directors expectation company adequate resources continue required operational existence foreseeable future reason select suitable accounting policies apply continue adopt going concern basis preparing consistently financial statements make judgements accounting estimates uk corporate governance code reasonable prudent board considers glaxosmithkline plc applies state regard parent company financial statements principles provisions uk corporate governance code applicable uk accounting standards followed maintained financial reporting council described subject material departures disclosed explained corporate governance section pages parent company financial statements complied provisions except disclosed required financial services authoritys listing rules directors responsible keeping adequate accounting auditors considered directors statement compliance records sufficient show explain companys relation points uk corporate governance code transactions disclose reasonable accuracy time specified review financial position company enable ensure parent company financial statements remuneration report comply companies act also responsible safeguarding assets sir christopher gent company hence taking reasonable steps chairman prevention detection fraud irregularities march parent company financial statements year ended december comprising balance sheet year ended december supporting notes set pages report responsibilities auditors relation parent company financial statements set independent auditors report financial statements year ended december included annual report published hard copy printed form made available website directors responsible maintenance integrity annual report website accordance uk legislation governing preparation dissemination financial statements access website available outside uk comparable legislation may different gsk annual report independent auditors report opinion matters prescribed companies act members glaxosmithkline plc opinion audited parent company financial statements glaxosmithkline plc year ended december part directors remuneration report audited comprise company balance sheet uk gaap properly prepared accordance companies related notes ah financial reporting framework act applied preparation applicable law information given directors report financia l united kingdom accounting standards united kingdom year parent company financial statements generally accepted accounting practice prepared consistent parent company financial respective responsibilities directors auditors statements explained fully directors statement matters required report responsibilities set directors responsible exception preparation parent company financial statements nothing report respect following matters satisfied give true fair view companies act requires us report responsibility audit express opinion opinion parent company financial statements accordance applicable law international standards auditing uk dequate accounting records kept parent ireland standards require us comply auditing company returns adequate audit practices boards ethical standards auditors received branches visited us report including opinions prepared parent company financial statements part companys members body accordance directors remuneration report audited chapter part companies act agreement accounting records returns purpose giving opinions accept assume c ertain disclosures directors remuneration specified law responsibility purpose person made report shown whose hands may come save expressly agreed prior consent writing w e received information explanations require audit scope audit financial statements matters audit involves obtaining evidence amounts disclosures financial statements sufficient give reasonable reported separately group financial statements assurance financial statements free material glaxosmithkline plc year ended december misstatement whether caused fraud error includes company passed resolution accordance section assessment whether accounting policies appropriate companies act senior statutory parent companys circumstances consistently auditors name stated applied adequately disclosed reasonableness significant accounting estimates made directors overall presentation financial statements addition read financial nonfinancial information annual pricewaterhousecoopers llp report identify material inconsistencies audited chartered accountants statutory auditors financial statements become aware apparent london material misstatements inconsistencies consider march implications report opinion financial statements opinion parent company financial statements give true fair view state companys affairs december properly prepared accordance united kingdom generally accepted accounting practice prepared accordance requirements companies act gsk annual report financial financial statements glaxosmithkline plc statements prepared uk gaap company balance sheet uk gaap december notes fixed assets investments debtors e cash bank current assets creditors amounts due within one year f net current assetsliabilities net assets capital reserves called share capital g share premium account g reserves h profit loss account h equity shareholders funds approved board march sir christopher gent chairman glaxosmithkline plc registered number gsk annual report notes company balance sheet expenditure uk gaap expenditure recognised respect goods services received supplied accordance contractual terms presentation financial statements provision made obligation exists future liability description business respect past event amount obligation reliably estimated glaxosmithkline plc parent company gsk major global healthcare group engaged creation discovery investments subsidiary companies development manufacture marketing pharmaceutical investments subsidiary companies held cost less products including vaccines overthecounter otc medicines provision impairment healthrelated consumer products impairment investments preparation financial statements carrying value investments reviewed impairment financial statements prepared going concern indication investment might basis drawn accordance uk generally accepted impaired provision resulting impairment review accounting principles uk gaap uk accounting charged income statement year concerned presentation december comparative figures december appropriate comparative share based payments figures reclassified ensure consistent presentation issuance company subsidiaries grant current year information companys options represents additional capital contributions permitted companies act profit company subsidiaries additional investment loss account company presented annual report subsidiaries results corresponding increase shareholders equity additional capital contribution based fair accounting convention standards value grant issued allocated underlying grants balance sheet prepared using historical cost vesting period convention complies applicable uk accounting taxation standards current tax provided amounts expected paid accounting principles policies applying tax rates enacted substantially enacted preparation balance sheet conformity generally balance sheet date accepted accounting principles requires management make company accounts taxation deferred estimates assumptions affect reported amounts accelerated reason timing differences originated assets liabilities disclosure contingent assets reversed balance sheet date deferred tax assets liabilities date balance sheet actual amounts could recognised extent considered differ estimates recoverable future taxable profits balance sheet prepared accordance deferred tax measured average tax rates companys accounting policies approved board expected apply periods timing differences described note b expected reverse deferred tax liabilities assets b accounting policies discounted foreign currency transactions financial guarantees foreign currency transactions recorded exchange rate liabilities relating guarantees issued company behalf ruling date transaction forward rate hedged subsidiaries initially recognised fair value forward exchange contract foreign currency assets amortised life guarantee liabilities translated rates exchange ruling balance c perating profit sheet date forward rate fee relating audit dividends paid received company charged operating profit dividends paid received included accounts period related dividends actually paid received gsk annual report financial financial statements glaxosmithkline plc statements prepared uk gaap notes company balance sheet uk gaap continued fixed assets shares glaxosmithkline services unlimited shares glaxosmithkline holdings one limited shares glaxosmithkline holdings limited shares glaxosmithkline mercury limited capital contribution relating share based payments e debtors amounts due within one year uk corporation tax recoverable amounts owed group undertakings amounts due one year amounts owed group undertakings f creditors amounts due within one year bank overdraft amounts owed group undertakings creditors company guaranteed debt issued one subsidiary companies receives annual fee subsidiary aggregate company outstanding guarantees billion debt instruments amount due subsidiary companies relation guarantee fees recovered life bonds disclosed within debtors see note e gsk annual report notes company balance sheet uk gaap continued g share capital share premium account share ordinary shares p premium number share capital authorised december december share capital issued fully paid january issued employee share schemes december issued employee share schemes share capital purchased cancelled december december december number shares issuable outstanding options number unissued shares option december issued share capital shares held esop trusts shares held treasury shares shares free issue issued shares fully paid nominal carrying market values shares held esop trusts disclosed note employee share schemes total million shares purchased company cost million year million shares cancelled million shares added treasury shares company expects make share repurchases billion exact amount timing purchases whether shares held treasury shares cancelled determined company dependent market conditions factors shares purchased period january february period february march million shares purchased cost million h reserves profit reserves loss account total january loss attributable shareholders dividends shareholders capital contribution relating share based payments december profit attributable shareholders dividends shareholders shares purchased cancelled held treasury share capital contribution relating share based payments december profit glaxosmithkline plc year million loss million dividends million million gave retained profit million loss million cost shares purchased cancelled held treasury shares million nil profit loss account reserve december stood million million million unrealised million gsk annual report shareholder information shareholder information quarterly trend unaudited analysis group results pharmaceuticals vaccines sales therapeutic area provided quarter sterling financial year income statement total months q q q q cer cer cer cer cer turnover pharmaceuticals vaccines consumer healthcare total turnover cost sales selling general administration research development operating income operating profit finance income finance costs profit disposal interest associates share tax profitslosses associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders basic earnings per share pence p p p p p diluted earnings per share pence p p p p p income statement results major restructuring total turnover cost sales selling general administration research development operating income operating profit finance income finance costs profit disposal interest associates share tax profitslosses associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders adjusted earnings per share pence p p p p p diluted earnings per share pence p p p p p calculation results major restructuring described note financial statements presentation financial statements gsk annual report quarterly trend unaudited analysis group results pharmaceuticals vaccines sales therapeutic area provided quarter sterling financial year income statement total months q q q q cer cer cer cer cer turnover pharmaceuticals vaccines consumer healthcare total turnover cost sales selling general administration research development operating income operating profit finance income finance costs profit disposal interest associates share tax profitslosses associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders basic earnings per share pence p p p p p diluted earnings per share pence p p p p p income statement results major restructuring total turnover cost sales selling general administration research development operating income operating profit finance income finance costs profit disposal interest associates share tax profitslosses associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders adjusted earnings per share pence p p p p p diluted earnings per share pence p p p p p calculation results major restructuring described note financial statements presentation financial statements gsk annual report shareholder quarterly trend continued information pharmaceuticals vaccines turnover therapeutic area total usa europe emerging markets rest world therapeutic area restated growth growth growth growth growth major products cer cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin xyzal zyrtec antivirals hepsera relenza valtrex zeffix central nervous system imigranimitrex keppra lamictal requip seroxatpaxil treximet wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza vesicare volibris metabolic avandia products bonvivaboniva antibacterials augmentin oncology emesis arzerra hycamtin promacta tyverbtykerb votrient vaccines boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix dermatologicals bactroban dermovate duac soriatane zovirax viiv healthcare hiv combivir epivir epzicomkivexa lexiva selzentry trizivir cer represents growth constant exchange rates represents growth actual exchange rates turnover quarter given pages gsk annual report pharmaceuticals vaccines turnover therapeutic area total usa europe emerging markets rest world therapeutic area restated growth growth growth growth growth major products cer cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin zyrtec antivirals hepsera relenza valtrex zeffix central nervous system imigranimitrex lamictal requip seroxatpaxil treximet wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza vesicare volibris metabolic avandia products bonvivaboniva antibacterials augmentin oncology emesis arzerra hycamtin promacta tyverbtykerb votrient vaccines boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix dermatologicals bactroban dermovate duac soriatane zovirax viiv healthcare hiv combivir epivir epzicomkivexa lexiva selzentry trizivir cer represents growth constant exchange rates represents growth actual exchange rates gsk annual report shareholder quarterly trend information pharmaceuticals vaccines turnover total group q q q q cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin xyzal zyrtec antivirals hepsera relenza valtrex zeffix central nervous system imigranimitrex keppra lamictal requip seroxatpaxil treximet wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza vesicare volibris metabolic avandia products bonvivaboniva antibacterials augmentin oncology emesis arzerra hycamtin promacta tyverbtykerb votrient vaccines boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix dermatologicals bactroban dermovate duac soriatane zovirax viiv healthcare hiv combivir epivir epzicomkivexa lexiva selzentry trizivir pharmaceutical turnover includes copromotion income gsk annual report pharmaceuticals vaccines turnover usa q q q q cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin xyzal zyrtec antivirals hepsera relenza valtrex zeffix central nervous system imigranimitrex keppra lamictal requip seroxatpaxil treximet wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza vesicare volibris metabolic avandia products bonvivaboniva antibacterials augmentin oncology emesis arzerra hycamtin promacta tyverbtykerb votrient vaccines boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix dermatologicals bactroban dermovate duac soriatane zovirax viiv healthcare hiv combivir epivir epzicomkivexa lexiva selzentry trizivir pharmaceutical turnover includes copromotion income gsk annual report shareholder quarterly trend continued information pharmaceuticals vaccines turnover europe q q q q cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin xyzal zyrtec antivirals hepsera relenza valtrex zeffix central nervous system imigranimitrex keppra lamictal requip seroxatpaxil treximet wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza vesicare volibris metabolic avandia products bonvivaboniva antibacterials augmentin oncology emesis arzerra hycamtin promacta tyverbtykerb votrient vaccines boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix dermatologicals bactroban dermovate duac soriatane zovirax viiv healthcare hiv combivir epivir epzicomkivexa lexiva selzentry trizivir pharmaceutical turnover includes copromotion income gsk annual report pharmaceuticals vaccines turnover emerging markets q q q q cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin xyzal zyrtec antivirals hepsera relenza valtrex zeffix central nervous system imigranimitrex keppra lamictal requip seroxatpaxil treximet wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza vesicare volibris metabolic avandia products bonvivaboniva antibacterials augmentin oncology emesis arzerra hycamtin promacta tyverbtykerb votrient vaccines boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix dermatologicals bactroban dermovate duac soriatane zovirax viiv healthcare hiv combivir epivir epzicomkivexa lexiva selzentry trizivir pharmaceutical turnover includes copromotion income gsk annual report shareholder quarterly trend continued information pharmaceuticals vaccines turnover rest world q q q q cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin xyzal zyrtec antivirals hepsera relenza valtrex zeffix central nervous system imigranimitrex keppra lamictal requip seroxatpaxil treximet wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza vesicare volibris metabolic avandia products bonvivaboniva antibacterials augmentin oncology emesis arzerra hycamtin promacta tyverbtykerb votrient vaccines boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix dermatologicals bactroban dermovate duac soriatane zovirax viiv healthcare hiv combivir epivir epzicomkivexa lexiva selzentry trizivir pharmaceutical turnover includes copromotion income gsk annual report consumer healthcare turnover q q q q cer cer cer cer overthecounter medicines oral healthcare nutritional healthcare q q q q cer cer cer cer usa europe rest world gsk annual report shareholder five year record information record financial performance provided analysed accordance current reporting practice information included five year record prepared accordance ifrs adopted european union also ifrs issued international accounting standards board turnover division pharmaceuticals excluding vaccines vaccines pharmaceuticals vaccines consumer healthcare group turnover geographic region usa europe emerging markets asia pacific japan group turnover segment pharmaceuticals vaccines usa europe emerging markets asia pacific japan viiv healthcare hiv trading unallocated pharma pharmaceuticals vaccines consumer healthcare pharmaceuticals vaccines turnover therapeutic area respiratory antivirals central nervous system cardiovascular urogenital metabolic antibacterials oncology emesis vaccines dermatology viiv healthcare hiv consumer healthcare turnover otc medicines oral healthcare nutritional healthcare gsk annual report financial results total turnover operating profit profit taxation profit taxation pence pence pence pence pence basic earnings per share diluted earnings per share financial results major restructuring turnover operating profit profit taxation profit taxation pence pence pence adjusted earnings per share adjusted diluted earnings per share millions millions millions millions millions weighted average number shares issue basic diluted return capital employed return capital employed calculated total profit taxation percentage average net assets year balance sheet noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net assets shareholders equity noncontrolling interests total equity gsk annual report shareholder five year record continued information number employees usa europe emerging markets asia pacific japan manufacturing selling administration research development geographic distribution employees table based location gsks subsidiary companies number employees number permanent employed staff end financial period excludes employees employed managed gsk contract basis exchange rates guide holders ads following tables set periods indicated information exchange rate us dollars sterling reported federal reserve bank new york noon buying rate average average rate year calculated average noon buying rates day year mar feb jan dec nov oct sep high low n december federal reserve bank new york ceased publishing noon buying rates bank england pm buying rates used subsequent calculations pm buying rate march us gsk annual report pharmaceuticals vaccines product development pipeline key inlicense alliance relationship third party maa marketing authorisation application europe month first submission nda new drug application usa month first regulatory approval maa first eu po month eu positive opinion approval letter phase evaluation clinical pharmacology usually conducted volunteers cr month complete response letter received indicates phase ii determination dose initial evaluation efficacy conducted ultimately approval may given subject resolution small number patients outstanding queries phase iii large comparative study compound versus placebo andor established bla biological license application treatment patients establish clinical benefit safety maa ndabla regulatory review milestones shown table achieved future filing dates included list achieved regulatory review milestones compound type indication phase maa ndabla biopharmaceuticals il monoclonal antibody type diabetes inflammatory bowel disease neurite outgrowth inhibitor nogoa amyotrophic lateral sclerosis multiple sclerosis monoclonal antibody tumour necrosis factor receptor tnfr acute lung injury domain antibody glucagon like peptide glp agonist obesity halflife improving domain antibody recombinant human angiotensin converting acute lung injury enzyme amp immunomodulator solid tumours otelixizumab cd monoclonal antibody sc iv rheumatoid arthritis myelinassociated glycoprotein monoclonal stroke ii antibody beta amyloid monoclonal antibody geographic retinal atrophy ii albiglutide glp agonist heart failure ii mepolizumab il monoclonal antibody severe asthma nasal polyposis ii ofatumumab cd human monoclonal antibody sc multiple sclerosis ii ofatumumab cd human monoclonal antibody sc rheumatoid arthritis ii sirukumab il human monoclonal antibody sc rheumatoid arthritis ii albiglutide glp agonist type diabetes iii arzerra ofatumumab cd human monoclonal antibody chronic lymphocytic leukaemia first line therapy use iii relapsed patients arzerra ofatumumab cd human monoclonal antibody diffuse large b cell lymphoma relapsed patients iii arzerra ofatumumab cd human monoclonal antibody follicular lymphoma refractory relapsed patients iii benlysta belimumab b lymphocyte stimulator monoclonal systemic lupus erythematosus iii antibody sc benlysta belimumab b lymphocyte stimulator monoclonal systemic lupus erythematosus approved jul mar antibody iv xgeva denosumab receptor activator nuclear kappa rank bone metastatic disease approved na na ligand human monocional antibody cardiovascular metabolic sodium dependent glucose transport sglt type diabetes inhibitor ileal bile acid transfer inhibitor type diabetes high affinity nicotinic acid receptor hma metabolic disorders ii agonist motilin receptor agonist delayed gastric emptying ii prolyl hydroxylase inhibitor peripheral arterial disease ii prolyl hydroxylase inhibitor anaemia associated chronic renal disease ii losmapimod p kinase inhibitor acute coronary syndrome also copd ii retosiban oxytocin antagonist threatened preterm labour ii ronacaleret calcium receptor antagonist allogeneic haematopoietic stem cell mobilisation ii darapladib lppla inhibitor atherosclerosis also diabetic macular oedema iii immunoinflammation transient receptor potential vanilloid trpv pruritis antagonist topical signalling inhibitor systemic lupus erythematosus antiinflammatory macrolide conjugate oral inflammatory bowel disease ii sirt activator psoriasis ii ccx ccr chemokine receptor antagonist rheumatoid arthritis ii ccr chemokine receptor antagonist crohn 's disease iii gsk annual report shareholder pipeline continued information achieved regulatory review milestones compound type indication phase maa ndabla infectious diseases type topoisomerase inhibitor bacterial infections leucyl trna synthetase inhibitor oral bacterial infections polypeptide deformylase inhibitor bacterial infections ii leucyl trna synthetase inhibitor iv bacterial infections ii hepatitis c virus inhibitor hepatitis c ii tafenoquine aminoquinoline plasmodium vivax malaria ii relenza iv zanamivir neuraminidase inhibitor iv influenza iii neurosciences phoshodiesterase inhibitor huntington 's disease orexin antagonist sleep disorders ii ht antagonist dementia ii firategrast dual alpha integrin antagonist vla multiple sclerosis ii rilapladib lppla inhibitor alzheimers disease ii ipx dopamine precursor dopa decarboxylase parkinson 's disease iii na inhibitor horizant gabapentin voltagegated calcium channel modulator postherpetic neuralgia submitted na aug enacarbil horizant gabapentin voltagegated calcium channel modulator restless legs syndrome approved na apr enacarbil trobaltpotiga neuronal potassium channel opener epilepsy partial seizures approved mar jun retigabineezogabine oncology akt protein kinase inhibitor cancer focal adhesion kinase inhibitor cancer phosphatidylinositol kinase pik inhibitor cancer trametinib mitogenactivated protein kinase inhibitor cancer bkm mek pik inhibitor vestipitant neurokinin antagonist iv post operative nausea vomiting akt protein kinase inhibitor langerhan cell histiocytosis ii dabrafenib braf protein kinase inhibitor nonsmall cell lung cancer ii foretinib mesenchymalepithelial transition factor papillary renal cell carcinoma cancers ii cmet kinase inhibitor revoladepromacta thrombopoietin receptor agonist haemeoncologyrelated thrombocytopaenia ii eltrombopag trametinib mek inhibitor kras mutant nonsmall cell lung cancer second line ii therapy trametinib mek inhibitor pancreatic cancer first line therapy ii trametinib mek inhibitor akt protein kinase cancer ii inhibitor trametinib mek inhibitor braf protein kinase metastatic melanoma ii dabrafenib inhibitor dabrafenib braf protein kinase inhibitor metastatic melanoma iii trametinib mek inhibitor metastatic melanoma iii revoladepromacta thrombopoietin receptor agonist hepatitis c induced thrombocytopaenia iii eltrombopag tyverbtykerb lapatinib human epidermal growth factor receptor breast cancer adjuvant therapy iii epidermal growth factor receptor egfr dual kinase inhibitor tyverbtykerb lapatinib egfr dual kinase inhibitor gastric cancer iii tyverbtykerb lapatinib egfr dual kinase inhibitor head neck squamous cell carcinoma resectable disease iii votrient pazopanib multikinase angiogenesis inhibitor ovarian cancer maintenance therapy iii votrient pazopanib multikinase angiogenesis inhibitor renal cell cancer adjuvant therapy iii tyverbtykerb lapatinib egfr dual kinase inhibitor metastatic breast cancer combination trastuzumab submitted feb feb votrient pazopanib multikinase angiogenesis inhibitor sarcoma submitted jul jun ophthalmology darapladib lppla inhibitor diabetic macular oedema also atheroscierosis ii pazopanib multikinase angiogenesis inhibitor agerelated macular degeneration also cancer ii eye drops indications gsk annual report achieved regulatory review milestones compound type indication phase maa ndabla respiratory cxcr chemokine receptor antagonist copd urotensin antagonist asthma tolllike receptor agonist asthma phosphoinositide kinase inhibitor asthma sodium channel blocker cough muscarinic antagonist beta agonist copd ii lipoxygenaseactivating protein flap asthma ii inhibitor dilmapimod p kinase inhibitor iv acute lung injury acute respiratory distress syndrome ii losmapimod p kinase inhibitor oral copd also cardiovascular disease ii muscarinic acetylcholine antagonist copd iii vilanterol muscarinic acetylcholine antagonist long copd iii acting beta agonist glucocorticoid agonist asthma iii vilanterol longacting beta agonist copd iii relovair longacting beta agonist glucocorticoid asthma iii vilanterol agonist relovair longacting beta agonist glucocorticoid copd iii vilanterol agonist paediatric vaccines malaria ng pf improved recombinant malaria prophylaxis plasmodium falciparum mmr live attenuated measles mumps rubella prophylaxis ii us nov pneumoniae paediatric recombinant conjugated streptococcus pneumoniae disease prophylaxis ii next generation mosquirix malaria rtss recombinant malaria prophylaxis plasmodium falciparum iii na menhibrix hibmencyttconjugated neisseria meningitis groups c haemophilus influenzae submitted na cr sep type b disease prophylaxis nimenrix menacwytt conjugated neisseria meningitis groups c w disease prophylaxis submitted po feb ii us vaccines flu pandemic cellculture based hn vaccine pandemic influenza prophylaxis staphylococcus aureus recombinant conjugated staphylococcus aureus prophylaxis hiv recombinant hiv disease prophylaxis hiv recombinant hiv disease immunotherapy ii tuberculosis recombinant tuberculosis prophylaxis ii zoster recombinant herpes zoster prevention iii flu pre pandemic hn inactivated split monovalent quebec prepandemic pandemic influenza prophylaxis submitted na sjun canada flu vaccine inactivated split quadrivalent seasonal influenza prophylaxis submitted feb pumarix hn inactivated split monovalent quebec pandemic influenza prophylaxis approved mar na antigen specific cancer immunotherapeutic asci nyeso recombinant treatment metastatic melanoma prame recombinant treatment metastatic melanoma prame recombinant treatment resectable nonsmall cell lung cancer wt recombinant treatment breast cancer wt recombinant treatment acute myelogenous leukaemia ii magea recombinant treatment bladder cancer ii magea recombinant treatment melanoma iii magea recombinant treatment nonsmall cell lung cancer iii gsk annual report shareholder pipeline continued information achieved regulatory review milestones compound type indication phase maa ndabla rare diseases antisense oligonucleotide duchenne muscular dystrophy iii exvivo stem cell gene therapy adenosine deaminase severe combined immune deficiency iii adascid migalastat hcl pharmacological chaperone fabry disease iii stiefel latestage assets novel glucocorticoid agonist topical atopic dermatitis ii duac low dose clindamycinbenzoyl peroxide gel acne vulgaris submitted nov nov sorilux vitamin analog scalp psoriasis submitted nov calcipotriene foam tazarotene foam retinoid foam acne vulgaris submitted jul hiv viiv healthcare sgsk hiv integrase inhibitor longacting parenteral hiv infections formulation lersivirine uk nonnucleoside reverse transcriptase inhibitor hiv infections ii dolutegravir hiv integrase inhibitor hiv infections iii sgsk dolutegravir hiv integrase inhibitor reverse transcriptase hiv infections iii sgsk inhibitors fixed dose combination abacavir sulphate lamivudine brand names appearing italics trademarks either owned andor licensed glaxosmithkline associated companies optionbased alliances third parties include assets phase later development company disease area phase cancer research uk cancer chemocentryx inflammatory disease ii concert pharmaceuticals hiv dynavax technologies cutaneous systemic lupus erythematosus ii isis pharmaceuticals transthyretinmediated amyloidosis oncomed pharmaceuticals oncology prosensa therapeutics neuroscience ii ranbaxy laboratories respiratory ii telethon institute gene therapy stem cell gene therapy ii affiris alzheimers disease treatment vaccine ii nabi nicotine vaccine iii ccx two assets gsk annual report pharmaceutical products competition intellectual property major patent expiry dates products compounds indications competitor brands usa eu respiratory veramyst fluticasone propionate rhinitiscopd nasacort flixotideflovent fluticasone propionate asthmacopd qvar singulair expired expired compound compound expired diskus device diskus device hfadevice hfadevice formulation formulation seretideadvair salmeterol xinafoat asthmacopd singulair symbicort expired fluticasone propionate spiriva asmanex combination combination pulmicort foster expired diskus device diskus device hfadevice hfadevice formulation formulation serevent salmeterol xinafoate asthmacopd foradil spiriva expired expired compound compound expired diskus device diskus device na hfadevice formulation ventolin hfa albuterol sulphate asthmacopd generic companies hfadevice hfadevice formulation formulation antivirals relenza zanamivir influenza tamiflu valtrex valaciclovir genital herpes coldsores famvir expired expired shingles zeffixepivirhbv lamivudine chronic hepatitis b hepsera expired use use central nervous system lamictal lamotrigine epilepsy bipolar disorder keppra dilantin expired expired imigranimitrex sumatriptan migraine zomig maxalt relpax expired expired requip xl ropinirole parkinsons disease mirapex expired formulation seroxatpaxil paroxetine depression various effexor cymbalta expired expired anxiety disorders lexapro treximet sumatriptan naproxen migraine zomig maxalt na relpax combination use wellbutrin bupropion depression effexor cymbalta expired expired lexapro cardiovascular urogenital arixtra fondaparinux deep vein thrombosis lovenox fragmin expired expired pulmonary embolism innohep avodart dutasteride benign prostatic hyperplasia proscar flomax finasteride benlysta belimumab systemic lupus erychematosus coreg cr carvedilol phosphate mildtosevere heart failure toprol xl na hypertension left ventricular formulation dysfunction post mi fraxiparine nadroparin deep vein thrombosis lovenox fragmin expired expired pulmonary embolism innohep see outlook details uncertainty timing followon competition generic competition possible generic competition possible gsk annual report shareholder pharmaceutical products competition intellectual property information major patent expiry dates products compounds indications competitor brands usa eu lovaza omega acid ethyl esters high triglycerides tricor na formulation volibris ambrisentan pulmonary hypertension tracleer revatio na antibacterials augmentin amoxicillinclavulanate common bacterial generic products na expired potassium infections oncology arzerra ofatumumab refractory chronic mabtherarituxan pending lymphocytic leukaemia hycamtin topotecan ovarian cancer small cell doxil gemzar expired expired lung cancer cervical cancer promacta eltrombopag idiopathic thrombocytopenic nplate revolade purpura tykerbtyverb lapatanib advanced metastatic herceptin breast cancer positive patients votrient pazopanib metastatic renal cell carcinoma sutent nexavar afinitor vaccines boostrix diphtheria tetanus acellular booster vaccination adacel pertussis infanrixpediarix diphtheria tetanus pertussis diphtheria tetanus pertussis pentacel pediacel polio hepatitis b hepb polio hepatitis b hepb pentaxim pentavac inactivated antigens cervarix hpv virus like particles human papilloma virus gardasil silgard vlps adjuvant mpl type aluminium hydroxide fluarix split inactivated influenza virus seasonal influenza vaxigrip mutagrip subtypes type b antigens fluzone influvac aggripal fluad flulaval split inactivated influenza virus seasonal influenza vaxigrip mutagrip none none subtypes type b antigens fluzone influvac aggripal fluad pandemrix derived split inactivated ahnv influenza focetria celvapan influenza virus antigen prophylaxis emerflu adjuvant prepandrix derived split inactivated influenza prophylaxis aflunov influenza virus antigen adjuvant synflorix conjugated pneumococcal invasive pneumococcal prevenar prevnar na polysaccharide disease hiv combivir lamivudine zidovudine hivaids truvada atripla combination combination epivir lamivudine hivaids truvada atripla expired expired epzicomkivexa lamivudine abacavir hivaids truvada atripla combination combination lexiva fosamprenavir hivaids prezista kaletra reyataz selzentry maraviroc hivaids isentress intelence prezista trizivir lamivudine zidovudine hivaids truvada atripla abacavir combination combination see note financial statements legal proceedings generic competition began december gsk annual report consumer healthcare products competition intellectual property brand products application markets competition oral healthcare sensodyne toothpastes toothbrushes prevention dental global colgatepalmolives mouthwashes sensitivity colgate pro relief polident denture adhesive denture improve comfort global none globally poligrip cleanser fitted dentures corega clean dentures aquafresh toothpastes toothbrushes prevention caries gum global colgatepalmolives colgate disease bad breath procter gambles crest otc medicines panadol tablets capulets infant drops paracetamolbased treatment global except usa reckittbenckisers nurofen headache joint pain fever cold symptoms nicoderm gum patch mini lozenge treatment nicotine global novartis nicotinell niquitin cq original lozenge withdrawal aid nicorette europe nicabate quitting smoking retailers brands also nicorette usa nutritional healthcare lucozade energy sports drinks energy hydration uk ireland pepsicos gatorade markets cocacolas powerade red bull horlicks malted milkbased drinks nutrition uk ireland india krafts bournvita foods nestles milo gsk annual report shareholder share price dividends information shares company listed london stock exchange dividends per ads new york stock exchange nyse form american table sets dividends per ads us dollars depositary shares ads details listed debt last five years translated us dollars applicable listed refer note financial statements net debt exchange rates share price year dividend us supplemental january december increasedecrease high year low year supplemental dividend relates disposal certain noncore table sets middle market closing prices otc brands north america paid fourth quarter companys share price increased compares ordinary dividend decrease ftse index year share price march dividend calendar us quarter exdividend date record date payment date q february february april supplemental february february april q may may july q august august october q november november january financial reporting calendar publication date results announcements uk share price us ads price us quarter april quarter july market capitalisation quarter october market capitalisation based shares issue excluding preliminaryquarter february treasury shares gsk december billion annual reportsummary februarymarch date gsk fifth largest company market capitalisation ftse index results announcements dividends results announcements issued london stock exchange available news service also sent gsk pays dividends quarterly continues increase cash us securities exchange commission nyse issued returns shareholders dividend policy ongoing media made available website longterm share buyback programme dividends remain essential component total shareholder return gsk financial reports committed increasing dividend longterm details gsk publishes annual report shareholder dividends declared amounts payment dates needing full detail annual report summary given note financial statements dividends documents available website date dividends per share publication summary sent shareholders shareholders may elect receive annual report contacting registrars table sets dividends per share last five alternatively shareholders may elect receive notification years email publication financial reports registering wwwshareviewcouk year dividend pence copies previous financial reports available gsks supplemental website printed copies obtained registrars uk gsk response center usa see contact details supplemental dividend relates disposal certain noncore otc brands north america paid fourth quarter ordinary dividend gsk annual report corporate responsibility report taxation publish corporate responsibility report online general information concerning uk us tax effects march outline gsks approach share ownership set pages taxation performance corporate responsibility areas including access information shareholders healthcare research business ethics environmental internet sustainability community investment information company including details share nature trading market price available website wwwgskcom information following tables set periods indicated high made available website constitute part low middle market closing quotations pence shares annual report london stock exchange high low closing annual general meeting prices us dollars ads nyse may pence per share queen elizabeth ii conference centre ordinary shares high low broad sanctuary westminster london swp ee quarter ended march february agm companys principal forum communication january private shareholders addition formal business december presentation ceo performance november group future development october opportunity questions asked board chairmen september boards committees take questions relating quarter ended december committees quarter ended september investors holding shares nominee service arrange quarter ended june nominee service appointed proxy respect quarter ended march shareholding order attend vote meeting quarter ended december quarter ended september adr holders wishing attend meeting must obtain proxy quarter ended june bank new york mellon enable quarter ended march attend vote business transacted adr holders year ended december may instruct bank new york mellon way year ended december shares represented adr voted year ended december completing returning voting card provided bank documents display us dollars per ads ads high low articles association company documents quarter ended march referred annual report available inspection february companys registered office website january exchange controls limitations affecting december security holders november october certain economic sanctions may place september time time currently uk laws decrees quarter ended december regulations restricting import export capital affecting quarter ended september remittance dividends payments holders quarter ended june companys shares nonresidents uk similarly quarter ended march certain economic sanctions may force quarter ended december time time limitations relating quarter ended september nonresidents uk english law companys quarter ended june articles association right holder vote quarter ended march respect companys shares year ended december duplicate publications year ended december year ended december please contact registrars receive duplicate copies gsk publication march gsk annual report shareholder investor relations registrars information investor relations share scam alert investor relations may contacted follows receive unsolicited phone call offering sell buy shares please take extra care caller may part highly uk organised financial scam great west road brentford middlesex tw gs uk shareholder please contact financial services tel authority information similar usa activities consumer helpline one franklin plaza po box philadelphia pa tel uk tel us toll free glaxo wellcome smithkline beecham tel outside usa corporate peps registrars share centre limited companys registrars oxford house oxford road aylesbury bucks hp sz equiniti limited tel aspect house spencer road lancing west sussex bn da adr programme administrator wwwshareviewcouk adr programme administered tel uk bank new york mellon tel outside uk po box uk lines open pm monday friday pittsburgh pa excluding uk public holidays wwwbnymelloncomshareowner equiniti also provides following services tel us toll free shareview service enables shareholders create free tel outside usa online portfolio get balance details movements update email shrrelationsbnymelloncom address dividend payment instructions register votes administrators also provide global buydirect direct ads cast agm wwwshareviewcouk purchasesale dividend reinvestment plan adr holders investment account individual savings account isa glaxosmithkline corporate sponsored nominee gsk response center share dealing service tel us toll free dividend reinvestment plan provision details intended share dealing service invitation inducement engage investment activity advice share dealing obtained stockbroker shareholders may trade shares either held certificates independent financial adviser corporate sponsored nominee internet telephone shareview dealing share dealing service provided equiniti financial services limited internet transactions please log wwwshareviewcouk dealing telephone transactions please call tel uk tel outside uk investment account isa services please log wwwshareviewcoukdealing telephone transactions please call tel uk tel outside uk uk lines open pm monday friday please note market trading hours pm gsk annual report number total total number analysis shareholdings december accounts accounts shares shares holding shares held nominee companies investment trust companies insurance companies individuals corporate bodies bny nominees limited held treasury shares glaxosmithkline bank new york mellons holding held bny nominees limited represents companys adr programme whereby ads represents two ordinary shares p nominal value march bny nominees limited held ordinary shares representing issued share capital excluding treasury shares held date march number holders shares usa holdings shares number registered holders ads holdings ads certain shares ads held brokers nominees result number holders record registered holders usa representative number beneficial holders residence beneficial holders taxation information shareholders taxation capital gains uk shareholders may liable uk tax gains disposal summary certain uk tax us federal income tax shares adr disposals individuals subject consequences holders shares adr citizens availability exemption relief annual exempt uk usa set complete analysis amount taxable capital gain accruing disposal shares possible tax consequences purchase ownership adr taxed allowable deductions sale securities intended general guide shareholders taxable income tax year exceeds basic rate holders advised consult advisers respect tax income tax limit cases taxable capital gain accruing consequences purchase ownership sale shares disposal shares adr may taxed adr consequences state local tax laws combination rates corporation taxpayers may entitled usa implications current ukus tax conventions indexation allowance applies reduce capital gains us holders adr generally treated owners extent gains arise due inflation indexation allowance underlying shares purposes current usauk double may reduce chargeable gain create allowable loss taxation conventions relating income gains income tax inheritance tax convention estate gift taxes estate gift tax convention purposes internal revenue code individual shareholders may liable inheritance tax amended code transfer shares adr tax may charged amount value shareholders estate reduced result uk shareholders transfer way gift disposal less full summary applies uk resident shareholder holds market value gift disposal subject shares capital assets uk inheritance tax us estate gift tax estate gift tax convention would generally provide tax paid usa taxation dividends credited tax payable uk uk resident shareholders generally subject uk income stamp duty tax full amount dividends paid grossed amount tax credit tax credit may set uk stamp duty stamp duty reserve tax sdrt subject individuals income tax liability respect gross dividend certain exemptions payable transfer shares rate repayable shareholders tax liability less consideration transfer associated tax credit tax year subsequent tax years additional rate income tax dividends imposed taxpayers whose income uk resident shareholders corporation taxpayers note dividends generally entitled exemption corporation tax gsk annual report shareholder taxation information shareholders information us shareholders estate gift taxes summary applies shareholder citizen resident estate gift tax convention us shareholder usa domestic corporation person otherwise generally subject uk inheritance tax subject us federal income tax net income basis respect stamp duty shares adr holds shares adr capital assets resident uk uk tax purposes hold uk stamp duty sdrt subject certain exemptions shares purposes trade profession vocation payable issue transfer shares adr carried uk branch agency custodian depository rate price issued amount consideration provided transferred sale summary also address tax treatment holders value transferred consideration subject special tax rules banks taxexempt entities insurance companies dealers securities currencies sdrt would payable transfer agreement persons hold shares adr part integrated transfer adr uk stamp duty payable investment including straddle comprised share adr transfer adr provided instrument transfer one positions persons directly executed remains times outside uk stamp duty indirectly voting stock gsk transfer adr would payable rate consideration transfer sale underlying shares taxation dividends would subject certain exceptions result liability uk stamp gross amount dividends received treated foreign source duty case may sdrt rate dividend income us tax purposes eligible dividend received deduction allowed us corporations dividends adr payable us dollars dividends shares payable sterling dividends paid pounds sterling included income us dollar amount calculated reference exchange rate day dividends received holder subject certain exceptions shortterm hedged positions individual eligible us holder subject us taxation maximum rate respect qualified dividends received taxation capital gains generally us holders subject uk capital gains tax subject us tax capital gains realised sale disposal shares adr gains longterm capital gains subject reduced rates taxation individual holders shares adr held one year information reporting backup withholding dividends payments proceeds sale shares adr paid within usa certain usrelated financial intermediaries subject information reporting may subject backup withholding unless us holder corporation exempt recipient provides taxpayer identification number certifies loss exemption occurred nonus holders generally subject information reporting backup withholding may required provide certification nonus status connection payments received amounts withheld allowed refund credit holders us federal income tax liability provided required information furnished irs gsk annual report glossary terms terms used annual report us equivalent brief description accelerated capital allowances tax allowance excess depreciation arising purchase fixed assets delay charging payment tax us equivalent tax depreciation american depositary receipt adr receipt evidencing title ads glaxosmithkline adr represents two ordinary shares american depositary shares ads listed new york stock exchange represents two ordinary shares basic earnings per share basic income per share calledup share capital ordinary shares issued fully paid cer growth growth constant exchange rates company glaxosmithkline plc currency swap exchange two currencies coupled subsequent reexchange currencies agreed exchange rates dates defined benefit plan pension plan specific employee benefits often called final salary scheme defined contribution plan pension plan specific contributions level pension dependent upon growth pension fund derivative financial instrument financial instrument derives value price rate underlying item diluted earnings per share diluted income per share employee share ownership plan trusts trusts established group satisfy sharebased employee incentive plans finance lease capital lease freehold ownership absolute rights perpetuity gearing ratio net debt percentage total equity group glaxosmithkline plc subsidiary undertakings hedging reduction risk normally relation foreign currency interest rate movements making offsetting commitments intangible fixed assets assets without physical substance computer software brands licences patents knowhow marketing rights purchased outside parties profit income profit attributable shareholders net income share capital ordinary shares capital stock common stock issued fully paid shareholders funds shareholders equity share option stock option share premium account additional paidup capital paidin surplus distributable shares issue number shares outstanding subsidiary entity glaxosmithkline holds majority shareholding andor exercises control treasury share treasury stock turnover revenue uk corporate governance code guidelines required listing rules financial services authority address principal aspects corporate governance gsk annual report shareholder index information accounting principles policies inventories acquisitions disposals investments associates joint ventures adjustments reconciling profit tax operating investor relations cash flows key accounting judgements estimates annual general meeting key performance indicators assets held sale latestage pipeline summary associates joint ventures legal proceedings board longterm incentive plans business review major restructuring programme cash cash equivalents movements equity chairmans statement net debt chief executives review new accounting requirements commitment access nonexecutive director terms conditions commitments nonexecutive directors fees committee reports notes financial statements competition operating profit consolidated balance sheet intangible assets consolidated cash flow statement investments consolidated income statement noncurrent assets consolidated statement changes equity noncurrent liabilities consolidated statement comprehensive income operating income contingent liabilities provisions corporate executive team outlook corporate governance pensions postemployment benefits critical accounting policies post balance sheet events directors senior management presentation financial statements directors emoluments total remuneration principal group companies directors interests product development pipeline directors interests contracts products directors statement responsibilities property plant equipment dividends quarterly trend donations political organisations reconciliation net cash flow movement net debt political expenditure registrars earnings per share related party transactions employee costs relations shareholders employee share schemes remuneration report employees research development exchange rates responsible business executive director terms conditions risk factors finance costs segment information finance income segment reviews financial instruments related disclosures share capital control financial position resources share capital share premium account financial review share price financial review shareholder information financial statements glaxosmithkline plc prepared strategy uk gaap taxation five year record taxation information shareholders foreign exchange risk management trade payables global manufacturing supply trade receivables glossary terms trademarks goodwill treasury operations governance policy uk corporate governance code independent auditors report us law regulation intellectual property world market interest rate risk management gsk annual report official laboratory services provider gsk challenging inspiring mission improve quality human life enabling people feel better live longer glaxosmithkline plc incorporated english public limited company december formed merger glaxo wellcome plc smithkline beecham plc gsk acquired two english companies december part merger arrangements shares listed london stock exchange new york stock exchange scientists work small entrepreneurial teams focused specific diseases areas science george brooks ceo sir andrew witty hears patients visiting hospital uganda tom whipps gsk official laboratory services provider london olympic paralympic games outreach programme scientists sport aims inspire young people science demonstrating role science plays games david tett children seven african countries taking part trial evaluate candidate malaria vaccine john michael maas back cover uk employ university students oneyear placements give experience workplace many students also support community programmes george brooks september lucozade started fiveyear partnership vodafone mclaren mercedes formula lat photographicsteven teewwwgskcom find downloadable pdfs annual report corporate responsibility report head office registered office glaxosmithkline plc great west road brentford middlesex tw gs united kingdom tel registered number printed amadeus offset recycled paper full fsc certification pulps used made deinked postconsumer waste elemental chlorine free ecf manufacturing mill holds iso eu ecolabel certificates environmental management mill zero landfill extremely low carbon emissions leading wwf approve papers environmentally sustainable uncoated recycled paper